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ABSTRACT 
 
Myocardial Infarction (MI) is caused by occlusion of the coronary artery following 
atheromatous plaque rupture, the subsequent ischemia in the myocardium leads to 
myocyte necrosis unless treated quickly. Bone marrow derived stem cell treatment is 
a promising therapy for improving the outcome of patients with MI.  The aim of this 
thesis was to study myocardial protein and gene expression changes in a rat 
ischemia/reperfusion (I/R) model in order to look for potential repair mechanisms of 
the myocardium triggered by endogenous bone marrow mononuclear cells 
(BMMNCs).  
 
Rat myocardial samples were obtained from three experimental groups: one group 
had a sham operation, the other two groups had undergone myocardial I/R injury 
induced by left anterior descending (LAD) coronary artery ligation followed by 
treatment with either a BMMNC preparation or PBS.  Comparative proteomic 
analyses were carried out using 2D electrophoresis; differentially expressed proteins 
were identified using LC-MS/MS.  Western blotting was used to confirm the most 
significant findings including expression of 14-3-3 epsilon protein.  Global 
comparative gene expression profiling was performed using Illumina RatRef12 
BeadChips and QPCR was used to validate the top results.  Bioinformatic tools were 
used to assess the biology of the differentially expressed genes and proteins. 
 
Thirty-seven proteins were found to be differentially expressed in I/R injury 
compared to sham. These were primarily sarcomeric, energy production or stress 
response proteins and most were down-regulated.  Expression levels were ‘corrected’ 
by BMMNC treatment for many of these proteins. Over 1500 genes were affected by 
I/R injury, 20 were affected by BMMNC treatment, and many of these were related to 
inflammation and apoptosis signalling and responses. The 14-3-3 epsilon protein was 
chosen for follow-up work as it presented as a good candidate for mechanistic 
involvement. This protein has many roles including interactions with the pro-
apoptotic BCL2-associated agonist of cell death (Bad) protein. Western blotting was 
used to look at Bad expression and found it to be significantly increased in the 
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treatment group, although I could not reliably measure the expression of 
phosphorylated (serine 136) form of Bad. A preliminary pull-down assay was 
performed to look for binding partners of 14-3-3 epsilon. Two ATP synthase 
subunits, one of which is known to bind 14-3-3 epsilon, a protein involved in fatty 
acid β-oxidation and a protein of unknown function were found to bind.  Further 
work will be required to follow up these findings and ascertain the exact role of 14-3-
3 epsilon in cardioprotection.  In summary, my data supports the power of profiling 
methods to derive new candidates for a role in repair mechanisms in this therapeutic 
model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 4 
DECLARATION 
 
The work presented in this thesis was performed on samples obtained from an animal 
model of ischemia/reperfusion injury with and without bone marrow cell treatment.  
The bone marrow cell preparation, animal model experiments, collection of 
phenotypic information from the model and measurements of Akt, p38 MAPK and 
GSK-3β phosphorylation, and NF-ĸB translocation by Western blotting were carried 
out by our collaborators in the William Harvey Research Institute and University 
College London.  The harvesting and preservation of the myocardial samples used for 
my analyses was also carried out by collaborators. 
 
For the gene expression studies I performed the cDNA preparation; hybridisation and 
reading of the chips was performed by Genome Centre Staff at Bart’s and The 
London School of Medicine and Dentistry.  Analysis of the gene expression data was 
carried out by me with some assistance from Dr Richard Dobson (Genome Centre 
staff). 
 
I declare all the work pertaining to the 2DE analysis, mass spectrometry, Western 
blotting (14-3-3 epsilon, Sdha, Pebp1, Atp5b and Bad), QPCR, the pull-down assay, 
data analysis and the bioinformatics analyses presented in this thesis is my own work.   
 
 
 
 
 
 
 
 
 
 
 
Page 5 
PUBLICATIONS & PRESENTATIONS 
 
Publications 
 
I have five publications arising from my participation in the Wellcome Trust Case 
Control Consortium: 
 Wellcome Trust Case Control Consortium.  Genome-wide association study of 
14,000 cases of seven common diseases and 3,000 shared controls. Nature. 
2007; 447; 661-78. 
 Wellcome Trust Case Control Consortium.  Association scan of 14,500 
nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat 
Genet. 2007 Nov;39(11):1329-37.  
 Wallace et al. Genome-wide Association Study Identifies Genes for 
Biomarkers of Cardiovascular Disease: Serum Urate and Dyslipidemia. Am J 
Hum Genet 2008 Jan;82: 139-149. 
 Newton-Cheh et al. Genome-wide association study identifies eight loci 
associated with blood pressure. Nat Genet. 2009 
 Wellcome Trust Case Control Consortium. Genome-wide association study of 
CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. 
Nature 2010; 464; 713-722. 
Other publications: 
 Newhouse et al. Polymorphisms in the WNK1 Gene Are Associated with 
Blood Pressure Variation and Urinary Potassium Excretion. PLoS One 2009 
April;  4: e5003. 
Submitted: 
 Lovell et al. Bone Marrow Mononuclear Cells Reduce Myocardial 
Reperfusion Injury by Activating the Pi3k/Akt Survival Pathway.  
Atherosclerosis 2010. 
 
 
 
Page 6 
Oral Presentations 
 Lee et al.  Protein expression analyses in bone marrow stem cell mediated 
restoration of myocardium after ischemic insult. Presented at the William 
Harvey Review, William Harvey Research institute, Bart’s and the London 
Queen Mary University, London, November 2008.  
 
Poster Presentations 
 Lee et al.  Protein expression analyses in bone marrow stem cell mediated 
restoration of myocardium after ischemic insult.  Poster presented at the 8th 
Sienna Meeting From Genome to Proteome: Integration and Proteome 
Completion Aug-Sep 2008. 
 Lee et al. Protein expression analyses in bone marrow stem cell mediated 
restoration of myocardium after ischemic insult.  Poster presented at the EuPA 
and DGP European Summer School "Proteomic Basics" July 2008. 
(Attendance for this course was sponsored by a BSPR Fellowship) 
 
Page 7 
ACKNOWLEDGEMENTS 
 
I would like to thank the Medical Research Council for funding this study, and the 
British Heart Foundation for funding the work of our collaborators. 
 
I would like to acknowledge the contributions of my supervisors Professor Munroe, 
Professor Mathur and Dr Leung for their support and mentorship; especially 
Professor Munroe for her patient and tireless guidance in writing this thesis.   
 
I woud also like to thank colleagues; Chaz and Rich, Mose and Mimi as well as those 
who have trodden this path before me and supplied advice and encouragement, 
especially Frankie.  Finally I would like to thank my patient husband Casey for his 
support and proof reading skills. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 8 
CONTENTS PAGE 
  
1. Introduction 19 
  
1.1 Myocardial infarction 
 1.1.1 Aetiology 
 1.1.2 Prognosis  
 1.1.3 Current therapy 
19 
  
1.2 The promise of autologous progenitor cells 
 1.2.1 Autologous stem cells 
 1.2.2 The evidence  
1.2.2.1 Animal models of bone marrow cell therapy for MI 
1.2.2.2 Human trials of bone marrow cell therapy for MI 
 1.2.3 Mechanism 
  1.2.3.1 IPC and cardioprotection 
  1.2.3.2 Paracrine mechanism of BMMNCs 
23 
  
1.3 Global protein and gene expression profiling 
 1.3.1 Proteomics 
  1.3.1.1 Proteomics and CVD 
 1.3.2 Transcriptomics 
  1.3.2.1 Transcriptomics and CVD 
 1.3.3 Integration of proteomic and genomic data 
1.3.4 Proteomics and gene expression studies of cardiac repair 
40 
  
1.4 Rat model of I/R injury and restoration of myocardium associated 
with BMMNCs 
53 
  
2. Hypothesis and aims 57 
  
2.1 Hypothesis 57 
  
2.2 Aims 57 
  
3. Materials and Methods 58 
  
3.1 Model and bone marrow mononuclear cell preparation 
3.1.1 Rat ischemia/reperfusion model 
3.1.2 Preparation and characterisation of bone marrow cells 
3.1.3 Collection of myocardial samples for proteomic and gene 
analysis 
58 
  
3.2 Proteomic analyses 
3.2.1 Sample preparation and quantification 
 
62 
Page 9 
3.2.1.1 Protein lysate preparation from rat myocardial 
samples 
3.2.1.2 Protein quantification 
3.2.2 Two dimensional gel electrophoresis (2DE) 
3.2.2.1 Isoelectric focussing (IEF) 
3.2.2.2 SDS – polyacrylamide gel electrophoresis (PAGE) 
3.2.3 Image analysis 
3.2.4 Statistical analysis 
3.2.5 Protein identification by LC-MS/MS  
3.2.5.1 Excision and trypsin digestion of spots 
3.2.5.2 LC-MS/MS 
  
3.3 Validation of proteomic data by Western blotting 
3.3.1 1D SDS-PAGE and blotting 
3.3.2 Antibody incubations and chemiluminescence 
3.3.3 Densitometry 
3.3.4 Statistical analysis 
75 
  
3.4 Gene expression analyses 
3.4.1 RNA preparation 
3.4.1.1 RNA extraction from tissue samples 
3.4.1.2 RNA quantification and quality assessment 
3.4.2 cDNA synthesis, purification and ‘in-vivo’ cRNA 
transcription 
3.4.3 Gene expression data pre-processing 
3.4.3.1 Quality assessment of gene expression data using 
BeadStudio 
3.4.3.2 Data preparation and normalisation 
3.4.4 Differential gene expression analysis using LIMMA 
81 
  
3.5 Validation of differentially expressed genes 
3.5.1 TaqMan gene expression assays 
3.5.2 RNA preparation 
3.5.3 QPCR using TaqMan gene expression assays 
3.5.4 Reference gene selection 
3.5.5 ∆∆Ct calculations and statistical analysis 
94 
  
3.6 Bioinformatic analysis of protein and gene expression data   
3.6.1 Protein ANalysis THrough Evolutionary Relationships 
(PANTHER) 
3.6.2 Database for Annotation, Visualization and Integrated 
Discovery (DAVID) 
3.6.3 Ingenuity Pathway Analysis (IPA) 
103 
 
 
 
 
Page 10 
3.7 Studies of 14-3-3 epsilon  
3.7.1 Validation of experiments using samples 10-18 
3.7.2 Expression and activation of BCL2-associated agonist of cell 
death (Bad) 
3.7.3 14-3-3 epsilon pull-down assay 
3.7.3.1 Bait protein immobilisation 
3.7.3.2 Prey protein preparation and capture 
3.7.3.3 Bait-Prey elution 
3.7.3.4 SDS-PAGE and protein detection 
3.7.3.5 LC-MS/MS protein identification 
107 
  
4. Proteomic results 111 
  
4.1 Wide-range protein profiling  
4.1.1 Protein quantification 
4.1.2 2DE 
4.1.3 Differentially expressed proteins 
111 
 
  
4.2 Narrow-range protein profiling  
4.2.1 2DE 
 4.2.1.1 pH 4.5-5.5 narrow-range 2DE analysis 
 4.2.1.2 pH 5.5-6.7 narrow-range 2DE analysis 
4.2.2 Differentially expressed proteins 
128 
  
4.3 Validation of proteomic data 139 
  
5. Gene expression results 144 
  
5.1 Gene expression profiles of samples 1-9 using Illumina RatRef12 
5.1.1 Quality control and quantification of RNA and cRNA 
5.1.2 Quality control of the RatRef12 gene expression chip data 
144 
  
5.2 Repeat of global expression profiles of samples 1-9 using Illumina  
RatRef12 
5.2.1 Quality control and quantification of RNA and cRNA 
5.2.2 Quality control and pre-processing of the repeat of the 
RatRef12 gene expression chip data 
 5.2.2.1 Quality control for the repeat chip data 
 5.2.2.2 Pre-processing of the repeat chip data 
5.2.3 Differentially expressed genes discovered using LIMMA 
152 
  
5.3 Validation of gene expression data 
 5.3.1 Reference gene selection 
 5.3.2 QPCR using Taqman gene expression assays 
  5.3.2.1 GeNorm 
  5.3.2.2 ∆∆Ct calculations and statistical analysis 
175 
Page 11 
5.3.2.3 QPCR analysis of Oas1k in samples 10-18 
  
6. Bioinformatic results 183 
  
6.1 Bioinformatic analysis of proteins found to be altered in 2DE 
analyses 
6.1.1 Protein Analysis Through Evolutionary Relationships 
(PANTHER) 
6.1.1.1 Sham vs. MI 
6.1.1.2 MI vs. BMMNC 
6.1.2 Database for Annotation, Visualisation and Integrated 
Discovery (DAVID) 
6.1.2.1 Sham vs. MI 
6.1.2.2 MI vs. BMMNC 
6.1.3 Ingenuity Pathway Analysis (IPA) 
6.1.3.1 Sham vs. MI 
6.1.3.2 MI vs. BMMNC 
6.1.4 Summary  
183 
  
6.2 Bioinformatic analysis of genes found to be differentially regulated 
in the Illumina RatRef12 analysis 
6.2.1 Protein Analysis Through Evolutionary Relationships 
(PANTHER) 
6.2.1.1 Sham vs. MI 
6.2.1.2 MI vs. BMMNC 
6.2.2 Database for Annotation, Visualisation and Integrated 
Discovery (DAVID) 
6.2.2.1 Sham vs. MI 
6.2.2.2 MI vs. BMMNC 
6.2.3 Ingenuity Pathway Analysis (IPA) 
6.2.3.1 Sham vs. MI 
6.2.3.2 MI vs. BMMNC 
           6.2.4 Summary  
220 
  
7.  Studies of 14-3-3 epsilon and Bad proteins 252 
  
7.1 Validation experiments using samples 10-18  252 
  
7.2 Western blot analysis of Bad proteins 
 7.2.1 Bad 
 7.2.2 Bad (phospho s136) 
255 
7.3 Preliminary pull-down assay of his-tagged 14-3-3 epsilon 
7.3.1 Pull-down assay and SDS-PAGE 
7.3.2 Protein identification by LC-MS/MS 
258 
 
 
 
Page 12 
8. Discussion and Future Work 263 
  
8.1 Proteomic changes in I/R model and treatment with BMMNCs 
            8.1.1 Mitochondrial/oxidative phosphorylation proteins 
            8.1.2 Antioxidant proteins 
            8.1.3 Energy metabolism proteins 
            8.1.4 Heat shock proteins 
264 
  
8.2 Candidate proteins for involvement in BMMNC afforded 
cardioprotection 
272 
  
8.3 Limitations of 2DE proteome analysis  277 
  
8.4 Gene expression changes in I/R and after treatment with BMMNCs 282 
  
8.5 Bioinformatic analysis of proteomic and gene expression datasets 288 
  
8.6 Conclusions 289 
  
8.7 Future work 291 
  
10. References 295 
  
11. Appendices 308 
  
APPENDIX 1: Genome Centre protocol for Illumina direct hybridisation 308 
APPENDIX 2: MASCOT search results from the wide-range 2DE 
analysis 
313 
APPENDIX 3: MASCOT search results from the pH 4.5-5.5 2DE analysis 323 
APPENDIX 4: MASCOT search results from the pH 5.5-6.7 2DE analysis   327 
APPENDIX 5: Abbreviations and identification codes for all proteins 
identified in the 2DE analyses 
330 
APPENDIX 6: Additional information on protein identifications which 
were based on a single peptide hit. 
331 
APPENDIX 7: LIMMA differential gene expression results 341 
APPENDIX 8: Probe level data for the top 433 probes  348 
APPENDIX 9: MASCOT search results from the 14-3-3 epsilon pull-
down analysis   
362 
APPENDIX 10: Manuscript submitted to Atherosclerosis 368 
 
 
 
 
 
 
 
Page 13 
LIST OF FIGURES PAGE
Figure 1.1 Apical myocardial infarction 20 
Figure 1.2 Progenitor cell classifications 24 
Figure 1.3 Pathways thought to be involved in ischemic preconditioning   37 
Figure 1.4 Tracking of BMMNCs 6 hours post-reperfusion 56 
Figure 3.1 BSA standard curve macro in Excel   65 
Figure 3.2 Assembly of XCell Blot Module [Invitrogen, UK] 76 
Figure 3.3 An example of band volume normalisation using Gapdh as a 
loading control 
80 
Figure 3.4 RNeasy fibrous tissue kit procedure as shown in the handbook 
[Qiagen, UK]  
83 
Figure 3.5 R script used to perform the LIMMA analysis 93 
Figure 3.6 Flowchart depicting the use of GeNorm to determine the most 
stable reference gene for a set of samples 
99 
Figure 3.7 Graphical out put of the example GeNorm analysis shown in 
figure 3.6 
100 
Figure 4.1 Venn diagram showing the distribution of 187 significantly 
differently expressed spots with >1.5 fold changes in the wide-range 2DE 
analysis 
112 
Figure 4.2 Venn diagram showing the distribution of 130 significantly 
differently expressed spots with >2.5 fold changes in the wide-range 2DE 
analysis 
112 
Figure 4.3 Graphs of p-values plotted against fold changes for 105 spots 
with significantly altered intensities in the pH 4-7 2DE analysis 
114 
Figure 4.4 Example of a wide range 2DE gel protduced for this analysis 119 
Figure 4.5 The relative positions of peptides 1-16 along the length of ATP 
synthase subunit β 
127 
Figure 4.6 The relative positions of protein sequence covered by the 
60kDa heat shock protein peptides identified in three spots from the 
narrow-range analyses 
133 
Figure 4.7 Example of the narrow range 2DE gel protduced for this 
analysis 
134 
Figure 4.8 Western blots of 14-3-3 epsilon (14-3-3ε), succinate 
dehydrogenase (Sdha), and phosphatidylethanolamine-binding protein 1 
(Pebp1) in samples 1-9 
141 
Figure 4.9 The average normalised spot volumes from the 2DE ananlysis 
(left) and normalised band volumes from Western blot (WB) analysis 
(right) for 14-3-3 epsilon (14-3-3ε), succinate dehydrogenase (Sdha), and 
phosphatidylethanolamine-binding protein 1 (Pebp1) in samples 1-9   
142 
Figure 4.10 Bands detected using an antibody to ATP synthase subunit β 143 
Figure 5.1 Summary from the Agilent Eukaryote Total RNA Nano Series 
II chip results for RNA extracted from samples 1-9    
145 
Figure 5.2 BeadStudio Plots of internal quality control features 148 
Figure 5.3 Scatter plots of average signal data from two samples 149 
Figure 5.4 Dendrogram produced by BeadStudio showing clustering of 
non-normalised probe data   
151 
Page 14 
Figure 5.5 Summary of the Agilent Eukaryote Total RNA Nano Series II 
chip results for RNA extracted from samples 1-9 for the repeat RatRef12 
analysis 
154 
Figure 5.6 Summary of the Agilent Eukaryote Total RNA Nano Series II 
chip for results of repeat RNA extracts RNA 1r, RNA 2r and RNA 5r for 
the repeat RatRef12 analysis   
155 
Figure 5.7 Beadstudio Plots of internal quality control features 157 
Figure 5.8 Scatter plots of average signal data from two samples 158 
Figure 5.9 Dendrogram produced by BeadStudio showing clustering of 
non-normalised probe data   
160 
Figure 5.10 Venn diagram of distribution of differently expressed probes 
in the gene expression analysed using LIMMA 
161 
Figure 5.11 Graphs of FDR adjusted p-values plotted against log fold 
change (for probes with significant differential expression) 
163 
Figure 5.12 Graphical output of the GeNorm analysis 178 
Figure 5.13 Graphs showing fold change (FC) results from the QPCR 
analysis (A-C) and LIMMA statistics from the Illumina RatRef12 chip 
analysis (D) for Iqgap1, Oas1k, and Sema4a 
181 
Figure 5.14 Graphs showing fold change (FC) results from the QPCR 
analysis for Oas1k in samples 10-18 
182 
Figure 6.1 PANTHER Pathways represented by the proteins differentially 
regulated in Sham vs. MI 
184 
Figure 6.2 PANTHER Biological processes represented by the proteins 
differentially regulated in Sham vs. MI   
185 
Figure 6.3 PANTHER Pathways represented by the proteins differentially 
regulated in MI vs. BMMNC 
187 
Figure 6.4 PANTHER Biological processes represented by the proteins 
differentially regulated in MI vs. BMMNC 
188 
Figure 6.5 KEGG Pathway - Oxidative Phosphorylation 198 
Figure 6.6 Two of three networks associated with the proteins altered in 
Sham vs. MI   
205 
Figure 6.7 Three networks associated with the proteins altered in MI vs. 
BMMNC   
215 
Figure 6.8 PANTHER Pathways represented by the genes up-regulated in 
Sham vs. MI 
222 
Figure 6.9 PANTHER Pathways represented by the genes down-regulated 
in Sham vs. MI 
223 
Figure 6.10 PANTHER Biological processes represented by the genes up-
regulated in Sham vs. MI 
225 
Figure 6.11 PANTHER Biological processes represented by the genes 
down-regulated in Sham vs. MI 
226 
Figure 6.12 PANTHER Biological processes represented by the genes 
differentially-regulated in MI vs. BMMNC 
228 
Figure 6.13 Networks associated with the genes altered in Sham vs. MI   240 
Figure 6.14 Top network associated with the 15 genes altered in MI vs. 
BMMNC   
249 
Page 15 
Figure 6.15 Sphingosine-1-phosphate signalling   250 
Figure 7.1 Western blots of 14-3-3 epsilon (14-3-3ε), succinate 
dehydrogenase (Shda), and phosphatidylethanolamine-binding protein 1 
(Pebp1) in samples 10-18 
253 
Figure 7.2 The normalised band volumes from Western blot analysis of 
samples 1-9 (left) and normalised band volumes from Western blot 
analysis of samples 10-18 (right) for 14-3-3 epsilon (14-3-3ε), succinate 
dehydrogenase (Sdha), and phosphatidylethanolamine-binding protein 1 
(Pebp1) 
254 
Figure 7.3 Western blots of Bad in samples 10-18 256 
Figure 7.4 SDS-PAGE of the preliminary 14-3-3 epsilon pull-down assay  259 
Figure 7.5 Band IDs from bait flow-through and eluate from the 
preliminary 14-3-3 epsilon pull-down assay  
260 
Figure 8.1 Mitochondrial oxidative phosphorylation chain   267 
Figure 8.2 Signalling pathway potentially triggered by BMMNC 
treatment:  Evidence from our model.    
274 
Figure 8.3 Example of wide- and narrow-range gel images 281 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 16 
LIST OF TABLES PAGE
Table 1.1 Summary of proteins found to be altered in expression or 
modified in 2DE comparative profiling experiments on animal models of 
I/R injury 
43 
Table 3.1 Myocardial samples collected for studies 61 
Table 3.2 Lysis buffer preparation  63 
Table 3.3 Concentrations of BSA standards used to obtain a calibration 
curve 
64 
Table 3.4 BSA standard curve preparation for performing the Bio-Rad 
protein assay on the NanoDrop 1000  
66 
Table 3.5 Rehydration buffer preparation 67 
Table 3.6 12% SDS acrylamide gel solution preparation 68 
Table 3.7 Displacing solution preparation  68 
Table 3.8 Equilibration buffer preparation  69 
Table 3.9 10 x SDS running buffer preparation  70 
Table 3.10 10 x Tris buffered Saline (TBS) buffer  77 
Table 3.11 1 x TBS-TWEEN buffer  77 
Table 3.12 Reagents supplied in the RNeasy fibrous tissue kit [Qiagen, 
UK] 
82 
Table 3.13 Ambion TotalPrep reverse transcription master mix 87 
Table 3.14 Ambion TotalPrep second strand master mix 87 
Table 3.15 Ambion TotalPrep in-vivo transcription (IVT) master mix 88 
Table 3.16 Promega reverse transcription master mix 95 
Table 3.17 TaqMan QPCR master mix 96 
Table 4.1 109 spots selected for protein identification by LC-MS/MS from 
the pH 4-7 2DE analysis   
115 
Table 4.2 Spots with significant fold changes for which a single protein ID 
was found from the wide-range analysis 
121 
Table 4.3 Proteins found to have significant fold changes in either the 
Sham vs. MI or the MI vs. BMMNC comparisons from the wide-range 
analysis 
123 
Table 4.4 Details of the ATP synthase subunit β peptides identified in 17 
different spots in the wide-range analysis  
126 
Table 4.5 Seventeen spots selected for protein identification from the pH 
4.4-5.5 narrow-range Progenesis 2DE analysis 
129 
Table 4.6 Fourteen spots selected for protein identification from the pH 
5.5-6.7 narrow-range Progenesis 2DE analysis   
131 
Table 4.7 Details of the ATP synthase subunit β peptides identified in 2 
different spots in the pH 4.5-5.5 narrow range analysis 
132 
Table 4.8  Spots with significant fold changes for which a single protein 
ID was found from the narrow range analyses 
136 
Table 4.9 Proteins found to have significant fold changes in either the 
Sham vs. MI or the MI vs. BMMNC comparisons from the narrow range 
analyses 
138 
Table 5.1 Preparation, quantification and QC of RNA samples   
 
144 
Page 17 
Table 5.2 Technical replicates of three RNA samples were processed into 
cRNA 
146 
Table 5.3 Nanodrop quantification of cRNA prepared using Ambion 
TotalPrep 
146 
Table 5.4 Quantification and QC of mRNA samples for repeated Illumina 
RatRef12 chip analysis   
153 
Table 5.5 Nanodrop quantification of cRNA prepared using the Ambion 
TotalPrep kit 
156 
Table 5.6 Top 30 probes found to be significantly altered in Sham vs. MI 166 
Table 5.7 Top 10 probes found to be significantly down-regulated in Sham 
vs. MI 
168 
Table 5.8 Twenty probes found to be significantly altered in MI vs. 
BMMNC 
169 
Table 5.9  Top 15 qualitatively altered spots found to be ‘ON’ in MI 
compared to Sham 
172 
Table 5.10 Top 5 qualitatively altered spots found to be ‘ON’ in MI 
compared to Sham and ‘OFF’ in BMMNC compared to MI   
173 
Table 5.11 Three qualitatively altered spots found to be ‘OFF’ in MI 
compared to Sham 
173 
Table 5.12 Three qualitatively altered spots found to be ‘OFF’ in 
BMMNC compared to MI 
174 
Table 5.13 Suitability of 5 potential reference genes 176 
Table 5.14 Normalised Ct values (∆Ct) for each gene of interest (GOI), 
group averages and standard deviations 
179 
Table 5.15 P-values from the Student’s t-test performed on ∆Ct values 
from QPCR analysis in for Iqgap1, Oas1k, and Sema4a 
180 
Table 6.1 Four different lists of Refseq protein accession codes were 
entered into PANTHER  
183 
Table 6.2 Cluster 1-7 of 9 clusters of biological process GO terms 
associated with protein up-regulated in Sham vs. MI   
190 
Table 6.3 Cluster 1-12 of 19 clusters of biological process GO terms 
associated with protein down-regulated in Sham vs. MI    
192 
Table 6.4 Cluster 1 -9 of 14 clusters of biological process GO terms 
associated with protein up-regulated in MI vs. BMMNC 
196 
Table 6.5 One cluster of biological process GO terms associated with 
protein down-regulated in MI vs. BMMNC 
197 
Table 6.6 Proteins and endogenous chemicals included in the IPA analysis 
of Sham vs. MI proteomics data    
201 
Table 6.7 Top 10 canonical pathways associated with the 36 proteins 
altered in Sham vs. MI  
207 
Table 6.8 Table showing proteins and endogenous chemicals included in 
the IPA analysis of MI vs. BMMNC proteomics data    
209 
Table 6.9 Top 10 canonical pathways associated with the 27 proteins 
altered in MI vs. BMMNC 
218 
Table 6.10 Three different lists of Refseq gene accession codes were 
entered into PANTHER 
220 
Page 18 
Table 6.11 Group 1 -25 of 65 groups of biological process GO terms 
associated with genes up-regulated in Sham vs. MI    
230 
Table 6.12 Group 1 of 11 groups of biological process GO terms 
associated with genes down-regulated in Sham vs. MI    
233 
Table 6.13  Top 25 networks associated with the genes altered in Sham vs. 
MI 
236 
Table 6.14 Top 20 canonical pathways associated with the genes altered in 
Sham vs. MI 
243 
Table 6.15 Proteins and endogenous chemicals included in the IPA 
analysis of MI vs. BMMNC gene expression data    
246 
Table 6.16 Canonical Pathways associated with the genes altered in MI vs. 
BMMNC   
250 
Table 7.1 Proteins identified by LC-MS/MS from the bands illustrated in 
Figure 7.5 
262 
  
  
  
  
 
 
 
 
 
 
Page 19 
1. Introduction 
 
Bone marrow derived progenitor cell therapy has been suggested as a novel 
therapeutic approach to cardiac repair following ischemia/reperfusion injury. Using a 
rat model of I/R injury in collaboration with Professors Mathur and Thiemermann we 
demonstrated that early injection of autologous bone marrow derived cells leads to a 
marked reduction in infarct size compared to controls. This research included 
measuring the mechanical and cellular improvements to myocardial function afforded 
by progenitor cell therapy and assessing the activation of some key survival 
signalling pathways. 
 
The analyses I performed to study alterations in gene and protein expression in 
relation to the reduction in infarct size in the I/R model treated with progenitor cells 
forms the basis of this thesis.  My aim was to use this data to look for clues to the 
cellular mechanisms by which the preservation of cardiac function was mediated.    
 
1.1 Myocardial infarction  
 
Myocardial infarction (MI) commonly known as a heart attack, is the descriptive term 
for death of myocardial tissue and resulting loss of overall cardiac function caused by 
a period of cardiac ischemia (interruption of blood flow). Taken together with stroke 
(infarction within the brain) these are the leading causes of mortality and morbidity 
worldwide [1]. 
 
1.1.1 Aetiology 
 
Cardiac ischemia can occur when an atheromatous plaque in a coronary artery 
ruptures leading to acute thrombosis and either complete or intermittent occlusion of 
the coronary artery, see Figure 1.1.  Atheromatous plaques are a lipid rich deposit in 
the intima of arteries which act as focal points for the accumulation of inflammatory 
and immune cells and debris, they are usually covered with a fibrous cap [2].   Partial 
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occlusion of the coronary artery can cause angina which is often characterised by 
exertional chest pain.  Sustained chest pain is usually an indication of MI or unstable 
angina in which near-complete occlusion of the coronary artery occurs.    
 
Figure 1.1 Apical myocardial infarction This figure illustrates the heart and the left 
coronary artery (LCA) and right coronary artery (RCA).  2 = area of infarction, 
shaded in dark grey. 1 = the position of the occlusion in the LCA. [3] 
 
 
 
 
Ischemia is not simply hypoxia (lack of oxygen) but also involves a drop in the 
supply of metabolic substrates and a build up of metabolites [4].  Twenty minutes of 
ischemia will initiate necrosis of the cardiomyocytes and cause an inflammatory 
response leading to further tissue damage.   Reperfusion reduces cell loss by initiating 
apoptosis (programmed cell death) which encourages rapid phagocytosis and a 
limited inflammatory response [5].   The final extent of myocardial damage is not 
only due to the ischemic insult, but is also due to cellular responses to reperfusion 
itself, termed ischemia/reperfusion (I/R) injury [6]. 
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1.1.2 Prognosis  
 
Cardiovascular disease (CVD) accounted for approximately a third of all annual 
deaths in the UK in 2007; coronary heart disease (CHD) is responsible for 
approximately half and stroke for a quarter of these CVD related deaths [7].  Nearly 
all the deaths from CHD were due to a heart attack [8].   Survival rates in patients 
who have suffered MI are highly dependant on the extent of the infarcted region 
which is determined by the duration of ischemia and size of the territory supplied by 
the occluded artery.    Approximately 1/3 of patients with acute myocardial infarction 
die before reaching hospital and in total MI is fatal in around 40% of cases even with 
modern therapy.  Infarcted myocardium eventually converts to scar tissue which is 
fibrotic and has reduced contractility.  The loss of contractile function may lead to a 
compensating hypertrophy of the remaining myocardium. The increased demand of 
the hypertrophied myocardium can lead to LV failure and ventricular arrhythmia 
which are the leading causes of post hospital mortality and morbidity [9].   
 
1.1.3 Current therapy 
Therapeutic approaches that aim to reperfuse the area of infarct in the first few hours 
are crucial to limiting the infarct size.  Thrombolytic therapy (such as streptokinase) 
and antiplatelet therapy (aspirin) are administered as soon as MI is diagnosed [10]. 
Primary angioplasty (direct balloon ‘unblocking’ of the coronary artery) for acute 
myocardial infarction is now becoming the first line treatment, it has been 
demonstrated to halve short-term mortality in some randomised clinical trials, 
although primary angioplasty must be performed within hours to have the most 
benefit [11, 12].  In the long term, patients are prescribed beta-blockers to inhibit 
beta-adrenergic stimulation which slows heart rate, lowers systemic blood pressure 
and reduces myocardial contractility thereby reducing the risk of ventricular 
arrhythmias [13, 14].  Angiotensin converting enzyme (ACE) inhibitors are also 
prescribed to inhibit fibrosis of the infarcted myocardium; part of the remodeling 
processes that can harm the contractile properties of the repaired myocardium and 
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reduce the haemodynamic changes due to ACE up-regulation [14-16].   Antiplatelet 
therapy (aspirin or clopidogrel) as well as lipid lowering statins can also be included 
in long term pharmacological interventions to reduce the potential for recurring MI 
[14].  Despite modern medical advances there is still a need to further reduce the 
mortality associated with MI.  Efforts are being made to reduce the time from the 
onset of ischemia to the point of reperfusion, but a therapeutic strategy which limits 
I/R injury and which could be given at the onset of reperfusion may have a significant 
impact in improving prognosis. 
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1.2 The promise of autologous progenitor cells 
 
Recovery from MI depends on both the extent of the tissue area affected and the 
duration of ischemia.  The ability of the myocardium to regenerate itself after damage 
is limited and after loss of cells due to infarct or other damage, remaining 
cardiomyocyte cells undergo hypertrophy to compensate [17].  It is now understood 
that the myocardium does have some ability for myocyte proliferation that may 
increase after cardiac damage [18].  This proliferation may be due to a limited 
resident progenitor cell population [19].  It has been suggested that these cardiac stem 
cells (CSC) reside in small niches and may differentiate into cardiomyocytes, smooth 
muscle cells and endothelial cells, making the heart a self renewing organ [20].  A 
recent study aimed to quantify cardiomyocyte renewal and their findings suggest that 
a 1% annual turnover at 25 years of age slows to 0.45% at age 75.  This was 
calculated to equate to ~45% of cardiomyocytes that would have been replaced over 
an entire lifespan [21].  However this regenerative capacity appears to be hindered by 
injury as all myocardial cell types die in the area of infarct including the CSCs [20].  
MI occurs more commonly in older people, for whom cardiac regeneration rates may 
have slowed, possibly in part due to lower CSC reserves, which would further reduce 
the hearts ability to renew large areas of damage without intervention [21].   
 
The natural mechanisms of myocyte hypertrophy accompanied by increased fibrosis 
and scar formation are often not sufficient to maintain functional capacity of the 
myocardium after damage and may even be detrimental in the long term; the 
prognosis associated with damage to the heart from MI and hypertrophy is poor.  
Therapeutic methods that either protect myocytes from I/R induced cell death or 
encourage the homing and proliferation of resident progenitor cells or other 
circulating stem cells that could re-populate the myocardium would be an ideal 
solution for cardiac repair.  
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1.2.1 Adult derived stem cells 
 
There are several classifications of stem cells which have the ability to self renew and 
go on to form several different types of fully differentiated cells, see figure 1.2.   
Stem cells can be derived from embryonic and adult sources and are defined by the 
range of cells they can differentiate into.  Totipotent cells can form all the cell types 
of the body and the placenta, whereas pluripotent cells can form all cell types of the 
body but not the placenta. Both of these stem cell classifications are of embryonic 
sources [22].  Embryonic stem cells generate the greatest range of potential cell types 
and there are several studies showing these cells improve myocardial repair and 
function in mouse and rat models of MI [23-25].  The risks of immunorejection and 
ethical concerns however, lean towards autologous adult stem cells as a preferable 
option.  Multipotent cells are obtained from a variety of adult tissues and are capable 
of differentiating into a limited range of cell types and their location appears to be an 
important factor in determining which cell types they can differentiate into [26].   
 
Figure 1.2 Stem cell classifications Figure courtesy of Professor Mathur 
 
TOTIPOTENT
PLURIPOTENT
ECTODERM ENDODERM MESODERM MULTIPOTENT
PROGENITOR CELL PROGENITOR CELL PROGENITOR CELL
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One main source of autologous adult stem cells is the bone marrow.  Bone marrow 
cells include a range of different cell types including mesenchymal stem cells (MSCs) 
and haematopoietic stem cells (HSCs).   HSCs were originally thought to only give 
rise to red and white blood cells and platelets, whereas MSCs were progenitor cells 
for muscle, connective tissue and other mesenchymal derived cell types.  However 
some experimental data has been interpreted as indicating that both of these cell types 
may have a much wider potential and may be coerced into forming cardiomyocytes, 
fibroblasts and indeed endothelial cells [27].   
 
1.2.2 The evidence  
 
1.2.2.1 Animal models of bone marrow cell therapy for MI 
A frequently used ‘in-vivo’ model for studying MI is a rat model that has undergone 
left anterior descending (LAD) coronary artery ligation to induce cardiac ischemia. 
Similar models using mice are also popular due to the ability to perform experiments 
on transgenic animals that enable the functions of certain genes in relation to I/R to be 
assessed [28].  Other ‘in-vivo’ models such as canine and porcine infarct models are 
also useful, especially in certain aspects of stem cell research such as studying cell 
delivery methods that can be more directly applied to humans [29-31]. 
 
The first published evidence that bone marrow derived cells could invoke improved 
cardiac repair and function post-MI was performed in a rat model of myocardial 
injury.  Bone marrow cells (BMCs) were isolated using a percoll gradient and either 
used fresh or after culturing for 7 days.  Some cultures were treated with either 
transforming growth factor β (TGF-) or 5-azacytidine (5-aza) added on the third day 
for 24 hours.   The fresh and cultured cells were also phenotypically characterised by 
immunohistochemical staining for cardiac specific troponin I and myosin heavy chain 
(MHC).   Following on from this, myocardial scarring was introduced by cryo-injury 
in adult Sprague-Dawley rats and after three weeks either freshly prepared BMSCs, 
cultured BMSCs, BMSCs cultured with 5-aza or cell culture medium were injected 
directly onto the scar.  During culture of the BMCs it was noted that the cells 
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expressed cardiac specific proteins such as troponin I and MHC, and formed 
myotubules and this only occurred when the cells were treated with 5-aza.  It was also 
noted that hematopoietic cells were eliminated during culturing process.  Five weeks 
after transplantation, the scar area was smaller for the 5-aza group and these animals 
had thickened left ventricles, which translated into improved ventricular function as 
measured by peak systolic pressure.  All scars transplanted with cells had increased 
angiogenesis as measured by capillary density.  To identify the BMSCs within the 
scar, a further set of experiments were performed in which transplanted cells had 
been labelled with bromodeoxyuridine [BrdU].   Histological examination of samples 
collected after 5 weeks revealed BrdU positive cells within the scar tissue and indeed 
within some newly formed capillary walls [32].  This set of early experiments 
suggested that both the freshly prepared BMSCs and cultured BMSCs have the ability 
to either induce or form new vasculature in scarred myocardium.  It was suggested 
that only cells that have been induced to differentiate into a cardiac-like phenotype by 
5-aza could cause an increase in muscle mass sufficient to regain function.  
 
Data from a study by Orlic et al (2001) was also interpreted to show that the BMCs 
transplanted 3-5 hours post-surgery were able to home and transdifferentiate in the 
infarct zone to replace dead myocytes [33].  They reported that BMCs, characterised 
as not expressing any differentiation markers (lin-) but expressing the receptor for 
stem cell factor (c-kit), when transplanted into the edge of the infarcted region of a 
mouse infarct model, generate new myocardial cells to replace the dead cells.  
Confirmation that the new myocardium was derived from the cell therapy came from 
an experiment where BMCs derived from male transgenic mice expressing enhanced 
green fluorescent protein (EGFP) were introduced into infarcted myocardium of 
female mice; subsequent immuno-staining for the Y chromosome histocompatibility 
antigen as well as expression of EGFP showed the donor cells had integrated into the 
female myocardium.  The new cells were also found to express cardiac proteins 
common to fully competent myocardial cells such as myocyte enhancing factor 2 
(MEF2) and the transcription factor GATA-4.   There was however only a 40% 
success rate in the survival of the mice in this study which was thought to be due to 
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damage to the myocardium incurred during the procedure of injecting the BMCs into 
beating myocardium; also it was proposed that the female mice may have rejected the 
BMCs from male mice [33].    
 
To get a more quantitative assessment for the migration and homing abilities of 
BMSCs, Sheik et al (2007) extracted bone marrow mononuclear cells (BMMNCs) 
from male transgenic mice expressing both firefly luciferase and EGFP and injected 
these (three hours post-surgery) into the tail vein of either sham operated or 
ischemia/reperfusion female mice.  Cell migration and survival was recorded using 
bioluminescence imaging for 4 weeks.  The BMMNCs were found in lung, spleen 
and femurs in both groups and the I/R group had much stronger fluorescent signals in 
the heart within the first 10 days [34].  Echocardiography showed a trend towards 
improved left ventricular fractional shortening (LVEF) which however was not 
statistically significant. This work did show that the cells were capable of homing 
even when introduced into the tail vein rather than directly transplanted to the heart.    
 
The higher energetic demands of the damaged and hypertrophied myocardium can 
outstrip the ability of repaired vasculature in the damaged section of myocardium 
which leads to further cell loss and fibrosis.  In 2001 Kocher et al studied the ability 
of different populations of BMCs to produce new vasculature as well as new 
myocardial cells.  Human derived BMCs were separated into MSC (CD34-) and HSC 
(CD34+) fractions.  The CD34+ fraction was then assessed for co-expression of 
CD117 (stem cell factor receptor), and vascular endothelial growth factor receptor-2 
(VEGFR-2).  A population of cells with co-expression of these factors was noted to 
have phenotypic characteristics of mature vascular endothelial cells and a further 
population of cells had characteristics of endothelial progenitor cells.  CD34+ cells 
were then introduced intravenously to mice post-MI.   These mice were found to have 
much improved neoangiogenesis in the infarct zone and in its periphery compared to 
control animals and compared to those treated with CD34- cells [35].   
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Toma and colleagues (2002) studied human bone marrow derived mesenchymal stem 
cells (hMSCs), and labelled them using a -galactosidase reporter gene (LacZ) 
expressing non-replicating virus.  These cells (500,000-1 million) were then 
transplanted directly into the left ventricle of immunodeficient CB17 SCID/beige 
male mice and animals were sacrificed for histological analysis at 30 minutes, 4, 14, 
21, 30 and 60 days after transplantation.   Interestingly after 4 days the majority of -
gal+ cells were found in the spleen, liver and lungs.  Up to 4 days, an estimated 
~2200 -gal+ cells remained in the heart, although the number seen decreased from 
this point.  The fact these cells had dispersed indicated a strong capability for 
migration.  Desmin was not expressed in -gal+ cells after 4 days but was present in 
all the cells after 60 days, as was cardiac-specific troponin T, -MHC, α-actinin and 
phospholamban.  The cells were also found to have the structural characteristics of 
cardiomyocytes [36].   In a later study in which bone marrow derived MSCs from 
transgenic female mice expressing GFP were co-cultured with rat embryonic 
cardiomyocytes derived from male embryos.   The MSCs did indeed express cardiac 
specific genes, and these were detected with mouse specific primers, but they also 
expressed collagen type IV (stromal cell marker absent in embryonic 
cardiomyocytes).  Fusion was also investigated, by looking for cells with XXY 
chromosomes, and only a very low rate of this phenomenon was measured.  The 
electrophysiological properties of the ‘differentiated’ MSCs were measured to look at 
the functional profile of these cell and these studies showed that the MSCs did not 
display spontaneous rhythmic activity and they were unable to produce action 
potentials [37].  A further study co-culturing HSCs and MSC with neonatal 
cardiomyocytes and differentiating factors were unable to produce evidence of 
transdifferentiation [38].  
 
The studies described so far have indicated that bone marrow derived cells may home 
in on injured myocardium and some may in fact survive within the host myocardium. 
The introduction of these cells is also associated with an increased number of 
surviving, functioning myocytes and a corresponding improvement in cardiac 
function.  However, to date there has been no definitive evidence that the introduced 
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cells in fact transdifferentiate and replace damaged myocardial cells.  Studies 
measuring the expression of cardiac specific proteins in transplanted or co-cultured 
BMCs may in fact be measuring proteins taken-up by these cells rather than 
expressed by these cells.  In the case of cells observed to have some physiological 
features in common with cardiomyocytes, they may still be unable to integrate and 
undergo spontaneous rhythmic contraction in unison with the surrounding 
myocardium [36, 37]. Indeed the number of BMCs homing and surviving within the 
damaged myocardium apear few.  Studies in animal models trying to elucidate the 
best methods for introducing cells, the best type of cell and indeed the mechanism by 
which the cells might work are ongoing. 
 
1.2.2.2 Human trials of bone marrow cell therapy for MI 
Animal models are a useful research tool but relating the results from ‘in-vivo’ 
studies to a clinical setting involves caution as there are inter species differences in 
structural proteins and ion exchange proteins essential for contraction [39, 40].  In 
addition, animal models have a much reduced level of genetic variation, as they often 
involve inbred strains, and although this reduces confounding factors in an 
experiment, it does not necessarily reflect the human population.  Experimental 
variation is also tightly controlled to levels not always possible in the clinical 
situation, for example, the time from onset of infarct to the application of therapy.   
The data from animal models suggests BMSCs may be an important therapeutic 
approach for MI.  Finally in all of the various animal models of MI the background of 
inflammatory atherosclerotic disease inherent in most human subjects is lacking.  
Therefore several studies have been initiated to address whether the application of 
autologous bone marrow cell therapy in humans would incur the same beneficial 
outcome that had been observed in animal models.   
 
Stamm et al (2003) performed one of the earliest exploratory experiments in humans.   
Six patients who had acute MI between 10 days and 3 months before admission for a 
coronary artery bypass graft (CABG) procedure were recruited into a small clinical 
trial.  BMC transplantation took place during the CABG procedure, with AC133+ 
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cells being injected into the infarct border.  Improved LVEF and diastolic function 
were observed in four of the six recruited patients 2 weeks post-surgery and 
improvements in perfusion of the infarct were seen in five patients.  Four patients had 
further complications following surgery, including supraventricular arrhythmia, and 
two patients had pericardial effusion (fluid around the heart) but a connection 
between these events and the cell therapy was difficult to ascertain [41].  These 
results are promising but without a control group, it is difficult to draw conclusions 
from this very small study. 
 
Another early clinical trial in humans was performed by Strauer et al (2002), it 
included 20 patients with MI. All patients received standard treatment with 10 also 
receiving ficoll-seperated BMCs using a balloon catheter 5 to 9 days after onset of 
MI.  Follow-up consisted of left ventriculography and coronary angiography after 3 
months.  The percentage infarct region was found to be reduced significantly in the 
cell therapy group compared to control, and improvements in wall movement were 
also recorded.  LVEF improved slightly but non-significantly in both groups. Other 
measurements of cardiac function e.g. stroke volume were also found to be improved 
in the cell treatment group [42].    
 
These early studies indicated this therapeutic approach could yield positive outcomes 
in humans but further investigation into the behaviour (homing and survival) of the 
BMCs within patients was needed.  Penicka et al (2007) tracked myocardially 
transplanted BMCs for 24 hours using radioisotope cell labelling in two groups of 
patients, 5 with acute MI (AMI) and 5 with chronic MI.  Myocardial radioactivity 
was observed in all acute patients and in all but one of the chronic patients after 2 
hours.  At 20 hours radioactivity was only detected in three of the acute patients.  
Similar to the animal studies, strong signals were also detected in the spleen, liver and 
lungs at 2 and 20 hours [43].   The data shows the homing abilities of BMCs and this 
may be enhanced in acute MI.   
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There have been many larger clinical trials in the last few years looking at the 
benefits of cell based therapy for cardiac ischemia.  Several gold-standard 
randomised controlled trials (RCT) have been carried out looking at BMC therapy in 
AMI with large enough cohorts to gain a more clear idea of the benefits of the 
therapy.   One such trial was the BOne marrOw transfer to enhance ST-elevation 
infarct regeneration (BOOST) Trial [44].  In this trial 60 AMI patients were 
randomised to receive either best care or unselected bone marrow cell transplant ~5 
days post percutaneous intervention (PCI).  All patients had baseline MRI and further 
scans at 6 and 18 months after discharge. The primary endpoint was LVEF change 
after 6 and 18 months follow up compared to baseline.  The LVEF at six months was 
significantly more improved in the treatment group than control, but at 18 months 
there was no significant difference between the improvements made in both groups 
[44].   
 
Lunde et al (2006) randomised 100 patients to receive either ficoll-separated BMCs 6 
days post-PCI or control.  The control arm did not have the bone marrow aspiration 
procedure or sham injection.  Single-photon-emission computed tomography 
(SPECT) and echocardiography were performed at baseline and at six months follow 
up.  MRI was also performed.  No statistically significant differences were found in 
LVEF, end-diastolic volume or infarct size at six months [45]. 
 
In a larger multi-centre trial, 204 AMI patients were randomised to receive either 
placebo medium or cell transplant with ficoll-separated BMCs ~4 days post PCI..  All 
patients had bone marrow cells aspirated.  Angiograms were performed immediately 
before the procedure and at 4 month follow-up. The primary end-point in this study 
was the absolute change in LVEF at 4 months compared to baseline.  In total 94 
controls and 92 treatment angiograms were used for quantitative analysis.  LVEF was 
found to be significantly higher (6%) in the treatment arm compared to control even 
after adjustments.  Adverse clinical outcomes were also recorded at 4 months and at 1 
year (for 168 patients).  This data revealed no significant difference between the 
groups in any of the events independently (death, recurring MI, re-hospitalisation for 
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heart failure), but the incidence of the combined events was significantly lower in the 
treatment group [46].   
 
A further study published alongside the two previously mentioned aimed to look at 
intracoronary infusion of enriched mononuclear cell preparations from either bone 
marrow or circulating blood in 75 patients.  The patients had myocardial infarction at 
least three months prior to entry in the trial.  The primary end points were  LVEF and 
function of the LV in the area of infarct, both measured by angiography.  After three 
months follow up, both primary end points were significantly improved in only the 
bone marrow cell preparations (3% in LVEF).  In a cross over study, some of the 
patients were assigned to receive a different treatment at the time of the 3 month 
follow-up and again BMC treatment caused significant improvements in LVEF in 
patients who previously received either control or circulating blood cell preparation.  
Only 35 of the patients underwent MRI to assess infarct size, and reductions were not 
seen in any of the study groups [47].  The composition of the cell preparations were 
not fully characterised, therefore differences in functional improvement between the 
two cell preparations may be due to differences in cell composition. 
 
Janssens et al (2006) randomised 67 AMI patients to receive either placebo medium 
or cell transplant with ficoll-seperated BMCs within 24 hours of PCI.  Again, all 
patients had bone marrow cells aspirated.  MRI was performed at baseline and at 4 
months follow-up.  Cell therapy was not found to significantly improve LVEF in this 
study, however a reduction in infarct volume was recorded.  Microvascular 
obstruction was also assessed in this study and the authors suggest that both LVEF 
and infarct size may be more improved in patients without microvascular obstruction, 
although the study was not powered to perform these calculations  [48]. 
 
A recent review of published trial data found approximately 60 on-going trials, many 
of these were not RCT design, used cultured cells, or were not using patients with 
acute MI and therefore only 13 trials were assessed [49].  They found that none of the 
studies were large enough to demonstrate whether BMC treatment had an effect on 
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morbidity and mortality, indeed no significant differences were detected between 
treatment and control arms.  Trends appeared to show the treatment was not 
associated with an increase in adverse events and there may be a short term benefit to 
LVEF [49].  A large amount of heterogeneity between study design and outcome 
measures make this ‘meta’-style analysis difficult to interpret.  In general the results 
from human studies have been much less striking than what was observed in the 
animal models, but a generally positive trend has been attributed to bone marrow cell 
based therapy in two separate meta-analyses [49, 50].   
 
The limitations within the clinical studies performed so far include differences in 
preparation of the cells to be injected (many studies using unselected heterogenous 
cell populations rather than purified HSCs); differences in the timing of cell 
transplantation (hours to months post PCI); and limited long-term outcome data to 
link any small improvements in LVEF with clinical benefit [51, 52].   The effect of 
cell infusion may be different in early treatment time points (hours or a few days) 
which may limit infarct size and lead to subsequent improvement in functional 
recovery compared to later time points (weeks to months) which don’t reduce infarct 
size but may improve function through a different mechanism.  Recommendations for 
cell type, method of introduction and timing of introducing the cells as well as the 
mechanism of benefit are yet to be determined and further data from animal studies 
may enable better design of future clinical trials yielding more definitive results.   
 
1.2.3 Mechanism 
 
Initially transplanted autologous bone marrow derived cells were thought to 
differentiate and replace dead cells within the infarct, replacing myocytes 
(cardiogenesis) and vasculature (angiogenesis), however, data from animal models 
have shown that only a limited amount of transdifferentiation of BMCs occurs, if at 
all.  Evidence suggests not enough of the transplanted cells survive within the infarct 
[53].  However, many progenitor cells secrete growth factors promoting vascular 
generation (e.g. vascular endothelial growth factor, VEGF) [54].  One of the strongest 
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mechanistic theories is that the BMCs are acting through a paracrine mechanism, 
whereby signals are secreted by the BMCs after they have homed-in on the site of 
injury, thereby inducing cell survival and angiogenesis.   
 
What is this paracrine signal, from which constituent of the bone marrow cell 
preparation dos this signal originate, and what is the target pathway or pathways of 
this signal?  Clues about the details of the mechanism by which the BMCs work may 
be taken from looking at what we already know about other triggers of 
cardioprotection.  Ischemic preconditioning (IPC) results in a striking level of 
cardioprotection from I/R injury and there have been decades of research into the 
triggers, mediating signalling pathways and potential end effectors of this 
phenomenon.   
 
1.2.3.1 IPC and cardioprotection 
IPC is a phenomenon in which one or more brief periods of non-lethal ischemia 
preceding a major infarct provides a significant level of protection to the myocardium 
downstream of the infarct.  Aside from prompt reperfusion, IPC is the most effective 
intervention at reducing resultant infarct size, although without eventual reperfusion, 
the protection from IPC will be lost [55]. This protection appears to have two phases 
(windows) of protection, the first window is up to ~2 hours after preconditioning and 
the second window is days after preconditioning [56]. Some level of cardioprotection 
can also be initiated by causing brief periods of ischemia in a distal part of the body, 
termed remote preconditioning [57].  The discovery of IPC in 1986 [58] has provoked 
a huge amount of research and animal models have been used extensively to look at 
what mechanisms may be involved.   
 
In terms of mechanism, the cardioprotective state is from 10 minutes after IPC and 
therefore suggests modification of pre-existing proteins may be involved [56].  The 
trigger is thought to be mediated through Gi-coupled receptors, with adenosine, 
bradykinin, norepinephrine and opioids all released by the heart during the 
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preconditioning stimulus and binding to these receptors with an additive effect [59], 
see Figure 1.3 overleaf. 
 
The pathways that are downstream from the receptors which carry the 
cardioprotection message (mediators) are known to include protein kinase C (PKC).  
The evidence for PKC involvement is strong, blockade of PKC abolished 
cardioprotection triggered by adenosine, bradykinin and opioids [60-62].  Adenosine 
appears to directly activate PKC, whereas bradykinin and opoids activate 
phosphatidylinositol 3-OH kinase (Pi3k)/Akt pathway and then diverge on PKC 
further downstream [63].  Studies using wortmannin, a Pi3k inhibitor, have revealed 
the role of the Pi3k/Akt pathway in IPC and have shown that it acts upstream of PKC 
activation [64].  Rabbit cardiomyocytes either treated with Akt inhibitor, or rendered 
dominant negative for Akt show no reactive oxygen species (ROS) production in 
response to acetylcholine or bradykinin treatment, revealing an important mediatory 
role for Akt [65].   The same group also confirmed the involvement of nitric oxide 
(NO) and its place downstream of Akt in the signalling cascade.  Guanylyl cyclase 
and protein kinase G (PKG) are also now thought to be downstream from NO [63], 
see Figure 1.3.  
 
Free radicals are also thought to be involved in the cardioprotective response, 
possibly by directly activating protective protein kinases.  Diazoxide mediated 
protection can be blocked by a free radical scavengers N-acetylcysteine and N-2-
(mercaptopropionyl)glycine (MPG) [66].  It has also been shown that there is 
increased radical production from mitochondria triggered by ischemia [67].   
 
Mitochondrial ATP sensitive potassium channels (mito-KATP channels) are thought to 
play an important role in IPC mediated cardioprotection, but how they are involved is 
only recently becoming clear.  A theory put forward by Pain et al (2000) is that 
receptor occupancy leads to mito-KATP channel opening, causing ROS production and 
these free radicals activate downstream kinases [68].  In fact ROS is now known to 
activate PKC.  Protein kinase G (PKG) has been shown to be capable of eliciting the 
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opening of mito-KATP channel channels, but is unlikely to be the final step in this 
signalling cascade, the intermediates between PKG and mito-KATP channel opening 
are as yet unknown [69].  
 
Although some of the survival signals have been elucidated, final mechanisms for 
cardioprotection are still unknown. One further proposition is that the inhibition of 
the mitochondrial permeability transition pore (mPTP) opening plays an important 
role in IPC mediated myocardial protection, see Figure 1.3 [70, 71].   The opening of 
mPTP is thought to induce mitochondrial swelling and rupture, releasing apoptotic 
agents into the cytoplasm.   
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Figure 1.3 Pathways thought to be involved in ischemic preconditioning  Protein 
kinase B (Akt), epidermal growth factor receptor (EGFR), extracellular signal-
regulated kinase (ERK), guanyly cyclase (GC), Gi protein coupled receptor (Gi), 
glycogen synthase kinase 3 beta (GSK-3β), mitochondrial permeability transition 
pore (mPTP), nitric oxide synthase (NOS), protein kinase C (PKC), protein kinase G 
(PKG), phospholipase C (PLC), phospholipase D (PLD), phosphatidylinositol 3-OH 
kinase (Pi3k), reactive oxygen species (ROS).  Adapted from Downey et al 2007 
[63]. 
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Glycogen synthase kinase 3β (GSK-3β) has been shown to inhibit mPTP opening 
[72].  GSK-3β, unusually, exists in its active conformation, and phosphorylation 
causes it to be inactivated.  PKC can directly phosphorylate GSK-3β, or can initiate 
phosphorylation through ERK and Pi3k [63].   Many other potential candidates have 
been suggested (ROS, Pi3k/Akt, PKC, ERK, mito KATP), work is ongoing to elucidate 
the exact mechanism of mPTP opening [73].  Whether mPTP opening is the end 
effector of the ‘intrinsic’ mitochondrial apoptosis pathway, which involves the B-cell 
lymphoma protein 2 (BCL-2) protein family is controversial [74]. 
 
Page 38 
The mechanistic pathways behind the late phase of cardioprotection afforded by 
preconditioning appear to be similar to those involved in early phase.  Studies using 
various inhibitors have also implicated important roles for COX-2, both endothelial 
and inducible nitric oxide (NO), and manganese superoxide dismutase (MnSOD) 
[56].  
 
Elucidating cardioprotective mechanisms may enable high risk patients to be treated 
with pharmacological agents which trigger activation of these pathways possibly 
through binding to the Gi-coupled receptors.  A carefully planned drug regimen 
would need to be used to maintain a cardioprotective response ready for a potential 
MI, the exact timing of which will be impossible to predict, but also to prevent over-
agonising and dampening receptor response [56].   Such an approach would only be 
suitable for very high risk patients.  The best strategy at present for MI patients in 
general is rapid reperfusion.  But there is potential for an additional intervention 
whereby autologous cells or a pharmacological mimic thereof may be administered in 
conjunction with reperfusion to enhance recovery. 
 
1.2.3.2 Paracrine mechanism of  BMMNCs 
Nakanishi et al (2008) hypothesised that growth factors and cytokines secreted by 
bone marrow derived MSCs may be responsible for activating resident stem cell 
populations in a paracrine manner.  They found that not only did MSC conditioned 
medium promote the proliferation of isolated cardiac stem cells (CSCs) ‘in-vitro’, but 
also protected them from serum starvation-induced apoptosis. They also 
demonstrated that conditioned medium also led to increased Akt phosphorylation in 
the CSCs [75].  This study provided evidence that secreted factors may be involved, 
and also suggests Akt may be involved in bone marrow cell mediated protection. 
 
Kubal et al (2006) performed a detailed ‘ex-vivo’ study using right atrial muscle 
slices from patients undergoing elective surgery.  The tissue slices were subjected to 
90 minutes simulated ischemia followed by 120 minutes reoxygenation.  The tissue 
slices were either co-incubated with BMMNCs (obtained from the same patients), 
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BMMNCs plus a PKC inhibitor, PKC inhibitor alone or neither.  The same set of 
experiments were carried out using a p38 MAPK inhibitor. Tissue injury as measured 
by creatine kinase release into the media was markedly reduced in the BMMNC 
treatment group, but the effects were countered by the PKC inhibitor.  Cell necrosis 
and apoptosis were also much reduced in the BMMNC group and again these affects 
were ameliorated by the presence of the PKC inhibitor.  The second set of 
experiments using the p38 MAPK inhibitor showed the same results [76].  This 
indicated that the BMMNCs might be working through PKC, p38 MAPK kinase 
signalling pathways, potentially indicating an overlap in the protective signal 
mediators involved in IPC.  
 
Candidates, including  interleukin-8 (IL-8), transforming growth factor β (TGF-β) 
and hepatocyte growth factor (HGF) among many others have evidence for 
involvement in mobilisation, homing, proliferation and survival, however, the 
mechanisms by which these processes occur in BMMNC mediated restoration of 
ischemic myocardium are not yet fully understood and therefore the design of 
therapeutic approaches cannot be refined [77].   
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1.3 Global protein and gene expression profiling 
 
Proteomics and transcriptomics are terms and indeed fields with fairly recent origins.  
The suffix ‘omic’ refers to the totality of the subject.  Proteomic techniques aim to 
study the entire proteome of an organism, tissue, or cell at a particular point in time 
under particular conditions i.e. measure the presence of all of the proteins and their 
modifications [78].  Transcriptomics aims to look at all of the gene expression 
activity present in an organism, tissue, or cell at a particular point in time under 
particular conditions.  In reality, the whole picture is currently beyond the abilities of 
current analysis techniques, particularly for the proteome [79].  Although gene chip 
technology is enabling us to get a much more complete picture of gene expression in 
a sample, currently we are only able to visualise at best ~1000 different proteins in a 
2DE analysis, perhaps twice that using a shotgun MS based proteomic method [80].  
As ~12,000 different gene products are estimated to be expressed in a mammalian 
cell, only 8-16% of the proteome can be visualised at best [81].  The most common 
use of proteomic and transcriptomics is to perform an exercise in ‘spot-the-
difference’ aimed at looking for differences between samples that reveal system-wide 
patterns or individual candidates that can act as biomarkers for diagnostic purposes or 
can indicate mechanism and thereby leading to potential new therapeutic targets.   
The results of such experiments will inform more targeted follow-up studies. 
 
1.3.1 Proteomics 
 
One of the most commonly applied proteomic methods is two-dimensional 
electrophoresis (2DE), which separates the proteins in a sample to enable 
visualisation.  Proteins are separated according to charge (isoelectric point, pI) in the 
first dimension, then by mass (relative molecular mass, Mr) in the second.  This 
method for visualisation allows differences between groups of samples to be detected 
by observing differences in the distribution and intensity of protein spots on the 2D 
gel after staining [82].  Identification of the proteins can be obtained using high 
performance liquid chromatography coupled to tandem mass spectrometry (MS/MS) 
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(LC-MS/MS) [83].  Information on post-translational modifications (PTMs) can be 
both observed in the 2DE patterns and further characterised using LC-MS/MS [84].   
 
1.3.1.1 Proteomics and CVD 
2DE has been used extensively for studying cardiovascular pathology, especially 
diseases of cardiac muscle which often result in cardiac failure.  The technique is 
amenable to looking at changes at the protein level which accompany the structural 
changes at a cellular level.  Such studies into cardiomyopathy and left ventricular 
hypertrophy (LVH) have been successful at finding alterations in 
cytoskeletal/contractile proteins and proteins involved in mitochondrial energy 
production which correlate with contractile dysfunction, and alterations in myocardial 
energetics which accompanies this form of cardiac remodelling [85].  The majority of 
2DE studies to date have been global scale ‘fishing expeditions’ looking for 
differences that may lead to clues relating to the mechanisms of disease onset and 
progression.  2DE has been used for a global comparative proteomic comparison of 
disease vs. non-disease in an animal model of dilated cardiomyopathy (DCM) [86]. 
The findings of this comparison led to a more targeted study of the ubiquitin 
proteasome system in human DCM myocardial samples. This revealed a large 
increase in ubiquitination of many proteins within the DCM hearts compared to 
ischemic heart disease and healthy (unused) donor tissue controls [87]. 
 
The proteome of any particular tissue type or even a homogenous cell population is a 
complex group of proteins which are constantly being processed, modified and 
degraded.   As a full picture of the entire proteome is currently unobtainable, many 
studies look at ‘sub-proteomes’ which may be based on cellular compartmentalisation 
(cytosolic, mitochondrial, membrane or nuclear extracts) or indeed on some other 
categorisation.  The previously mentioned study separated ubiquitinated proteins for 
comparison by 2DE, another study looking at PKC kinase cascade signalling in IPC 
created sub-proteomes by co-immunoprecipitating PKCε complexes using PKCε 
monoclonal antibodies.  This sub-proteome could then be further studied using 1D 
and 2DE as well as western blotting. These functional proteomic techniques led to the 
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discovery that PKCε binds and phosphorylates a large number of proteins involved in 
a diverse array of functions from stress response to regulation of transcription and 
translation [88].    
 
The 2DE approach has also been employed to look at ischemic vs. non ischemic 
myocardium in animal models and the approach has successfully found patterns of 
protein alterations in sarcomeric proteins, proteins involved in cellular energy 
metabolism and proteins of the mitochondrial respiration chain.  Some of these 
studies have also compared the proteome after cardioprotective interventions such as 
IPC and the use of free-radical scavengers.  See Table 1.1 for a list of proteins found 
to be altered in these studies.    
 
2DE has been used to compare protein profiles from an I/R model using isolated 
rabbit hearts.   Myocardial samples were obtained from two I/R injured groups, 
stunned (15 minutes of ischemia followed by 60 minutes reperfusion) and infarcted 
(60 minutes ischemia followed by 60 minutes of reperfusion) and a control group 
[89].  They identified many affected proteins which were categorised into 
cytoskeletal/sacomeric proteins, energy metabolism proteins, redox regulation 
proteins (NADH oxidoreductase, cytochrome c oxidate, perodiredoxin and 
superoxide dismutase), stress response and others such as voltage-dependant anion 
channel 1 (VDAC1), fatty acid binding protein 3 and calcium independent 
phospholipase A2.   Many of the proteins identified in this study were seen to be 
modified by ischemia, rather than being simply up-or down-regulated.   Examples 
were VDAC1 in which a spot that appeared to be the native form decreased in both 
the stunned and infarcted myocardial samples and another spot (also VDAC1) which 
was of a lower molecular mass increased in both models of ischemia.  There was also 
a significant decrease in the abundance of a spot identified as native Troponin T (pI 
5.5) in both stunned and infarcted myocardium and an increase in the abundance of a 
seemingly basic (pI 7) form of Troponin T in the infarcted samples.  The increased 
abundance of spots identified as myosin light chain 2 in the I/R injured samples also 
indicated cleavage of the native protein as both were smaller masses than the native 
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protein [89].  A follow up study looked at the proteome in the stunned I/R rabbit 
model with and without treatment with an oxygen free-radical scavenger, and 
discovered that therapy rectified some of the modifications in sarcomeric proteins 
caused by I/R injury, suggesting free radicals were responsible for sarcomeric 
damage and contractile dysfunction in stunned myocardium [90]. 
 
Table 1.1 Summary of proteins found to be altered in expression or modified in 
2DE comparative profiling experiments on animal models of I/R injury.  a = 
references in which this protein was found to alter in association with I/R injury 
compared to control; b = references in which this protein was found to alter in 
association with a cardioprotective intervention compared to no intervention; c = 
references in which this protein was found to alter in association with ischemia only 
(no reperfusion). References: 1 =[89]; 2 =[90]; 3 =[91]; 4 =[92];  5 =[93].  
 
 
Protein name a b c
2-oxoglutarate dehydrogenase 3 3
3 Hydroxybutyrate dehydroganase 3 3
3-Mercaptopryuvare sulfurtransferase 5
Actin alpha 1, 3 3
Actinin alpha 2 1, 2 2
Aldehyde dehydrogeanse 5
alpha B crystallin 1, 2 2
ATP Synthase alpha 1, 2 2 5
ATP Synthase D 1, 2 2
ATP Synthase delta 1, 2, 5 2
ATP synthase F0 complex 3 3
beta enolase 1, 2 2
Calcium independent phospholipase A2 1
Creatine kinase B 1, 2 2
Creatine kinase M 1, 2, 4 2, 4
Creatine kinase, Sarcomeric 1
Cytochrome c oxidase 1, 2 2
Dehydrogenase /Reductase SDR Family 2 2
Delta(3,5)-delta(2,4)-dienoyl-CoA isomerase 5
Dihydrolipoamide dehydrogenase 1 1
DJ-1 protein 5 5
Enolase 1 alpha 5 5
Enoyl-CoA hydratase-like protein 3 3
Fatty acid binding protein 3 1
Glutathione S-Transferase Mu 2 2
Glyceraldehyde 3-phosphate-dehydrogenase 5
Reference(s)
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Table 1.1 continued 
 
 
Protein name a b c
Heat shock protein 20kDa 5
Heat shock protein 27kDa 1, 2 2
Heat shock protein 27kDa (phosphorylated) 2 2
Heat shock protein 70kDa 1, 2 2
Isocitrate dehydrogenase B 5
Isovaleryl coA dehydroganase 5
Lactate dehydrogenase 1 2 5
Lactate dehydrogenase, M subnit 2 2
Long chain acyl-CoA dehydrogenase 3 3
Malate dehydrogenase 3 3
Microfilin 3 3
Mitochondrial protein P1 precursor (chaperonin) 4 4
Myoglobin 1
Myosin H 5
Myosin light chain 1 5
Myosin light chain 2 1, 2 2
Myosin light chain 3 3 3
NADH dehydrogenase 3 3
NADH oxidoreductase 1, 2, 3 2, 3
Peroxiredoxin 2 1, 2 2
Peroxiredoxin 3 1, 2
Peroxiredoxin 6 1, 2, 5 2 5
Phosphoglycerate mutase 1
Prohibitin 3 3
Pyruvate dehydroganase 1, 3 3
Rieske ion sulphur protein 3
Skeletal LIM domain protein 2 1, 2 2
Superoxide dismutase 1, 2, 4 2, 4
Translation elongation factor 1, 3 3
Translationally controlled tumour protein 1 1, 2 2
Triose phosphate Isomerase 1, 2 2
Tropomyosin 3 3
Troponin C 1, 2 2
Troponin T 1, 4 4
Trypsinogen 11 2 2
Ubiquinol cytochrome c reductase 1 2 2 5
Voltage-dependant anion channel 1 1, 2 2
Voltage-dependant anion channel 2 3 3
Reference(s)
 
 
Another 2DE profiling study also using isolated rabbit hearts, they compared 
myocardial samples from control, I/R and IPC.  In this study the mitochondrial 
protein fraction was isolated for 2DE analysis.  Many proteins were found to be up- 
and down-regulated in I/R compared to control including; a reduction in TCA-cycle 
related proteins, an increase in the E1-beta subunit of pyruvate dehydrogenase, an 
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increase in NADH dehydrogenase (mitochondrial respiration chain, complex I), but a 
decrease in the rieske iron sulfur protein (mitochondrial respiration chain, complex 
III), a significant decrease in the expression of VDAC and a large increase in the 
expression of long chain acyl-CoA dehydrogenase.  Almost all of these proteins were 
returned to levels similar to control in the IPC group [91].   These results give a 
snapshot of mitochondrial behaviour in response to I/R injury and IPC-induced 
protection.     
 
An I/R model has also been created using isolated perfused rat hearts which were 
subjected to either: I/R, ischemia with no reperfusion, or control.  Several different 
times of ischemia (15, 25 and 30 minutes) were looked at in both I/R and ischemia 
only.  Protein was prepared from myocardial samples and from coronary effluents for 
2DE analysis.  The 2DE analysis revealed the majority of altered protein spots to be 
up-regulated in the ischemia group compared to control hearts after 25 minutes of 
ischemia; this effect was more pronounced for 30 minutes of ischemia.  In the I/R 
samples compared to control the majority of proteins were down-regulated.  There 
was also an increase in total protein concentration in effluent from I/R hearts 
compared to control.  Enolase and myosin light chain 1 were both down-regulated in 
I/R and both appeared alongside ATP synthase in increased concentrations in the 
effluent.  This study highlighted some of the individual proteins which are affected by 
I/R injury and also separated those which may specifically be up-regulated in 
ischemia from those alterations only seen once reperfusion ensues.   This data also 
suggests that firstly protein expression may be up-regulated during ischemia and that 
there may be a ‘flushing out’ of proteins from ischemic tissue occurring during 
reperfusion [93].  This possibly adds add an extra layer of complexity when 
interpreting the post I/R proteome.   
 
Other proteomic analyses of I/R in animal models have aimed to look at protein 
differences that may elucidate the mechanisms behind IPC. An investigation on 
PKCε’s mechanistic involvement in cardioprotection has been carried out using an 
array of proteomic techniques in concert with metabolomic analysis (profiling the 
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metabolome).  Using transgenic mice with cardiac specific expression of either active 
(AE) or dominant negative (DN) PKCε.  The AE mice exhibited innate PKCε 
dependant resistance to ischemic injury compared to wild type.  Difference in-gel 
electrophoresis (DIGE), a 2DE method in which Cye (cyanine) dyes are used to label 
two different samples to be electrophoresed on the same 2D gel, was used to look at 
the myocardial proteome of wild type, AE and DN mice.  This analysis revealed 
previously unknown PKCε-influenced alterations in cytosolic glucose and energy 
metabolism proteins and also a strong negative influence of PKCε inhibition on the 
pyruvate dehydrogenase complex [94].  The metabolic profiles obtained using nuclear 
magnetic resonance (NMR) showed discriminate differences between control AE and 
DN samples.  This group also looked at metabolic profiles in the transgenic mice vs. 
control within an I/R model (LAD coronary artery ligation) and found further 
evidence of an improved metabolic recovery in AE hearts [94].  This study provides 
further clues of the mechanisms relating to PKCε cardioprotection.  It was not shown 
whether the moderate restoration of myocardial energetics measured is secondary to 
some other preceding cardioprotective action of PCKε. 
 
1.3.2 Transcriptomics 
 
Transcriptomics is the study of gene expression, or the global analysis of mRNA 
within a sample. In cardiovascular disease, there have been many studies in 
cardiomyopathy and heart failure but there are only a limited number in MI [95].  
There are two main approaches for studying gene expression, one being the 
comparison of the global gene expression in treated vs. non-treated (or disease vs. 
non-disease), the other is to look at the effect of genetic manipulation on gene 
expression to explore the functionality of specific candidate genes.   
 
1.3.2.1 Transcriptomics and CVD 
Early experiments looking at gene expression in I/R injury were limited by 
technology and only measured a small number of pre-specified genes [96, 97].   
Expression of TNF-α, IL-1 and IL-6 within the infarct area and in surrounding non-
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infarct myocardium was measured 1, 8 and 20 weeks post surgery in a rat I/R model 
using quantitative polymerase chain reaction (QPCR).  Expression levels of all three 
genes increased in the infarct area and decreased thereafter to levels lower than seen 
in surrounding non-infarct myocardium [97].  A further study looking at early (3 
days) and late (21 days) gene expression changes, also in a rat I/R model, were 
measured using an RNase protection assay.   The proto-oncogene c-fos was found to 
have a large (10 fold) increase at 3 days and remained 3 fold up-regulated even at 21 
days.  Previously noted up-regulation in the fetal form of MHC (-MHC) was seen at 
3 days but returned to normal levels at 21 days.  Adult isoforms of Na-K ATPase 
decreased 5 fold at 3 days and again were returned to normal after 21 days [96].  
These studies were very limited, and only a handful of genes for which there was 
prior evidence for involvement were measured.  
 
Early cDNA microarrays enabled more global analysis of I/R influenced genes, but 
even these were limited to a few thousand.  This approach however led to the 
discovery of genes not previously known to be affected by MI {e.g. cardiac ankyrin 
repeat protein (CARP) transforming growth factor β – stimulated clone (TSC)-22}, 
and indeed produced large enough datasets to cluster the affected genes into 
functional groups (e.g. protein expression, metabolism, cell signalling and cell 
structure) giving a better overall picture of the biological processes underlying MI 
and LV remodelling [98].   
 
From the late 1990’s GeneChips were available from Affymetrix containing much 
larger numbers of transcripts, these have been used in several studies looking at I/R in 
rat models [99-101].  Simkhovich et al (2003) looked at gene expression changes in 
young (4 months) and old (25 months) rats after three brief 3 minute periods of 
ischemia with 5 minutes reperfusion in between.  The hearts were excised 24 hours 
after surgery and comparative gene expression analysis using Affymetrix U34A 
GeneChips was performed.  In the ischemic tissue of younger rats compared to non-
ischemic tissue, the majority of genes appeared to be down-regulated whereas many 
more up-regulated genes were found in the older rats [99].  Another study by the 
Page 48 
same team looked at gene expression changes initiated by brief ischemic episodes, to 
look for potentially protective gene expression profiles again using Affymetrix U34A 
GeneChips.  The samples included heart tissue from control, sham operated and 
ischemic as well as non-ischemic tissue from ischemia animals subjected to 20 mins 
ischemic followed by 4 hours reperfusion in 8-9 months old rats.  These 
investigations found several genes (many inflammation-associated) to be up-
regulated in non-ischemic tissue and sham operated tissue compared to control, 
possibly indicating some induction of gene expression related to operative stress.  
When comparing ischemic vs. non-ischemic tissue they found most of the altered 
genes were up-regulated including; heat shock proteins, activating transcription factor 
3 (Atf3), early growth response 1 (Egr1), vascular endothelial growth factor (Vegf), 
b-cell translocation gene 2 (Btg2) and growth arrest and DNA damage inducible 45 α 
(Gadd45α).  Atrial myosin light chain 1 and sulfontransferase hydroxysteroid gene 2 
(Sth2) were both found to be down-regulated [100].   The up-regulation of heat shock 
proteins, growth factors and other genes previously associated with inhibition of 
apoptosis, i.e Atf3, and were interpreted to indicate innate cardioprotective response.  
An increase in inflammation-associated genes, over and above those induced by 
surgery alone, was also noted.     
 
Affymetrix U34A GeneChips have also been used to study gene expression changes 
induced by IPC and preconditioning triggered through the use of volatile anesthetics 
(APC).   LV tissue was taken from animals after 110 minutes of isoflurane infusion 
(APC group), three 3 minute episodes of ischemia with 5 minutes reperfusion in 
between and 85 minutes reperfusion afterwards (IPC group), 110 minutes of no-flow 
ischemia (ischemia group) and a sham operated control group.   In the APC group 
~400 transcripts were altered by >2 fold, and these included an approximately equal 
number of up- and down-regulated genes compared to control, whereas ~290 
transcripts were altered in IPC and the vast majority were up-regulated compared to 
control.  Ischemia alone altered 78 transcripts including both up and down-regulated 
genes.  The overlap between these lists of altered transcripts were relatively small 
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consistent with the idea that they represent different cardioprotective mechanisms 
[101].   
 
All of the above studies show that comparative global gene-expression profiling can 
reveal clues regarding mechanisms of cardiac injury and protection in animal models.   
The same techniques have also been used to study the mechanism of BMSC-induced 
protection in I/R.  As c-kit positive bone marrow derived cells have been used in 
many of the animal models of bone marrow cell transplantation in MI, Ayach et al 
(2006) wanted to look at the importance of c-kit.  This group used the Affymetrix 
GeneChips to look at the gene expression changes in an I/R model using c-kit 
deficient (Wv) and wild-type (WT) mice with and without bone marrow derived HSC 
transplantation [102].  WT/WT and WT/Wv transplantations were also looked at in 
this study.  Evidence for involvement of c-kit was clear as Wv mice suffered worse 
heart function than WT mice after MI.  Transplantation of Wv mice with WT bone 
marrow cells rescued the defective cardiac repair that was seen in the Wv mice.  The 
gene expression results revealed a strong up-regulation in genes which regulate 
natural-killer cells and natural-killer cell markers in bone marrow transplanted Wv 
animals compared to infarcted Wv animals.  The anti-apoptotic genes; protein kinase 
B (Akt), bcl-2–associated X protein (BAX) and tyrosine kinase with 
immunoglobulin-like and EGF-like domains 1 (TIE1) as well as the angiogenic 
vascular endothelial growth factor (Vegf) were also up-regulated [102].   
 
Ip et al (2007) used microarray chips to look at ischemic myocardium compared to 
non-ischemic myocardium following LAD induced ischemia in mice.  They 
concentrated on a subset of genes on the Affymetrix chips, specifically chemokines, 
cytokines and cell adhesion genes [103].    They also studied the corresponding 
ligands and receptors in bone marrow derived MSCs.  They found nine different 
receptors in the MSCs corresponding to eight cytokines to be up-regulated in 
ischemic myocardium.  Selectively blocking some of these receptors and measuring 
MSC homing to the ischemic myocardium revealed a potential role for integrin 1 
but not integrin α4 or CXCR4.  As CXCR4 has previously been shown to be 
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important in HSC, they postulated different pathways for migration might exist in 
these two cell types [104].  
 
1.3.3 Integration of proteomic and genomic data 
 
The measurement of mRNA abundance in a sample or the qualitative comparisons 
between two samples that diverge by one biological variable enables some insight 
into gene regulation.  Gene regulation is however poorly correlated with protein 
abundance and regulation which is more indicative of biological processes, as it is 
proteins and not mRNA which are functional units.  The reason for this poor 
correlation is that although gene expression is inherently linked to protein production, 
subsequent processes of translation, post-transcriptional modification of proteins 
mean that every mRNA does not correlate to a molecule of protein; and the ever fluid 
nature of protein production and degradation also means that a quick glimpse of the 
transcriptome will not fully correlate to the proteome that exists in a biological 
sample at the same moment.  The half lives of protein and mRNA range from 0.1-10 
hours and 0.5-500 hours respectively [79]. It is important therefore to look at both 
thereby obtaining a view of the variation in genetic regulation and the variation in the 
biological system.  How to integrate the two sets of data in a way in which they 
become more informative is a key issue.   
 
Sampling processes also differentially affect the transcriptome and the proteome.  
During the processes of extracting and preserving samples the nucleic acid content is 
relatively stable as long as the operator is careful to limit RNA degradation by RNase 
enzymatic action.  Proteins are however affected by various proteolytic enzymes, 
temperatures, pH etc.  Even mRNAs present in low numbers can be measured by 
modern chip experiments, and the coverage of the transcriptome is ever improving.  
Low abundance proteins and hydrophobic membrane proteins are notoriously 
difficult to visualise and proteomic methods are limited in the ability to have a full 
view of proteins across the pI and molecular size scales.    The proteome as seen by 
2DE is limited to the pI range specified by the chosen IPG strip, even 2D gels made 
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using strips with a full pH 3-10 range rarely have high quality focussing of proteins at 
the extreme ends of the pH range, especially in very alkaline proteins [105].  Other 
proteomic approaches, such as shotgun proteomics, which is a ‘bottom-up’ approach 
where a complex protein sample is digested into peptides then analysed using LC-
MS/MS, remove some of the limitations of gels-based methods.  Low abundance and 
hydrophobic proteins are more easily identified, however, the ability to see all of the 
sample is still limited by the separation abilities of the LC (i.e. peptides run off the 
LC column and into the MS faster than they can be identified) [81].  Quantification 
issues also arise with the shotgun approach. Relative quantity between experimental 
groups can be calculated from the intensity of spots which are known to contain a 
particular protein in a 2DE analysis.  Labelling with stable isotope tags is one method 
employed to quantify changes in protein expression with bottom-up methods, 
although label-free methods, such as peak area intensities and spectral counting, are 
becoming more popular [81].  In summary, in addition to the inherent differences 
between proteome and transcriptome, many proteomic techniques only visualise a 
portion of the global proteome and the portion viewed between different experiments 
may differ.  This should be taken into account when integrating these two types of 
datasets.   
 
1.3.4  Proteomic and gene expression studies of cardiac repair 
 
Proteomic and gene expression studies have already been used to some extent to look 
for the biological responses of ischemic tissue to preconditioning as decribed.  
Recently, Fert-Bober et al (2008) produced a dataset which showed the merits of 
measuring both gene and protein expression to get a more complete picture of cellular 
responses. Protein expression alone after I/R showed a strong down-regulation in 
many proteins, whereas the gene expression data revealed this down-regulation was 
hiding an increase in transcriptional activity [93].  
 
These approaches have not yet been used to compare gene and protein expression 
profiles of I/R injured myocardium and bone marrow cell ‘restored’ myocardium, and 
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to try to relate these findings directly to histological and functional measurements in 
the same model.  It is possible results from such a study may reveal mechanistic 
information and may provide evidence for overlap of mechanism with that already 
well characterised in IPC.  This information is especially important as human trials 
using bone marrow cells are ongoing and our knowledge of how these cells work is 
poor.  There is a possibility that these cells may be secreting paracrine factors which 
could be pharmacologically mimicked therefore removing the need for cell 
harvesting.  Even if the cells themselves were the best therapeutic approach there may 
also be a possibility to engineer them in some way to enhance whatever 
cardioprotective signals they are producing.  
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1.4 Rat model of I/R injury and restoration of myocardium associated with 
BMMNCs   
 
In 2006 a set of experiments were initiated to study BMMNC treatment in a rat I/R 
model (LAD coronary artery ligation) in collaboration with Professors Mathur and 
Thiemermann and teams from the William Harvey Research Institute and University 
College London.  Several parallel experiments were performed due to the mutually 
exclusive nature of the various assays to be performed.  The main aims of these 
experiments were to study the effects of early introduction of bone marrow cells and 
to look for evidence of a paracrine mechanism of action.   
 
The first experiment aimed to look at the early application of BMMNCs in a rat I/R 
model, and to measure changes in infarct size in comparison to IPC.   Four groups 
were studied, these included sham surgery treated with PBS vehicle, I/R treated with 
PBS vehicle, I/R treated with BMMNCs and a preconditioned group with I/R and 
treated with PBS vehicle.  Cells or PBS were delivered immediately upon reperfusion 
intravenously.  The ischemic episode was 25 minutes, and 2 hours post reperfusion 
the area at risk (AAR) was measured by perfusing the heart with Evan’s blue and the 
infarct was demarcated using nitro blue tetrazolium as previously described [106].    
There was a 42% reduction in infarct size afforded by the BMMNC treatment, and 
this was comparable to the reduction afforded by IPC. 
 
The second parallel experiment aimed to measure cell death by assessing apoptosis 
and necrosis, as well as caspase activation in this early intervention model.  Three 
experimental groups were studied and included: sham surgery treated with PBS 
vehicle, I/R with PBS vehicle and I/R with BMMNCs.   As before, the ischemic 
episode was 25 minutes, cardiomyocytes were isolated 2 hours post reperfusion. 
Apoptosis and necrosis were assessed immediately using flow cytometry (Annexin 5-
FITC/propodium iodide dual staining), caspase-9 activity was assessed using 
Fluorescent-Labeled Inhibitor of CAspases (FLICA).  Apoptosis, necrosis and 
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caspase activation were all found to be reduced in the BMMNC group compared to 
MI.   
 
The third parallel experiment looked at cardiac function and the extent of myocardial 
fibrosis in the model. Three experimental groups were studied including sham 
surgery treated with PBS vehicle, I/R with PBS vehicle and I/R with BMMNCs.  
Baseline echocardiography was performed before surgery. The ischemic episode was 
25 minutes for this experiment and 7 days after onset of reperfusion, 
echocardiography was repeated.  Hearts were excised and sections stained with 
picrosirius red for histological assessment of fibrosis.   Fibrosis was found to be 
reduced in the BMMNC group compared to MI, and this was accompanied by 
improvements in systolic and diastolic function as measured by left ventricular 
ejection fraction (LVEF), fractional area change (FAC) and Contractility index. 
 
The final parallel experiment involved studying kinase signalling pathways known to 
be involved in IPC mediated cardioprotection, this was performed using five 
experimental groups including: sham surgery treated with PBS vehicle, I/R with PBS 
vehicle, I/R with BMMNCs, I/R with PBS vehicle and pi3k inhibitor (LY294002) 
and I/R with BMMNCs and LY294002.  The ischemic episode was 25 minutes and 
assays were performed on protein lysates from cardiac samples taken 2 hours post 
reperfusion; Western blotting was used to measure protein expression.  BMMNC 
were found to be associated with a Pi3k dependant phosphorylation of serine-473Akt 
(activation of Akt), serine-9GSK-3β (inhibition of GSK-3β), as well as 
phosphorylation of p38-MAPK and nuclear translocation of NF-κB. 
 
Separate studies were also carried out by Matthew Lovell (William Harvey Research 
Institute) looking at the presence of BMMNC cells stained with cell tracker dye 
carboxyfluorescein diacetate succinimidyl ester (CFDA SE) [Molecular probes, UK] 
in the hearts (whole, atria, ventricle and apex) 6 hours post reperfusion.  Studies were 
performed in sham operated animals treated with cells, animals treated with cells 
upon initiation of ischemia and those treated with cells upon initiation of reperfusion.  
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The results of these studies showed that cells injected into the right internal jugular 
vein were present in heart tissue 6 hours post reperfusion (Figure 1.4 A and B). The 
cells were homing in on the the injured heart and there were more cells in the region 
downstream of the occlusion within the left ventricle (Figure 1.4 C, D and E). More 
cells successfully homed in if they were injected at the point at which reperfusion 
ensued (Figure 1.4 D and E).   This study illustrates that the introduced cells do 
indeed home in on the site of injury in our model and it is estimated that 1% of cells 
are present after 6 hours.  It also shows that injecting cells at the point of reperfusion 
improves the number of cells homing in on the injured myocardium, the viability of 
the cells was undetermined. 
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Figure 1.4 Tracking of BMMNCs 6 hours post-reperfusion.  A and B) 
Histological sections of heart tissue stained with hematoxylin-eosin, with fluorescent 
CFDA SE stained BMMNC cells green. C) Stained BMMNC cells per mm2 found in 
atrial sections. D) Stained BMMNC cells per mm2 found in left ventricle sections.  E) 
Stained BMMNC cells per mm2 found in the apical section.  Experiments, data 
analysis and preparation of figures (Lovell). 
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2. Hypothesis and aims 
 
2.1 Hypothesis 
 
The protein profile and gene expression pattern of rat myocardium with and without 
BMMNC treatment after experimentally induced infarct will differ, and these 
differences may guide us to 1) the pathways involved in myocardial regeneration, 2) 
the method of cellular repair and 3) may reveal similarities in the mechanism of 
BMMNC myocardial repair and IPC.   
 
2.2 Aims 
 
1. To perform comparative proteomic analysis using 2DE to identify proteins which 
have been altered (expression or modification) by I/R injury and proteins 
subsequently altered by treatment with BMMNCs.  
 
2. To perform comparative gene expression profiling using the RatRef12 BeadChip 
(Illumina, UK) to determine if genes are differentially expressed in I/R injury and are 
activated by treatment with BMMNCs.  
 
3. To utilise bioinformatic tools in a search for patterns which may indicate specific 
signalling pathways involved in the cellular repair induced by BMMNC. 
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3. Materials and Methods 
 
3.1 Model and bone marrow mononuclear cell preparation 
 
All experiments were carried our in accordance with the Guide for Care and Use of 
Laboratory Animals published by the US National Institute of Health (NIH 
Publication No 85-23, revised 1996).  The animals were purchased from Harlan, UK 
or Charles River UK, Ltd and were cared for in accordance with both the UK Home 
Office Guidance in the Operation of the Animals (Scientific Procedures) Act 1986, 
published by Her Majesty’s Stationery Office, London, UK and the Guide for the 
Care and Use of Laboratory Animals, published by the American Physiological 
Society.  All animal model work was carried out by our collaborators. 
 
3.1.1 Rat ischemia/reperfusion model 
 
The I/R model was created using male Wistar rats weighing 250-300g [Charles River 
UK, Ltd].   Two groups of animals underwent alternative procedures.  The first group 
of animals were sham operated (Sham n = 3) and the second group had ischemia 
induced (n = 6) before being treated with either PBS vehicle (MI n = 3) or a bone 
marrow mononuclear cell (BMMNC) preparation (BMMNC n = 3) infused 
intravenously at the point of reperfusion. 
 
All animals were anesthetised and ventilated; body temperature and mean arterial 
pressure (MAP) were monitored thought the procedures.  A thoractomy was 
performed and the pericardium was dissected to reveal the left anterior descending 
(LAD) coronary artery and a snare occluder was placed around the LAD.  This was 
used to induce ischemia for 25 minutes before allowing reperfusion to ensue for 6 
hours.  For the sham animals, the thoractomy was undertaken but the LAD was not 
occluded.    
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3.1.2 Preparation and characterisation of bone marrow cells 
 
The preparation and characterisation of bone marrow mononuclear cells was carried 
out by Matthew Lovell (Bart’s and the London, UK).  Cells were harvested from 
donor male Wistar rats which were killed using a schedule 1 listed technique of 
concussion.  The fibias and tibias were excised and cleaned of all tissue before the 
bones were broken open and bone marrow cells were flushed out with Dulbecco’s 
Modified Eagle’s Medium (DMEM) and 10% fetal calves serum (FCS) [Sigma-
Aldridge, UK].   The mononuclear cell fraction was then separated using Percoll [GE 
Healthcare Lifesciences, UK] density gradient centrifugation according to the 
manufacturer’s protocol.    
 
The cells were counted using a haemocytometer [Improved Neubauer, VWR 
International, UK] and viewed using a microscope [Keyence BZ8000, UK]. The 
viability of the cells was then tested by mixing an aliquot of the cell suspension with 
an equal volume of trypan blue [Invitrogen, UK].  After 5 minutes incubation at 
37oC, the dead cells stain blue whereas viable cells are unstained.   
 
Data on the presence of various cluster of differentiation (CD) antigens measured 
using fluorescence activated flow cytometry (FACS) [FACScan, Becton Dickinson, 
UK] were compared between the bone marrow cell preparation and whole bone 
marrow.  These included CD45 which a leukocyte marker, CD45RA which is a 
marker of naïve T-cells, CD3 which is a T lymphocyte marker and CD90 which is 
thought to be a marker of several different cell types including MSCs and HSCs.  The 
bone marrow cell preparation was enriched ~2-fold for CD45 and CD3 and 3 fold for 
CD90.  The preparation was also characterised as being 7% c-Kit+ which is a HSC 
marker, specifically a stem cell factor receptor; 7% CD34+ which is also a HSC 
marker and 15% CD133+ which is a marker of HSCs and endothelial progenitor cells.  
CD45+ cells made up 54% of the population.    
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The cells to be used in the rat I/R model were washed immediately after being taken 
from the interface of the percoll gradient preparation and then re-suspended in PBS 
ready for injection into the right internal jugular vein at the start of reperfusion.  
Control I/R animals received a PBS injection instead of cells which will control for 
any effect of the saline in which the cells are suspended may have on the animals.  
This allows any differences between MI and BMMNC groups to be reasonably 
attributable to one or more components of the cellular content of the BMMNC 
preparation. 
 
3.1.3 Collection of myocardial samples for proteomic and gene analysis 
 
Tissue samples for proteomic and transcriptomic analyses were obtained from the 
excised hearts of sham, MI and BMMNC animals.   All animals were sacrificed at 6 
hours post reperfusion.  Excised hearts were dyed with Evan’s Blue dye to stain the 
perfused area and distinguish the unstained ‘area at risk’ (AAR) which is the area 
downstream from arterial ligand within which the actual area of infarct would lie.  
The AAR was dissected, rinsed with cold PBS and then wrapped in foil and snap 
frozen in liquid nitrogen before being stored at -80oC.   A section of tissue at 
approximately the same size and position (LV apex) was excised from sham hearts.  
Myocardial samples from two experiments, performed at different time-points were 
obtained. Samples 1-9 were obtained from an experiment performed in 2007 and 
samples 10-18 came from an experiment using the same conditions, performed in the 
same laboratory by the same personnel in 2009 (Table 3.1).  Samples 1-9 were used 
for proteomic and transcriptomic (gene expression) profiling.  Samples 10-18 were 
used for studies of 14-3-3 epsilon as detailed in sections 3.7 and 7.0. 
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Table 3.1 Myocardial samples collected for studies 
Experimental 
Group SAMPLE_ID
Experimental 
Group SAMPLE_ID
Sham -1 1 Sham -1 10
Sham-2 2 Sham-2 11
Sham-3 3 Sham-3 12
MI-1 4 MI-1 13
MI-2 5 MI-2 14
MI-3 6 MI-3 15
BMMNC-1 7 BMMNC-1 16
BMMNC-2 8 BMMNC-2 17
BMMNC-3 9 BMMNC-3 18  
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3.2 Proteomic analyses 
 
Two dimensional gel electrophoresis (2DE) was used for profiling the proteomes of 
the myocardial samples from the rat I/R model.  In the first instance, a wide pH range 
was analysed (pH 4-7), followed by two narrow-range analyses looking at pH 4.5-5.5 
and pH 5.5-6.7.  The same experimental procedures were used for all of these 
analyses.   All methods used for 2DE proteome profiling experiments are described 
below. 
 
3.2.1 Sample preparation and quantification 
 
3.2.1.1 Protein lysate preparation from rat myocardial samples 
Frozen tissue samples (~600mg per sample) were taken from the -80oC freezer and 
transported to the laboratory on dry ice.  The samples were then crushed into 
fragments using a pre-chilled agate mortar and pestle.  Approximately 80-140mg was 
taken and added to 1ml of lysis buffer (see Table 3.2).   Complete protease inhibitor 
cocktail was supplied by Roche, UK.  CHAPS and DTT were supplied by VWR 
International, UK.  All other reagents were supplied by Sigma-Aldridge, UK.  
 
The samples were then homogenised, using an Ultra-Turrax T8 with a small 
dispersing tool [IKA-Werke Staufen, Germany].  The remainder of the frozen 
samples were replaced in the -80oC freezer.   The homogenates were vortexed before 
being placed in a sonication bath containing ice (to ensure the samples do not 
overheat) for 10 minutes.  The homogenates were spun in a Sigma 1-15K 
microcentrifuge [Phillip Harris, UK] at 1500rpm (revolutions per minute) for 10 
minutes at 17oC and the resulting supernatant was then split into aliquots of 500µl 
and stored at -20oC.   
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Table 3.2 Lysis buffer preparation 
 
Reagent Final conc. required
Volume to 
add
Urea * 9.5M 30g 
3-[(3-Cholamidopropyl)dimethylammonio]-
1-propane sulphonate  (CHAPS)
4% 2g
(D,L)-1,4-Dithiothreitol (DTT) 1% 0.5g
Complete protease inhibitor 1x 1 tablet
Phosphatase inhibitor cocktail 1x 0.5µl
Milli-Q water to 50ml  
*Urea was made up to 45ml with Milli-Q water and stirred with Amberlite MB-1 and 
then filtered before the other reagents were added.  Once prepared, lysis buffer was 
split into 50 x 1ml aliquots and stored at -80oC.   
 
 
3.2.1.2 Protein quantification 
The concentration of the protein samples were assessed using the Bio-Rad protein 
assay [Bio-Rad, UK], a modified version of the Bradford Assay [107].  The assay is 
based on the colour change of Coomassie Brilliant Blue G-250 dye when combined 
with different concentrations of protein.   The assay was originally performed in 
3.6ml volumes and read by a UV-160 spectrophotometer [Shimadzu, UK].   The 
protocol was later modified for smaller volumes, specifically adapted to be read on 
the NanoDrop 1000 Spectrophotometer [Thermo Scientific, UK].  Samples that had 
been quantified with the original protocol were re-quantified using the NanoDrop 
protocol to ensure the consistency of results. 
 
 Protein quantification by spectrophotometer  
First 0.1N HCl:water (1:8) was prepared by adding 4.3ml of HCl to 495.7ml water 
(0.1N HCl), 62.5ml was then added to 437.5ml water.  A working concentration of 
Bio-Rad dye reagent was prepared by adding 25ml of 4 x Bio-Rad solution to 75ml 
water and mixing gently.   Standard curves were prepared using bovine serum 
albumin [Sigma-Aldridge UK] as detailed in Table 3.3, these were measured in the 
spectrophotometer at 595nm and the results checked to ensure that the curve had a 
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correlation of >0.98 before being aliquotted and stored at -20oC.  Figure 3.1 shows 
how the standard curve was computed using Excel [Microsoft, US]. 
 
To perform the assay, 10µl of the pre-prepared standard curve solutions were added 
to 90µl of 0.1N HCl:water (1:8) and then dispensed into a cuvette [VWR, UK].  For 
the samples, 2µl was added to 8µl of lysis buffer and 90µl of 0.1N HCl:water (1:8) 
and this was dispensed into a cuvette.  To each cuvette, 3.5ml of the working 
concentration dye reagent was added before being vortexed gently and left to settle 
for 2-3 minutes.  The absorbance of the samples and standards were then measured on 
the spectrophotometer at 595nm; all readings were done in triplicate.    The standard 
curve was computed in Excel [Microsoft, US] from which slope and intercept values 
were taken and used to calculate the concentration of the samples:     
 
 
total µg in the assay = (average absorbance at 595nm - intercept)  
                                  slope 
 
concentration (µg/µl) = total µg in the assay 
2 
 
 
 
Table 3.3 Concentrations of BSA standards used to obtain a calibration curve 
 
Standards
Standards 
(mg/ml)
Vol of BSA 
stock (ul)
Vol of lysis 
buffer (ul) 
0 0 0 500
1 0.5 50 450
2 1 100 400
3 2 200 300
4 4 400 100
5 5 500 0  
BSA stocks at 5mg/ml BSA in lysis buffer were used. 
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Figure 3.1 BSA standard curve macro in Excel  Curve is created from the ‘total µg 
in the assay’ (i.e. total µg in 10µl used in the assay) and the average absorbance at 
595nm.   
 
 
 
 Protein quantification by NanoDrop 1000  
The ‘regular assay’ procedure was used as detailed in the NanoDrop 1000 manual 
[Thermo Scientific, UK].  A working concentration of Bio-Rad dye reagent was 
prepared by adding 12.5ml of 4 x Bio-Rad solution to 37.5ml water and mixing 
gently.   The BSA standard curve for this protocol was prepared as detailed in Table 
3.4.    
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Table 3.4 BSA standard curve preparation for performing the Bio-Rad protein 
assay on the NanoDrop 1000  
 
Standards
Standards 
(mg/ml)
Vol of BSA 
stock (ul)
Vol of lysis 
buffer (ul) 
0 0 0 500
1 0.2 50 450
2 0.4 100 400
3 0.6 150 350
4 0.8 200 300
5 1 250 250  
 
The BSA stocks were 2mg/ml BSA in lysis buffer. 
 
The standards were prepared in triplicate by adding 10µl of standard to 490µl of the 
working concentration dye reagent.  The samples were prepared by diluting 5µl in 
45µl of lysis buffer, then adding 10µl of this dilution to 490µl of working 
concentration dye reagent.  The samples were mixed thoroughly and left for 2-3 
minutes before being read on the NanoDrop.  The NanoDrop software has a Bradford 
assay setting which allows the user to record the blank (Standard 0) first, followed by 
the standard curve (up to five repetitions per standard), then the samples.  All 
absorbance readings were exported to Excel [Microsoft, US] and protein 
concentrations were calculated as before. 
 
3.2.2 Two dimensional gel electrophoresis (2DE) 
 
3.2.2.1 Isoelectric Focussing (IEF) 
Immobilised pH gradient (IPG) strips were rehydrated overnight in a total volume of 
400µl (200µl lysis buffer containing 200µg total protein, 191µl rehydration buffer 
(Table 3.5) and 9µl Pharmalyte 3-10 [GE-healthcare Lifesciences, UK]) in a re-
swelling tray [GE-healthcare Lifesciences, UK] and covered with silicone oil to 
prevent evaporation.  For the rehydration buffer, Urea was supplied by Sigma-
Aldridge, UK and all other reagents were from VWR International, UK.   
The following day, the fully rehydrated IPG strips were placed onto the ceramic 
manifold of an Ettan IPGphor system for isoelectric focussing (IEF) [GE-Healthcare 
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Lifesciences, UK].  Dampened paper wicks were placed at either end to improve 
electrode contact and the manifold was again covered in silicon oil to prevent 
evaporation.  IEF was carried out overnight at 20oC with 50µA per strip using a 
gradient of 0 to 100V for 1Vhour, 100V to 3400V for 7kVhours, followed by ‘Step n 
hold’ at 3500V for a total of ~65kVhours. 
 
Table 3.5 Rehydration buffer preparation  
 
Reagent Final conc. required
Volume to 
add
Urea * 8M 25g
3-[(3-Cholamidopropyl)dimethylammonio]-1-
propane sulphonate  (CHAPS) 0.50% 0.25g
(D,L)-1,4-Dithiothreitol (DTT) 0.20% 0.1g
Bromophenol Blue Trace of Trace of
Milli-Q water to 50ml  
*Urea was made up to 45ml with Milli-Q water and stirred with Amberlite MB-1 and 
then filtered before the other reagents were added. Once prepared, rehydration 
buffer was split into 50 x 1ml aliquots and stored at -20oC.   
 
 
3.2.2.2 SDS – polyacrylamide gel electrophoresis (PAGE) 
Large format, homogenous, 12% SDS PAGE gels were cast using the Ettan Dalt 
twelve system [GE-Healthcare Lifesciences, UK].  Glass plates (276mm x 216mm x 
3mm) and plastic spacers (15mm x 216mm x 1.5mm) were assembled into gel casting 
cassettes and secured with gel-sealing tape.  The reagents for the 12% SDS 
acrylamide gel solution are described in Table 3.6. All reagents were supplied by 
Sigma-Aldridge, UK.  Bis-Acrylamide stock was deionised by stirring with amberlite 
MB-1 [Sigma-Aldridge Co] for 1 hour at room temperature, then the amberlite was 
removed by filtration before the Acrylamide gel solution was prepared.   
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Table 3.6 12% SDS acrylamide gel solution preparation  
 
Reagent Final conc. required
Volume to 
add
* Bis-Acrylamide 40% 37.5:1 12.50% 510ml
* 1.5M tris(hydroxymethyl)aminomethane 
(Tris) (pH8.8) 0.375M 425.1ml
10% Sodium dodecyl sulphate (SDS) 0.10% 17ml
10% Ammonium Persulphate (APS) 0.05% 8.5ml
N,N,N′,N′-Tetramethylethylenediamine 
(TEMED) 0.02% 255µl
* Milli-Q water 739.14ml  
 
* Combine water, acrylamide and 1.5M Tris, then de-gas for 1-2 hours before adding 
the other reagents. 
 
 
The casting equipment was assembled according to manufacturers’ instructions and 
the acrylamide gel mix was poured into the system, followed by displacing solution 
(Table 3.7).  Then 1-2ml of overlay solution (isobutanol and water 10:1) was pipetted 
onto the top edge of each gel.  For the displacing solution, Bromophenol Blue was 
supplied by VWR International.  All other reagents were supplied by Sigma-
Aldridge, UK.   
 
 
Table 3.7 Displacing solution preparation  
 
Reagent Final conc. required
Volume to 
add
1.5M Tris (pH8.8) 25% 25ml
Glycerol 50% 50ml
Milli-Q water 25% 25ml
Bromophenol Blue Trace Trace  
 
Once the gels were set, the casting equipment was dismantled and cleaned.  Gels 
were wrapped in damp tissue and cling-wrap to prevent drying out and were stored at 
4oC until use.  
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Once IEF had been completed the IPG strips were equilibrated, first in equilibration 
buffer (Table 3.8) containing 2% DTT for 15 minutes then equilibration buffer 
containing 4.8% iodoacetamide for a further 15 minutes.  Glycerol and Tris were 
supplied by Sigma-Aldridge, UK.  Second dimension was performed using an Ettan 
Dalt twelve system [GE-Healthcare Lifesciences, UK].  The equilibrated IPG strips 
were placed in a horizontal alignment along the top edge of the SDS-PAGE gels.  The 
strips were placed with the plastic backing in contact with the glass plate and the 
contact between the IPG strips and the SDS-PAGE gel was continual with no gaps.  
Molecular weight marker [GE Healthcare, UK] (3µl) was added to a 17µl of 1% 
agarose stained with bromophenol blue, and once solidified this was placed at one 
end of the gel.  A 0.5% agarose solution (made with 1 x SDS running buffer, see 
below) was applied over the IPG strip to hold the strip in place.    
 
1 x SDS running buffer was freshly prepared (10 x buffer stock detailed in Table 3.9). 
All reagents were supplied by Sigma-Aldridge, UK.  The SDS buffer was poured into 
the Ettan Dalt Twelve tank [GE Healthcare, UK] to equilibrate to 10oC.  A re-
circulating cooling unit ensured the buffer remained at 10oC through out the run.  The 
assembled gels were placed in the tank.  The conditions for overnight running were 
0.5W/gel for 1 hour, 0.75W/gel for 1 hour, 2W/gel for 22 hours.    
 
Table 3.8 Equilibration buffer preparation  
 
Reagent Final conc. 
required
Volume to 
add
Urea 6M 18g
Sodium dodecyl sulphate (SDS) 2% 1g
Glycerol 30% 15g
tris(hydroxymethyl)aminomethane (Tris) 50mM 1.65ml of 
Bromophenol Blue Trace of Trace of
Milli-Q water to 50ml  
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Table 3.9 10 x SDS running buffer preparation  
 
Reagent Final conc. 
required
Volume to 
add
Tris base 250mM 60.5g
Glycine 192mM 288.2g
Sodium dodecyl sulphate (SDS) 1% 20g
Milli-Q water to 2L  
 
The gels were removed from the tank and cassettes when the dye-front was ~1cm 
from the bottom of the glass-plates.  They were placed in fixing solution (30% 
methanol, 10% acetic acid) overnight and stained the following day using the Plus 
One silver staining kit [GE-Healthcare Lifesciences, UK] following manufacturers 
instructions.  Stained images were scanned at medium-high resolution using a GS-
800 scanner [Bio-Rad, UK].   
 
3.2.3 Image analysis 
 
Gels from each sample were produced in duplicate for both the wide-and narrow-
range analyses.  Two different software packages were used to analyse the gel 
images; PDQuest Advanced [Bio-Rad,UK] was used to analyse the wide-range gel 
images and Progenesis SameSpots [Nonlinear Dynamics, UK] was employed for 
analysing both sets of narrow-range gel images.   
 
 PDQuest Advanced 2D gel image analysis. 
Analysis using PDQuest Advanced software [BioRad, UK] was performed using the 
following workflow.  The scanned images were all cropped using the same settings in 
the ‘advanced crop’ feature before being saved in a reduced file size format of 48 KB 
using Quantity One software [BioRad, UK].  Filters were used for 6 of the 18 gel 
images that had pepper type artifactual features (black speckles) that would reduce 
the impact of this ‘noise’ in the image during spot detection.  Gels were then loaded 
into an experiment and spot detection parameters were set.  Manual editing was then 
carried out for all gels. Artefacts and wrongly indicated spots were removed.  The gel 
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with the most spots was chosen as the master (image to which the other images are 
matched) and automatic spot matching was initiated after marking several landmark 
spots.  A second session of manual editing followed this.  Spot intensity values were 
then ‘normalised’ using ‘total density in gel’ method.  All spots indicated as differing 
by more than 1.5 fold were checked to make sure they were correctly detected and 
matched.  Once any false spots were removed from the analysis all the normalised 
spot intensity values for all gels were exported to Excel [Microsoft, US].   
 
 Progenesis SameSpots 2D gel image analysis 
The workflow for Progenesis SameSpots analysis is as follows.  Un-cropped gel 
images were loaded into SameSpots and automatic alignment was carried out on all 
of the gel images.  The results from this were then checked manually gel by gel and if 
areas of the gel had not aligned sufficiently extra landmarks were added before auto 
alignment was repeated.  This was repeated for all gels until they were aligned 
sufficiently.   Progenesis analysis was then carried out.  The top scoring spots were 
checked to ensure they were actual spots, were correctly outlined and aligned in each 
gel.   Any spots which were artifactual or mismatched were excluded.  After this, the 
normalised spot volumes for all of the spots were exported to Excel [Microsoft, US].   
 
3.2.4 Statistical analysis 
 
Excel [Microsoft, US] was used to calculate average, standard deviation, standard 
error and 95% upper and lower confidence intervals for each spot in each group using 
the normalised spot volumes for each gel.  Fold changes and Student’s t-test p-values 
were calculated for two intergroup comparisons; ‘SHAM vs. MI’ and ‘MI vs. 
BMMNC’.  All spots with significant differences (>1.5 fold) in either comparison 
were checked again in either PDQuest or Progenesis.  All spots found to significantly 
differ by more than 2.5 fold (wide-range) or 1.5 fold (narrow-range) were excised for 
protein identification.   
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3.2.5 Protein identification by LC-MS/MS  
 
3.2.5.1 Excision and trypsin digestion of spots 
The spots were excised from the gel using a disposable pipette tip which had the end 
sliced off to increase the size of the aperture at the tip.  The aperture was made to 
correspond roughly with the size of the spot to be excised.  The excised piece of gel 
was then further cut with a razor blade to pieces no larger than 2mm cubed and 
placed in 1ml eppendorfs.  The gel pieces were washed with 100mM ammonium 
bicarbonate (Ambic) for 15 minutes before the solution was decanted to waste and 
replaced with acetonitrile (ACN) for 5 minutes.  The ACN was then decanted to 
waste and the dehydrated gel pieces were further dehydrated in a speedvac 
concentrator [Savant, UK] connected to a compressor vacuum pump [Compton, UK] 
for 10 minutes.  The gel pieces were rehydrated in 10mM DTT dissolved in 100mM 
Ambic and heated to 56oC for 30 minutes.  The DTT solution was decanted to waste 
and replaced with ACN for 5 minutes before decanting again and dehydrating the gel 
pieces in the speedvac for 10 minutes.   
 
Gel pieces were rehydrated in 55mM Iodoacetamide dissolved in 100mM Ambic and 
placed in the dark for 20 minutes.  The solution was again decanted to waste before 
the gel pieces were dehydrated in ACN for 5 minutes and then placed in the speedvac 
for 10 minutes.  Finally the gel pieces were rehydrated in 50mM Ambic containing 
13ng/µl bovine trypsin or methylated porcine trypsin [Sigma-Aldridge, Co].  The 
samples were placed at 4oC for 45-60 minutes to allow complete rehydration before 
being placed at 37oC for 1 hour.  The samples were then left at room temperature 
overnight.   
 
The following morning any remaining supernatant was decanted into a fresh labelled 
microcentrifuge tube and the gel pieces were washed in a small volume of 50mM 
Ambic for 15 minutes at 37oC.  The supernatant was decanted to the fresh 
microcentrifuge tube and a further small volume of ACN was added before another 
15 minute incubation at 37oC.  The supernatant was added to the fresh 
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microcentrifuge tube before and then 50mM Ambic and the ACN steps were 
repeated.  The fresh eppendorfs containing the supernatant laden with digested 
peptides were dried down to completion in the speedvac and stored at -20oC.   
 
3.2.5.2 LC-MS/MS 
For protein identification, the lyophilised peptide samples were re-suspended in 6µl 
of 50mM Ambic and were vortexed for 1 minute before incubation at 37oC for 5 
minutes.  They were briefly vortexed again and then centrifuged at maximum speed 
for 1 minute.  The supernatant was transferred to a sample vial for injection.  Samples 
were analysed using LC-MS/MS [CapLC and QTof-micro, Waters, UK].   
 
Peptides were separated on a 75µm x 150mm Nanoease 3µm Atlantis dC18 column 
[Waters, UK].  A 30 minute solvent gradient of 1% to 95% B (A is 100ml H2O and 
50µl Formic acid, B is 20ml H2O, 80ml ACN and 50µl Formic acid) was used at a 
flow rate of 200nl/min.  Separated peptides were introduced into the mass analyser 
using a nanospray ESI source.   
 
The QTof is a hybrid mass analyser combining quadrupole and time of flight (Tof) 
analysers.   Peptide ions enter the QTof under vacuum, and are guided through the 
first quadrupole.  These then pass though to the second quadrupole where collision 
induced dissociation (CID) occurs.  The MS/MS fragment ions resulting from CID 
are then further resolved as they pass along the third quadrupole to the detector.  Data 
was obtained using Data Dependant Acquisition (DDA) using two MS/MS channels. 
 
The instrument was calibrated using glu-fibrinogen [Sigma-Aldridge, UK] prior to 
running samples to ensure mass accuracy.  The raw peptide and fragment mass data 
was processed using ProteinLynx software [Waters, UK] and the processed peak list 
data (PKL file) was then used to search the SwissProt database using the MASCOT 
search engine [Matrix Science, UK].  For the MASCOT search, trypsin was set as the 
enzyme used, allowing up to one missed cleavage.  Variable modifications were set 
for oxidation of methionine residues and carbamidomethylation of cysteine residues.  
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Peptide tolerance was set at +/- 2.0 Daltons and MS/MS tolerance of +/- 0.8 Daltons.  
MASCOT protein scores and percentage sequence coverage were calculated from 
only the peptides scoring over 35.   For proteins only identified by a single peptide, 
the mass spectra were checked these are shown in Appendix 6.  Expectation values 
are also included in the MASCOT data for these proteins.  Proteins identified as 
specific isoforms were confirmed by BLASTing the peptide sequences which had 
scores over 35 [108]. 
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3.3 Validation of proteomic data by Western blotting 
 
Western blotting was used as a semi-quantitative method to validate observations 
made in the 2DE analysis.  Specifically, antibodies for 14-3-3 epsilon (14-3-3ε), 
succinate dehydrogenase (Sdha), phosphatidylethanolamine-binding protein 1 
(Pebp1) and ATP synthase subunit beta  (Atp5b) were used to measure expression of 
these proteins in the samples from our experiment.  Antibodies for Glyceraldehyde-3-
phosphate dehydrogenase (Gapdh) were used to normalise protein loading.  All 
antibodies were supplied by Abcam, UK.  The methodology for Western blotting is 
detailed here.   
 
Each assay required optimisation before a final blot was produced for densitometry 
and analysis.    The Gapdh antibodies worked well with either 10µg or 20µg total 
protein loading which were the two concentrations at which all of our analytical 
assays were optimised to.  The approximate antibody dilution suitable for western 
blotting was suggested by the manufacturer and this was always used as the starting 
point for optimisation. 
 
3.3.1 1D SDS-PAGE and blotting 
 
Protein lysates were electrophoretically separated on NuPAGE® Novex 10% Bis-Tris 
Gels in an XCell SureLockTM Mini-Cell electrophoresis tank [both from Invitrogen, 
UK]. Unless otherwise stated, all reagents were supplied by Invitrogen.  
 
Protein lysates were prepared by mixing with ‘LDS’ sample buffer at an appropriate 
concentration (determined by optimisation) in enough volume to load onto two gels 
(30µl).  They were then heated to 70oC for 10 minutes to denature the proteins.   
Meanwhile, two pre-cast gels were placed in the tank and the combs were removed.  
Antioxidant (500µl) was added to 200ml of running buffer (1x) and this was poured 
into the central well of the tank and a pipette was used to wash out the wells.   Once 
the samples had been incubated at 70oC, they were spun briefly in a microcentrifuge 
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and then 15µl of each sample preparation was loaded onto each gel, making two 
identical gels.  See-Blue protein molecular weight marker [Invitrogen, UK] and 
CruzMarker TM molecular weight marker [Santa Cruz,UK] were also loaded onto the 
gels.  The former is a pre-stained marker and the latter is designed to react with the 
secondary antibodies and therefore will be detected by chemiluminescence (see 
section 3.3.2.2).  Running buffer (1x) was added to the outer chamber and 
electrophoresis was run at 200V for 50 minutes and then the gel cassettes were 
cracked open and the gels were prepared for transfer onto nitrocellulose membrane.   
 
Blotting pads, nitrocellulose membranes (Hybond ECL from GE Healthcare), and 
blotting paper [Whatman, UK] were pre-soaked in transfer buffer [Invitrogen, UK].  
The surfaces of the gels were rinsed in transfer buffer and the membrane was placed 
over it.  Two ‘cut-to-size’ sheets of blotting paper were placed onto each side of the 
gel/membrane to make a sandwich.   A falcon tube was then rolled over the sandwich 
to exclude any air bubbles.  All gels were prepared in this way.  An XCell II Blot 
Module [Invitrogen, UK] was then assembled with sponge blotting pads and the 
gel/membrane/filter paper sandwiches as shown in Figure 3.2.   
 
Figure 3.2 Assembly of XCell Blot Module [Invitrogen, UK] 
 
Cathode-core 
of XCell II Blot 
Module
Anode-core of 
XCell II Blot 
Module
Both sides of the XCell II Blot Module are 
held tightly together within the XCell
SureLock Mini-Cell electrophoresis tank 
Blotting Pad
Filter paper x 2
Gel
Membrane
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The module was closed and placed in the   XCell SureLockTM Mini-Cell tank before 
being topped up with transfer buffer.  The outer chamber was filled with deionised 
water and electrophoresis was run at 30V for 1hour.  After one hour the tank was 
disassembled and the membranes which now held the separated protein samples were 
placed in 10ml of 3% skimmed milk made with tris buffered saline (TBS) containing 
0.5% Tween (TBS-TWEEN) buffer (see Tables 3.10 and 3.11) and left overnight at 
4oC. 
 
Table 3.10 10 x Tris buffered Saline (TBS) buffer  
 
Reagent Final conc. 
required
Volume to 
add
NaCl 20mM 31.6g 
Tris-HCl 137mM 79.46g 
Milli-Q H2O to 1L  
Once solution was prepared, pH was adjusted to pH 7.6. 
 
 
Table 3.11 1 x TBS-TWEEN buffer  
 
Reagent Final conc. 
required
Volume to 
add
10 x TBS buffer 1 x 100ml
Polysorbate 20 (TWEEN-20) 0.05% 0.5ml
Milli-Q H2O to 1L  
Once solution was prepared, pH was adjusted to pH 7.6. 
 
 
3.3.2 Antibody incubations and chemiluminescence 
 
After the membranes had been ‘blocked’ overnight in the milk solution, they were 
incubated for 90 minutes in 7ml of 3% milk made with TBS-TWEEN containing the 
relevant primary antibody at the appropriate concentration on a shaking platform.  
Following this the antibody solution was replaced by TBS-TWEEN and the 
membranes were incubated for 10 minutes on a shaking platform.  This wash step 
was repeated twice before the secondary antibody incubation.  The membranes were 
covered in 7ml of 3% milk made with TBS-TWEEN and the secondary, HRP 
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conjugated Goat anti-rabbit [Santa Cruz, UK] antibody at a concentration of 1 in 
5000 and incubated on a shaking platform for one hour.   A further three wash steps 
followed the secondary antibody incubation.   
 
ECL Plus detection reagents [GE Healthcare, UK] were used to detect the HRP 
conjugated secondary antibodies on the membranes.  The secondary antibodies are 
linked to horseradish peroxidase (HRP) which then reacts with the Acridan substrate 
(in the ECL Plus detection reagents) to generate acridinium ester, this is further 
oxidised by the peroxidase and produces a strong chemiluminescent signal detectable 
on autoradiographic film.  Following the final wash step, the membranes were 
drained of TBS-TWEEN buffer and placed on a level clean surface.  ECL detection 
reagents (Solution A and B in ratio 40:1) were mixed and gently poured over the 
membrane (0.1ml used per cm2 membrane) and left to incubate for 5 minutes.  The 
membranes were again drained and placed onto a pre-cut piece of cling wrap which 
was folded over to cover the membrane.  The cling wrap covered membranes were 
then placed in an x-ray film cassette [GE Healthcare, UK] and taken to a dark-room.    
 
A cut-to size piece of x-ray film (Hyperfilm ECL also from GE Healthcare) was 
placed over the membrane and the cassette was closed over it for 30 seconds.  The 
film was then placed into 1 x Kodak GBX developing solution [Sigma-Aldridge, UK] 
till the bands appeared.   The film was then rinsed briefly in water before being 
placed in 1 x Kodak GBX fixer solution.  This first film was used to judge the 
optimal exposure time, and the exposure was repeated with some fresh film to ensure 
a clear image of the bands without overexposure which could lead to low dynamic 
range when quantifying the bands.  
 
3.3.3 Densitometry 
 
The developed Hyperfilms were scanned in using a Photosmart C3180 [Hewlett 
Packard, UK] at a resolution of 1200dpi in greyscale and saved as .tif images.  These 
images were then analysed using TotalLab v1.10 software [Phoretix] which calculates 
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band volume by plotting band intensity x103 against band area.  The volumes of the 
bands for the protein of interest and those of the GAPDH bands were then exported to 
Excel [Microsoft, US].   
 
3.3.4 Statistical analysis 
 
The band volumes for the protein of interest were normalised using the band volumes 
of Gapdh.  This was done for each band by first dividing the value of each Gapdh 
band by the average of all the Gapdh bands to obtain a ‘normalisation factor’.  Each 
band volume of the protein of interest were then divided by this normalisation factor.  
Figure 3.3 below illustrates an example of this simple normalisation method.  
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Figure 3.3 An example of band volume normalisation using Gapdh as a loading 
control. 
 
•GAPDH band volumes (a): 
6500 6590 4980 4857 7400 
Average = 6065.4 (b)
•Normalisation factors (a/b = c):
1.072 1.086 0.821 0.800 1.220
•Protein of Interest (PoI) band volumes (d):
9869 8352 2433 6398 8283
•Normalised PoI band volumes (d/c):
9209 7687 2963 7989 6789
Band volume normalisation using GAPDH as a 
loading control.
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To investigate whether differences in expression measured using western blotting are 
statistically significant the normalised volumes of the protein of interest are analysed 
in GraphPad Prism 5 [GraphPad, UK].  A one-way ANOVA was used to see if there 
was a statistically significant difference between the three groups and this was 
followed by Bonferroni’s post-hoc test for multiple comparisons to look at the 
statistical difference between pairs of groups.  P-values of <0.05 were considered 
statistically significant.  
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3.4 Gene expression analyses 
 
A whole genome scale comparative gene expression profiling experiment was carried 
out using Illumina’s Rat Ref-12 BeadChip.   
 
3.4.1 RNA preparation 
 
3.4.1.1 RNA extraction from tissue samples 
The RNeasy Fibrous Tissue Mini Kit [Qiagen, UK] was used to extract total RNA 
from the myocardial tissue samples 1-9.  A fraction (20-30mg) of the crushed frozen 
tissue was taken and added to Precellys CK14 tubes containing ceramic beads and 
300µl of RLT Buffer. The samples were then homogenised in a Precellys 24 bench 
top homogeniser [Bertin technologies].  The RNA extraction was then performed on 
these lysates following the protocol outlined in the RNeasy Fibrous Tissue Mini Kit 
handbook.  Figure 3.4 shows a flow chart of the procedure and Table 3.12 lists the 
reagents supplied in the kit.  
 
All steps were carried out at room temperature unless specified otherwise.  The 
lysates were transferred into new eppendorfs along with 590µl of RNase-free water 
and 10µl of proteinase K and then incubated at 55oC for 10 minutes in a water bath.  
Following this incubation, the samples were spun for 3 minutes at 10,000 x g and the 
supernatant transferred to a new microcentrifuge tube.    
 
The nucleic acid content was then precipitated from the solution by adding 0.5 
volume of ethanol and mixing thoroughly with a pipette.  This solution was 
immediately added to an RNeasy spin column which was placed in a collection tube 
and spun at room temperature for 15 seconds at 8,000 x g.  The flow through was 
discarded and any remaining solution was added to the same column and the 
centrifugation step was repeated.   
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Table 3.12 Reagents supplied in the RNeasy fibrous tissue kit [Qiagen, UK] 
Buffer RPE requires the addition of 4 volumes of ethanol before use. -
Mercaptoethanol (β-ME) must be added to Buffer RLT before use. 
 
              Buffer RDD
              RNase-Free Water
Buffer RPE (concentrate)
Rnase-free Water
RNase-Free DNase Set:
              RNase-Free DNase I (lyophilised)
RNeasy Kit Reagents
Proteinase K
Buffer RLT
Buffer RW1
 
 
Once the nucleic acids had been captured on the spin column, a wash step was 
performed by adding 350µl of RW1 buffer to the column which was then spun at 
room temperature for 15 seconds at 8,000 x g and the flow-through was again 
discarded.  DNase (10µl) was added to the column in 70µl of RDD buffer and was 
left on the bench top (room temperature) for 15 minutes to allow time for the enzyme 
to work.  Another wash step was then performed by adding 350µl of RW1 buffer to 
the column which was then spun at room temperature for 15 seconds at 8,000 x g and 
the flow-through was again discarded.   
 
500µl of RPE buffer containing a high concentration of ethanol was then added to the 
column to precipitate the RNA and the column was spun at room temperature for 15 
seconds at 8,000 x g and flow through was discarded.  The RPE precipitation step 
was repeated but with a longer centrifugation (2 minutes) to ensure all the ethanol 
was removed before RNA elution.  The dried spin column was then placed in a fresh 
collection tube and 30µl of RNase free water was added to the column to elute the 
RNA.  The column was spun at room temperature for 1 minute at 8,000 x g.  A 
second volume of 20µl was added to the column and the centrifugation step was 
repeated.  This ensured all of the total RNA was eluted in a final volume of 50µl. 
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Figure 3.4 RNeasy fibrous tissue kit procedure as shown in the handbook 
[Qiagen, UK]  
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3.4.1.2 RNA quantification and quality assessment 
 NanoDrop 1000 
To check the efficiency of the RNA extraction, the RNA samples were quantified 
using the NanoDrop 1000 Spectrophotometer.   Using the RNA-40 setting, only 1µl 
of sample was required to measure absorbance at 260nm, 280nm and 230nm.   The 
following ratios were then calculated; 260/280 ratio, which should be ~2.0 for pure 
RNA samples, and the 260/230 ratio which should be higher than the 260/280 ratio.   
The NanoDrop 1000 software also calculated the concentration of the sample 
according to Beer’s Law.  The modified version of the Beer-Lambert equation used 
for this calculation was: 
c = (A x e)/b 
o c is the concentration of the nucleic acid sample.  
o A is the absorbance units at 260nm. 
o e is the wavelength dependant extinction coefficient (50ng-cm/µl for 
dsDNA, 33ng-cm/ul for ssDNA or 40ng-cm/µl for RNA).  
o b is the path length in cm. (The absorbance was actually measured at a 
1mm path length, but the reading is converted as if it were measured in a 
conventional 10mm path length by the NanoDrop 1000 software.  
 
[Nanodrop user’s manual, Thermo Scientific, UK.  
http://www.nanodrop.com/Library/nd-1000-v3.7-users-manual-8.5x11.pdf]. 
 
 Agilent 2100 Bioanalyser 
The Agilent 2100 bioanalyser can assess the quality and quantity of nucleic acid and 
protein samples using microfluidic ‘chips’ in which picogram quantities of sample 
can be electrophoretically separated and analysed.  The RNA 6000 Nano Assay kit 
[Agilent] is specifically used to separate total RNA for size and quantity 
measurements.  The associated software computes both quantity in ng/µl and an RNA 
Page 85 
Integrity Number (RIN) which indicates the quality of the RNA in a sample 
independent of quantity.  
 
The RNA 6000 Nano assay kit comes with chip, gel matrix, dye and a size marker.  
The samples were prepared and run on the chip according to manufacturer’s 
instructions as follows.  Reagents were allowed to come to room temperature whilst 
the electrodes of the bioanalyser were decontaminated with RNaseZAP.  The gel 
matrix was prepared by adding 1ml to a spin filter and centrifuging for 10 minutes at 
1,500 x g.  1µl of Nano dye concentrate was then added to 65µl of the filtered gel 
matrix and the solution was mixed thoroughly on a vortex.   
 
A chip was then placed on the Agilent chip priming station and 9µl of the pre-
prepared gel matrix/dye solution was pipetted into position (G) and the plunger was 
used to pressurize the gel into the system.  A further 9µl was the pipetted into the two 
positions marked G.   The Nano marker was then added to the chip; 6µl pipetted into 
each sample well plus 5µl pipetted into the ladder well.  The RNA samples, 1.5µl of 
each sample, were pre-heated to 70oC for 2 minutes on a thermocycler along with 
1.5µl of the ladder before analysis in 0.2ml microtubes.  Then 1µl of the denatured 
ladder was placed in the ladder well and 1µl of each sample was placed in the sample 
wells.  The chip was then vortexed on the specially adapted vortex [Agilent] before 
being placed in the bioanalyser.   
 
The correct assay programme was selected in the 2100 expert software and the run 
was initiated.  Once the run was complete an electrophoresis file run summary was 
obtained.  A RIN number of less than 8 may indicate RNA degradation has occurred 
and this may affect analysis results.  A yield of 250ng of total RNA was required for 
the next stages of processing at a concentration of at least 25ng/µl. 
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3.4.2 cDNA synthesis, purification and ‘in-vivo’ cRNA transcription 
 
The Ambion Illumina TotalPrep kit [Applied Biosystems, UK] was used to process 
total RNA samples prior to analysis on the Illumina Rat Ref12 BeadChip. The RNA 
was initially transcribed into cDNA which involves a polymerase chain reaction 
(PCR) which utilises reverse transcriptase as the reaction enzyme instead of DNA 
polymerase which is used in a standard PCR.  Reverse transcriptase in this case is 
‘Array Script’ which is a modified enzyme that has enhanced performance at 
synthesising full length cDNAs.  The T7 oligo dT primer ensures all the generated 
cDNA contain a T7 promoter sequence which ensures all of the cDNAs are 
transcribed in the in-vivo transcription (IVT) stage.    
 
In the next step the complementary strands for the newly generated cDNAs are 
synthesised using DNA polymerase, at the same time RNase H degrades the RNA 
present in the reaction.  The double stranded cDNA is cleaned up and the degraded 
RNA is eliminated.   The IVT step then generates biotin labelled RNA from all the 
cDNAs present using T7 enzyme.  This reaction contains an excess of biotinylated 
dNTPs to allow transcription to continue uninhibited until the reaction stops, thereby 
allowing amplification of copies relative to the number of copies in the original 
sample.  The cRNA is then cleaned up ready for hybridisation.  The methods for 
cDNA and subsequent cRNA preparation are as per manufacturer’s protocols.    
 
First 250ng of total RNA was made up to a volume of 11µl with RNase free water 
and placed in a 96 well skirted PCR plate [Thermo Scientific, UK].  This was placed 
on ice whilst the reverse transcription master mix was made up at room temperature 
in a nuclease free microcentrifuge tube, vortex mixed and spun briefly (see Table 
3.13) then 9µl of the master mix was added to each sample to make a total volume of 
20µl.  The 96well plate was then sealed before being vortexed and briefly spun.  The 
samples were then incubated at 42oC for 2 hours on a PTC-225 thermal cycler [MJ 
Research, UK].   
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Table 3.13 Ambion TotalPrep reverse transcription master mix Components are 
shown per reaction and also per 12 reactions (13.2 to account for pipetting error). 
 
Reagent 1 reaction 13.2 reactions
T7 Oligo (dT) primer 1 13.2
10 x First strand buffer 2 26.4
dNTP mix 4 52.8
RNase Inhibitor 1 13.2
Array script 1 13.2  
 
Once complete the plate is again spun briefly in a microcentrifuge before being 
placed on ice for the next step.  The second strand master mix was prepared on ice 
(see Table 3.14) and again vortexed briefly to ensure components were well mixed.  
80µl of this mix was pipetted into each sample to make 100µl total reaction volume 
and the plate was covered with a fresh seal.  The plate is again vortexed and spun 
briefly, before being incubated at 16oC for 2 hours on a thermal cycler.  Following 
this incubation the plate was placed on ice (or was placed at -20oC overnight).   
 
Table 3.14 Ambion TotalPrep second strand master mix Components are shown 
per reaction and also per 12 reactions (13.2 to account for pipetting error). 
 
Reagent 1 reaction 13.2 reactions
Nuclease-free water 63 831.6
10 x Second strand buffer 10 132
dNTP mix 4 52.8
DNA polymerase 2 26.4
Rnase H 1 13.2  
 
For cDNA purification, nuclease-free water was pre-heated to 55oC and cDNA 
binding buffer was warmed to room temp.  1.5ml centrifuge tubes and cDNA filters 
were labelled before 250µl of cDNA binding buffer was added to the labelled 1.5ml 
eppendorfs.  The samples were transferred one at a time from the 96 well plate and 
added to 250µl of buffer and mixed with a 1ml pipette before being put immediately 
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onto the filter cartridges.  The cartridges were then spun for 1 minute at 10,000rcf 
(relative centrifugal force).  The flow-through was discarded and 500µl of ethanol 
containing wash buffer was then added to the cartridge and they were spun again for 
1 minute at 10,000rcf.  The flow through was discarded and the filter was spun again 
to dry it out before it was transferred to a fresh labelled microcentrifuge tube for 
cDNA elution.   
 
A small volume (10µl) of nuclease-free water was added to the filter and left to stand 
for 2 minutes at room temperature, before the filters were again spun for 1 minute at 
10,000rcf.  A further 9µl was added to the filter and the centrifugation was repeated 
to make a final elution volume of 17-18µl. 
 
The Illumina oven was pre-heated to 37oC before beginning the cRNA in-vivo 
transcription (IVT) stage.  The eluted cDNAs were made up to 17.5µl if they were 
less than 16µl, and the IVT master mix was made up at room temperature (see Table 
3.15).  The master mix was vortexed before 7.5µl was added to each cDNA sample, 
the tubes were then placed in the oven overnight.  The exact length of time for this 
incubation was noted as this needed to be identical for all samples which are to be 
compared in the gene expression analysis.  The following morning the reaction was 
stopped by adding 75µl of nuclease-free water.   
 
Table 3.15 Ambion TotalPrep in-vivo transcription (IVT) master mix 
Components are shown per reaction and also per 12 reactions (13.2 to account for 
pipetting error). 
 
Reagent 1 reaction 13.2 reactions
T7 10 x reaction buffer 2.5 33
T7 enzyme mix 2.5 33
Biotin-NTP mix 2.5 33  
 
Before starting cRNA purification the nuclease-free water was again pre-heated to 
55oC and cRNA filters and microcentrifuge tubes were labelled.  To each sample 
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350µl of cRNA binding buffer was added followed by 250µl of ethanol before being 
mixed thoroughly with a 1ml pipette.  The mixed samples were then transferred 
immediately onto the cRNA filter cartridges and were spun for 1 minute at 10,000rcf.  
The flow-through was discarded and 650µl of wash buffer was added before a further 
centrifugation.  The flow-through was discarded and the filter was spun again to dry it 
out.  The filter was then placed in a new labelled microcentrifuge tube and 100µl of 
pre-heated nuclease-free water was added to the filter and left to stand at room 
temperature for 2 minutes before the cartridges were spun at 10,000rcf for 1.5 
minutes.     
 
The size distribution of the labelled cRNA was assessed on the Agilent 2100 
Bioanalyser before the samples were hybridised onto an Illumina RatRef12 Beadchip 
by Genome Centre staff (the Genome Centre protocol for hybridisation is shown in 
Appendix 1) before being washed, stained and scanned on the Genome Analyser.   
The cRNA samples extracted from tissue samples 1-9 were hybridised onto the chip 
along with three technical replicates. 
 
3.4.3 Gene expression data pre-processing 
 
Once the chip had been scanned, the data was examined using the gene expression 
analysis module of Illumina’s proprietary software package ‘BeadStudio’ which is 
designed for reading and viewing data generated by the Genome Analyser hardware.   
The gene expression module contains tools for looking at internal QC features on the 
chips, normalising data, performing background subtraction as well as statistical tools 
for performing a simple differential expression analysis.    
 
3.4.3.1 Quality assessment of gene expression data using BeadStudio 
A new ‘Direct Hyb’ gene expression project was created and named, and all the 
image data files from the chip were loaded.  Once the project was created, the internal 
QC features were checked by looking at the control summary plots.  These included 
several histograms, one summarising the results of each control feature.   The first 
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three plots show data independent of samples and illustrate signals originating from 
the oligonucleotides that were spiked into the hybridisation solution.   
 
o Plot 1 = ‘Hybridisation controls’ – This shows a histogram of high, medium 
and low relative quantity oligos. These should have high, medium and low 
intensity signals.   
o Plot 2 = ‘Low stringency’ – This shows the signals of perfect match (PM and 
mismatch (MM2) oligos.  This histogram should show the PM signal to be 
much higher than the MM2 signal. 
o Plot 3 = ‘Biotin and high stringency’ - Both of these signals should be high 
especially the high stringency signal. 
o Plot 4 = ‘Negative controls’ - This should indicate the background and noise 
to have low signals.   
o Plot 5 = ‘Gene intensity’ – This shows the signal of the housekeeping genes 
against the signal from all the other genes together.  This histogram should 
show a much higher signal coming from the housekeeping genes 
 
Another tool used to check the data were the scatter plots.  This tool was used to look 
at the average signals from probes in one sample against another.  These checks will 
give some indication of how well matched any technical and biological replicates 
were and the relationship between samples of different experimental groups.  Any 
strong skew or asymmetry in these plots would indicate poor sample quality or 
saturation at the higher intensities.   
 
Clustering dendrograms were used to look at probe level data without normalisation 
to see if technical replicates clustered together and if the study groups clustered 
separately.  Finally, the RIN numbers were also checked to see if they explained the 
cluster pattern of the samples.   
 
 
 
Page 91 
3.4.3.2 Data preparation and normalisation 
Following pre-processing, a new project was created with only the image data files of 
the samples to be analysed (i.e. excluding the technical replicates) were loaded and 
the study groups were defined.  The data was then normalised using the quantile 
normalisation method.  The normalised probe level data, with no background 
subtraction, was exported including the all fields as a .txt file.   For the individual 
probes there are probe ID, gene symbol, search key (GI), chromosome, definition, 
synonyms, GI, accession, probe type and probe sequence.  For every sample there are 
the average signal (normalised), detection p-value, bead standard error and average 
number of beads.   
 
3.4.4 Differential gene expression analysis using LIMMA 
 
Linear Models for Microarray Data (LIMMA) is an R software package especially 
designed to determine genes which are differentially expressed in large datasets 
produced by microarray analyses [109, 110].   LIMMA has also been shown to 
perform well in analysis of microarray experiments with a small n-number [111, 
112].  The data files were prepared for LIMMA analysis in Excel. Firstly the non-
detected probes were removed, the criteria for identifying non-detected probes are 
detection p-values >0.05 for 8 or 9 of the 9 samples.   For the remaining probes, the 
following data was assembled in a format suitable for LIMMA analysis; average 
signal, array standard deviation, bead standard error, average number of beads and 
detection p-value.  The file was saved as a comma separated values (CSV) format 
file.  A second CSV file was created with the headings ‘sample’, ‘disease’ and ‘time’, 
the sample IDs were placed under ‘sample’ in the same order in which they appeared 
in the main data file.  Sham, MI or BMMNC were placed under the disease file 
depending on which group the sample was from, and as the second variable (time) 
wasn’t being used; the value ‘1’ was entered for all samples.  This file is named 
‘targets’ and will be used to define the experimental design.   
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Once an ‘R’ workspace was opened the code detailed in Figure 3.5 below was entered 
to perform LIMMA analysis.  The blue text contains details on what function each set 
of commands was performing.  The .txt files containing the normalised gene 
expression data and the targets file are highlighted in bold text.  The write.table 
function enables the statistical details to be written to a text file which can then be 
handled in Excel.  The figures returned by the command summary(results) 
informed the number of results to get R to write to the text files.   
 
The Illumina codes contained in the text files returned by LIMMA were then used to 
define which genes were determined as being significantly up or down-regulated in 
either Sham vs. MI, MI vs. MNC or Sham vs. MNC.   
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Figure 3.5 R script used to perform the LIMMA analysis  Text in black is the 
code.  Text in blue describes the functions of the various parts of the script. 
 
> library(limma) 
> library(beadarray) 
Opens the libraries of command codes for LIMMA and Beadarray. 
 
BSData=readBeadSummaryData("DATA_TABLE.csv",sep=",",ProbeID="PROBE_I
D",skip=0) 
> BSData 
Opens the .csv files containing the normalised data prepared earlier. 
 
> targets<-readTargets("targets.csv",sep=",") 
> targets 
Opens the .csv targets file containing the experimental design. 
> f<-paste(targets$disease,sep="") 
> f<-factor(f) 
> design<-model.matrix(~0+f) 
> colnames(design)<-levels(f) 
> design 
Determines the experimental design using the targets.csv file. 
> fit<-lmFit(log2(exprs(BSData)),design) 
> cont.matrix<-makeContrasts(Sham_MI="MI-Sham",MI_MNC="MNC-
MI",Sham_MNC="MNC-Sham",levels=design) 
> fit2<-contrasts.fit(fit, cont.matrix) 
> fit2<-eBayes(fit2) 
> colnames(fit2) 
Instructions to perform the linear modelling using Bayes statistics on the log2 of the 
expression values in the data file ‘BSData’.  Then use the previously defined contrast 
matrix to perform three different two group comparisons, Sham vs. MI, MI vs. MNC 
and Sham vs. MNC. 
 
> topTable(fit2, coef=1, number=10, adjust="fdr") 
Returns a table detailing the top 10 results of the first contrast (Sham vs. MI) with p-
values adjusted for fdr (false discovery rate). 
 
> results<-decideTests(fit2) 
> summary(results) 
Returns a summary of the analyses done so far in terms of the number of probes with 
statistically significant positive or negative fold changes in the three comparisosnt 
performed. 
 
> write.table(topTable(fit2, coef=1, number=1550, 
adjust="fdr"),file="shamvsMI1550.txt",sep=",") 
Writes a .txt file summarising the top 1550 results from the first contrast (Sham 
vs.MI). 
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3.5 Validation of differentially expressed genes 
 
Validation of gene expression results was performed using quantitative real-time PCR 
(QPCR).  The mRNA samples are converted into cDNA using in vitro reverse 
transcription and the cDNA population is then used as a template for a modified 
polymerase chain reaction (PCR) reaction termed QPCR.   QPCR utilises the in-vitro 
transcription technique PCR to amplify specific transcripts in a prepared mRNA 
sample.  The transcripts of interest should amplify at an equal rate and therefore their 
relative abundance at a certain time point during the exponential phase of 
amplification should be related to their proportion in the original mRNA sample.  The 
abundance of transcripts is measured through the use of fluorescent probes or labels 
which can be detected on a flourescence microplate reader.     
 
Firstly several genes were tested to ascertain the most suitable genes to use for 
normalisation in our expression analysis, then comparative gene expression was 
determined by using the ∆∆ CT method to normalise gene expression and to calculate 
relative gene expression in the MI and BMMNC groups against the Sham group  
 
3.5.1 TaqMan gene expression assays 
 
TaqMan Gene Expression assays utilise 5’ nuclease activity of the Taq polymerase 
enzyme.  A short oligo (probe) which has a minor groove binder (MGB) and a non-
fluorescent quencher at the 3’ end and a fluorescent reporter dye at the 5’ end.  These 
probes are termed hydrolysis probes.  The MGB binder increases binding of the probe 
and therefore shorter probes can be used and higher melting temperatures (Tm).   
 
At the annealing/extension stage (60oC) of the PCR reaction a forward and reverse 
primer anneal to either end of the sequence of interest in the cDNA template, at the 
same time the TaqMan hydrolysis probe binds to a complementary sequence within 
the sequence of interest.  The Taq polymerase then catalyses the polymerisation of a 
complementary strand extending for the primers in a 5’ to 3’ direction.  When it 
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reaches the hydrolysis probe it will dislodge first the reporter dye from the probe, 
separating it from the influence of the quencher and creating a fluorescent signal.  As 
Taq polymerase will only cleave probes that are complimentarily bound to the 
sequence of interest whilst that sequence is being replicated then the amount of 
fluorescing reporter dye in the reaction is proportional to the number of copies of the 
sequence of interest. 
 
3.5.2 RNA preparation 
 
The RNeasy Fibrous Tissue Mini Kit [Qiagen] was used to extract RNA from the rat 
myocardial tissue samples as before and these were quantified and quality was 
assessed using the NanoDrop 1000 Spectrophotometer as before.   
 
To prepare cDNA for QPCR a Reverse Transcription System kit [Promega, UK] was 
used.  Firstly a master mix was prepared containing all the reaction components 
except the RNA template (See Table 3.16).  Then 1µg of the RNA was then diluted to 
a final volume of 9.8µl in nuclease-free water.  These samples were heated to 70oC 
for 1 minute in a thermal cycler and then 10.2µl of the master mix was added to the 
microtubes to make up 20µl reaction volumes.   The tubes were incubated at room 
temperature for 10 minutes and then at 42oC for 15 minutes on a thermal cycler.  The 
temperature was the taken up to 95oC  for 5 minutes and down to 4oC  for a further 5 
minutes to denature and inactivate the reverse transcriptase enzyme.  The cDNA 
samples could then be stored at -20oC until needed for the QPCR reaction.  
 
Table 3.16 Promega reverse transcription master mix 
Reagent 1 reaction 15 reactions
MgCl2 (25mM) 4 60
10 x Reverse Transcription Buffer 2 30
dNTP mix (10mM) 2 30
Recombinant RNasin Ribonuclease Inhibitor 0.5 7.5
AMV Reverse Transcriptase (15 units) 0.7 10.5
Random Primers 1 15
Nuclease free water 0.6 9  
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3.5.3 QPCR using TaqMan gene expression assays 
 
Absolute QPCR ROX Mix [Thermo Scientific, UK] was used for the QPCR reaction.  
This pre-prepared reaction cocktail contains Thermo-StartTM DNA Polymerase, ROX 
Dye which is used as a passive internal reference for normalising the signal from the 
reporter dye, dNTPs and buffers for optimal reaction conditions.   
 
cDNA samples were diluted 1:100 in nuclease-free water and 5µl of this dilution was 
pipetted into the wells of a 384 well optical reaction plate [Applied Biosystems, UK] 
in triplicate.  The master mixes (see Table 3.17) were prepared on ice, one for each 
different gene (assay) to be used, in sufficient volume to do all the reactions plus a 
no-template control.   The master mixes were then added to the diluted cDNA 
samples, 16µl of master mix for each 20µl reaction.  Once the 384 well optical plate 
was prepared, it was sealed with an optical plate seal [Thermo Scientific, UK] and 
was briefly spun down in a Sigma 4K15C centrifuge [Phillip Harris, UK].   
 
Table 3.17 TaqMan QPCR master mix 
 
Reagent
1 
reaction
30 
reactions
Absolute QPCR ROX Mix 10 300
TaqMan assay 1 30
Nuclease-free water 4 120  
 
A new ‘absolute quantification’ TaqMan 2900HT run was set up using the SDS v2.3 
software, and the barcode of the optical reaction plate was scanned.  A marker for 
each assay is selected in the detection manager, with a FAM fluorescent label and a 
non-fluorescent marker.  The wells used for the reactions are highlighted and the 
marker is linked to them.  The samples were then named in the left hand grid panel.  
The thermal profile was left as default i.e. 50oC for 2 minutes, 95oC for 10 minutes 
followed by 40 cycles of 95oC for 15 minutes and 60oC for 1 minute.  The file was 
saved before the run was commenced.  Once complete, the data was analysed using 
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the SDS v2.3 software and the data was exported to Excel [Microsoft, US].  
Triplicate Ct values for each sample were averaged after removing any outliers as 
suggested by high CV values (CV>2). 
 
3.5.4 Reference gene selection 
 
As TaqMan gene expression assays are already optimised to be 100% efficient there 
is no real requirement to put a standard curve on every plate.  Comparative gene 
expression can be determined by using the ∆∆ Ct method to normalise gene 
expression and to calculate relative gene expression in one group against a reference 
group.  Selecting a suitable reference gene is important to get accurate results as is the 
use of more than one reference gene [113].  
 
Five reference genes for rat were available in-house these were ATP synthase subunit 
beta (ATP5B), beta-2 microglobulin (B2m), eukaryotic translation initiation factor 
4A2 (Eif4a2), glyceraldehydes-3-phosphate dehydrogenase (Gapdh) and ubiquitin C 
(Ubc).  Initially the performance of these as endogenous controls were looked at in 
the pre-existing Illumina chip data to see they are expressed at a reasonable level and 
to see how stable expression was across samples and also to see if there is any 
evidence that these genes are differentially expressed in our experiment, i.e affected 
by our experimental conditions.   Statistics were performed to measure variation of 
signal across the samples (standard deviation and CV of the Average signal over all 
samples), one way ANOVA was also performed using GraphPad Prism 5 [GaphPad, 
UK] to look for differences between experimental groups.    QPCR was then 
performed on each of the suitable best candidates in all of the cDNA samples (in 
triplicate).   
 
The geNorm VBA Excel macro was downloaded from the geNorm website 
(http://medgen.ugent.be/~jvdesomp/genorm/).  The QPCR data for all of the 
reference genes that were tested were put into an Excel data table with sample names 
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in the left column and gene names along the top.  The values needed for this table 
were quantities (QREF) calculated using the ∆Ct method: 
 
∆Ct = Ct target – Ct reference 
 
The reference was the sample with the smallest Ct (highest expression) which was 
then set to 1: 
 
QREF = E ∆Ct 
 
QREF = Quantity of reference converted from Ct values.   
E = amplification efficiency (2 = 100%). 
 
The geNorm macro was opened and the newly created table was uploaded and the 
macro was set to calculate.  The macro calculated a measure of gene expression 
stability ‘M’ for each reference gene from the average pairwise variation ‘V’ for that 
gene against all the other tested reference genes.  The ‘M’ value for the least stable 
gene was highlighted in red and this column was deleted and the calculations were 
repeated.  This is repeated until you have the two best reference genes (see Figure 3.6 
for an example).  To check no additional genes would add value to the accuracy of 
the normalisation, the ‘bar chart’ symbol was selected and this will produce two types 
of chart both indicating the pairwise variation between two sequential normalisation 
factors.  If this value was over 0.15 then the inclusion of data from the next best gene 
in the normalisation factor calculation would be desirable (see Figure 3.7 for an 
example).  The cut-off value was suggested by Vandesompele et al 2002 [114].   
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Figure 3.6 Flowchart depicting the use of GeNorm to determine the most stable 
reference gene for a set of samples.  1) First the dataset is uploaded and the macro is 
told to make the calculations.  2)  The column with the highest scoring gene (‘M’ 
value in red) is deleted and the analysis is repeated.  3) The highest scoring gene is 
again deleted and the analysis is repeated. 4) This is repeated till there are only the 
two best genes remaining.   
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Figure 3.7 Graphical output of the example GeNorm analysis shown in Figure 
3.6 The top chart plots the ‘M’ values for each gene, the two most stably expressed 
genes with the lowest ‘M’ value on the left.  The bottom chart shows the pairwise 
variations for V2/3 (i.e between the normalisation factor calculated for the best 2 
genes and the normalisation factor calculated from the best three genes), and V3/4 (i.e 
best three genes and the best four genes).  Both values are <0.15 and so the additive 
effect of the third and fourth genes is negligible. 
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3.5.5 ∆∆Ct calculations and statistical analysis 
 
The average Ct values for each of the reference genes suggested by GeNorm in each 
sample were calculated to give an average reference Ct (Ct REF) value for each 
sample.  
 
The ∆Ct for each gene of interest (∆Ct GOI) was calculated using the ∆Ct method to 
calculate the difference between the Ct of the GOI and the Ct REF : 
 
∆Ct GOI = Ct GOI – Ct REF 
 
Then the average (AVE) and standard deviation (StDEV) of the ∆Ct GOI was 
calculated for each of the experimental groups (Sham, MI and BMMNC). 
 
The ∆∆Ct values were then calculated using the Sham group as reference: 
 
 ∆∆Ct Sham = Ave ∆Ct Sham - Ave ∆Ct Sham (= 0) 
 ∆∆Ct MI = Ave ∆Ct MI -  Ave ∆Ct Sham 
 ∆∆Ct BMMNC = Ave ∆Ct BMMNC - Ave ∆Ct Sham 
 
The ∆∆Ct values are then used to calculate fold changes (FC) between groups 
(relative expression) as shown below.  In this case the FC of the MI group compared 
to Sham (FC1) and the FC of the BMMNC group compared to Sham (FC2).  The 
Sham group value is also converted to 1 using the  same calculation: 
 
  FC1= 2-∆∆Ct MI 
  FC2= 2-∆∆Ct BMMNC 
  Sham = 2-∆∆Ct Sham (= 1) 
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The StDEV of the group average Ct values were used to calculate 95% upper and 
lower confidence intervals (CI) which were shown on the histogram with the FC 
values.  A Student’s t-test was performed on the ∆Ct GOI values to look for significant 
differences between the Sham vs. MI and MI vs. BMMNC groups. 
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3.6 Bioinformatic analysis of protein and gene expression data   
 
Several bioinformatics tools were employed to draw biologically relevant information 
from the lists of genes and proteins created in the comparative 2DGE and gene 
expression chip analyses.  These tools were also used to look firstly at what 
information could be drawn from the proteomic analyses and from our gene 
expression analysis and then to combine the datasets and see if they yielded any extra 
information over and above that gained in looking at the datasets separately.  
 
3.6.1 Protein ANalysis THrough Evolutionary Relationships (PANTHER) 
 
PANTHER is an online database originally designed to look at the evolutionary 
relationship of sequence and protein function [115, 116].  An online tool interface has 
now been developed to utilise the database for expression data analysis among other 
things.  Specifically the tool provides functional classification information when 
supplied with a list of genes or proteins.   
 
When lists of gene or protein Refseq codes were entered into the ‘batch search’ 
function of PANTHER, the tool looked for genes in the database which matched 
those in the list.   The resulting table shows the entered Refseq codes and gene names 
for these alongside the ‘best hit’ found in PANTHER and a score for this.  A 
PANTHER score of 1 indicated a match couldn’t be found, a score of 0 was a perfect 
match and other scores in between were graded ‘closely related’, ‘related’ and 
‘distantly related’.  All of the PANTHER hits were returned along with PANTHER 
annotations for pathways, molecular functions and biological processes.  PANTHER 
contains ~ 30 annotated biological process, ~30 molecular function categories as well 
as ~150 annotated pathways.  These tables were exported.  Before functional 
classification analysis was performed the threshold cut-off for the Panther score was 
set to exclude all genes with no hit, ‘distantly related’ hits and ‘related’ hits.  This 
ensured only exact matches and closely related hits were included.   
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The ‘pie-chart’ function was then used to look at the pathways represented by the 
genes in the lists.  Then the pie-chart showing the molecular functions and one 
showing the biological processes represented by our lists were studied and again data 
for these charts was exported as text files that could be looked at again in Excel 
[Microsoft, US].   
 
Separate lists were entered into PANTHER for genes and proteins up- and down-
regulated in the two comparisons to look for distinct pathways, functions or processes 
that were being up- or down-regulated 
 
3.6.2 Database for Annotation, Visualization and Integrated Discovery (DAVID) 
 
DAVID is a publicly available online tool for performing enrichment analysis on 
large gene lists produced from gene expression data [117, 118].  In a similar fashion 
to PANTHER, DAVID first matched a list of identifiers to genes in the database, and 
their annotations.  DAVID includes many annotations from gene ontology (GO) 
terms and KEGG pathways, to annotations on protein domains and tissue expression.  
As before the separate gene lists for probes or proteins up- or down-regulated in 
either Sham vs. MI or MI vs. BMMNC were uploaded.  For the gene expression data 
Illumina-ID codes were uploaded and ‘RatRef12 Illumina chip dataset’ was used as 
background upon which any enrichment was assessed.   For the protein lists, the 
Uniprot accession codes were uploaded and Rattus Norvegicus was used as 
background.  Functional annotation clustering was performed on each separate list of 
genes or proteins.   
 
First the biological process (BP) GO terms were clustered.  High stringency was 
chosen which gives smaller more specific clusters of terms rather than broader ones.  
The GO terms within each cluster, count (number of genes from list with this 
annotation), fold enrichment (the fold enrichment of this annotation in the uploaded 
gene list versus the proportion of this annotation in the background dataset), % 
(percentage of the inputted genes found with this annotation), p-value (modified 
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Fisher’s exact test (EASE score) and benjamini adjusted p-values (corrected to 
control family-wide false discovery rate).   In the analysis of proteomic data, GO 
terms with p-values of <0.05 were taken to be significantly associated. In the larger 
gene-expression dataset benjamini adjusted p-values of <0.05 were taken to be 
significantly associated.   
 
Secondly we clustered the KEGG pathways represented in our gene lists.  This time 
using a medium stringency setting and again we recorded the same output measures.  
 
3.6.3 Ingenuity Pathway Analysis (IPA) 
 
IPA is a literature mining tool and database resource (Ingenuity Systems®, 
www.ingenuity.com).  Lists of proteins or genes with fold changes and p-values were 
entered into the online tool and a core-analysis was performed.   IPA returned 
information on how the proteins/genes in the list are linked, which cellular functions, 
signalling pathways or disease states they were linked to and which other proteins 
they were linked to within these networks and pathways.  From the large amount of 
information resulting from the core analysis, the most highly scoring networks were 
recorded, as were the top functions, and canonical pathways.    
 
The lists were not split into up-and down-regulated members as the output of IPA 
shows direction of influence.  A core analysis was performed on all of the proteomic 
data; Refseq codes, fold changes and p-values for Sham vs. MI (Observation 1) and 
MI vs. BMMNC (Observation 2).   A second core analysis was performed on all of 
the significant LIMMA data; Refseq codes, log fold changes and adjusted p-values 
for Sham vs. MI (Observation 1) and the same data for MI vs. BMMNC (Observation 
2).   
 
In each core analysis, the functional/canonical pathway analysis used the Ingenuity 
Knowledge Base (genes only) as a reference set and both direct and indirect 
relationships were selected for the network analysis, including endogenous chemicals 
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e.g. hydrogen peroxide and Ca2+.  The most significantly associated functions and 
canonical pathways were looked at and the networks generated in each of these core 
analyses were saved.  In the case of very large numbers of networks generated by the 
larger datasets, only the top five were looked at in detail.  P-values for the association 
of a functional annotation or canonical pathway with the datasets are based on a right-
tailed Fisher’s Exact Test.  Canonical pathways are returned with a log10 p-value 
(negative values) from the Fisher’s Exact Test and ratios which are calculated from 
the number of entered molecules found in the pathway divided by the total number of 
molecules in the pathway.  Network scores are based on the number of genes/proteins 
they contain that are from the input dataset (focus molecules). The higher the score, 
the lower the probability of finding the observed number of focus molecules in a 
given network by random chance 
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3.7 Studies of 14-3-3 epsilon  
 
3.7.1 Validation of experiments using samples 10-18  
 
Western blotting was used to measure protein expression of 14-3-3ε, Sdha and Pebp1 
in samples 10-18 (See Table 3.1).  If expression changes between the groups reflected 
the results from samples 1-9 we would take this as validation for the use of freshly 
prepared samples for experiments which would further investigate findings of interest 
from our proteomic and gene expression analyses which were obtained using sample 
1-9.    The methodology for performing these western blots in samples 10-18 were 
identical to those described in section 3.3.      
 
3.7.2 Expression and activation of BCL2-associated agonist of cell death (Bad) 
 
Western blotting was used to measure BCL2-associated agonist of cell death (Bad) as 
well as the phosphorylated form, phosphorylated at serine 136, in protein lysates from 
samples 10-18.  Antibodies for both Bad and  phosphorylated Bad were supplied by 
Abcam, and an alternative antibody for phosphorylated Bad was purchased from Cell 
Signalling Technology [supplied by New England Biolabs, UK].  The methodology 
for these assays was the same as that described previously in section 3.3, except that 
the blocking step was reduced to 2-3 hours at room temperature on a shaker instead of 
overnight at 4oC, and the primary antibody incubations were left overnight at 4oC, 
then 2 hours at room temperature on a shaker.   
 
3.7.3 14-3-3 epsilon pull-down assay 
 
A pull-down assay was performed using the ProFoundTM Pull-Down PolyHis 
Protein:Protein Interaction Kit [Pierce, US].  His-tagged 14-3-3 epsilon protein 
[Abcam, UK] was used at bait protein and freshly prepared protein lysates from 
samples 10-18 were used as prey.   An initial experiment was performed to test the 
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methodology using 60µg of His-tagged 14-3-3 epsilon protein and a protein lysate 
prepared from a mix of three tissue samples, one from each experimental group.   
 
3.7.3.1 Bait protein immobilisation 
BupHTM Tris buffered saline (TBS) was made up to 500ml with Milli-Q water and 
filter sterilised using a 0.2µm filter and a 50ml syringe.  The buffer was then stored at 
4oC until required.   Enough HandeeTM spin columns for the experiment, one for each 
prey sample plus a no-bait control were labelled.   Wash solution was made up by 
mixing TBS and Profound lysis buffer (1:1) and adding 4M imidazole stock to get a 
final concentration of 40mM.  Only enough wash solution was prepared for 
immediate use.  The immobilised cobalt chelate resin was thoroughly resuspended 
using a vortex mixer, and 25µl was pipetted into each column using a wide-bore 
pipette tip.   200µl of wash solution was added to each spin column, caps were placed 
over both ends and the column inverted several times.   Both caps were removed and 
the column placed in a collection tube before being spun at 1,250 x g for 30 seconds.  
The flow-through was discarded and the bottom cap replaced.  This wash step was 
repeated four times.  After the fifth wash, 60µg of the bait protein was added to the 
column in 300µl total volume of wash solution and the top cap was replaced.  The 
columns were then incubated at 4oC for 30 minutes on a rocking platform.  Prey 
protein preparation was carried out during this incubation step.  
 
Both caps were then removed and the columns were placed in a collection tube before 
being spun at 1,250 x g for 30sec.  The flow-through was labelled as ‘bait-flow 
through’ and stored on ice.  The resin was then washed five times using the same 
procedure as before. 
 
3.7.3.2 Prey protein preparation and capture 
Approximately 100mg of ground tissue from samples 12, 13 and 16 was added to 
250µl of ice cold TBS containing protease inhibitor cocktail in a Precellys CK14 
tubes, and this pooled sample was homogenised in a Precellys 24 bench top 
homogeniser [Bertin technologies].  An equal volume of Profound lysis buffer was 
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added and the sample was mixed gently then placed on ice for 30 minutes and 
inverted occasionally.  The lysate was then decanted to a microcentrifuge tube and 
spun at 12,000 x g for 5 minutes.  The supernatant was decanted and stored on ice.  
4M imidazole was added to a final concentration of 40mM and the tube was 
immediately inverted to mix thoroughly and labelled ‘prey lysate’. 
 
The columns were removed from 4oC storage, and the top cap was removed.  The full 
volume of prey protein lysate was added to the column except 10-15µl kept for 
quantification and SDS-PAGE. The top cap was replaced and the columns incubated 
at 4oC for at least 1 hour with gentle rocking.    Both caps were then removed and the 
column was placed in a fresh collection tube and spun for 1,250 x g for 30 seconds. 
The flow through was labelled ‘prey flow through’ and placed on ice.  The resin was 
then washed five times using the same procedure as before. 
 
3.7.3.3 Bait-Prey elution 
1ml of 290mM imidazole elution buffer was prepared by adding 63µl of 4M 
imidazole stock to 937µl wash solution already containing 40mM imidazole and 
mixing with a pipette.  The bottom caps were applied to the columns and the top caps 
removed.  30µl of elution buffer was added to the spin columns and the top cap was 
replaced then the columns were incubated at room temperature for 5 minutes.  Both 
caps were then removed from the columns and they were placed in a collection tube 
and spun for 1,250 x g for 1 minute.  The flow-through was labelled Elution 1 and 
placed on ice. 
 
3.7.3.4 SDS-PAGE and protein detection 
Prey protein lysate, bait-flow through and eluate preparations were separated on SDS 
PAGE gels as described in section 3.3.1.1.  Reducing agent was added to the samples 
(1.5µl to 15µl sample) along with 5µl of LDS buffer.  Once run, the gel was silver 
stained using the plus one silver staining kit [GE Healthcare] according to 
manufacturer’s instructions.   
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3.7.3.5 LC-MS/MS protein identification 
Bands were cut from the gel using a scalpel, cut into pieces no bigger than 2mm2 and 
placed in microcentrifuge tubes.  Trypsin digestion was carried out using the same 
methodology already described in section 3.2.5.  Lyophilised peptide samples were 
then reconstituted for LC/MS-MS and identification using the MASCOT database as 
described in section 3.2.6.    
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4. Proteomic results 
 
4.1 Wide-range protein profiling  
 
4.1.1 Protein quantification 
 
Samples of 80-140mg were taken from myocardial samples 1-9 for protein lysate 
preparation.  These protein lysates were quantified as being between 2-6µg/ul (total 
protein yields of between 1.6-7mg per sample, average 5mg).  The average yield was 
0.5mg of protein per 10 mg of starting material. 
 
4.1.2 2DE 
 
Two gels for each sample (18 gels in total) were analysed with PDQuest Advanced 
software [BioRad, UK].  An example of the gels produced for this analysis is shown 
in Figure 4.4. Normalised spot intensities for 1081 spots were analysed in Excel 
[Microsoft, US] to look for significant fold changes >1.5.  A total of 187 spots had 
fold changes >1.5 in either the Sham vs. MI, MI vs. BMMNC or both comparisons 
(Figure 4.1).  This list was narrowed down to those with the most significant fold 
changes (FC >2.5).  This left 130 spots (Figure 4.2).  All 130 spots were then checked 
in the gel images to confirm these changes by visual inspection and to check if there 
was sufficient sample to yield identification. 
 
105/130 spots were chosen to take forward for identification by LC-MS/MS.  There 
were also 4 spots with qualitative differences; 2 spots which were not present in the 
MI gels but were present in both the Sham and BMMNC gels, and 2 other spots 
which were not present in the Sham gels but were present in the MI and BMMNC 
gels.  These spots were also included and taken forward for LC-MS/MS (total 
n=109).   
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Figure 4.1 Venn diagram showing the distribution of 187 significantly differently 
expressed spots with >1.5 fold changes in the wide-range 2DE analysis Sham = 
sham operated group, MI = MI group treated with PBS, BMMNC = MI group treated 
with bone marrow mononuclear cells.  Arrowheads indicate direction of expression 
change in the Sham vs. MI or the MI vs. BMMNC comparisons or Both comparisons. 
 
52▼
22 ▲
▼ 29 ▲
▲ 6 ▼
69 ▲
9 ▼
Sham vs. MI  Both MI vs. BMMNC  
 
 
Figure 4.2 Venn diagram showing the distribution of 130 significantly differently 
expressed spots with >2.5 fold changes in the wide-range 2DE analysis Sham = 
sham operated group, MI = MI group treated with PBS, BMMNC = MI group treated 
with bone marrow mononuclear cells.  Arrowheads indicate direction of expression 
change in the Sham vs. MI or the MI vs. BMMNC comparisons or Both comparisons. 
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The median and standard error of spot intensities as well as differences between 
groups, 95% confidence interval (CI) of the differences, and Student’s t-test statistics 
for Sham vs. MI and MI vs. BMMNC comparisons for the 109 spots taken into 
protein identification are detailed in the Table 4.1.  The distribution of fold changes 
and p-values of these spots (not including the 4 qualitatively altered spots) in both 
comparisons is shown in Figure 4.3.  The larger proportion of spots were down-
regulated in Sham vs. MI  with up to 5 fold change and up-regulated in MI vs. 
BMMNC  again up to 5 fold change.     
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Figure 4.3 Graphs of p-values plotted against fold changes for 105 spots with 
significantly altered intensities in the pH 4-7 2DE analysis Sham = sham operated 
group, MI = MI group treated with PBS, BMMNC = MI group treated with bone 
marrow mononuclear cells.  A data for spots significantly altered in Sham vs. MI 
analysis.  The points highlighted in blue show data for the spots which were also 
significantly different in MI vs. BMMNC.  B data for spots significantly altered in MI 
vs. BMMNC analysis.  The points highlighted in blue show data for the spots which 
were also significantly different in Sham vs. MI.   
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 Table 4.1 109 spots selected for protein identification by LC-MS/MS from the pH 4-7 2DE analysis Sham = sham operated 
group, MI = MI group treated with PBS, BMMNC = MI group treated with bone marrow mononuclear cells.  Median spot intensities 
and standard errors for each group are shown alongside the difference, 95% confidence interval and Student’s t-test p-value for both 
Sham vs. MI and MI vs. BMMNC comparisons. 
 
 
SSP Med. SE Med. SE Med. SE Difference 95% CI p-value Difference 95% CI p-value
1206 487.8 96.56 229.0 148.12 0.6 ns
1207 42.6 260.00 1530.6 330.15 1523.0 347.47 3.8 (2.15 - 5.52) 0.027 0.9 ns
1213 136.0 63.03 1056.0 157.18 693.0 197.05 7.1 (5.02 - 9.20) 0.002 0.6 ns
1223 73.9 56.30 10.8 12.32 137.8 56.06 0.2 ns 7.4 (2.89 - 11.98) 0.022
1224 493.69 147.22 87.61 124.58 893.49 142.04 0.4 ns 3.9 (2.53 - 5.30) 0.032
1225 312.0 61.87 11.6 13.78 233.9 94.57 0.1 (-0.02 - 0.17) 0.021 12.7 ns
1226 120.48 37.30 52.89 25.10 188.10 32.78 0.4 ns 3.0 (1.83 - 4.14) 0.037
1248 49.1 93.34 53.7 99.59
1301 739.1 221.10 146.0 156.50 684.0 55.51 0.3 (0.01 - 0.64) 0.036 2.1 ns
1304 672.9 239.84 114.8 68.51 556.1 172.21 0.2 (0.03 - 0.36) 0.025 4.6 (2.39 - 6.75) 0.014
1307 211.1 80.22 88.0 69.00 466.8 32.92 0.6 ns 3.2 (2.76 - 3.65) 0.002
1320 182.5 27.95 17.3 5.61 179.7 47.29 0.1 (0.04 - 0.16) 0.007 11.3 (5.95 - 16.66) 0.037
1424 331.0 121.77 342.8 67.56 803.2 92.83 0.7 ns 2.8 (2.18 - 3.52) 0.001
1429 1485.96 278.53 168.43 300.06 1714.20 309.05 0.4 ns 2.8 (1.79 - 3.82) 0.036
1430 258.6 68.41 23.8 6.82 271.9 73.49 0.1 (0.05 - 0.17) 0.027 12.5 (6.69 - 18.32) 0.007
1705 558.6 129.30 74.3 60.24 406.6 182.62 0.2 (0.03 - 0.45) 0.013 4.4 (1.77 - 7.07) 0.037
2119 210.0 166.12 1898.8 544.35 146.7 52.53 5.8 (2.53 - 8.99) 0.015 0.1 (0.04 - 0.15) 0.007
2226 420.9 115.81 139.9 41.72 324.0 78.51 0.3 (0.09 - 0.44) 0.020 2.9 (1.60 - 4.11) 0.029
2443 822.3 203.40 77.4 109.59 639.7 69.66 0.3 ns 3.6 (2.84 - 4.38) 0.005
2546 94.4 18.13 22.2 6.06 146.3 23.56 0.2 (0.11 - 0.38) 0.010 6.2 (4.08 - 8.34) 0.002
2607 18.5 33.03 258.6 32.73 213.1 59.97 4.8 (3.56 - 6.12) 0.008 0.9 ns
2609 777.2 121.29 301.0 68.67 783.6 55.55 0.5 ns 2.5 (2.16 - 2.86) 0.0003
2616 70.1 52.24 79.2 24.41 266.7 68.21 0.9 ns 3.3 (1.73 - 4.94) 0.035
2624 221.1 35.26 27.9 17.63 149.8 34.87 0.2 (0.05 - 0.41) 0.007 3.4 (1.87 - 4.99) 0.031
2626 95.1 30.14 68.6 23.54 301.7 91.19 1.0 ns 3.7 (1.71 - 5.65) 0.042
2701 39.5 78.78 366.4 83.13 441.1 323.49 2.9 (1.78 - 3.94) 0.034 1.7 ns
2712 631.5 180.42 184.6 102.51 715.4 244.00 0.4 ns 3.3 (1.63 - 4.90) 0.031
2722 36.3 17.57 21.9 7.86 134.4 32.10 0.5 ns 6.1 (3.36 - 8.92) 0.021
3208 216.1 68.85 123.4 57.84 469.2 48.71 0.5 ns 3.8 (3.11 - 4.54) 0.001
3209 258.8 91.71 30.9 50.70 470.1 103.23 0.4 ns 4.6 (2.63 - 6.60) 0.009
3228 140.9 89.60 1730.7 506.98 507.5 607.20 9.0 (4.19 - 13.90) 0.010 0.7 ns
3305 2089.7 390.71 502.1 203.38 1385.5 369.28 0.3 (0.09 - 0.56) 0.026 2.7 ns
3322 220.3 96.04 553.3 126.00
3433 811.3 136.32 461.2 102.82 1104.6 142.91 0.4 (0.17 - 0.60) 0.008 2.9 (2.16 - 3.73) 0.003
On in MI
Off in MI On in BMMNC
Off in MI On in BMMNC
Change in intensity (BMMNC/MI)SHAM MI MNC Change in intensity (MI/SHAM)
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 Table 4.1 continued. 
SSP Med. SE Med. SE Med. SE Difference 95% CI p-value Difference 95% CI p-value
3441 348.29 68.63 169.22 38.60 443.34 63.06 0.4 ns 3.0 (2.18 - 3.89) 0.008
3518 377.5 58.22 69.5 59.19 332.7 91.32 0.3 (-0.01 - 0.62) 0.011 2.9 ns
3523 551.1 129.94 256.8 55.88 637.8 48.63 0.5 ns 2.7 (2.36 - 3.14) 0.0002
3526 242.73 55.37 91.61 25.78 281.45 76.05 0.4 ns 3.2 (1.58 - 4.79) 0.045
3622 712.5 106.89 341.2 96.15 729.8 158.88 0.5 ns 2.5 (1.57 - 3.52) 0.024
3626 863.3 63.65 397.5 87.61 1075.1 161.82 0.5 ns 3.0 (2.23 - 3.87) 0.002
3627 326.7 118.43 221.5 20.72 531.0 74.46 0.4 ns 2.6 (1.93 - 3.35) 0.003
3629 285.7 66.51 111.4 38.11 462.1 81.22 0.4 ns 4.4 (3.03 - 5.76) 0.006
3632 113.8 33.21 55.4 24.43 209.8 41.26 0.6 ns 2.9 (1.81 - 3.93) 0.014
3636 270.6 49.01 32.2 26.40 384.8 46.73 0.2 (-0.012 - 0.37) 0.009 8.7 (6.76 - 10.64) 0.0004
3638 99.9 33.83 20.4 12.24 138.9 25.32 0.3 (0.06 - 0.50) 0.041 4.7 (3.11 - 6.34) 0.002
3706 409.7 65.23 164.3 47.79 738.6 136.53 0.5 ns 4.5 (2.95 - 6.06) 0.009
4207 524.5 164.16 802.8 238.61 435.2 110.88 2.0 ns 0.3 (0.14 - 0.56) 0.028
4217 903.56 209.86 161.41 117.70 197.14 101.48 0.3 (0.04 - 0.61) 0.047 1.0 ns
4235 50.0 26.86 23.0 7.03 188.1 41.90 0.3 ns 8.2 (4.36 - 11.95) 0.040
4244 238.0 51.56 22.9 10.24 173.3 41.23 0.1 (0.05 - 0.23) 0.004 5.5 (2.81 - 8.11) 0.009
4329 110.5 14.54 8.9 11.78 96.4 37.74 0.2 (-0.03 - 0.39) 0.002 5.4 ns
4406 721.4 140.81 188.0 125.34 922.2 144.33 0.4 ns 2.8 (1.81 - 3.86) 0.024
4418 75.6 65.92 76.5 30.65 392.7 75.29 0.6 ns 3.9 (2.31 - 5.44) 0.007
4511 400.3 89.46 50.0 61.54 505.2 88.15 0.4 ns 3.8 (2.50 - 5.20) 0.007
4513 95.23 6.54 38.34 19.65 156.51 30.81 0.5 ns 3.2 (1.80 - 4.50) 0.050
4521 426.8 306.05 44.7 141.22 752.4 71.75 0.4 ns 2.7 (2.12 - 3.24) 0.028
4522 295.8 67.87 130.8 42.86 421.3 41.77 0.6 ns 2.7 (2.06 - 3.25) 0.003
4523 691.1 89.08 73.8 86.61 403.7 130.40 0.2 (-0.02 - 0.46) 0.002 2.6 ns
4525 27.71 13.21 20.47 7.75 118.43 26.06 0.7 ns 4.3 (2.03 - 6.64) 0.022
4702 362.2 74.95 196.0 56.06 483.4 89.06 0.5 ns 2.7 (1.88 - 3.54) 0.006
4703 140.7 41.45 84.3 45.50 294.2 75.91 0.7 ns 2.7 (1.54 - 3.92) 0.035
4722 178.5 31.16 16.4 34.68 207.4 49.49 0.4 (-0.01 - 0.77) 0.048 3.3 (1.88 - 4.79) 0.028
4734 116.9 33.58 46.3 13.31 120.3 34.12 0.4 (0.21 - 0.56) 0.030 1.9 ns
4740 73.96 54.44 352.83 38.71 143.83 106.81 2.6 (2.00 - 3.15) 0.037 0.6 ns
4741 50.8 64.33 58.0 24.54 245.6 46.22 0.6 ns 3.4 (2.20 - 4.65) 0.011
5311 237.03 75.58 805.08 176.20 723.36 82.71 2.9 (1.55 - 4.31) 0.030 0.9 ns
5315 34.70 6.36 8.62 1.74 8.27 24.66 0.2 (0.13 - 0.35) 0.011 5.0 ns
5408 462.1 81.80 110.2 63.93 435.4 50.44 0.4 (0.09 - 0.70) 0.038 2.4 ns
5422 58.09 7.41 9.51 3.20 38.88 18.03 0.2 (0.06 - 0.28) 0.014 5.5 ns
5501 304.76 82.79 51.41 42.67 260.90 47.80 0.4 ns 2.8 (1.77 - 3.80) 0.030
5601 549.0 42.09 131.6 32.75 362.4 20.96 0.3 (0.18 - 0.42) 0.00005 2.2 ns
5618 214.0 60.27 82.5 26.17 168.3 48.73 0.3 (0.11 - 0.52) 0.039 2.3 ns
Change in intensity (BMMNC/MI)SHAM MI MNC Change in intensity (MI/SHAM)
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 Table 4.1 continued. 
SSP Med. SE Med. SE Med. SE Difference 95% CI p-value Difference 95% CI p-value
5715 297.4 68.71 1034.7 422.40 485.8 126.94 4.2 (1.66 - 6.79) 0.035 0.4 ns
5805 68.1 58.86 436.3 98.64 465.0 184.05 3.1 (1.65 - 4.54) 0.035 1.2 ns
6123 414.9 106.53 33.9 13.72 88.4 76.84 0.1 (0.02 - 0.16) 0.047 3.9 ns
6413 217.9 119.81 1003.8 358.86 483.1 173.02 4.3 (1.83 - 6.87) 0.033 0.5 ns
6424 666.28 136.76 142.75 51.98 519.16 163.44 0.3 (0.11 - 0.49) 0.038 3.2 ns
6425 472.7 60.58 31.0 36.97 211.2 195.97 0.2 (-0.01 - 0.33) 0.001 5.6 ns
6533 119.8 50.88 539.4 84.12 795.0 58.49 3.6 (2.47 - 4.76) 0.006 1.5 ns
6538 179.5 61.92 97.4 23.11 237.1 31.58 0.3 (0.09 - 0.46) 0.033 3.6 (2.67 - 4.48) 0.002
6545 327.4 66.83 24.3 32.13 365.9 1416.03 0.2 (0.02 - 0.46) 0.016 25.7 ns
6603 89.93 16.82 393.30 75.99 160.83 49.96 3.4 (1.98 - 4.88) 0.017 0.5 ns
6616 69.7 56.65 216.5 51.88 21.1 28.47 3.5 ns 0.2 (-0.05 - 0.42) 0.021
6636 73.8 29.65 54.9 9.36 189.4 50.56 0.8 ns 2.9 (1.44 - 4.39) 0.048
6732 94.7 26.36 290.3 43.99 208.0 21.75 2.6 (1.93 - 3.35) 0.005 0.6 ns
6746 121.13 26.77 289.95 89.33 80.84 22.70 2.5 ns 0.3 (0.14 - 0.43) 0.037
6813 226.80 48.49 68.00 28.53 131.83 36.14 0.3 (0.07 - 0.56) 0.036 1.8 ns
7110 174.4 508.95 23.5 45.40 0.1 ns
7111 775.4 210.42 209.4 78.54 491.4 156.98 0.2 (0.08 - 0.40) 0.009 2.6 ns
7112 122.4 41.78 18.5 4.08 69.5 45.67 0.1 (0.05 - 0.15) 0.007 7.1 ns
7228 17.6 63.73 1039.8 299.68 692.5 167.62 16.2 (8.75 - 23.74) 0.013 0.4 ns
7306 348.1 53.40 61.0 33.94 352.6 69.19 0.2 (0.04 - 0.38) 0.001 3.5 (1.90 - 5.14) 0.021
7323 690.6 163.55 1689.3 151.49 602.2 248.60 2.4 ns 0.4 (0.09 - 0.69) 0.007
7327 18.8 55.22 451.6 86.47 274.0 50.06 5.1 (2.79 - 7.48) 0.029 0.8 ns
7508 132.0 58.73 394.6 48.28 103.3 57.82 2.8 (2.08 - 3.51) 0.043 0.4 (0.06 - 0.68) 0.021
7515 175.0 21.33 85.3 15.95 205.6 27.55 0.4 ns 3.0 (2.29 - 3.78) 0.002
7608 52.2 19.59 489.2 130.60 338.9 126.82 9.3 (4.44 - 14.06) 0.028 0.7 ns
7612 44.8 26.50 174.3 39.00 31.9 8.07 3.4 (2.13 - 4.77) 0.029 0.2 (0.09 - 0.25) 0.010
7702 136.1 40.33 42.2 19.75 183.0 42.28 0.4 ns 3.7 (2.15 - 5.18) 0.011
7722 31.3 9.89 260.5 67.25 41.4 10.18 5.8 (2.41 - 9.17) 0.021 0.2 (0.11 - 0.29) 0.039
7723 314.1 82.71 99.4 26.05 275.5 58.44 0.4 (0.21 - 0.53) 0.045 2.4 ns
7730 101.6 20.08 46.3 8.07 76.6 30.21 0.4 (0.26 - 0.54) 0.012 2.5 ns
7737 170.2 41.43 53.4 18.41 117.7 36.79 0.3 (0.13 - 0.54) 0.040 2.5 ns
8128 511.6 99.61 194.5 79.76 380.8 134.24 0.4 (0.10 - 0.61) 0.012 1.9 ns
8520 136.2 17.54 22.6 21.09 136.6 14.96 0.3 (0.01 - 0.56) 0.005 3.0 (2.36 - 3.73) 0.008
8525 158.8 99.49 19.7 8.98 366.2 149.02 0.1 ns 13.4 (4.31 - 22.43) 0.023
8526 88.67 32.58 53.09 12.28 184.79 36.30 0.4 ns 3.5 (1.92 - 5.08) 0.024
8710 274.7 87.42 174.8 35.96 373.4 88.51 0.5 ns 2.7 (1.66 - 3.71) 0.014
8853 242.8 90.52 101.5 36.04 317.4 97.84 0.4 ns 3.4 (1.76 - 4.95) 0.033
SHAM MI MNC Change in intensity (MI/SHAM) Change in intensity (BMMNC/MI)
On in MI
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4.1.3 Differentially expressed proteins 
 
Of the 109 spots selected for protein identification 45 spots yielded no identification 
and 13 spots contained more than one protein. 51 spots yielded single protein 
identification including a total of 28 different proteins, 5 proteins were found in more 
than one spot.  An example of the 2DE gels produced by this analysis is shown in 
Figure 4.4, the spots from which a single protein identification was obtained are 
highlighted.  All of the MASCOT search results for the wide-range analysis are 
detailed in Appendix 2.  A summary of the 51 spots with single protein identification 
is shown in Table 4.2 and the fold change and p-values for these proteins, organised 
into functional categories is shown in Table 4.3.   
 
ATP synthase subunit β (Atp5b) was found in 17 different spots, L-lactate 
dehydrogenase B (Ldhb) chain was found in 3 different spots (although the peptide 
found in spot 4521 could not be distinguished from L-lactate dehydrogenase A 
chain), rat serum albumin (Alb) and myosin regulatory light chain-2 (Myl2) were also 
each found in 3 different spots and stress-70 protein (Hspa9) was found in 2 different 
spots. 
 
All of the Atp5b spots were down-regulated in Sham vs. MI and up-regulated in MI 
vs. BMMNC, only spots 3626, 3636 and 3433 were significantly altered in both 
comparisons.  The fold changes seen in these 17 spots ranged from 2 to 13 fold.  All 
spots had an estimated mass of between 19 and 57kDa and a range of pI from 4.5 to 
5.4.  The theoretical mass of Atp5b is 56.3kDa and pI is 5.2.  The details of all 17 
spots and the Atp5b peptides identified in each are shown in Table 4.4 and Figure 4.5.  
 
The most statistically significant alterations in Sham vs. MI were in the down-
regulated Ldhb, tubulin α-4A chain (Tuba4a) and Atp5b and in the up-regulated 
enoyl-CoA hydratase (Echs1) and Myl2.  Some of the highest fold change values in 
Sham vs. MI were seen in the down-regulated Atp5b, tropomyosin (Tpm1), NADH-
ubiquinone oxidoreductase 75kDa subunit (Ndufs1) and 14-3-3 epsilon (Ywhae) and 
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the up-regulated Myl2 and Alb.  Three spots with qualitative differences yielded 
protein identification results. These were galectin-5 (Lgals5) and Myl2 which were 
both absent in Sham and present in the MI gels, and troponin T (Tnnt2) which was 
present in Sham but absent in the MI gels.   
 
Figure 4.4 Example of a wide-range 2DE gel produced for this analysis   Image 
shows the positions of spots which differed significantly and from which protein 
identifications were obtained.  Spots identified as ATP synthase subunit β shown in 
pink, all others in yellow.  Numbers next to spots are SSP identifiers assigned by 
PDQuest. 
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Other proteins altered in Sham vs. MI were peroxiredoxin-6 (Prdx6) which was up-
regulated and thioredoxin-dependent peroxide reductase (Prdx3) which was down-
regulated.  The heat shock protein stress-70 (Hspa9) was also down-regulated.  
 
Some of the above proteins were also altered in MI vs. BMMNC.  Many of the spots 
identified as Atp5b were up-regulated in MI vs. BMMNC, as was one of the spots 
identified at L-lactate dehydrogenase (B or A chain).  Tpm1 and Ywhae were also 
strongly up-regulated in MI vs. BMMNC and Echs1 was significantly down-
regulated.   Hspa9 and Hspa8 were both up-regulated in MI vs. BMMNC.  
 
Other proteins of interest shown to be altered in MI vs. BMMNC were Cytochrome 
b-c1 complex subunit 6 (Uqcrh) which was down-regulated by 10 fold (5 fold up-
regulation in Sham vs. MI). Adenylyl cyclase-associated protein 1 (Cap1) and 
Desmin (Des) were significantly up-regulated in MI vs. BMMNC after being down-
regulated in Sham vs. MI.   
 
 Table 4.2 Spots with significant fold changes for which a single protein ID was found from the wide-range analysis.  SSP are 
spot identification numbers assigned by PDQuest software.  Mascot details are as follows; mascot score (the sum of the peptide 
scores), the number of peptides found and the sequence coverage of these peptides (only including peptides with individual scores 
over 35).  Theoretical Mr and pI values for the protein identified are shown as well as the observed Mr and pI of the spot as estimated 
from its position in the gel.  
 
 
Mr Pl Mr Pl Score pep's % sc
1206 17500 4.40 18868 4.86 Myosin regularory light chain 2 P08733 57 1 8
1207 19000 4.40 113780 8.4 NAD(P) transhydrogenase Q61941 58 1 2
1213 17500 4.40 18868 4.86 Myosin regularory light chain 2 P08733 108 2 16
1225 21000 4.50 56318 5.19 ATP synthase subunit beta P10719 192 2 7
1226 19000 4.50 56318 5.19 ATP synthase subunit beta P10719 105 2 6
1248 25000 4.50 35709 4.95 Troponin T, cardiac muscle P50753 59 1 3
1320 29000 4.50 32661 4.69 Tropomyosin alpha-1 chain  (or Tropomyosin beta chain) P04692 58 1 4
1424 34000 4.60 56318 5.19 ATP synthase subunit beta P10719 131 2 8
1430 34500 4.40 29155 4.63 14-3-3 protein epsilon P62260 164 3 20
2119 14500 4.80 10417 4.90 Cytochrome b-c1 complex subunit 6 Q5M9I5 131 1 20
2443 35000 4.80 56318 3.00 ATP synthase subunit beta P10719 91 1 3
2546 45000 4.80 51556 7.16 Adenylyl cyclase-associated protein 1 Q08163 55 1 4
2609 47500 4.80 56318 5.19 ATP synthase subunit beta P10719 457 6 12
2616 47500 4.80 32803 4.80 40S ribosomal protein SA P38983 50 1 4
2626 52500 4.90 56318 5.19 ATP synthase subunit beta P10719 167 3 8
2712 57500 4.90 56318 5.19 ATP synthase subunit beta P10719 707 8 26
3208 22000 5.00 56318 5.19 ATP synthase subunit beta P10719 51 1 4
3209 20000 5.00 56318 5.19 ATP synthase subunit beta P10719 144 2 5
3228 15000 5.20 18868 4.86 Myosin regularory light chain 2 P08733 135 3 20
3305 25000 5.00 22142 5.03 Myosin light chain 3 P16409 334 5 33
3433 34000 5.00 56318 5.19 ATP synthase subunit beta P10719 436 6 18
3441 35000 5.00 68686 6.09 Serum albumin P02770 46 1 2
3518 42500 5.10 73812 5.97 Stress-70 protein (aka HSPA9) P48721 85 1 2
3523 40000 5.20 56318 5.19 ATP synthase subunit beta P10719 280 4 14
3626 54500 5.20 56318 5.19 ATP synthase subunit beta P10719 711 9 29
SSP Protein name
UniProtKB/S
wiss-Prot 
Accession
MascotObserved in gel Theoretical
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 Table 4.2 continued. 
 
Mr Pl Mr Pl Score pep's % sc
3627 57000 5.20 53424 5.21 Desmin P48675 463 7 20
3632 47000 5.20 56318 5.19 ATP synthase subunit beta P10719 314 5 16
3636 57000 5.10 56318 5.19 ATP synthase subunit beta P10719 226 5 15
3706 57000 5.10 56318 5.19 ATP synthase subunit beta P10719 215 3 9
4207 19000 5.40 223370 5.59 Myosin-6 P02563 279 4 3
4217 21500 5.50 42000 5.23 Actin , alpha cardiac muscle 1 (or ACTS, or ACTA) P68035 218 3 10
4235 24000 5.40 56318 5.19 ATP synthase subunit beta P10719 110 2 4
4329 29000 5.40 56318 5.19 ATP synthase subunit beta P10719 69 1 2
4521 37000 5.40 36589 5.70 L-lactate dehydrogenase B chain (or LDHA) P42123 72 1 3
4523 43000 5.60 49892 4.95 Tubulin alpha-4A chain Q5XIF6 191 3 11
4702 60000 5.20 73812 5.97 Stress-70 protein (aka HSPA9) P48721 739 10 21
5311 29000 6.00 28277 7.14 Thioredoxin-dependent peroxide reductase (Peroxiredoxin-3) Q9Z0V6 89 2 0
5408 32000 5.80 24803 5.64 Peroxiredoxin-6 O35244 388 7 44
5715 70000 5.90 68686 6.09 Serum albumin P02770 379 5 11
6424 38500 6.20 36589 5.70 L-lactate dehydrogenase B chain P42123 85 1 4
6425 37000 6.20 36589 5.70 L-lactate dehydrogenase B chain P42123 77 1 6
6636 50000 6.10 ~70000 ~5.45 Heat shock cognate 71Da (aka HSPA8) P63018 46 1 2
7110 16000 6.30 16186 6.17 Galectin-5 P47967 157 3 21
7112 17000 6.50 79362 5.65 NADH-ubiquinone oxidoreductase 75 kDa subunit Q66HF1 102 2 2
7323 31500 6.60 31496 8.39 Enoyl-CoA hydratase P14604 71 1 3
7608 52500 6.50 68686 6.09 Serum albumin P02770 177 3 6
7702 70000 6.40 58307 5.85 Hydroxysteroid dehydrogenase-like protein 2 Q4V8F9 75 2 4
7722 62000 6.60 67123 8.76 Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex P08461 228 4 9
7723 67500 6.60 71570 6.75 Succinate dehydrogenase [ubiquinone] flavoprotein subunit Q920L2 73 1 2
8710 67000 6.60 66140 6.15 WD repeat-containing protein 1 Q5RKI0 157 4 11
8853 67500 6.70 79293 7.70 Methylcrotonoyl-CoA carboxylase subunit alpha (mouse) Q5I0C3 166 3 6
UniProtKB/S
wiss-Prot 
Accession
Mascot
SSP
Observed in gel Theoretical
Protein name
 
 
Page 122 
 Table 4.3 Proteins found to have significant fold changes in either the Sham vs. MI or the MI vs. BMMNC comparisons from 
the wide-range analysis. SSP are spot identification numbers assigned by PDQuest software.  Sham = sham operated group, MI = MI 
group treated with PBS, BMMNC = MI group treated with bone marrow mononuclear cells.  Fold changes are shown alongside the p-
values (Student’s t-test).  ‘On’ and ‘Off’ in the FC column indicate presence or absence of the spots,  e.g  in spot 1206 ‘On’  indicates 
the spot was absent in Sham but present in MI. 
 
 
SSP Protein name FC p-value FC p-value 
1225 ATP synthase subunit beta -13.1 0.021 12.7 ns
1226 ATP synthase subunit beta -2.4 ns 3.0 0.037
1424 ATP synthase subunit beta -1.5 ns 2.8 0.001
2443 ATP synthase subunit beta -3.7 ns 3.6 0.005
2609 ATP synthase subunit beta -2.0 ns 2.5 0.000
2626 ATP synthase subunit beta -1.0 ns 3.7 0.042
2712 ATP synthase subunit beta -2.4 ns 3.3 0.031
3208 ATP synthase subunit beta -1.9 ns 3.8 0.001
3209 ATP synthase subunit beta -2.6 ns 4.6 0.009
3433 ATP synthase subunit beta -2.6 0.008 2.9 0.003
3523 ATP synthase subunit beta -1.9 ns 2.7 0.000
3626 ATP synthase subunit beta -2.2 0.002 3.0 0.002
3632 ATP synthase subunit beta -1.7 ns 2.9 0.014
3636 ATP synthase subunit beta -5.7 0.009 8.7 0.0004
3706 ATP synthase subunit beta -2.1 ns 4.5 0.009
4235 ATP synthase subunit beta -3.3 ns 8.2 0.040
4329 ATP synthase subunit beta -5.6 0.002 5.4 ns
2119 Cytochrome b-c1 complex subunit 6 5.8 0.015 -10.2 0.007
7112 NADH-ubiquinone oxidoreductase 75 kDa subunit -9.8 0.007 7.1 ns
1207 NAD(P) transhydrogenase 3.83 0.027 -1.11 ns
7723 Succinate dehydrogenase [ubiquinone] flavoprotein subunit -2.7 0.045 2.4 0.026
SHAM vs. MI MI vs. BMMNC
Mitochondrial/Oxidative Phosphorylation
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 Table 4.3 continued. 
 
SSP Protein name FC p-value FC p-value 
7722 Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex 5.8 0.021 -5.0 0.039
7323 Enoyl-CoA hydratase 2.4 0.002 -2.6 0.007
6425 L-lactate dehydrogenase B chain -6.2 0.001 5.6 ns
6424 L-lactate dehydrogenase B chain -3.3 0.038 3.2 ns
4521 L-lactate dehydrogenase B chain (or LDHA) -2.8 ns 2.7 0.028
8853 Methylcrotonoyl-CoA carboxylase subunit alpha (mouse) -2.7 ns 3.4 0.033
5408 Peroxiredoxin-6 -2.5 0.038 2.4 0.018
5311 Thioredoxin-dependent peroxide reductase (PRDX3) 2.9 0.030 -1.1 ns
6636 Heat shock cognate 71Da (aka HSPA8) -1.3 ns 2.9 0.048
3518 Stress-70 protein (aka HSPA9) -3.3 0.011 2.9 ns
4702 Stress-70 protein (aka HSPA9) -1.9 ns 2.7 0.006
Antioxidants
Heat Shock Proteins
Energy Metabolism
SHAM vs. MI MI vs. BMMNC
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 Table 4.3 continued. 
SSP Protein name FC p-value FC p-value 
4217 Actin , alpha cardiac muscle 1 (or ACTS, or ACTA) -3.1 0.047 1.0 ns
3627 Desmin -2.4 0.045 2.6 0.003
3305 Myosin light chain 3 -3.1 0.026 2.7 ns
1206 Myosin regulatory light chain 2 On - -1.6 ns
1213 Myosin regulatory light chain 2 7.1 0.002 -1.7 ns
3228 Myosin regulatory light chain 2 9.1 0.010 -1.5 ns
4207 Myosin-6 2.0 ns -2.9 0.028
1320 Tropomyosin alpha-1 chain  (or Tropomyosin beta chain) -9.95 0.007 11.30 0.037
1248 Troponin T, cardiac muscle Off - On -
4523 Tubulin alpha-4A chain -4.5 0.002 2.6 ns
1430 14-3-3 protein epsilon -9.1 0.027 12.5 0.007
2616 40S ribosomal protein SA -1.2 ns 3.3 0.035
2546 Adenylyl cyclase-associated protein 1 -4.1 0.010 6.2 0.002
7110 Galectin-5 On - -9.9 ns
7702 Hydroxysteroid dehydrogenase-like protein 2 -2.7 ns 3.7 0.011
8710 WD repeat-containing protein 1 -2.1 ns 2.7 0.014
5715 Serum albumin 4.23 0.035 -2.61 ns
7608 Serum albumin 9.25 0.028 -1.45 ns
3441 Serum albumin -2.36 ns 3.04 0.008
Cytoskeletal/Sarcomeric
Others
SHAM vs. MI MI vs. BMMNC
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Table 4.4 Details of the ATP synthase subunit β peptides identified in 17 
different spots in the wide-range analysis.  A SSP are spot identification numbers 
assigned by PDQuest software.  Significant fold changes are shown for both the 
Sham vs. MI and the MI vs. BMMNC comparisons.  Then the ‘Observed’ Mr and pI 
as determined from the position of the spot in the gel are shown.  Mascot details are 
as follows; mascot score (the sum of the peptide scores), the number of peptides 
found and the sequence coverage of these peptides (only including peptides with 
individual scores over 35), and the peptides identified for this spot are shown in the 
right hand column (* see Table B).  B The amino acids included in peptides 1-16 (M) 
is oxidation of methionine.   
A 
 
Score pep's % sc
1226 3.0 19.0 4.5 105 2 6 13, 14
3209 4.6 20.0 5.0 144 2 5 2, 4
1225 -13.1 21.0 4.5 192 2 7 13, 14
3208 3.8 22.0 5.0 51 1 4 3
4235 8.2 24.0 5.4 110 2 4 2, 14
4329 -5.6 29.0 5.4 69 1 2 2
1424 2.8 34.0 4.6 131 2 8 13, 15
3433 -2.6 2.9 34.0 5.0 436 6 18 1, 2, 4, 5, 7, 10
2443 3.6 35.0 4.8 91 1 3 13
3523 2.7 40.0 5.2 280 4 14 8, 10, 13, 14
3632 2.9 47.0 5.2 314 5 16 4, 8, 13, 14, 15
2609 2.5 47.5 4.8 457 6 12 2, 4, 7, 9, 10, 11
2626 3.7 52.5 4.9 167 3 8 2, 4, 13
3626 -2.2 3.0 54.5 5.2 711 9 29 2, 3, 4, 7, 9, 10, 12, 13, 15
3636 -5.7 8.7 57.0 5.1 226 5 15 3, 4, 12, 14, 16
3706 4.5 57.0 5.1 215 3 9 2, 8, 13
2712 3.3 57.5 4.9 707 8 26 2, 4, 7, 9, 10, 11, 13, 15
Peptides identified *MascotSham vs. MI
MI vs. 
BMMNCSSP Obs. Mr Obs. pI
 
                                  
             B 
 
1 9
2 10
3 11
4 12
5 13
6 14
7 15
8 16
388-406
407-422 (M)
433-456 (M)
463-480
282-294
282-310 
295-310
311-324
144-159 (M)
189-198
213-225 (M)
265-279 (M)
95-109
110-121 (M)
125-143
144-155 (M)
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Figure 4.5 The relative positions of peptides 1-16 along the length of ATP 
synthase subunit β.   Peptides indicated in red include an oxidated methionine. 
 
100                     200            300                     400                     500
1   2    3    4    6         7         8     9      12      13   14   15    16
5                                 10
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Peptides 1-16
ATP synthase subunit beta  (~500 amino acids)
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4.2 Narrow-range protein profiling 
 
4.2.1 2DE 
 
4.2.1.1 pH 4.5-5.5 narrow-range 2DE analysis 
17 gel images were selected to be analysed by Progenesis, two images for each 
sample except for one of the Sham samples for which an image had to be dropped 
due to low quality.  Once gels were aligned and the analysis was run the first 150 
spots were checked to remove artefacts wrongly identified as spots. Data for all the 
spots (~2500) were then exported to Excel [Microsoft, US] and statistics were 
calculated in the same manner as for the wide-range analysis including Student’s t-
test p-values and fold changes calculated for Sham vs. MI and MI vs. BMMNC.   
 
96 spots were identified as having significant (t-test) fold changes >1.5 in either 
Sham vs. MI or MI vs. BMMNC.  After reviewing these 96 spots in Progenesis and 
excluding spots with poor alignment and definition, 17 were selected to be taken 
forward for protein identification by LC-MS/MS (see Table 4.5).  
 
 
 
 Table 4.5 Seventeen spots selected for protein identification from the pH 4.4-5.5 narrow-range Progenesis 2DE analysis  Sham 
= sham operated group, MI = MI group treated with PBS, BMMNC = MI group treated with bone marrow mononuclear cells.  Median 
spot intensities and standard errors for each group are shown alongside the difference, 95% confidence interval and Student’s t-test p-
value for both Sham vs. MI and MI vs. BMMNC comparisons. 
 
 
Spot Med. SE Med. SE Med. SE Difference 95% CI p-value Difference 95% CI p-value
17 16456.3 4431.3 5640.1 1772.5 8480.4 1374.9 0.4 (0.15 - 0.59) 0.020 1.5 ns
21 8890.0 1877.1 3321.8 381.8 3923.2 548.8 0.4 (0.34 - 0.50) 0.010 1.0 ns
32 25970.6 4797.7 10230.7 2151.3 10346.0 1971.2 0.4 (0.28 - 0.60) 0.007 1.2 ns
35 11583.3 2135.0 6222.6 290.6 7095.7 1593.0 0.5 (0.42 - 0.50) 0.017 1.2 ns
40 9421.0 4032.9 26788.2 889.6 17615.3 3641.5 2.2 (2.04 - 2.34) 0.017 0.7 (0.37 - 0.93) 0.046
48 19787.0 1447.0 9636.8 3353.0 12276.5 4568.0 0.5 (0.17 - 0.81) 0.010 1.6 ns
54 2798.3 508.9 1384.3 245.1 2081.2 696.7 0.5 (0.32 - 0.64) 0.012 1.7 ns
60 22653.6 4681.6 11979.1 1371.5 16697.1 1627.3 0.5 (0.40 - 0.61) 0.023 1.3 ns
63 4282.4 371.7 6774.7 857.7 8899.7 758.3 1.6 (1.25 - 1.99) 0.018 1.1 ns
66 25427.2 3840.9 13570.1 2168.5 12566.8 418.5 0.6 (0.40 - 0.78) 0.017 1.0 ns
73 3522.3 486.8 2327.3 76.2 2637.9 391.5 0.6 (0.57 - 0.65) 0.026 1.2 ns
75 27861.0 1725.5 17381.1 1804.0 18996.7 2817.7 0.6 (0.47 - 0.71) 0.000 1.2 ns
77 2093.8 204.8 3818.1 354.3 3779.6 324.6 1.5 (1.24 - 1.86) 0.028 1.1 ns
1182 30814.0 6956.4 15009.9 887.0 17102.4 5783.5 0.5 (0.45 - 0.56) 0.024 1.2 ns
1281 34504.8 1132.9 19194.1 2708.5 12648.8 3342.6 0.6 (0.39 - 0.72) 0.010 1.0 ns
1364 5998.1 563.0 3530.0 657.7 5045.9 1661.7 0.6 (0.38 - 0.82) 0.027 1.7 ns
1663 38987.4 4766.1 23396.9 4432.4 40817.8 6880.9 0.7 (0.44 - 0.87) 0.042 1.5 (1.01 - 2.03) 0.049
Change in intensity BMMNC/MISHAM MI BMMNC Change in intensity MI/Sham
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4.2.1.2 pH 5.5-6.7 narrow-range 2DE analysis 
The analysis was initially attempted with all 18 gel images, but the images from one 
batch of gels were aligning poorly with the others.  To achieve good alignment in the 
experiment and therefore to be able to analyse as many spots as possible, only  nine 
gel images were used for this analysis, one from each sample.   Once gels were 
aligned and the analysis was run the first 150 spots were checked to remove artefacts 
wrongly identified as spots. Data for all the spots (~2600) was then exported to Excel 
[Microsoft, US] and statistics were calculated in the same manner as for the wide-
range analysis including Student’s t-test p-values and fold changes calculated for 
Sham vs. MI and MI vs. BMMNC.   
 
94 spots were identified as having significant (t-test) fold changes >1.5 in either 
Sham vs. MI or MI vs. BMMNC.  After checking these 94 spots in Progenesis and 
excluding spots with poor alignment and definition, 14 were selected to be taken 
forward for protein identification by LC-MS/MS (see Table 4.6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 4.6 Fourteen spots selected for protein identification from the pH 5.5-6.7 narrow-range Progenesis 2DE analysis  Sham = 
sham operated group, MI = MI group treated with PBS, BMMNC = MI group treated with bone marrow mononuclear cells.  Median 
spot intensities and standard errors for each group are shown alongside the difference, 95% confidence interval and Student’s t-test p-
value for both Sham vs. MI and MI vs. BMMNC comparisons. 
 
 
Spot Med. SE Med. SE Med. SE Difference 95% CI p-value Difference 95% CI p-value
29 8735.992 617.74 5558.378 908.20 12429.01 1143.667 0.65 (0.46 - 0.84) 0.041 1.94 (1.56 - 2.31) 0.018
34 18169.01 1289.21 11292.49 853.45 21551.9 2266.008 0.68 (0.58 - 0.78) 0.025 1.81 (1.43 - 2.20) 0.018
35 8308.627 948.29 4885.619 867.98 10435.32 1214.333 0.62 ns 1.78 (1.33 - 2.22) 0.049
36 2404.492 262.51 1463.403 142.25 1876.293 41.88562 0.56 (0.46 - 0.67) 0.018 1.25 ns
39 901.7728 41.37 580.4419 62.77 526.7505 70.22686 0.69 (0.55 - 0.83) 0.023 0.85 (0.62 - 1.08) 0.390
40 4820.258 252.30 7663.654 653.48 4678.896 642.1923 1.48 (1.23 - 1.74) 0.026 0.58 (0.41 - 0.75) 0.028
47 15318.98 566.70 8966.973 619.22 13567.18 1070.384 0.61 (0.53 - 0.69) 0.002 1.38 (1.15 - 1.60) 0.048
49 18272.07 2154.48 14653.65 863.18 23616.89 1006.345 0.78 ns 1.56 (1.43 - 1.69) 0.003
55 15529.82 1089.72 9726.604 981.33 14224.74 374.0915 0.67 (0.54 - 0.80) 0.030 1.46 (1.38 - 1.53) 0.013
1090 5961.77 1141.30 10343.13 522.75 6971.644 1756.699 1.83 (1.65 - 2.01) 0.020 0.62 ns
1112 10372.36 1216.51 6442.62 1464.36 14588.66 1344.001 0.70 ns 1.81 (1.45 - 2.16) 0.039
1189 6443.015 640.87 10478.82 1216.55 10479.68 2394.395 1.76 (1.39 - 2.12) 0.023 0.75 ns
1303 18950.07 1647.97 9461.704 2063.09 13524.28 1919.984 0.59 (0.37 - 0.81) 0.048 1.40 ns
1331 8171.816 905.59 4696.44 245.64 6083.712 945.8495 0.60 (0.54 - 0.66) 0.033 1.34 ns
SHAM MI BMMNC Change in intensity MI/Sham Change in intensity BMMNC/MI
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4.2.2 Differentially expressed proteins 
 
Of the 35 spots in total that were selected for protein identification from the two 
narrow-range analyses, more than one protein was identified in three spots, and no 
identity was obtained in six spots.  In total 22 spots yielded a single protein identity 
(12 from pH4.5-5.5 and 10 from the pH5.5-6.7 analysis) and 16 different proteins 
were identified.  Examples of 2DE gels from both the narrow-range experiments are 
shown in Figure 4.7.  All of the MASCOT search results are detailed in Appendices 3 
and 4.  A summary table of the 22 spots with single protein identification from each 
narrow-range analysis are shown in Table 4.8A and B and the fold change and p-
values for these 24 spots, organised into functional categories is shown in Table 4.9. 
 
The 12 spots with single protein identifications from the pH 4.5-5.5 narrow range 
analysis identified seven different proteins.  Atp5b subunit was found in two spots, 
both with a ~2 fold decrease in Sham vs. MI but no significant difference in MI vs. 
BMMNC.  Both of these spots had a lower observed mass than the predicted mass of 
the full length protein (Table 4.7).  Two spots were identified as Tpm1, both of which 
had increased in Sham vs. MI by ~1.5 fold but no significant difference in MI vs. 
BMMNC; again one of the spots had a mass much smaller than that predicted for this 
protein. 
 
Table 4.7 Details of the ATP synthase subunit β peptides identified in 2 different 
spots in the pH 4.5-5.5 narrow range analysis.  SSP are spot identification numbers 
assigned by Progenesis software.  Significant fold changes are shown for both the 
Sham vs. MI and the MI vs. BMMNC comparisons.  The ‘Observed’ Mr and pI as 
determined from the position of the spot in the gel are shown.  Mascot details are as 
follows; mascot score (the sum of the peptide scores), the number of peptides found 
and the sequence coverage of these peptides (only including peptides with individual 
scores over 35), and the peptides identified for this spot are shown in the right hand 
column (* see Table 4.3 B).   
 
SSP 
Sham 
vs. 
MI 
MI vs. 
BMMNC 
Obs. 
Mr 
Obs. 
pI 
Mascot 
Peptides identified * Score pep's % sc 
21 -2.39   45 5.00 166 3 7 1, 4, 6 
1281 -1.80   15 4.95 209 2 6 13, 14 
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The 60 kDa heat shock protein (Hspd1) was found in 2 spots in the pH 4.5-5.5 
analysis (spots 75 and 1364), both with a 1.7 fold down-regulation in Sham vs. MI 
and no significant difference in MI vs. BMMNC.   These two spots have much lower 
mass than predicted for the full length protein (35 and 40 compared to 61kDa).  This 
protein was also found in the pH 5.5-6.7 analysis (spot 1090) but had a 1.8 fold up-
regulation in Sham vs. MI.  This spot is again much smaller than the predicted mass 
of the full size protein but larger (49kDa) than both of the spots found in the pH 4.5-
5.5 analysis.   In the two spots from the pH 4.5-5.5 analysis, Hspd1 peptides 
identified covered 26% of the amino acid sequence between 293 and 493 for spot 75 
and 12% of the amino acid sequence between 251 and 493 for spot 1364.  In spot 
1090 from the pH 5.5-6.7 analysis, Hspd1 peptides identified covered 42% of the 
amino acid sequence between 61 and 446.  This is illustrated in Figure 4.6. 
 
 
Figure 4.6 The relative positions of protein sequence covered by the 60kDa heat 
shock protein peptides identified in three spots from the narrow-range analyses.    
 
100                 200                  300                 400                 500            573
Area of 60kDa heat shock protein covered by the peptides identified in two spots from the  
pH4.5-5.5 narrow range analysis which both had -1.7 fold change in Sham vs. MI comparison.
Area of 60kDa heat shock protein covered by the peptides identified in one spots from the 
pH5.5-6.7 narrow range analysis which had +1.8 fold change in Sham vs. MI comparison.
60kDa heat shock protein  (573 amino acids)
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Figure 4.7 Examples of the narrow range 2DE gels produced in this analysis  A) 
Example of a pH4.5-5.5 2DE gel. B) Example of a pH5.5-6.7 2DE gel. Images shows 
the positions of spots which differed significantly and from which protein 
identifications were obtained.    Numbers next to spots are SSP identifiers assigned 
by Progenesis. 
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A fragment of Myosin-6 (Myh6) was identified from spot 1663 shown to be down-
regulated in Sham vs. MI.  This was the only protein identified from the pH 4.5-5.5 
analysis which had a significant difference in the MI vs. BMMNC analysis.  Two 
other proteins were identified as being down-regulated in Sham vs. MI but unaltered 
in MI vs. BMMNC, namely phosphatidylethanolamine-binding protein 1 (Pebp1) and 
heat shock protein beta-8 (Hspb8). In the pH 4.5-5.5 analysis, four proteins were 
found in more than one spot.   Actin (Actc1) was found in three spots all of which 
had ~2 fold decrease in Sham vs. MI but no significant difference in MI vs. 
BMMNC.  
 
In the pH 5.5-6.7 analysis, 10 different proteins were identified, including Hspd1 
already mentioned.   Two different forms of creatine kinase were identified (Ckm and 
Ckmt2) in two spots which both had significant down-regulation in Sham vs. MI and 
were both up-regulated in MI vs. BMMNC.   Subunit 10 of NADH dehydrogenase 1 
alpha (Ndufa10) was identified as being significantly down-regulated in Sham vs. MI 
and up-regulated in MI vs. BMMNC.  Several energy metabolism proteins were 
identified, which were down-regulated in Sham vs. MI, namely short chain acyl-CoA 
dehydrogenase (Acads), phosphoglycerate mutase 1 (Pgam1) and electron transfer 
flavoprotein subunit alpha (Etfa).  Pgam1 and Etfa were also significantly up-
regulated in MI vs. BMMNC.  Another energy metabolism protein lipoamide 
acyltransferase component of branched-chain alpha keto acid dehydrogenase (Dbt) 
was up-regulated in Sham vs. MI but was not significantly altered in MI vs. 
BMMNC. 
 
A table detailing all of the proteins identified in the 2DE analyses along with full 
protein names, accession codes, and the abbreviations used thought this thesis can be 
found in Appendix 5. 
 
 
 
 
 Table 4.8  Spots with significant fold changes for which a single protein ID was found from the narrow range analyses.   
A) Spots from the pH 4.5-5.5 range analysis. B) Spots from the pH 5.5-6.7 range analysis.  SSP are spot identification numbers 
assigned by Progenesis software.  Mascot details are as follows; mascot score (the sum of the peptide scores), the number of peptides 
found and the sequence coverage of these peptides (only including peptides with individual scores over 35).  Theoretical Mr and pI 
values for the protein identified are shown as well as the observed Mr and pI of the spot as estimated from its position in the gel. 
 
A 
 
Mr Pl Mr Pl Score pep's % sc
21 45000 5.00 56318 5.19 ATP synthase subunit beta ATPB_RAT 166 3 7%
35 42000 5.40 41992 5.23 Actin, alpha cardiac muscle 1 ACTC_RAT 229 3 13%
48 25000 5.30 20788 5.48 Phosphatidylethanolamine-binding protein 1 PEBP1_RAT 388 5 41%
60 43000 5.40 41992 5.23 Actin, alpha cardiac muscle 1 ACTC_RAT 1220 19 48%
63 37000 4.70 32661 4.69 Tropomyosin alpha-1 chain TPM1_RAT 70 1 5%
73 27500 4.80 21579 4.92 Heat shock protein beta-8 (HSPB8) HSPB8_RAT 73 2 10%
75 35000 4.85 60917 5.91 60 kDa heat shock protein CH60_RAT 895 11 26%
77 20000 4.90 32661 4.69 Tropomyosin alpha-1 chain TPM1_RAT 132 3 9%
1182 35000 5.35 41992 5.23 Actin, alpha cardiac muscle 1 ACTC_RAT 909 10 27%
1281 15000 4.95 56318 5.19 ATP synthase subunit beta ATPB_RAT 209 2 6%
1364 40000 5.00 60917 5.91 60 kDa heat shock protein CH60_RAT 316 5 12%
1663 42000 5.45 223370 5.59 Myosin-6 MYH6_RAT 155 3 2%
SSP
Observed in gel Theoretical
Protein name
UniProtKB/ 
Swiss-Prot 
Accession
Mascot
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 Table 4.8 B 
 
Mr Pl Mr Pl Score pep's % sc
29 35000 6.4 47443 8.64 Creatine kinase, sarcomeric KCRS_MOUSE 183 3 6%
35 37500 6.45 43018 6.58 Creatine kinase M-type KCRM_RAT 82 2 4%
47 37000 6.6 34929 8.62 Electron transfer flavoprotein subunit alpha ETFA_RAT 232 4 18%
49 37000 6.55 28814 6.67 Phosphoglycerate mutase 1 PGAM1_RAT 333 4 24%
55 37000 6.55 73812 5.97 Stress-70 protein  (HSPA9) GRP75_RAT 241 4 7%
1090 49000 5.8 60917 5.91 60 kDa heat shock protein CH60_RAT 1453 21 42%
1112 41000 5.9 40468 7.64 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10 NDUAA_RAT 679 9 38%
1189 52000 6 53127 8.88 Lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex ODB2_MOUSE 758 13 19%
1303 48000 6.3 44737 8.47 Short-chain specific acyl-CoA dehydrogenase ACADS_RAT 286 5 12%
1331 85000 5.75 83717 6.95 Elongation factor G 1 EFG1_RAT 120 3 4%
UniProtKB/ 
Swiss-Prot 
Accession
Mascot
SSP
Observed in gel Theoretical
Protein name
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 Table 4.9 Proteins found to have significant fold changes in either the Sham vs. MI or the MI vs. BMMNC comparisons from 
the narrow range analyses  SSP are spot identification numbers assigned by PDQuest software.  Fold changes are shown alongside 
the p-values (t-test).   
 
 
SSP Protein name FC p-value FC p-value 
21 ATP synthase subunit beta -2.4 0.010 1.0 ns
1281 ATP synthase subunit beta -1.8 0.010 1.0 ns
1112 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10 -1.4 ns 1.8 0.039
1303 Short-chain specific acyl-CoA dehydrogenase -1.7 0.048 1.4 ns
47 Electron transfer flavoprotein subunit alpha -1.6 0.002 1.4 0.048
1189 Lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex 1.8 0.023 ‐1.3 ns
49 Phosphoglycerate mutase 1 -1.3 ns 1.6 0.003
55 Stress-70 protein (aka HSPA9) -1.5 0.03 1.5 0.013
75 60 kDa heat shock protein -1.7 0.000 1.2 ns
1364 60 kDa heat shock protein -1.7 0.027 1.7 ns
73 Heat shock protein beta-8 (HSPB8) -1.6 0.026 1.2 ns
1090 60 kDa heat shock protein 1.8 0.020 -1.6 ns
35 Actin, alpha cardiac muscle 1 -2.2 0.017 1.2 ns
60 Actin, alpha cardiac muscle 1 -2.0 0.023 1.3 ns
1182 Actin, alpha cardiac muscle 1 -2.0 0.024 1.2 ns
1663 Myosin-6 -1.5 0.042 1.5 0.049
63 Tropomyosin alpha-1 chain 1.6 0.018 1.1 ns
77 Tropomyosin alpha-1 chain 1.5 0.028 1.1 ns
48 Phosphatidylethanolamine-binding protein 1 -2.0 0.010 1.6 ns
1331 Elongation factor G 1 -1.7 0.033 1.3 ns
29 Creatine kinase, sarcomeric -1.5 0.041 1.9 0.018
35 Creatine kinase M-type -1.6 0.049 1.8 0.049
Others
Heat Shock Proteins
Cytoskeletal/Sarcomeric
SHAM vs. MI MI vs. BMMNC
Mitochondrial/Oxidative Phosphorylation
Energy Metabolism
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4.3 Validation of proteomic data 
 
Four proteins were chosen for Western blotting to verify the results obtained from 
both the wide- and narrow-range 2DE experiments.  14-3-3 epsilon and the 
mitochondrial protein Sdha were chosen for validation as they were functionally 
interesting proteins which had significant changes in both Sham vs. MI and MI vs. 
BMMNC comparisons.  Atp5b was found not only to differ significantly in our 
analysis but it was also identified as having several different fragments. Western 
blotting was used to visualise these.  Pebp1 was significantly altered in Sham vs. MI 
in our narrow range analysis, it was chosen to verify this analysis. 
 
 14-3-3 epsilon (14-3-3ε) 
An assay using a rabbit polyclonal to 14-3-3ε antibody was used to detect a band at 
approximately 29kDa using an antibody dilution of 1 in 1000 and 20μg total protein 
loading.  The bands from 14-3-3ε and the GAPDH gel run simultaneously can be 
seen in Figure 4.6.  The average normalised band volumes and associated statistics 
are in Figure 4.7.  The average spot intensity data is also shown in Figure 4.7 for 
comparison.   The western blotting revealed a significant 3 fold decrease in 14-3-3ε 
concentration in Sham vs. MI and a significant 3.2 fold increase in MI vs. BMMNC.  
The direction of regulation reflected the 2DE data but western blotting fold changes 
were much more modest than the 2DE data (-9 fold and +12.5 fold respectively). 
 
 Succinate dehydrogenase (Sdha) 
An assay using a rabbit polyclonal to Sdha antibody was used to detect a band at 
approximately 73kDa using an antibody dilution of 1 in 280 and 20ug total protein 
loading.  The bands from Sdha and the GAPDH gel run simultaneously can be seen in 
Figure 4.6.  The average normalised band volumes and associated statistics are in 
Figure 4.7.  The average spot intensity data is also shown in Figure 4.7 for 
comparison.  The western blotting revealed significant differences between the 
groups in concentration of Sdha.  A 1.5 fold decrease in MI compared to Sham did 
not reach significance in post hoc testing, but a 1.7 fold increase in BMMNC 
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compared to Sham did reach significance.  The fold changes seen in the western blot 
analysis were slightly smaller than those measured in 2DE analysis. 
 
 Phosphatidylethanolamine-binding protein 1  (Pebp1) 
An assay using a rabbit polyclonal to Pebp1 antibody was used to detect a band at 
approximately 21kDa using an antibody dilution of 1 in 5000 and 10ug total protein 
loading.  The bands from Pebp1 and the GAPDH gel run simultaneously can be seen 
in Figure 4.6.  The average normalised band volumes and associated statistics are in 
Figure 4.7.  The average spot intensity data is also shown in Figure 4.7 for 
comparison.   The direction of change in Pebp1 reflected the 2DE data but did not 
reach significance.   
 
 ATP synthase subunit  (Atp5b) 
An assay using a rabbit polyclonal to ATP synthase beta antibody was optimised at 
20ug of total protein lysate, a 1 in 1000 antibody dilution and blocking in 3% milk 
overnight with 1.5 hour incubations for both primary and secondary antibodies.  The 
antibodies picked up multiple bands between the sizes of 34 and 56kDa.  The 
estimated mass of ATP synthase subunit beta is ~56kDa.  Quantification was not 
performed on this assay however the multiple bands are shown in Figure 4.8.  
Although quantification was not performed, the sham bands were of a much stronger 
intensity than MI.  BMMNC bands were also more intense than MI but slightly 
fainter than Sham, reflecting the 2DE results.  The same distribution of bands can be 
seen in all three samples.   
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Figure 4.8 Western blots of 14-3-3 epsilon (14-3-3ε), succinate dehydrogenase 
(Sdha), and phosphatidylethanolamine-binding protein 1 (Pebp1) in samples 1-9  
S = sham operated group, M = MI group treated with PBS, B = MI group treated with 
bone marrow mononuclear cells.  Both Pebp1 and Sdha were only measured in 2 of 
the 3 MI samples.  Glyceraldehyde 3-phosphate dehydrogenase (Gapdh) was used for 
normalisation.  
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Figure 4.9 The average normalised spot volumes from the 2DE ananlysis (left) 
and normalised band volumes from Western blot (WB) analysis (right) for 14-3-
3 epsilon (14-3-3ε), succinate dehydrogenase (Sdha), and 
phosphatidylethanolamine-binding protein 1 (Pebp1) in samples 1-9  Sham = 
sham operated group, MI = MI group treated with PBS, BMMNC = MI group treated 
with bone marrow mononuclear cells.  Error bars indicate standard deviation. 2DE 
graphs; significance in Sham vs. MI and MI vs. BMMNC comparisons indicated by 
the bars, * = t-test p-value of 0.05-0.01, ** = t-test p-value <0.01, ns = not significant. 
WB graphs; significance in one way ANOVA indicated in top right hand corner of 
charts, significance in Sham vs. MI and MI vs. BMMNC comparisons indicated by 
the bars, * = post-hoc bonferroni p-value of 0.05-0.01, ** = post-hoc bonferroni p-
value <0.01, ns = not significant. 
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Figure 4.10 Bands detected using an antibody to ATP synthase subunit β S = 
sham operated group, M = MI group treated with PBS, B = MI group treated with 
bone marrow mononuclear cells.  The Santa Cruz protein molecular weight ladder is 
on the left of the blot image and the masses of the ladder (in kDa) are labelled on the 
left of the figure. 
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5. Gene expression results 
 
5.1 Global expression profiles of samples 1-9 using Illumina RatRef12  
 
5.1.1 Quality control and quantification of RNA and cRNA 
 
Total RNA was extracted from tissue samples 1-9 using the RNeasy Fibrous Tissue 
Mini Kit from Qiagen.  Approximately 20-30mg of tissue was used from each 
sample.  Yields of RNA ranged from 55-350ng/µl (2.5-17.5µg in total) as recorded 
by the Agilent bioanalyser 2100, see Table 5.1. 
 
Table 5.1 Preparation, quantification and QC of RNA samples The mRNA 
samples were prepared from tissue samples 1-9. RNA concentration (ng/µl) and 
260/280 ratios are shown for two repeated readings on the Nanodrop.  RNA 
concentration (ng/µl) and RIN scores as read by the Agilent Bioanalyser are shown in 
the left hand columns. 
 
RNA_ID SAMPLE_ID (Tissue)
Nano 
conc. 
ng/ul
260/280 
Ratio
Nano 
conc. 
ng/ul
260/280 
Ratio
Ave. nano 
conc. ng/ul 
Agilent 
conc.  
ng/ul
RIN
Rat MI  1 7 160.3 2.04 153.2 2.07 156.75 185 9.1
Rat MI  2 6 45.7 1.93 45.3 2.09 45.5 55 8.6
Rat MI  3 3 146.6 2.09 158.9 2.02 152.75 210 9.1
Rat MI  4 1 134.3 2.07 129.9 2.06 132.1 200 9
Rat MI  5 4 114.6 2.06 115 2.08 114.8 158 8.6
Rat MI  6 9 91.6 2.09 91.6 2.05 91.6 130 8.1
Rat MI  7 2 151.9 2.07 146 2.08 148.95 261 9.2
Rat MI  8 8 154.8 2.09 145.1 2.07 149.95 245 8.9
Rat MI  9 5 192.6 2.08 201.9 2.07 197.25 335 8.5
Nanodrop Agilent results
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Figure 5.1 Summary from the Agilent Eukaryote Total RNA Nano Series II chip 
results for RNA extracted from samples 1-9   A) electrophoresis results. B) 
electropherograms including the RIN score for each sample.  
 
B
A
 
 
 
All of the RNA samples had a RIN score of over 8, their purity is illustrated in the 
Agilent Bioanalyser summary in Figure 5.1.   In a total RNA extraction, mRNA will 
only make up 1-3% of the total RNA, >80% is ribosomal RNA, specifically 18S and 
28S units. Non-degraded samples should therefore show clear well defined peaks 
representing these two components, these peaks will appear as broader humps in 
degraded samples.   The first small peak visible in the electropherograms represents 
the marker.    
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Approximately, 250ng from each sample (1-9) was selected for cDNA synthesis, 
purification, cRNA ‘in-vivo’ transcription and labelling using the Ambion Illumina 
TotalPrep Amplification kit.   For this purpose, 100ng/ul stocks were made up for all 
except Rat MI 2 for which the mRNA concentration was too low; for this sample a 
55ng/ul stock was made.  One RNA sample from each group was processed in 
duplicate to assess experimental reproducibility; these were labelled Rat MI 7a, Rat 
MI 8a and Rat MI 9a and were replicates of Rat MI 7, Rat MI 8 and Rat MI 9 
respectively (see Table 5.2). 
 
Table 5.2 Technical replicates of three RNA samples were processed into cRNA 
 
Original RNA 
sample_ID 
Technical replicate 
for cRNA prep.
Rat MI  7 Rat MI  7a
Rat MI  8 Rat MI  8a
Rat MI  9 Rat MI  9a  
 
 
The resultant cRNA was quantified using the nanodrop and quality was again assessed 
using the Agilent Bioanalyser.  The cRNA concentrations as determined by the 
nanodrop ranged from 200-500ng/ul (Table 5.3).  The 12 samples were then 
hybridised to the chip by Genome Centre staff. 
 
Table 5.3 Nanodrop quantification of cRNA prepared using Ambion TotalPrep 
 
cRNA_ID Nano Conc (ng/ul)
Rat MI 1 454.3
Rat MI 2 453.1
Rat MI 3 425.5
Rat MI 4 410.3
Rat MI 5 504.4
Rat MI 6 200.5
Rat MI 7 428.1
Rat MI 8 406.4
Rat MI 9 328
Rat MI 7a 326.3
Rat MI 9a 459.9
Rat MI 8a 358.8  
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5.1.2 Quality control of the RatRef12 gene expression chip data 
 
The results from the internal quality control features on the RatRef12 chip were all 
above accepted ranges, this illustrated the chip run had been successful (Figure 5.2). 
The hybridization controls showed the high, medium and low values as expected.  
Both background and noise were well below the accepted levels of 30-60.  The low 
stringency control showed PM>MM2. The gene intensity showed that the 
housekeeping genes had a much higher average intensity than the average of all the 
genes.  Finally the biotin and high stringency control plot also showed high values.   
 
Scatter plots were used to check for any large differences in signal that may be due to 
poor data quality.  Figure 5.3 shows three scatter plots which compare a technical 
replicate (scatter plot 1), biological replicates (scatter plot 2) and two samples from 
different groups (scatter plot 3).  A good level of convergence was seen in plot 1, a 
greater level of divergence was seen in plot 2 and again in plot 3.  Plot three shows 
several points clustering below the line of equal fit indicating several genes had 
higher expression in sample 8 (Sham) than in sample 7 (MI). 
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Figure 5.2 BeadStudio Plots of internal quality control features  
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Figure 5.3 Scatter plots of average signal data from two samples Scatter plot 1 
shows sample 7 and 7a (technical replicates).  Scatter plot 2 shows sample 2 and 9 
(closely related samples, both from MI). Scatter plot 3 shows sample 7 and 8 
(distantly related MI and Sham) 
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Clustering of the non-processed probe expression data (Figure 5.4 A) reveals that all 
the samples on the chip were highly related with all samples clustering below ~0.037.  
Clustering of the technical replicates shows they bear the closest relationships with 
each pair of technical replicates clustering <0.012.   The clustering shows that there 
are two main clusters, the first contains all of the Sham samples and one sample from 
the BMMNC group.  The second cluster contains all of the MI samples and two of 
the BMMNC samples. 
 
Clustering of the groups according to differently expressed probes (Figure 5.4 B) 
indicated the MI and BMMNC group were more highly related to each other than to 
the Sham group.   This data indicates that there are few probes differentially 
expressed between MI and BMMNC.  More probes were differentially expressed 
between Sham and MI as well as between Sham and BMMNC.  
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Figure 5.4 Dendrograms produced by BeadStudio showing clustering of non-
normalised probe data  Sham = sham operated group, MI = MI group treated with 
PBS, BMMNC = MI group treated with bone marrow mononuclear cells A) Shows a 
dendrogram illustrating clustering for non-normalised data of all samples and 
replicates.  Pink indicates Sham samples and the paler pink indicates 7a which is a 
replicate of the Sham sample 7. Green indicates MI samples and the paler green 
indicates 9a which is a replicate of the MI sample 9. Blue indicates BMMNC samples 
and the paler blue indicates 8a which is a replicate of the BMMNC sample 8.  B) 
Shows a dendrogram illustrating experimental groups clustered according to 
differentially expressed probes. 
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5.2 Repeat of global expression profiling for samples 1-9 using Illumina 
RatRef12  
 
5.2.1 Quality control and quantification of RNA and cRNA 
 
The same 9 tissue samples were used in the repeat experiment but this time the 
samples were heavily ground whilst still frozen before a portion was removed for 
RNA extraction.  The exact quantity of tissue used for each extraction was not 
measured as the samples were now more prone to defrosting during processing.  The 
amount of tissue was estimated to be 15-25mg.  RNA yields were all between 55 to 
374ng/ul according to the nanodrop, but the Agilent Bioanalyser estimated them to be 
approximately 10 times higher (see Table 5.4 A).  Figure 5.5 shows the Agilent 
summary report for these samples, an error in the ladder (see Figure 5.5 A) would 
explains the high RNA quantification results, and therefore only the Nanodrop 
quantifications were used.    
 
The RNA qualities were poor for two samples (RNA 1 and RNA 5) and yield was 
low for one sample (RNA 2) therefore RNA preparation was repeated for these three 
samples (RNA 1r, RNA 2r and RNA 5r).   These three new RNA preparations 
yielded 43-313ng/ul according to the Nanodrop (see table 5.4 B).  All repeated RNA 
samples were again assessed using the Agilent Bioanalyser.   RNA quality was good 
for all of the samples except RNA 1 and RNA 1r.  Agilent quantifications were again 
very high which was due to an error with the ladder, as seen in the first lane of the 
image in Figure 5.6 A. 
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Table 5.4 Quantification and QC of mRNA samples for repeated Illumina 
RatRef12 chip analysis  The mRNA samples were prepared from c.15-25mg tissue 
samples 1-9. A) Quantification and QC results of first attempt at RNA preparations 
from tissue samples 1-9 for the repeated Illumina chip analysis.  B) Quantification 
and QC results from the three repeated RNA preparations (RNA 1r, RNA 2r and 
RNA 5r).  RNA 1, RNA 2 and RNA 5 were run alongside RNA 1r, RNA 2r and RNA 
5r in the Agilent analysis. 
 
A   
RNA_ID SAMPLE_ID (Tissue)
 Nano 
conc. ng/ul 260/280 Ratio
Agilent 
conc. ng/ul RIN
RNA 1 7 269.66 2.04 2,363 5
RNA 2 4 55.23 1.93 479 8.1
RNA 3 1 185.71 2.09 1895 8.6
RNA 4 8 170.12 2.07 1797 8.8
RNA 5 5 108.31 2.06 1149 N/A
RNA 6 2 186.27 2.09 2040 8.8
RNA 7 9 117.78 2.07 1294 8.3
RNA 8 6 114.04 2.09 1356 8.8
RNA 9 3 374.45 2.08 5026 8.7
AgilentNanodrop
 
 
 
B   
RNA_ID SAMPLE_ID (Tissue)
 Nano 
conc. ng/ul 260/280 Ratio
Agilent 
conc. ng/ul RIN
RNA 1r 7 313.38 2.1 14111 4.3
RNA 2r 4 43.51 2.12 1636 8.2
RNA 5r 5 55.87 2.14 2003 8.2
RNA 1 12369 4.6
RNA 2 2158 8.6
RNA 5 4253 8.4
Nanodrop Agilent results
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Figure 5.5 Summary of the Agilent Eukaryote Total RNA Nano Series II chip 
results for RNA extracted from samples 1-9 for the repeat RatRef12 analysis.  A) 
electrophoresis results. Red markers indicate a failed ladder and a failed RIN score.  
B) electropherograms including the RIN score for each sample.  
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Figure 5.6 Summary of the Agilent Eukaryote Total RNA Nano Series II chip 
for results of repeat RNA extracts RNA 1r, RNA 2r and RNA 5r for the repeat 
RatRef12 analysis.  RNA 1, RNA 2 and RNA 5 were also run. A) electrophoresis 
results. B) electropherograms including the RIN score for each sample. 
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After repeating three of the RNA extractions, eight of the nine samples had RNA with 
RIN scores > 8.  RNA 1 and RNA 1r both had low RIN scores of below 5.    The 
RNA samples RNA 1, 2, 3, 4, 5r, 6, 7, 8, 9 and 1r were all taken forward for cDNA 
synthesis, purification, cRNA in vivo transcription and labelling.   As before, 
100ng/ul stocks were made up for each except for RNA 2 and RNA 5r where 50ng/ul 
stocks were prepared. 
 
The resultant cRNA at the end of processing was quantified using the nanodrop and 
quality was again checked using the Agilent Bioanalyser.  The cRNA samples were 
determined to be between 95 and 495ng/ul (Table 5.5).  The cRNA produced from 
RNA 1r was of a low concentration and so was not used for hybridisation.   
 
Table 5.5 Nanodrop quantification of cRNA prepared using the Ambion 
TotalPrep kit 
 
cRNA_ID 
Nano Conc 
(ng/ul)
RNA 1 327.3
RNA 2 448.3
RNA 3 446.1
RNA 4 495.2
RNA 5r 360.5
RNA 6 450.9
RNA 7 428.3
RNA 8 465.7
RNA 9 430.5
RNA 1r 95.7  
 
To look at reproducibility in the hybridisation stages three cRNA samples (RNA 1, 
RNA 2 and RNA 3), one from each group, were hybridised twice to the chip and 
referred to as (RNA 1a, RNA 2a and RNA 3a), 12 samples in total. 
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5.2.2 Quality control and pre-processing for the repeat of the RatRef12 gene 
expression chip data 
 
5.2.2.1 Quality control for the repeat chip data 
The results from the internal quality control features on the RatRef12 chip were again 
all within accepted ranges showing the chip run had again been successful as shown 
in Figure 5.7. The hybridization controls showed the high, medium and low values as 
expected.  Both background and noise were well below the accepted levels of 30-60.  
The low stringency control showed PM>MM2. The gene intensity showed that the 
housekeeping genes had a much higher average intensity than the average of all the 
genes.  Finally the biotin and high stringency control plot also showed high values.  
Scatter plots were again used to check for any large differences in signal that may 
indicate poor data quality.  These are shown in Figure 5.8 below.   
 
Figure 5.7 Beadstudio Plots of internal quality control features  All QC tools 
were used except the ‘Labelling and Background’ feature.  Mm2 = mismatch oligos   
pm = perfect match oligos. 
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Figure 5.8 Scatter plots of average signal data from two samples Scatter plot 1 
shows sample 3 and 3a (technical replicates).  Scatter plot 2 shows sample 3 and 6 
(closely related samples, both from Sham). Scatter plot 3 shows sample 5 and 9 
(distantly related MI and Sham)   
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Clustering of the samples according to non processed probe level data is shown in 
Figure 5.9 A.  The samples were more divergent compared to the first chip 
experiment with all samples clustering below 0.045 apart from RNA 1 which was 
strongly divergent from the others.  The technical replicates all clustered together 
well, with 3 and 3a just over 0.005, and the other two pairs (1 and 1a, 2 and 2a) just 
below 0.005.  
 
There are three main clusters.  Sample RNA 1 and it’s technical replicate 1a are in 
one cluster, highly divergent from the other samples as already mentioned.  This is 
the sample which had a very poor RIN score of <5 in comparison to all other samples 
which had scores >8.  The second cluster contains all of the MI samples and the 
technical replicate of RNA 2 (RNA 2a).  The third cluster contains the Sham samples 
RNA 3 and RNA 6 which are closely related.    The other Sham sample, RNA 9 is 
also in this cluster closely associated with the two BMMNC samples RNA 4 and 
RNA 7.   Clustering of the groups according to differently expressed probes is 
illustrated in Figure 5.9 B.  This dendrogram shows that Sham and BMMNC are the 
most closely related groups and are divergent from the MI group.  This data indicates 
there are few probes differentially expressed between the Sham and BMMNC groups.   
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Figure 5.9 Dendrograms produced by BeadStudio showing clustering of non-
normalised probe data  Sham = sham operated group, MI = MI group treated with 
PBS, BMMNC = MI group treated with bone marrow mononuclear cells. A) Shows a 
dendrogram illustrating clustering for non-normalised data of all samples and 
replicates.  Pink highlighting indicates Sham samples and the paler pink shading 
indicates a replicate of the Sham sample 1. Green highlighting indicates MI samples 
and the paler green shading indicates a replicate of the MI sample 2. Blue 
highlighting indicates BMMNC samples and the paler blue shading indicates a 
replicate of the BMMNC sample 3.  B) Shows a dendrogram illustrating experimental 
groups clustered according to differentially expressed probes. 
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5.2.2.2 Pre-processing of the repeat chip data 
Sample 1 was excluded from all further analysis as the probe level data was most 
certainly affected by low quality of starting material.  The probe level intensity data 
was normalised using Quantile method in BeadStudio and then all data was exported 
to Excel [Microsoft, US].   Non-detected probes were removed from the dataset 
(probes with detection p-values >0.05 in 8 or 9 of the 9 samples) leaving a total of 
11,701 probes.  
 
5.2.3 Differentially expressed genes discovered using LIMMA 
 
Analysis using LIMMA of the Sham vs. MI comparison revealed 860 probes to be 
significantly up-regulated and 677 to be down-regulated (FDR adjusted p-value of 
≤0.05), 13% of the probes had significant differences between the two groups (see 
Figure 5.10).   In MI vs. BMMNC comparison there were 19 probes significantly 
down-regulated, 18 of which were in the list of probes significantly up-regulated in 
Sham vs. MI comparison.  Only one probe was significantly up-regulated by 
BMMNC treatment, this probe was also found to be significantly altered in Sham vs. 
MI. 
 
Figure 5.10 Venn diagram of distribution of differently expressed probes in the 
gene expression analysed using LIMMA Sham = sham operated group, MI = MI 
group treated with PBS, BMMNC = MI group treated with bone marrow 
mononuclear cells. 
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Figure 5.11 shows the distribution of the data for both the Sham vs. MI and the MI 
vs. BMMNC comparisons.  The probes found to be significantly altered by treatment 
were all probes that also had highly significant differences in MI compared to Sham 
(highlighted pink in graph 5.11 A).   Approximately 40% of the up-regulated probes 
had highly significant alterations (p<0.01) in MI whereas only about 10% of the 
down-regulated probes had significance values p<0.01. 
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Figure 5.11 Graphs of FDR adjusted p-values plotted against log fold change 
(for probes with significant differential expression) Sham = sham operated group, 
MI = MI group treated with PBS, BMMNC = MI group treated with bone marrow 
mononuclear cells. A) shows the data for probes significantly altered in Sham vs. MI 
analysis.  The points highlighted in pink are the data for those probes which also had 
significant alterations in MI vs. BMMNC.  B) shows data for probes significantly 
altered in MI vs. BMMNC analysis 
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A list of the top 433 probes {including all probes with significant difference in MI vs. 
BMMNC (p<0.05) and all probes with significant alteration in Sham vs. MI 
Page 164 
(p<0.01)} identified in the LIMMA analysis are shown in Appendix 6 and further 
details of these probes are shown in Appendix 7.  Table 5.6 shows the top 30 probes 
altered in Sham vs. MI according to FDR adjusted p-values, these probes are all up-
regulated.  The top 10 probes that were found to be down-regulated in Sham vs. MI 
are listed in Table 5.7.   Of the top 30 probes up-regulated in Sham vs. MI, 13 were 
also found to be significantly down-regulated in MI vs. BMMNC.  All 20 probes 
found to be significantly altered in MI vs. BMMNC are in Table 5.8.  
 
The five most significantly up-regulated probes in Sham vs. MI were also found to be 
the most significantly down-regulated in MI vs. BMMNC.  These probes were from 
transcripts encoding the sema domain immunoglobulin domain transmembrane 
domain and short cytoplasmic domain 4A (Sema4a), 2’ -5’ oligoadenylate synthetase 
1K (Oas1k), a transcript predicted to be Stefin A2 (Stfa2), and a transcript similar to 
Stfa2.  The first two (Sem4a and Oas1k) were up-regulated in Sham vs. MI by 5 and 
6 fold respectively and were subsequently down-regulated in the BMMNC group.  
Both the Stfa2 probes were up-regulated by around 25 fold in Sham vs. MI, and 
expression significantly down-regulated by 3 fold in MI vs. BMMNC. The GLI 
pathogenesis-related 1 (glioma) (Glipr1), was also both significantly up-regulated in 
Sham vs. MI and down-regulated in MI vs. BMMNC.   
 
The other eight probes significantly up-regulated in Sham vs. MI (Table 5.6) which 
are also significantly altered in MI vs. BMMNC are shown in Table 5.8 and are; 
antigen presenting cell lectin-like receptor A1 (Aplra1), coagulation factor 5 
(mapped) (F5_mapped), endothelial differentiation G-protein-coupled receptor 6 
(predicted) (Edg6_predicted) a.k.a. sphingosine-1-phosphate receptor 4 (S1PR4), 
coronin actin binding protein 1A (Coro1a), embigin (Emb), resistin like alpha 
(Retnla), serine/threonine kinase 17b (apoptosis-inducing) (Stk17b), as well as a 
hypothetical protein (LOC308990).   
 
Of the top 30 most significantly up-regulated probes in Sham vs. MI, 17 were not 
significantly altered in MI vs. BMMNC.  Six however were up-regulated by >5 fold; 
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liver glycogen phosphorylase (Pygl), lymphocyte selectin (Sell), matrix 
metallopeptidase 8 (Mmp8),  napsin A aspartic peptidase (Napsa), a transcript similar 
to Clecsf12 protein (predicted) and a transcript similar to a hypothetical protein 
(LOC199675).   The other nine were more modestly up-regulated and these included 
gamma cytoplasmic actin (Actg_predicted), lymphocyte cytosolic protein 1 (Lcp1), 
PDZ and LIM domain 7 (Pdlim7), Kruppel-like factor 5 (Klf5), nuclear factor 
erythroid derived 2 (Nfe2), and ERBB receptor feedback inhibitor 1 (Errfi1) an 
epidermal growth factor (EGF) receptor. 
 
The 10 most significantly down-regulated probes in Sham vs. MI all had no 
significant alterations in MI vs. BMMNC.  A probe from a transcript predicted to be 
leucine-rich repeat-containing 10 (Lrrc10_predicted) was down-regulated 3 fold,  
protein kinase C and casein kinase substrate in neurons 2 (Pacsin2) and a transcript 
similar to RIKEN cDNA D430028G21 (MGC93707) were both down-regulated by 
>2 fold.  The other 7 probes were down-regulated by <2 fold and include; G7c 
protein (G7c), ATP-binding cassette sub-family C (CFTR/MRP) member 8 (Abcc8), 
molybdenum cofactor synthesis 2 transcript variant 1 (Mocs2), coenzyme Q3 
homolog methyltransferase (yeast) (Coq3) and a transcript predicted to be 
mitochondrial ribosomal protein L50 (Mrpl50_predicted). 
 
Of the 20 probes found to be significantly altered in MI vs. BMMNC, all were down-
regulated except calsequestrin 2 (Casq2) which was up-regulated by ~2.5 fold.  Only 
one, the ring finger protein 149 (Rnf149) probe was not significantly altered in Sham 
vs. MI.  Other than the 13 probes already mentioned which were in the top 30 most 
significantly up-regulated in Sham vs. MI; carbohydrate (keratan sulfate Gal-6) 
sulfotransferase 1 (Chst1), a transcript predicted to be docking protein 3 
(Dok3_predicted) and a transcript predicted to be sortilin-related receptor L (DLR 
class) A repeats-containing (Sorl1_predicted) were among the other probes 
significantly down-regulated in MI vs. BMMNC. 
 Table 5.6 Top 30 probes found to be significantly altered in Sham vs. MI Illumina probe ID, gene symbol, definition and 
accession code are detailed alongside the log fold change and FDR adjusted p-value for the Sham vs. MI analysis. 
 
Probe  ID Symbol Accession Definition logFC P.Val
ILMN_1376428 Sema4a NM_001012078.1
sema domain, immunoglobulin domain (Ig), transmembrane domain 
(TM) and short cytoplasmic domain, (semaphorin) 4A (Sema4a), 
mRNA.
2.25 2.81E-05
ILMN_1358567 Oas1k NM_001009489.1 2 ' -5 ' oligoadenylate synthetase 1K (Oas1k), mRNA. 2.57 2.81E-05
ILMN_1364315 RGD1560676_predicted XM_573293.1 similar to stefin A2 (predicted) (RGD1560676_predicted), mRNA. 4.70 2.81E-05
ILMN_1352951 Stfa2_predicted XM_001070786.1 stefin A2 (predicted) (Stfa2_predicted), mRNA. 4.63 2.81E-05
ILMN_1376740 Glipr1 NM_001011987.1 GLI pathogenesis-related 1 (glioma) (Glipr1), mRNA. 2.34 0.000263
ILMN_1651187 LOC497712 XM_579055.1 hypothetical gene supported by NM_001001511 (LOC497712), mRNA. 1.72 0.000327
ILMN_1362269 Actg_predicted XM_213540.3 actin, gamma, cytoplasmic (predicted) (Actg_predicted), mRNA. 1.77 0.000327
ILMN_1349760 Pygl NM_022268.1 liver glycogen phosphorylase (Pygl), mRNA. 2.34 0.00039
ILMN_1650752 Aplra1 NM_001005896.1 antigen presenting cell lectin-like receptor A1 (Aplra1), mRNA. 1.82 0.000418
ILMN_1350326 LOC308990 NM_001025001.1 hypothetical protein LOC308990 (LOC308990), mRNA. 1.51 0.000425
ILMN_1376765 Lcp1 NM_001012044.1 lymphocyte cytosolic protein 1 (Lcp1), mRNA. 1.91 0.000425
ILMN_1371753 F5_mapped XM_222831.4 coagulation factor 5 (mapped) (F5_mapped), mRNA. 1.75 0.000498
ILMN_1369190 Pdlim7 NM_173125.1 PDZ and LIM domain 7 (Pdlim7), mRNA. 1.46 0.000498
ILMN_1361302 Klf5 NM_053394.2 Kruppel-like factor 5 (Klf5), mRNA. 1.31 0.000498
ILMN_1351274 RGD1565374_predicted XM_573339.2
similar to hypothetical protein LOC199675 (predicted) 
(RGD1565374_predicted), mRNA. 3.23 0.000572
ILMN_1371493 Edg6_predicted XM_234930.2 endothelial differentiation, G-protein-coupled receptor 6 (predicted) (Edg6_predicted), mRNA. 1.63 0.00067
ILMN_1364468 Coro1a NM_130411.2 coronin, actin binding protein 1A (Coro1a), mRNA. 1.89 0.000703
ILMN_1349113 Sell NM_019177.1 selectin, lymphocyte (Sell), mRNA. 3.06 0.000705
PROBE DATA LIMMA RESULTS
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 Table 5.6 continued 
 
Probe  ID Symbol Accession Definition logFC P.Val
ILMN_1376772 Stom NM_001011965.1 stomatin (Stom), mRNA. 1.45 0.000754
ILMN_1371081 Mmp8 NM_022221.1 matrix metallopeptidase 8 (Mmp8), mRNA. 3.20 0.000754
ILMN_1374896 Napsa NM_031670.1 napsin A aspartic peptidase (Napsa), mRNA. 2.98 0.000754
ILMN_1359464 Emb NM_053719.1 embigin (Emb), mRNA. 1.08 0.000766
ILMN_1362534 Retnla NM_053333.1 resistin like alpha (Retnla), mRNA. 1.54 0.000766
ILMN_1370817 Stk17b NM_133392.1 serine/threonine kinase 17b (apoptosis-inducing) (Stk17b), mRNA. 1.48 0.000766
ILMN_1350897 Pfc_mapped XM_001056015.1 properdin factor, complement (mapped) (Pfc_mapped), mRNA. 1.37 0.000766
ILMN_1376557 Nfe2 NM_001012224.1 nuclear factor, erythroid derived 2 (Nfe2), mRNA. 2.06 0.000766
ILMN_1349895 RGD1565140_predicted XM_001067977.1
similar to Clecsf12 protein (predicted) (RGD1565140_predicted), 
mRNA. 2.49 0.000766
ILMN_1374845 MGC105649 NM_001008518.1 hypothetical LOC302884 (MGC105649), mRNA. 2.16 0.000766
ILMN_1366212 Errfi1 NM_001014071.1 ERBB receptor feedback inhibitor 1 (Errfi1), mRNA. 2.44 0.000819
ILMN_1368490 LOC24906 NM_031537.1 RoBo-1 (LOC24906), mRNA. 1.53 0.000842
PROBE DATA LIMMA RESULTS
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 Table 5.7 Top 10 probes found to be significantly down-regulated in Sham vs. MI Illumina probe ID, gene symbol, definition and 
accession code are detailed alongside the log fold change and FDR adjusted p-value for the Sham vs. MI analysis. 
 
Probe  ID Symbol Accession Definition logFC P.Val
ILMN_1368846 Pacsin2 NM_130740.2 protein kinase C and casein kinase substrate in neurons 2 (Pacsin2), mRNA. -1.15914 0.0009676
ILMN_1348962 Lrrc10_predicted XM_001080952.1 leucine-rich repeat-containing 10 (predicted) (Lrrc10_predicted), mRNA. -1.59641 0.0011253
ILMN_1348979 MGC93707 NM_001005556.1 similar to RIKEN cDNA D430028G21 (MGC93707), mRNA. -1.08306 0.0013971
ILMN_1353208 G7c NM_212499.1 G7c protein (G7c), mRNA. -0.94906 0.0014257
ILMN_1374611 RGD1306595 NM_001025626.1 similar to hypothetical protein (RGD1306595), mRNA. -0.95577 0.001684
ILMN_1366054 Abcc8 NM_013039.1 ATP-binding cassette, sub-family C (CFTR/MRP), member 8 (Abcc8), mRNA. -0.88671 0.0020688
ILMN_1367596 Mocs2 XM_001067999.1 molybdenum cofactor synthesis 2, transcript variant 1 (Mocs2), mRNA. -0.8026 0.0020688
ILMN_1359089 Coq3 NM_019187.1 coenzyme Q3 homolog, methyltransferase (yeast) (Coq3), mRNA. -0.81278 0.0025027
ILMN_1359659 Mrpl50_predicted XM_342835.2
mitochondrial ribosomal protein L50 (predicted) (Mrpl50_predicted), 
mRNA. -0.75424 0.0026191
ILMN_1359578 RGD1305574_predicted XM_341388.2
similar to polymerase (RNA) III (DNA directed) (155kD) (predicted) 
(RGD1305574_predicted), mRNA. -0.63994 0.0027451
PROBE DATA LIMMA RESULTS
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 Table 5.8 Twenty probes found to be significantly altered in MI vs. BMMNC  Illumina probe ID, gene symbol and definition and 
accession code are detailed alongside the log fold change and FDR adjusted p-value for the MI vs. BMMNC analysis. 
 
Probe  ID Symbol Accession Definition logFC P.Val
ILMN_1376428 Sema4a NM_001012078.1
sema domain, immunoglobulin domain (Ig), transmembrane domain 
(TM) and short cytoplasmic domain, (semaphorin) 4A (Sema4a), 
mRNA.
-1.32 0.006666
ILMN_1358567 Oas1k NM_001009489.1 2 ' -5 ' oligoadenylate synthetase 1K (Oas1k), mRNA. -1.59 0.006666
ILMN_1650752 Aplra1 NM_001005896.1 antigen presenting cell lectin-like receptor A1 (Aplra1), mRNA. -1.63 0.008608
ILMN_1364315 RGD1560676_predicted XM_573293.1 similar to stefin A2 (predicted) (RGD1560676_predicted), mRNA. -2.56 0.012004
ILMN_1352951 Stfa2_predicted XM_001070786.1 stefin A2 (predicted) (Stfa2_predicted), mRNA. -2.48 0.012004
ILMN_1376740 Glipr1 NM_001011987.1 GLI pathogenesis-related 1 (glioma) (Glipr1), mRNA. -1.62 0.013690
ILMN_1376641 Chst1 NM_001011955.1 carbohydrate (keratan sulfate Gal-6) sulfotransferase 1 (Chst1), mRNA. -1.10 0.018974
ILMN_1357616 Casq2 NM_017131.1 calsequestrin 2 (Casq2), mRNA. 1.25 0.018974
ILMN_1350326 LOC308990 NM_001025001.1 hypothetical protein LOC308990 (LOC308990), mRNA. -1.04 0.028309
ILMN_1371493 Edg6_predicted XM_234930.2 endothelial differentiation, G-protein-coupled receptor 6 (predicted) (Edg6_predicted), mRNA. -1.22 0.030115
ILMN_1372230 Rnf149 XM_343561.3 ring finger protein 149 (Rnf149), mRNA. -1.78 0.039782
ILMN_1370914 Dok3_predicted XM_001069255.1 docking protein 3 (predicted) (Dok3_predicted), mRNA. -1.07 0.042063
ILMN_1371753 F5_mapped XM_222831.4 coagulation factor 5 (mapped) (F5_mapped), mRNA. -1.12 0.046911
ILMN_1364468 Coro1a NM_130411.2 coronin, actin binding protein 1A (Coro1a), mRNA. -1.27 0.046911
ILMN_1359464 Emb NM_053719.1 embigin (Emb), mRNA. -0.75 0.046911
ILMN_1362534 Retnla NM_053333.1 resistin like alpha (Retnla), mRNA. -1.12 0.046911
ILMN_1370817 Stk17b NM_133392.1 serine/threonine kinase 17b (apoptosis-inducing) (Stk17b), mRNA. -1.02 0.046911
PROBE DATA LIMMA RESULTS
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 Table 5.8 continued. 
Probe  ID Symbol Accession Definition logFC P.Val
ILMN_1370198 LOC363060 NM_001014209.1 similar to RIKEN cDNA 1600029D21 (LOC363060), mRNA. -0.87 0.046911
ILMN_1366128 RGD1562311_predicted XR_008266.1 similar to PIRA5 (predicted) (RGD1562311_predicted), mRNA. -0.83 0.046911
ILMN_1363716 Sorl1_predicted XM_001065506.1 sortilin-related receptor, L(DLR class) A repeats-containing (predicted) (Sorl1_predicted), mRNA. -1.02 0.046911
PROBE DATA LIMMA RESULTS
Page 170 
Page 171 
Several of the probes (75) within the 1538 which had a significant change in either 
the Sham vs. MI or MI vs. BMMNC comparisons had qualitative differences.  There 
were 69 probes which were not significantly detected in any of the Sham samples 
(detection p-values >0.05) but were detected in all of the MI samples.  These were 
termed to be ‘ON’ in MI.  Seventy one were found to be significantly up-regulated in 
the LIMMA analysis.  Fourty three of the 71 were not altered in MI vs. BMMNC, but 
three were significantly down-regulated in MI vs. BMMNC according to LIMMA 
and 23 were not significantly detected in BMMNC (‘OFF’ in BMMNC).  Only one of 
these was identified as significantly altered in the LIMMA analysis, this was the 
probe with the highest average probe intensity in the MI group.  The top 15 probes 
which were ‘ON’ in MI compared to Sham and which were also detected in the 
BMMNC group are in Table 5.9.  The top 5 probes found to be ‘ON’ in MI compared 
to Sham and ‘OFF’ in BMMNC compared to MI are in Table 5.10. 
 
Three probes were not significantly detected in any of the Sham samples but were 
detected in all of the MI samples (‘ON’ in MI).  All three were determined to be 
significantly altered by LIMMA analysis, see Table 5.11.  Two of these probes were 
significantly detected in the both of the BMMNC samples (‘ON’ in BMMNC) 
including cytoplasmic linker associated protein 1 (Clasp1); the third was detected in 
one of the BMMNC samples and not in the other.  The intensity values in these 
probes, even when significantly detected is quite low.  
 
Three probes were significantly detected in all of the MI samples but were not 
significantly detected in any of the BMMNC samples (‘OFF’ in BMMNC), see Table 
5.12.  None of them had a significantly altered expression in MI vs. BMMNC 
according to the LIMMA analysis results.  All three were significantly detected in at 
least one of the Sham samples and so could not be classed as being ‘ON’ in MI 
compared to Sham.  All were however shown to be significantly up-regulated in 
Sham vs. MI according to LIMMA.  The intensity values, even in the MI group, did 
not go above 100. 
 
 Table 5.9  Top 15 qualitatively altered probes found to be ‘ON’ in MI compared to Sham  Sham = sham operated group, MI = 
MI group treated with PBS, BMMMNC = MI group treated with bone marrow mononuclear cells. Illumina probe ID, gene symbol 
and average probe intensities for Sham, MI and BMMNC are detailed alongside the significant LIMMA results; log fold change and 
FDR adjusted p-value for the Sham vs. MI analysis (logFC_1 and P.Val_1) and the log fold change and FDR adjusted p-value for the 
MI vs. BMMNC analysis (logFC_2 and P.Val_2).  The direction of the qualitative differences are detailed in the right-hand columns.  
Average intensities shaded grey were from probes which were not significantly detected (all detection p-values >0.05).  The average 
intensities shaded blue indicate that not all probes were significantly detected (some detection p-values >0.05).   
 
Probe  ID Symbol Ave Sham
Ave     
MI
Ave 
BMMNC logFC_1 P.Val_1 logFC_2 P.Val_2
Sham → 
MI
MI → 
BMMNC
ILMN_1352340 Il8rb 38.1 188.4 84.7 2.21 0.00187 - - ON -
ILMN_1351430 Serpinb10 36.5 156.0 53.0 2.04 0.00114 - - ON -
ILMN_1371753 F5_mapped 43.3 146.1 67.1 1.75 0.00050 -1.12 0.04691 ON -
ILMN_1360221 Tacstd1 36.9 133.2 87.6 1.77 0.00773 - - ON -
ILMN_1350326 LOC308990 43.1 123.6 59.7 1.51 0.00042 -1.04 0.02831 ON -
ILMN_1370914 Dok3_predicted 45.5 103.7 49.4 1.18 0.00130 -1.07 0.04206 ON -
ILMN_1362050 RGD1563994_predicted 37.6 96.9 49.4 1.33 0.00391 - - ON -
ILMN_1362786 Cias1_predicted 42.6 95.9 59.4 1.16 0.00609 - - ON -
ILMN_1376946 Clec4d 43.5 95.6 46.8 1.11 0.00584 - - ON -
ILMN_1358847 Fcar 41.2 94.5 49.3 1.18 0.00285 - - ON -
ILMN_1361075 RGD1560915_predicted 43.6 87.3 60.9 0.95 0.02231 - - ON -
ILMN_1372294 LOC499078 40.5 86.7 48.4 1.08 0.00315 - - ON -
ILMN_1353222 hshin7 36.9 86.2 66.5 1.13 0.02195 - - ON -
ILMN_1650491 Arl5b 42.7 79.2 54.6 0.87 0.01237 - - ON -
ILMN_1369853 Il22ra2 43.5 77.2 54.9 0.78 0.03376 - - ON -
PROBE DATA LIMMA RESULTS QUALITATIVE:
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 Table 5.10 Top 5 qualitatively altered probes found to be ‘ON’ in MI compared to Sham and ‘OFF’ in BMMNC compared to 
MI  Sham = sham operated group, MI = MI group treated with PBS, BMMMNC = MI group treated with bone marrow mononuclear 
cells. Illumina probe ID, gene symbol and average probe intensities for Sham, MI and BMMNC are detailed alongside the significant 
LIMMA results; log fold change and FDR adjusted p-value for the Sham vs. MI analysis (logFC_1 and P.Val_1) and the log fold 
change and FDR adjusted p-value for the MI vs. BMMNC analysis (logFC_2 and P.Val_2).  The direction of the qualitative difference 
are detailed in the right-hand columns.  Average intensities shaded grey were from probes which were not significantly detected (all 
detection p-values >0.05).   
 
Probe  ID Symbol Ave Sham
Ave     
MI
Ave 
BMMNC logFC_1 P.Val_1 logFC_2 P.Val_2
Sham → 
MI
MI → 
BMMNC
ILMN_1650752 Aplra1 31.6 112.7 36.0 1.82 0.00042 -1.63 0.00861 ON OFF
ILMN_1373925 Pirb 35.3 109.6 45.3 1.50 0.01304 - - ON OFF
ILMN_1374520 RGD1563073_predicted 38.5 85.6 42.0 1.14 0.00201 - - ON OFF
ILMN_1354457 LOC316207 34.1 78.9 41.9 1.19 0.00285 - - ON OFF
ILMN_1350738 Gpr109a 33.3 76.0 43.2 1.18 0.00097 - - ON OFF
PROBE DATA LIMMA RESULTS QUALITATIVE:
 
 
Table 5.11 Three qualitatively altered probes found to be ‘OFF’ in MI compared to Sham  Sham = sham operated group, MI = 
MI group treated with PBS, BMMMNC = MI group treated with bone marrow mononuclear cells. Illumina probe ID, gene symbol 
and average probe intensities for Sham, MI and BMMNC are detailed alongside the significant LIMMA results; log fold change and 
FDR adjusted p-value for the Sham vs. MI analysis (logFC_1 and P.Val_1) and the log fold change and FDR adjusted p-value for the 
MI vs. BMMNC analysis (logFC_2 and P.Val_2).  The direction of the qualitative differences are detailed in the right-hand columns.  
Average intensities shaded grey were from probes which were not significantly detected (all detection p-values >0.05).  The average 
intensities shaded blue indicate that not all probes were significantly detected (some detection p-values >0.05).   
 
Probe  ID Symbol Ave Sham
Ave     
MI
Ave 
BMMNC logFC_1 P.Val_1 logFC_2 P.Val_2
Sham → 
MI
MI → 
BMMNC
ILMN_1360605 Clasp1 56.5 43.0 54.1 -0.39 0.03613 - - OFF ON
ILMN_1356665 RGD1310121_predicted 55.4 40.5 48.8 -0.45 0.02562 - - OFF ON
ILMN_1362596 MGC114379 51.0 39.7 47.4 -0.36 0.03257 - - OFF -
PROBE DATA QUALITATIVE:LIMMA RESULTS
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 Table 5.12 Three qualitatively altered probes found to be ‘OFF’ in BMMNC compared to MI  Sham = sham operated group, MI 
= MI group treated with PBS, BMMMNC = MI group treated with bone marrow mononuclear cells. Illumina probe ID, gene symbol 
and average probe intensities for Sham, MI and BMMNC are detailed alongside the significant LIMMA results; log fold change and 
FDR adjusted p-value for the Sham vs. MI analysis (logFC_1 and P.Val_1) and the log fold change and FDR adjusted p-value for the 
MI vs. BMMNC analysis (logFC_2 and P.Val_2).  The direction of the qualitative difference are detailed in the right-hand columns.  
Average intensities shaded grey were from probes which were not significantly detected (all detection p-values >0.05).  The average 
intensities shaded blue indicate that not all probes were significantly detected (some detection p-values >0.05).   
 
Probe  ID Symbol Ave Sham
Ave     
MI
Ave 
BMMNC logFC_1 P.Val_1 logFC_2 P.Val_2
Sham → 
MI
MI → 
BMMNC
ILMN_1375210 RGD1561730_predicted 48.7 71.0 44.6 0.53 0.04793 - - - OFF
ILMN_1376826 Il13ra2 48.1 68.4 44.6 0.50 0.03140 - - - OFF
ILMN_1366137 Actn1 47.8 67.9 47.0 0.51 0.01627 - - - OFF
PROBE DATA LIMMA RESULTS QUALITATIVE:
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5.3 Validation of gene expression data 
 
5.3.1 Reference gene selection 
 
Five reference genes for rat were available ‘in-house’ for testing.  These were ATP 
synthase subunit beta (Atp5b), beta-2 microglobulin (B2m), eukaryotic translation 
initiation factor 4A2 (Eif4a2), glyceraldehydes-3-phosphate dehydrogenase (Gapdh) 
and ubiquitin C (Ubc). Initially the performance of these genes as endogenous 
controls was checked in the Illumina chip data, to assess if; 1) they were expressed at 
reasonable levels, 2) expression was stable across samples, 3) there was any evidence 
that these genes were differentially expressed in our experiment, i.e affected by our 
experimental conditions.  The resulting statistics are shown in Table 5.13, including 
the coefficient of variation (CV) which indicates overall stability of expression of 
each gene and one way ANOVA statistics looking for within group variation. 
 
Two genes, Atp5b and Ubc had minimal coefficient of variance, 4 and 7% 
respectively.  The other genes also had relatively good stability.  Gapdh was the least 
stable with a CV of 11%.   None of the genes had significant differential expression 
according to the LIMMA analysis, but a one-way ANOVA revealed that B2m is the 
gene most likely to have significant variation between our experimental groups.  This 
indicates that 4 of the 5 genes were potentially suitable reference genes.  These four 
were assessed further using QPCR in 8 of the 9 experimental samples 1-9 (one 
sample from the Sham group (tissue sample 3) had no tissue remaining). 
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Table 5.13 Suitability of 5 potential reference genes Sham = sham operated group, 
MI = MI group treated with PBS, BMMNC = MI group treated with bone marrow 
mononuclear cells. A) Illumina data from the 5 potential genes indicates average 
signal (AVE_Signal) and standard deviation (ARRAY_STDEV)  B) Statistical 
analysis of variation across all samples; average (Ave), standard deviation (StDev) 
and coefficient of variance (CV) and variation between groups (One way ANOVA). 
 
A 
SYMBOL PROBE_ID
AVG_Sig
nal
ARRAY_S
TDEV
AVG_Sig
nal
ARRAY_
STDEV
AVG_Sig
nal
ARRAY_S
TDEV
Atp5b ILMN_1350324 15547 1144 15883 1037 16797 1615
B2m ILMN_1368656 15256 869 18016 837 15975 1030
Eif4a2 ILMN_1372755 2862 318 3108 375 3367 1090
Gapdh ILMN_1649859 9064 1291 7634 310 9337 1121
Ubc ILMN_1350494 14326 817 14027 1484 12478 1572
BMMNCSham MI
 
B 
SYMBOL PROBE_ID Ave StDev CV
One_Way_A
NOVA
Atp5b ILMN_1350324 16076 647 4 ns
B2m ILMN_1368656 16416 1432 9 0.0245
Eif4a2 ILMN_1372755 3113 252 8 ns
Gapdh ILMN_1649859 8678 915 11 ns
Ubc ILMN_1350494 13610 992 7 ns
STATS
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5.3.2 QPCR using TaqMan gene expression assays 
 
Three genes were followed up using QPCR; Sema4a, Oas1k and Iqgap1.  Both 
Sema4a and Oas1k had the highest and most significant alterations in expression 
in both the Sham vs. MI and the MI vs. BMMNC comparisons.  The adjusted p-
values in MI vs. BMMNC were several orders of magnitude higher than Sham vs. 
MI.  Iqgap1 had much lower fold change difference and much higher adjusted p-
values.  QPCR results for these three gene would help to determine the reliability 
of the gene expression dataset from the most highly significant data to data with 
lesser significance. Reactions were performed in triplicate for each cDNA sample 
and for the reference genes.  The amplification curves were checked in SDS2.3 
[Applied Biosystems, U.K] and wells with errors were noted, the data was 
exported to Excel [Microsoft, US] for analysis.  Triplicate Ct values for each 
sample were averaged after removing any outliers as suggested by high CV values 
(CV>2). 
 
5.3.2.1 GeNorm 
The Ct values for the reference genes were converted into ‘quantities’ (Q) and 
entered into the GeNorm macro.  The macro found the gene with the highest M 
value (1.724) was Atp5b, this column was discarded and the analysis was rerun 
and showed that GAPDH was the next highest value with 0.526.  This meant that 
Ubc and Eif4a2 were the best performing reference genes with an M value of 
0.355.   The charts were checked with data for all 4 genes uploaded to check the 
pairwise variation values (Figure 5.12).  As seen in Figure 5.12 B the V2/3 value 
is 0.172, which is above the 0.15 threshold suggested by Vandesompele et al 2002 
[114] therefore including the data for third best gene (GAPDH) in the 
normalisation factor calculation would be desirable.  The V3/4 was 0.429 
indicating this gene should also be included.   
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Figure 5.12 Graphical output of the GeNorm analysis A) plots the ‘M’ values 
for each gene, the two most stably expressed genes with the lowest ‘M’ value on 
the left.  B) shows the pairwise variations for V2/3 (i.e between the normalisation 
factor calculated for the best 2 genes and the normalisation factor calculated from 
the best three genes), and V3/4 (i.e best three genes and the best four genes).   
 
B
A
 
 
 
 
Page 179 
5.3.2.2 ∆∆Ct calculations and statistical analysis. 
The average Ct values for all four reference genes in each sample were calculated 
to give an average reference Ct (Ct REF) value.  These values were used to 
calculate the  ∆Ct for each gene of interest (∆Ct GOI) and then average and 
standard deviations in each experimental group were calculated Table 5.14. 
 
Table 5.14 Normalised Ct values (∆Ct) for each gene of interest (GOI), group 
averages and standard deviations Sham = sham operated group, MI = MI group 
treated with PBS, BMMNC = MI group treated with bone marrow mononuclear 
cells. Only two of the three Sham samples were tested and one of the MI samples 
failed in two of the three GOI. A) Results from Sema4a.  B) Results from Oas1k. 
C) Results from Iqgap1. 
 
A
Sample ∆ Ct
Group Ave 
∆Ct
Group 
StDev
Sham 2 5.18
Sham 3 6.18 5.68 0.71
MI 1 4.26
MI 2 -
MI 3 4.61 4.43 0.25
BMMNC 1 4.18
BMMNC 2 5.33
BMMNC 3 5.64 5.05 0.77
B
Sample ∆ Ct
Group Ave 
∆Ct
Group 
StDev
Sham 2 6.89
Sham 3 5.19 6.04 1.20
MI 1 3.16
MI 2 -
MI 3 3.37 3.27 0.15
BMMNC 1 2.29
BMMNC 2 4.74
BMMNC 3 3.80 3.61 1.23
C
Sample ∆ Ct
Group Ave 
∆Ct
Group 
StDev
Sham 2 4.48
Sham 3 4.70 4.59 0.15
MI 1 4.35
MI 2 3.79
MI 3 4.17 4.10 0.29
BMMNC 1 3.90
BMMNC 2 4.52
BMMNC 3 3.70 4.04 0.42  
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The ∆Ct were then used to calculate ∆∆Ct using Sham as the reference group and 
fold changes were calculated from this.  These fold changes are shown in  Figure 
5.13 with error bars indicating 95% confidence interval on the fold change values.  
The pattern of gene expression over the three groups was similar to the LIMMA 
data in all three genes i.e. Sema4a and Oas1k had strong up-regulation in MI 
group compared to Sham and a lesser down-regulation in BMMNC compared to 
MI.  Iqgap also showed an up-regulation in MI compared to Sham, but no 
difference between MI and BMMNC.  Large error bars are present in the FC2 
calculations from Sema4a and Oas1k.    
 
To look for statistical differences the ∆Ct values were used to perform a Student’s 
t-test.  As mentioned previously, one of the three Sham samples was not analysed 
due to lack of tissue sample for RNA extraction and one of the three MI samples 
failed in both the Oas1k and the Sema4a.  This meant an n of 2 in some of the t-
tests.   No significant differences were found (Table 5.15).    
 
Table 5.15 P-values from the Student’s t-test performed on ∆Ct values from 
QPCR analysis in for Iqgap1, Oas1k, and Sema4a  
 
Sham vs. MI MI vs. BMMNC
Sema4a 0.150 0.422
Oas1k 0.084 0.734
Iqgap1 0.124 0.842  
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Figure 5.13 Graphs showing fold change (FC) results from the QPCR 
analysis (A-C) and LIMMA statistics from the Illumina RatRef12 chip 
analysis (D) for Iqgap1, Oas1k, and Sema4a A-C) The FC of the MI group 
compared to Sham (FC1) and the FC of the BMMNC group compared to Sham 
(FC2).  Error bars indicate upper and lower 95% confidence interval (CI) of the 
FC.  D) Log fold changes and FDR adjusted p-values for Sham vs. MI and MI vs. 
BMMNC as calculated by LIMMA from the Illumina RatRef12 chip analysis. 
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5.3.2.3 QPCR analysis of Oas1k in samples 10-18 
QPCR analysis was also performed on cDNA prepared from tissue samples 10-18 
for one of the genes (Oas1k).  The four previously used endogenous controls and 
Oas1k were run in triplicate on one plate.  GeNorm analysis of the endogenous 
controls data suggested the use of just Ubc and Eif4a2 for normalisation in this 
sample set.  ∆∆Ct calculations were performed as before and Figure 5.14 shows 
the results for Oas1k gene expression.  Again, the error bar is especially large for 
the FC1 calculation.  P-values for Sham vs. MI and MI vs. BMMNC are shown in 
the white boxes.   
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Figure 5.14 Graphs showing fold change (FC) results from the QPCR 
analysis for Oas1k in samples 10-18 The FC of the MI group compared to Sham 
(FC1) and the FC of the BMMNC group compared to Sham (FC2).  Error bars 
indicate upper and lower 95% confidence interval (CI) of the FC. P values for 
Sham vs. MI and MI vs. BMMNC are shown in the white boxes.   
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6. Bioinformatic results 
 
6.1 Bioinformatic analysis of proteins found to be altered in 2DE analyses 
 
6.1.1 Protein ANalysis THrough Evolutionary Relationships (PANTHER) 
 
Four different lists of proteins were entered into PANTHER the number of 
proteins in each list is shown in Table 6.1. 
 
Table 6.1 Four different lists of Refseq protein accession codes were entered 
into PANTHER  
 
 
PANTHER Dataset Number of Proteins
Sham vs. MI - Up 11
Sham vs. MI - Down 23
MI vs. BMMNC - Up 22
MI vs. BMMNC - Down 4  
 
6.1.1.1 Sham vs. MI  
From the proteins up-regulated in Sham vs. MI, all 11 were mapped by 
PANTHER, with exact hits.  Of the 23 proteins down-regulated in Sham vs. MI, 
PANTHER hits were found for 22; stress-70 protein was un-mapped. 
 
The 11 up-regulated proteins were not represented by any different PANTHER 
pathways.   The 22 down-regulated proteins represented 10 different pathways, as 
shown in Figure 6.1.    The epidermal growth factor (EGF) and fibroblast growth 
factor (FGF) pathways are represented by the presence of both Ywhae and Pebp1.  
The other eight pathways were only represented by a single protein from our 
dataset, either Myh6, Atp5b or Ywhae.  
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Figure 6.1 PANTHER Pathways represented by the proteins differentially 
regulated in Sham vs. MI  Pathways represented by 22 proteins found to be 
Down-regulated in Sham vs. MI.  Numbers in brackets indicate the number of 
proteins associated with the term. 
 
 
p53 pathway (1)
Inflammation mediated by chemokine and cytokine signaling
pathway (1)
Wnt signaling pathway (1)
Parkinson disease (1)
PI3 kinase pathway (1)
ATP synthesis (1)
Cytoskeletal regulation by Rho GTPase (1)
Nicotinic acetylcholine receptor signaling pathway (1)
FGF signaling pathway (2)
EGF receptor signaling pathway (2)
 
 
The most highly represented biological process represented in both the up- and 
down-regulated proteins in Sham vs. MI was ‘muscle contraction’, represented by 
Tpm1 and Myl 2 from the up-regulated proteins and Ckm, Ckmt2, Myh6, Tnnt2, 
Tpm1 and myosin light chain 3 (Myl3), see Figure 6.2.   
 
Many other biological processes were included in both up-regulated and down-
regulated lists including; carbohydrate metabolism, cell structure and motility, 
immunity and defence and electron transport. Carbohydrate metabolism was 
represented by dihydrolipoyllysine-residue acetyltransferase component of 
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pyruvate dehydrogenase complex a.k.a E2 component of pyruvate dehydrogenase 
(Dlat) and Echs1 from up-regulated protein list; succinate dehydrogenase (Sdha) 
and Ldhb from down-regulated protein list.  Cell structure and motility was 
represented by Tpm1 and Myl2 from the up-regulated list; Cap1, Tuba4a, Actc1, 
Des and Tpm1 from the down-regulated list.  Immunity and defence was 
represented by Prdx3 and Lgal5 from up-regulated list; Prdx6 and Hspb8 from the 
down-regulated list.  Finally, electron transport was represented by NAD(P) 
transhydrogenase (Nnt) and Uqcrh from the up-regulated list; Acads, Ndufs1, 
Sdha and Atp5b from the down-regulated list.  
 
Figure 6.2 PANTHER Biological processes represented by the proteins 
differentially regulated in Sham vs. MI  A) Processes represented by 11 
proteins found to be Up-regulated in Sham vs. MI. B) Processes represented by 22 
proteins found to be Down-regulated in Sham vs. MI. Numbers in brackets 
indicate the number of proteins associated with the term. 
 
A
Transport (1)
Protein metabolism and modification  (1)
Other metabolism  (1)
Lipid, fatty acid and steroid metabolism  (1)
Cell adhesion  (1)
Apoptosis  (1)
Developmental processes (2)
Carbohydrate metabolism (2)
Coenzyme and prosthetic group metabolism (2)
Electron transport (2)
Cell structure and motility (2)
Immunity and defense (2)
Muscle contraction (2)
B
Transport (1)
Biological process unclassified (1)
Protein targeting and localization (1)
Nucleoside, nucleotide and nucleic acid metabolism  (1)
Lipid, fatty acid and steroid metabolism  (1)
Carbohydrate metabolism (2)
Intracellular protein traffic  (2)
Immunity and defense (2)
Protein metabolism and modification (3)
Developmental processes (3)
Signal transduction(3)
Cell cycle (4)
Electron transport (4)
Cell structure and motility (5)
Muscle contraction (6)
 
 
Biological processes unique to the up-regulated protein list included coenzyme 
and prosthetic group metabolism (Dlat and Echs1).  Biological processes only 
associated with the down-regulated proteins included; cell cycle (Myh6, Ywhae, 
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Tuba4a and Actc1) signal transduction (Cap1, Ywhae and Pebp1) and 
intracellular protein traffic (Tuba4a and Actc1). 
 
The molecular functions represented by these proteins reveal two functions to be 
highly represented by several proteins in both lists.  From the list of proteins up-
regulated ‘Oxidoreductase’ is represented by the presence of four different 
proteins, Nnt, Prdx3, Echs1 and Uqcrh.  The same function was also represented 
by five of the proteins down-regulated; Acads, Prdx6, Ndufa10, Sdha and Ldhb.  
Two up-regulated proteins were cytoskeletal, namely Tpm1 and Myl2, however 
eight cytoskeletal proteins were down-regulated; Myh6, Tnnt2, Cap1, Tuba4a, 
Actc1, Des and Myl3. 
 
6.1.1.2 MI vs. BMMNC 
The two lists of Refseq protein accession codes for proteins up- and down-
regulated in MI vs. BMMNC were successfully mapped by PANTHER except 
Hspa9 from the up-regulated proteins list.  Myh6 was in both the up and down-
regulated protein list.   
 
The pathways represented by up-regulated proteins from the MI vs. BMMNC 
comparison (Figure 6.3 A) include Parkinson’s disease represented by Ywhae and 
Hspb8, All other pathways are represented by a single protein from the list.  The 
EGF, FGF Pi3 kinase and p53 signalling pathways are represented by Ywhae.  
Apoptosis is represented by hspb8; glycolysis by Pgam1 and ATP synthesis by 
Atp5b.  Myh6 accounts for the other four pathways including Wnt signalling.  All 
four pathways represented by the down-regulated proteins are represented by only 
one protein, namely Myh6 (Figure 6.3 B).     
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Figure 6.3 PANTHER Pathways represented by the proteins differentially 
regulated in MI vs. BMMNC A) Pathways represented by 21 proteins found to 
be Up-regulated in MI vs. BMMNC. B) Pathways represented by 4 proteins found 
to be Down-regulated in MI vs. BMMNC. Numbers in brackets indicate the 
number of proteins associated with the term. 
 
B
Wnt signaling pathway (1)
Nicotinic acetylcholine receptor signaling pathway (1)
Inflammation mediated by chemokine and cytokine signaling
pathway (1)
Cytoskeletal regulation by Rho GTPase (1)
A
Apoptosis signaling pathway  (1)
p53 pathway  (1)
Inflammation mediated by chemokine and cytokine signaling
pathway  (1)
Wnt signaling pathway  (1)
Glycolysis (1)
PI3 kinase pathway  (1)
FGF signaling pathway (1)
ATP synthesis (1)
EGF receptor signaling pathway (1)
Cytoskeletal regulation by Rho GTPase (1)
Nicotinic acetylcholine receptor signaling pathway (1)
Parkinson disease (2)
 
 
Many biological processes were represented by the proteins both up- and down-
regulated in MI vs. BMMNC including carbohydrate metabolism, muscle 
contraction and electron transport.  Carbohydrate metabolism was represented by 
Ldhb, methylcrotonoyl-CoA carboxylase alpha (Mccc1), Sdha and Pgam1 from 
the up-regulated list and both Dlat and Echs1 from the down-regulated list.  
Muscle contraction was represented by Ckm, Ckmt2, Myh6, Tnnt2, Tpm1 from 
the up-regulated list and Myh6 from the down-regulated list. Electron transport 
was represented by Atp5b, Ndufa10 and Sdha from the up-regulated list; Uqcrh 
from the down-regulated list.   
 
Processes unique to the up-regulated proteins included cell structure and motility 
(Cap1, Ndufa10, Des and Tpm1), signal transduction (Cap1, Ywhae and Pebp1) 
and immunity and defence (Prdx6 and Hspb8).   Whereas the processes unique to 
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the down-regulated proteins were; coenzyme and prosthetic group metabolism 
(Dlat and Echs1) and fatty acid steroid metabolism (Echs1). 
 
Figure 6.4 PANTHER Biological processes represented by the proteins 
differentially regulated in MI vs. BMMNC A) Processes represented by 22 
proteins found to be Up-regulated in MI vs. BMMNC. B) Processes represented 
by 4 proteins found to be Down-regulated in MI vs. BMMNC. Numbers in 
brackets indicate the number of proteins associated with the term. 
 
A
Transport (1)
Protein targeting and localization (1)
Protein metabolism and modification (1)
Nucleoside, nucleotide and nucleic acid metabolism (1)
Other metabolism (1)
Sensory perception (1)
Biological process unclassified (2)
Signal transduction (2)
Cell cycle (2)
Immunity and defense (2)
Developmental processes (3)
Electron transport  (3)
Carbohydrate metabolism (4)
Cell structure and motility (4)
Muscle contraction (5)
B
Lipid, fatty acid and steroid metabolism (1)
Muscle contraction (1)
Electron transport (1)
Developmental processes (1)
Cell cycle (1)
Coenzyme and prosthetic group metabolism (2)
Carbohydrate metabolism (2)
 
 
The molecular functions represented by the two lists of proteins altered in MI vs. 
BMMNC reveal two functions to be highly represented in both lists.  From the list 
of proteins up-regulated ‘Oxidoreductase’ is represented by the presence of five 
different proteins; Ldhb, Ndufa10, Sdha, Prdx6 and hydroxysteroid 
dehydrogenase-like protein 2 (Hsdl2).  The same function was also represented by 
two of the proteins down-regulated; Echs1 and Uqcrh.  Six up-regulated proteins 
were cytoskeletal but only one cytoskeletal protein was down-regulated (Myh6).   
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6.1.2 Database for Annotation, Visualization and Integrated Discovery 
(DAVID) 
 
The same four protein lists that were entered into PANTHER were also entered 
into DAVID (see Table 6.1).   
 
6.1.2.1 Sham vs. MI  
The cluster analysis of the biological process GO terms associated with the 
proteins up-regulated in Sham vs. MI returned 9 clusters.  Only GO terms in the 
first seven groups had p-values <0.05.  The first cluster of terms were all related 
to negative regulation of cellular processes, the second were related to positive 
regulation of hydralase and catalytic activity, the third relates to stress responces, 
circulation made up the fourth cluster, reaction to ROS was the fifth cluster.  
Groups 1 -7 are shown in Table 6.2. 
 
The clustering of biological process GO terms associated with the proteins down-
regulated in Sham vs. MI returned 19 clusters.  There were significant p-values in 
clusters 1-13 (these are detailed in Table 6.3).  These thirteen clusters contained 
terms associated with muscle contraction (cluster 1), muscle and organ 
development (cluster 2 and 5), transport and localisation (cluster 3 and 6), stress 
response (cluster 4) and apoptosis (cluster 7). 
 
 
  
Table 6.2 Cluster 1 -7 of 9 clusters of biological process GO terms associated with proteins up-regulated in Sham vs. MI  The GO terms 
within each cluster, count (number of proteins from list with this annotation), % (percentage of the input proteins found with this annotation), p-
value (modified Fisher’s exact test (EASE score) and fold enrichment (the fold enrichment of this annotation in the uploaded protein list versus 
the proportion of this annotation in the background dataset).  Only significantly associated GO terms (p-value <0.05) are shown. 
 
 
Cluster GO Biological Process Term Count % PValue Fold Enrichment
1 GO:0043066~negative regulation of apoptosis 4 33 0.00097 17
GO:0043069~negative regulation of programmed cell death 4 33 0.00101 16
GO:0060548~negative regulation of cell death 4 33 0.00102 16
GO:0051704~multi-organism process 4 33 0.00188 13
GO:0051093~negative regulation of developmental process 4 33 0.00402 10
GO:0042981~regulation of apoptosis 4 33 0.00738 8
GO:0043067~regulation of programmed cell death 4 33 0.00764 8
GO:0010941~regulation of cell death 4 33 0.00773 8
GO:0050793~regulation of developmental process 4 33 0.01757 6
GO:0010033~response to organic substance 4 33 0.01858 6
2 GO:0051345~positive regulation of hydrolase activity 3 25 0.00320 30
GO:0051336~regulation of hydrolase activity 3 25 0.01172 16
GO:0043085~positive regulation of catalytic activity 3 25 0.03073 9
3 GO:0042542~response to hydrogen peroxide 3 25 0.00129 48
GO:0032496~response to lipopolysaccharide 3 25 0.00241 35
GO:0002237~response to molecule of bacterial origin 3 25 0.00338 30
GO:0009617~response to bacterium 3 25 0.00831 19
GO:0002520~immune system development 3 25 0.01188 15
GO:0051707~response to other organism 3 25 0.01196 15
GO:0009607~response to biotic stimulus 3 25 0.01717 13
4 GO:0003013~circulatory system process 3 25 0.00430 26
GO:0008015~blood circulation 3 25 0.00430 26
5 GO:0000302~response to reactive oxygen species 4 33 0.00003 52
GO:0006979~response to oxidative stress 4 33 0.00020 28
GO:0044093~positive regulation of molecular function 4 33 0.00323 11
GO:0050790~regulation of catalytic activity 4 33 0.00767 8
GO:0065009~regulation of molecular function 4 33 0.01186 7  
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Table 6.2 continued 
 
Cluster GO Biological Process Term Count % PValue Fold Enrichment
6 GO:0065008~regulation of biological quality 5 42 0.00585 5
GO:0006950~response to stress 5 42 0.00735 5
GO:0048523~negative regulation of cellular process 5 42 0.00760 5
GO:0048519~negative regulation of biological process 5 42 0.01108 4
GO:0048518~positive regulation of biological process 5 42 0.01920 4
7 GO:0048584~positive regulation of response to stimulus 3 25 0.01006 17
GO:0048583~regulation of response to stimulus 3 25 0.03288 9  
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Table 6.3 Cluster 1-13 of 19 clusters of biological process GO terms associated with proteins down-regulated in Sham vs. MI   The GO 
terms within each cluster, count (number of proteins from list with this annotation), % (percentage of the input proteins found with this 
annotation), p-value (modified Fisher’s exact test (EASE score) and fold enrichment (the fold enrichment of this annotation in the uploaded 
protein list versus the proportion of this annotation in the background dataset).  Only significantly associated GO terms (p-value <0.05) are 
shown. 
Cluster GO Biological Process Term Count % PValue Fold Enrichment
1 GO:0033275~actin-myosin filament sliding 3 13 0.00003 351
GO:0030049~muscle filament sliding 3 13 0.00003 351
GO:0070252~actin-mediated cell contraction 3 13 0.00005 251
GO:0043462~regulation of ATPase activity 3 13 0.00017 146
GO:0045214~sarcomere organization 3 13 0.00030 110
2 GO:0060415~muscle tissue morphogenesis 5 21 0.00000 91
GO:0055008~cardiac muscle tissue morphogenesis 5 21 0.00000 91
GO:0006941~striated muscle contraction 5 21 0.00000 71
GO:0030048~actin filament-based movement 4 17 0.00000 180
GO:0048738~cardiac muscle tissue development 5 21 0.00000 44
GO:0060048~cardiac muscle contraction 4 17 0.00000 123
GO:0008016~regulation of heart contraction 5 21 0.00000 42
GO:0003015~heart process 4 17 0.00001 102
GO:0060047~heart contraction 4 17 0.00001 102
GO:0055010~ventricular cardiac muscle morphogenesis 4 17 0.00001 102
GO:0003007~heart morphogenesis 5 21 0.00001 38
GO:0030239~myofibril assembly 4 17 0.00001 97
GO:0055002~striated muscle cell development 4 17 0.00001 94
GO:0006936~muscle contraction 5 21 0.00001 31
GO:0031032~actomyosin structure organization 4 17 0.00002 75
GO:0055001~muscle cell development 4 17 0.00002 75
GO:0030705~cytoskeleton-dependent intracellular transport 4 17 0.00002 69
GO:0003012~muscle system process 5 21 0.00002 28
GO:0010927~cellular component assembly involved in morphogenesis 4 17 0.00003 63
GO:0051146~striated muscle cell differentiation 4 17 0.00007 47
GO:0003013~circulatory system process 5 21 0.00013 18
GO:0008015~blood circulation 5 21 0.00013 18  
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Table 6.3 continued. 
Cluster GO Biological Process Term Count % PValue Fold Enrichment
2 cont. GO:0014706~striated muscle tissue development 5 21 0.00017 17
GO:0060537~muscle tissue development 5 21 0.00020 16
GO:0030036~actin cytoskeleton organization 5 21 0.00023 15
GO:0030029~actin filament-based process 5 21 0.00027 15
GO:0007517~muscle organ development 5 21 0.00040 13
GO:0007507~heart development 5 21 0.00040 13
GO:0042692~muscle cell differentiation 4 17 0.00052 24
GO:0048729~tissue morphogenesis 5 21 0.00055 12
GO:0048646~anatomical structure formation involved in morphogenesis 5 21 0.00161 9
GO:0044057~regulation of system process 5 21 0.00174 9
GO:0007010~cytoskeleton organization 5 21 0.00195 9
GO:0032989~cellular component morphogenesis 5 21 0.00301 8
GO:0009887~organ morphogenesis 6 25 0.00596 5
GO:0009888~tissue development 5 21 0.02292 4
3 GO:0006810~transport 11 46 0.00114 3
GO:0051234~establishment of localization 11 46 0.00123 3
GO:0051179~localization 11 46 0.00500 2
4 GO:0009408~response to heat 4 17 0.00032 28
GO:0009266~response to temperature stimulus 4 17 0.00084 20
GO:0009628~response to abiotic stimulus 4 17 0.03046 6
5 GO:0048856~anatomical structure development 12 50 0.00031 3
GO:0048731~system development 11 46 0.00112 3
GO:0032502~developmental process 12 50 0.00147 3
GO:0007275~multicellular organismal development 11 46 0.00295 3
6 GO:0046907~intracellular transport 6 25 0.00112 7
GO:0051649~establishment of localization in cell 6 25 0.00419 5
GO:0051641~cellular localization 6 25 0.00609 5  
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Table 6.3 continued. 
Cluster GO Biological Process Term Count % PValue Fold Enrichment
7 GO:0006915~apoptosis 5 21 0.00307 8
GO:0012501~programmed cell death 5 21 0.00331 7
GO:0008219~cell death 5 21 0.00466 7
GO:0016265~death 5 21 0.00493 7
8 GO:0010926~anatomical structure formation 7 29 0.00395 4
GO:0022607~cellular component assembly 6 25 0.00599 5
GO:0044085~cellular component biogenesis 6 25 0.00927 4
9 GO:0051336~regulation of hydrolase activity 5 21 0.00092 11
GO:0051345~positive regulation of hydrolase activity 4 17 0.00148 17
GO:0050790~regulation of catalytic activity 5 21 0.02626 4
GO:0043085~positive regulation of catalytic activity 4 17 0.03707 5
10 GO:0009117~nucleotide metabolic process 4 17 0.01303 8
GO:0006753~nucleoside phosphate metabolic process 4 17 0.01303 8
GO:0055086~nucleobase, nucleoside and nucleotide metabolic process 4 17 0.01752 7
11 GO:0046034~ATP metabolic process 3 13 0.01666 14
GO:0009205~purine ribonucleoside triphosphate metabolic process 3 13 0.02073 13
GO:0009199~ribonucleoside triphosphate metabolic process 3 13 0.02101 13
GO:0009144~purine nucleoside triphosphate metabolic process 3 13 0.02216 12
GO:0009141~nucleoside triphosphate metabolic process 3 13 0.02424 12
GO:0009150~purine ribonucleotide metabolic process 3 13 0.02672 11
GO:0009259~ribonucleotide metabolic process 3 13 0.02831 11
GO:0006163~purine nucleotide metabolic process 3 13 0.04704 8
12 GO:0048468~cell development 6 25 0.01822 4
GO:0048869~cellular developmental process 7 29 0.03722 3
13 GO:0048545~response to steroid hormone stimulus 4 17 0.01303 8
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6.1.2.2 MI vs. BMMNC 
Biological process GO terms associated with the proteins up-regulated in MI vs. 
BMMNC grouped into 14 clusters.  Clusters 1-9 all contained terms with p-values 
<0.05.  Clusters 1 to 9 contained terms related to the following; transport and 
localisation (cluster 1 and 2), muscle development and contraction (cluster 3 and 
4) and circulation (cluster 5). Groups 1 to 9 are detailed in Table 6.4. 
 
There were only 4 proteins down-regulated in MI vs. BMMNC, and the biological 
process GO terms formed one cluster, this group included two terms relating to 
cellular catabolic process and is shown in Table 6.5. 
 
Clustering of associated KEGG pathway terms was not possible for the proteomic 
data.  There was only a single pathway associated with the Sham vs. MI down-
regulated and MI vs. BMMNC up-regulated gene lists, this was oxidative 
phosphorylation (Figure 6.5).  The four proteins associated with this pathway 
were NADH-ubiquinone oxidoreductase 75kDa subunit (Ndufs1), succinate 
dehydrogenase (Sdha), cytochrome b-c1 complex subunit Rieske (Uqcrfs1) and  
ATP synthase subunit β (Atp5b).  
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 6.4 Clusters 1 -9 of 14 clusters of biological process GO terms associated with proteins up-regulated in MI vs. BMMNC   
The GO terms within each cluster, count (number of genes from list with this annotation), % (percentage of the inputted genes found 
with this annotation), p-value (modified Fisher’s exact test (EASE score) and fold enrichment (the fold enrichment of this annotation 
in the uploaded gene list versus the proportion of this annotation in the background dataset).  Only significantly associated GO terms 
(p-value <0.05) are shown. 
 
 
Cluster GO Biological Process Term Count % PValue Fold Enrichment
1 GO:0006810~transport 12 55 0.00003 4
GO:0051234~establishment of localization 12 55 0.00004 4
GO:0051179~localization 12 55 0.00020 3
2 GO:0051641~cellular localization 7 32 0.00038 6
GO:0046907~intracellular transport 6 27 0.00052 8
GO:0051649~establishment of localization in cell 6 27 0.00201 6
3 GO:0030049~muscle filament sliding 3 14 0.00002 406
GO:0033275~actin-myosin filament sliding 3 14 0.00002 406
GO:0070252~actin-mediated cell contraction 3 14 0.00004 290
GO:0043462~regulation of ATPase activity 3 14 0.00012 169
GO:0030048~actin filament-based movement 3 14 0.00014 156
GO:0045214~sarcomere organization 3 14 0.00022 127
GO:0055010~ventricular cardiac muscle morphogenesis 3 14 0.00046 88
GO:0030239~myofibril assembly 3 14 0.00050 85
GO:0055002~striated muscle cell development 3 14 0.00054 81
GO:0055001~muscle cell development 3 14 0.00084 66
GO:0055008~cardiac muscle tissue morphogenesis 3 14 0.00090 63
GO:0060415~muscle tissue morphogenesis 3 14 0.00090 63
GO:0030705~cytoskeleton-dependent intracellular transport 3 14 0.00101 60
GO:0006941~striated muscle contraction 3 14 0.00147 50
GO:0051146~striated muscle cell differentiation 3 14 0.00218 41
GO:0008016~regulation of heart contraction 3 14 0.00411 29
GO:0003007~heart morphogenesis 3 14 0.00509 26
GO:0006936~muscle contraction 3 14 0.00734 22
GO:0042692~muscle cell differentiation 3 14 0.00812 21
GO:0003012~muscle system process 3 14 0.00945 19
GO:0014706~striated muscle tissue development 3 14 0.02494 11  
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Table 6.4 continued. 
 
Cluster GO Biological Process Term Count % PValue Fold Enrichment
3 cont. GO:0060537~muscle tissue development 3 14 0.02680 11
GO:0007507~heart development 3 14 0.03754 9
GO:0007517~muscle organ development 3 14 0.03754 9
GO:0048729~tissue morphogenesis 3 14 0.04361 8
4 GO:0030036~actin cytoskeleton organization 4 18 0.00220 14
GO:0030029~actin filament-based process 4 18 0.00247 14
GO:0007010~cytoskeleton organization 4 18 0.01087 8
GO:0032989~cellular component morphogenesis 4 18 0.01502 7
5 GO:0008015~blood circulation 4 18 0.00144 17
GO:0003013~circulatory system process 4 18 0.00144 17
6 GO:0048646~anatomical structure formation involved in morphogenesis 4 18 0.00944 8
GO:0010926~anatomical structure formation 5 23 0.04394 3
8 GO:0010926~anatomical structure formation 5 23 0.04394 3
9 GO:0048856~anatomical structure development 8 36 0.02768 2  
 
Table 6.5 One cluster of biological process GO terms associated with proteins down-regulated in MI vs. BMMNC   The GO 
terms within each cluster, count (number of genes from list with this annotation), % (percentage of the inputted genes found with this 
annotation), p-value (modified Fisher’s exact test (EASE score) and fold enrichment (the fold enrichment of this annotation in the 
uploaded gene list versus the proportion of this annotation in the background dataset).  Only significantly associated GO terms (p-
value <0.05) are shown. 
 
Cluster GO Biological Process Term Count % PValue Fold Enrichment
1 GO:0044248~cellular catabolic process 3 75 0.01087 12
GO:0009056~catabolic process 3 75 0.02956 7
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Figure 6.5 KEGG Pathway - Oxidative Phosphorylation  Proteins identified as being down-regulated in Sham vs. MI and up-
regulated in MI vs. BMMNC are highlighted by red stars. 
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6.1.3 Ingenuity Pathway Analysis (IPA) 
 
Data from 73 spots for which there was a single protein identity were uploaded in 
the form of RefSeq ID’s with fold changes and p-values for both the Sham vs. MI 
and the MI vs. BMMNC comparisons.   
 
6.1.3.1 Sham vs. MI  
 
31 proteins differentially expressed in Sham vs. MI mapped in IPA (Table 6.6 A), 
and these were associated within three different networks along with a further 42 
different proteins and endogenous chemicals (Table 6.6 B).  Networks 1 and 2 had 
scores of 35 and 33 respectively; network 3 had a much lower score of 2.  
Networks 1 and 2 are shown in Figures 6.6 A and B. 
 
Network 1 contains 16 proteins from our dataset and is mainly related to 
cardiovascular system development and function and has several major hubs 
including nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) 
complex, p38 mitogen activated protein kinase (p38 MAPK), protein kinase C 
(Pkc), Insulin and Myosin see Figure 6.6 A.  NFkB is linked to one down 
regulated protein (Pebp1) and three up-regulated proteins (Dbt, Alb and Hspd1).  
There is evidence that Hspd1 and Albumin (both up-regulated) are involved in 
increased translocation and activation of NFkB [119-121].  Whereas, the down-
regulated Pebp1 has been shown to antagonise activation of NFkB [122].  P38 
MAPK, which increases activation of NFkB, is linked to two down-regulated 
proteins (Des and Hspb8) and to the up-regulated hspd1.  Both heat shock proteins 
have been shown to increase activation of p38 MAPK as part of apoptosis 
signalling cascades [123, 124].  Insulin is linked to Alb, Actc1 and Ywhae.  
Insulin has been shown to increase the binding of Ywhae and Pkc α; Ywhae 
overexpression has also been shown to increase downstream ERK1/2 and Akt 
activation [125].  Insulin has also been shown to regulate transcription of Albumin 
[126].   The Myosin hub consists of links between the myofibrillar/contractile 
proteins, including Actc1, Tnnt2, Myh6 and Myl2.   
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Network 2 contains 15 proteins from our dataset and is mainly related to lipid 
metabolism and small molecule biochemistry and contains several major hubs 
including tumour necrosis factor (Tnf), v-myc myelocytomatosis viral oncogene 
homolog (Myc), and the endogenous chemicals cholesterol, beta-estradiol and 
hydrogen peroxide see Figure 6.6 B. Myc is thought to cause reduced expression 
of Tpm1 and increase expression of Prdx6. Myc also interacts with Ywhae [127].  
Myc also has known but undefined associations with Tuba4a and Ndufs1.  Tnf has 
known associations with Tpm1 and Ldhb, and is also known to decrease 
expression of Acads [128]. 
 
Network 3 consists of the interaction of membrane metallo-endopeptidase (Mme) 
with NADP transhydrogenase a.k.a nicotinamide nucleotide transhydrogenase 
(Nnt). 
 
 
 
 
 
 
  
Table 6.6 Proteins and endogenous chemicals included in the IPA analysis of Sham vs. MI proteomics data   A) Proteomic results mapped 
into IPA for core analysis. B) Associated proteins and endogenous chemicals also included in the Sham vs. MI IPA core analysis.  Protein 
symbol and Entrez gene names are shown alongside the network(s) the protein/chemical is found in, the sub-cellular localisation and molecule 
type. 
 
A 
 
 
Symbol Entrez Gene Name Networks Location Type(s)
TNNT2 troponin T type 2 (cardiac) 1 Cytoplasm other
ATP5B ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide 1 Cytoplasm transporter
YWHAE tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon polypeptide 1 Cytoplasm other
CAP1 CAP, adenylate cyclase-associated protein 1 (yeast) 1 Plasma Membrane other
ACTC1 actin, alpha, cardiac muscle 1 1 Cytoplasm enzyme
MYL3 myosin, light chain 3, alkali; ventricular, skeletal, slow 1 Cytoplasm other
DES desmin 1 Cytoplasm other
PEBP1 phosphatidylethanolamine binding protein 1 1 Cytoplasm other
CKM creatine kinase, muscle 1 Cytoplasm kinase
HSPB8 heat shock 22kDa protein 8 1 Cytoplasm kinase
MYH6 myosin, heavy chain 6, cardiac muscle, alpha 1 Cytoplasm enzyme
DBT dihydrolipoamide branched chain transacylase E2 1 Cytoplasm enzyme
HSPD1 heat shock 60kDa protein 1 (chaperonin) 1 Cytoplasm enzyme
ALB albumin 1 Extracellular Space transporter
MYL2 myosin, light chain 2, regulatory, cardiac, slow 1 Cytoplasm other
TPM1 tropomyosin 1 (alpha) 1,2 Cytoplasm other
NDUFS1 NADH dehydrogenase (ubiquinone) Fe-S protein 1, 75kDa (NADH-coenzyme Q reductase) 2 Cytoplasm enzyme
LDHB lactate dehydrogenase B 2 Cytoplasm enzyme
TUBA4A tubulin, alpha 4a 2 Cytoplasm other
HSPA9 heat shock 70kDa protein 9 (mortalin) 2 Cytoplasm other
SDHA succinate dehydrogenase complex, subunit A, flavoprotein (Fp) 2 Cytoplasm enzyme  
Page 201 
  
Table 6.6 A continued. 
 
Symbol Entrez Gene Name Networks Location Type(s)
PRDX6 peroxiredoxin 6 2 Cytoplasm enzyme
ACADS acyl-Coenzyme A dehydrogenase, C-2 to C-3 short chain 2 Cytoplasm enzyme
GFM1 G elongation factor, mitochondrial 1 2 Cytoplasm translation regulator
ETFA electron-transfer-flavoprotein, alpha polypeptide 2 Cytoplasm transporter
CKMT2 creatine kinase, mitochondrial 2 (sarcomeric) 2 Cytoplasm kinase
ECHS1 enoyl Coenzyme A hydratase, short chain, 1, mitochondrial 2 Cytoplasm enzyme
PRDX3 peroxiredoxin 3 2 Cytoplasm enzyme
DLAT dihydrolipoamide S-acetyltransferase 2 Cytoplasm enzyme
HCG 25371 (Uqcrh) ubiquinol-cytochrome c reductase hinge protein-like 2 Cytoplasm enzyme
NNT nicotinamide nucleotide transhydrogenase 3 Cytoplasm enzyme  
Table 6.6 B 
Symbol Entrez Gene Name Networks Location Type(s)
Actin -- 1 unknown group
Akt -- 1 unknown group
ATPase -- 1 unknown group
Insulin -- 1 unknown group
Mlc -- 1 unknown group
Mlcp -- 1 Cytoplasm complex
MYL4 myosin, light chain 4, alkali; atrial, embryonic 1 Cytoplasm other
Myosin -- 1 Cytoplasm complex
Myosin Light Chain 
Kinase -- 1 unknown group
NFkB (complex) -- 1 Nucleus complex
P38 MAPK -- 1 unknown group
Pkc(s) -- 1 unknown group
RNA polymerase II -- 1 Nucleus complex
SLC9A8 solute carrier family 9 (sodium/hydrogen exchanger), member 8 1 Cytoplasm transporter  
Page 202 
  
Table 6.6 B continued. 
 
 
Symbol Entrez Gene Name Networks Location Type(s)
SPAST spastin 1 Nucleus enzyme
Tni -- 1 unknown group
Tropomyosin -- 1 unknown group
Troponin t -- 1 unknown group
TNNC1 troponin C type 1 (slow) 1,2 Cytoplasm other
ABCC9 ATP-binding cassette, sub-family C (CFTR/MRP), member 9 2 Plasma Membrane ion channel
ACADVL acyl-Coenzyme A dehydrogenase, very long chain 2 Cytoplasm enzyme
AGT angiotensinogen (serpin peptidase inhibitor, clade A, member 8) 2 Extracellular Space other
ATP -- 2 unknown
chemical - 
endogenous 
mammalian
ATP5O ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit 2 Cytoplasm transporter
beta-estradiol -- 2 unknown
chemical - 
endogenous 
mammalian
CFD complement factor D (adipsin) 2 Extracellular Space peptidase
cholesterol -- 2 unknown
chemical - 
endogenous 
mammalian
CNN1 calponin 1, basic, smooth muscle 2 Cytoplasm other
CTNNB1 catenin (cadherin-associated protein), beta 1, 88kDa 2 Nucleus transcription regulator
FCGRT Fc fragment of IgG, receptor, transporter, alpha 2 Plasma Membrane transmembrane receptor
hydrogen peroxide -- 2 unknown
chemical - 
endogenous 
mammalian  
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Table 6.6 B continued. 
 
Symbol Entrez Gene Name Networks Location Type(s)
MYC v-myc myelocytomatosis viral oncogene homolog (avian) 2 Nucleus transcription regulator
PDK3 pyruvate dehydrogenase kinase, isozyme 3 2 Cytoplasm kinase
PPARGC1B peroxisome proliferator-activated receptor gamma, coactivator 1 beta 2 Nucleus transcription regulator
PRDX2 peroxiredoxin 2 2 Cytoplasm enzyme
SLC25A13 solute carrier family 25, member 13 (citrin) 2 Cytoplasm transporter
TNF tumor necrosis factor (TNF superfamily, member 2) 2 Extracellular Space cytokine
TRAF6 TNF receptor-associated factor 6 2 Cytoplasm enzyme
MME membrane metallo-endopeptidase 3 Plasma Membrane peptidase
NAD(P) 
transhydrogenase 
(AB-specific)
-- 3 unknown group
NAD(P) 
transhydrogenase 
(B-specific)
-- 3 unknown group
phosphate -- 3 unknown
chemical - 
endogenous 
mammalian  
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Figure 6.6 Two of three networks associated with the proteins altered in 
Sham vs. MI  A) Network 1. B) Network 2. Proteins highlighted in red were 
found to be up-regulated, and those highlighted in green were down-regulated in 
Sham vs. MI.  Full names of these proteins can be found in Table 6.5. 
 
A 
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Figure 6.6 B 
 
 
 
 
 
The top canonical pathways associated with the proteins altered in Sham vs. MI 
are shown in Table 6.7.    Pathways relating to small molecule biochemistry make 
up the main part of these pathways.  Calcium signalling is highlighted due to the 
presence of proteins involved in muscle cell contraction.  There are several 
proteins involved in oxidative phosphorylation and the up-regulation of Prdx3 
suggests mitochondrial dysfunction. 
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Table 6.7 Top 10 canonical pathways associated with the 36 proteins altered 
in Sham vs. MI  
 
 
 
 
6.1.3.2 MI vs. BMMNC 
25 proteins that were differentially expressed in Sham vs. MI were mapped in IPA 
(Table 6.8 A).  These were associated within three different networks along with a 
further 79 different proteins and endogenous chemicals (Table 6.8 B).  These 
three networks are shown in Figures 6.7 A-C.  Networks 1 and 2 had scores of 27 
and 22 respectively, network 3 had a much lower score of 5.   
 
Network 1 contains 12 proteins from our dataset and is mainly related to cell cycle 
and muscle system development and function. Hepatocyte nuclear factor 4 alpha 
(Hnf4a), Beta-estradiol (E2), transforming growth factor beta 1 (Tgf-β) and 14-3-
3 zeta (Ywhaz) are all hubs within this network see Figure 6.7 A.  Binding of 
Hnf4a and two of our proteins (Mccc1 and Hsdl2) is known to occur in the liver 
[129].  E2 is a hormone with many different roles besides its main actions on 
reproductive function. It has been linked to cardioprotection during 
hypoxia/reoxygenation induced apoptosis through the inhibition of mitochondrial 
ROS formation (antioxidant properties) and p38 α MAPK activation, activation of 
Pi3k, and activation of p38 β MAPK [130]. E2 has also been shown to limit 
Angiotensin II (Ang II) induced hypertriophy [131]. These modes of functionality 
explain why it has been liked to expression of structural proteins Myh6 and Tnnt2 
and expression of Ckm and modification of the antioxidant Prdx6.  Tgf-β is 
involved in many functions, but mainly growth arrest and signals through Smad 
and p38 MAPK/JNK pathways [132].   Tgfβ has known to increase the expression 
of both Tpm1 and Tnnt2 and inhibit expression of Ckm [133-135].  Ywhaz is a 
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molecular chaperone related to the epsilon isoform found in our dataset and has 
uncharacterised associations with Ndufa10, Pgam1 and Echs1.   
 
Network 2 contains ten proteins from dataset and is mainly related to DNA 
replication, recombination and repair as well as energy production.  The main 
hubs within this network are Ywhae, Ang II receptor type 1 (Agtr1), Insulin and 
Vascular endothelial growth factor (Vegf), see Figure 6.7 B.   Ywhae is only liked 
to a single other protein (Hsp70) from our dataset and this is due to evidence of a 
binding interaction [136].  In a study of the effects of Agtr1 mediated effects of 
Ang II on beta arrestin complex formation; Ywhae, Atp5b and Sdha were all 
identified as proteins which dissociate from beta arrestin upon Agtr1 stimulation 
[137]. Insulin is linked to both Ywhae and Alb and these connections were 
detailed in section 6.1.3.1. Glycated Alb has been shown to increase expression of 
Vegf and Vegf has also been liked to increased expression of Etfa (up-regulated in 
MI vs. BMMNC) [138, 139]. 
 
 
 
  
Table 6.8 Table showing proteins and endogenous chemicals included in the IPA analysis of MI vs. BMMNC proteomics data   A) 
Proteomic results mapped into IPA for core analysis. B) Associated proteins and endogenous chemicals also included in the Sham vs. MI IPA 
core analysis.  Protein symbol and Entrez gene names are shown alongside the network(s) the protein/chemical is found in, the sub-cellular 
localisation and molecule type. 
 
A 
 
Symbol Entrez Gene Name Networks Location Type(s)
HCG 25371 (Uqcrh) ubiquinol-cytochrome c reductase hinge protein-like 1 Cytoplasm enzyme
MYH6 myosin, heavy chain 6, cardiac muscle, alpha 1 Cytoplasm enzyme
ECHS1 enoyl Coenzyme A hydratase, short chain, 1, mitochondrial 1 Cytoplasm enzyme
PGAM1 phosphoglycerate mutase 1 (brain) 1 Cytoplasm phosphatase
CKM creatine kinase, muscle 1 Cytoplasm kinase
NDUFA10 (includes 
EG:4705) NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 10, 42kDa 1 Cytoplasm enzyme
CKMT2 creatine kinase, mitochondrial 2 (sarcomeric) 1 Cytoplasm kinase
PRDX6 peroxiredoxin 6 1 Cytoplasm enzyme
MCCC1 methylcrotonoyl-Coenzyme A carboxylase 1 (alpha) 1 Cytoplasm enzyme
HSDL2 hydroxysteroid dehydrogenase like 2 1 Cytoplasm transporter
TPM1 tropomyosin 1 (alpha) 1 Cytoplasm other
TNNT2 troponin T type 2 (cardiac) 1 Cytoplasm other
DLAT dihydrolipoamide S-acetyltransferase 2 Cytoplasm enzyme
ETFA electron-transfer-flavoprotein, alpha polypeptide 2 Cytoplasm transporter
SDHA succinate dehydrogenase complex, subunit A, flavoprotein (Fp) 2 Cytoplasm enzyme
HSPA9 heat shock 70kDa protein 9 (mortalin) 2 Cytoplasm other
LDHB lactate dehydrogenase B 2 Cytoplasm enzyme
HSPA8 heat shock 70kDa protein 8 2 Cytoplasm enzyme
ALB albumin 2 Extracellular Space transporter
ENSMUSG0000004
7676 (RPSA) ribosomal protein SA pseudogene 2 Plasma Membrane
transmembrane 
receptor
ATP5B ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide 2 Cytoplasm transporter  
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Table 6.8 A continued. 
 
Symbol Entrez Gene Name Networks Location Type(s)
YWHAE tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon polypeptide 2 Cytoplasm other
DES desmin 3 Cytoplasm other
WDR1 WD repeat domain 1 3 Extracellular Space other
CAP1 CAP, adenylate cyclase-associated protein 1 (yeast) 3 Plasma Membrane other  
Table 6.8 B  
Symbol Entrez Gene Name Networks Location Type(s)
beta-estradiol -- 1 unknown
chemical - 
endogenous 
mammalian
CNN1 calponin 1, basic, smooth muscle 1 Cytoplasm other
Cofilin -- 1 unknown group
CYC1 cytochrome c-1 1 Cytoplasm enzyme
dCTP -- 1 unknown
chemical - 
endogenous 
mammalian
DSTN destrin (actin depolymerizing factor) 1 Cytoplasm other
GH1 growth hormone 1 1 Extracellular Space cytokine
HNF4A hepatocyte nuclear factor 4, alpha 1 Nucleus transcription regulator
hydrogen peroxide -- 1 unknown
chemical - 
endogenous 
mammalian
MAP3K5 (includes 
EG:293015) mitogen-activated protein kinase kinase kinase 5 1 unknown kinase
MAPK13 mitogen-activated protein kinase 13 1 Cytoplasm kinase   
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Table 6.8 B continued. 
 
Symbol Entrez Gene Name Networks Location Type(s)
MLL2 myeloid/lymphoid or mixed-lineage leukemia 2 1 Nucleus transcription regulator
SIK1 salt-inducible kinase 1 1 Cytoplasm kinase
TEAD3 TEA domain family member 3 1 Nucleus transcription regulator
TGFB1 transforming growth factor, beta 1 1 Extracellular Space growth factor
TMOD2 tropomodulin 2 (neuronal) 1 Cytoplasm other
Tni -- 1 unknown group
TNNC1 troponin C type 1 (slow) 1 Cytoplasm other
TNNT1 troponin T type 1 (skeletal, slow) 1 unknown other
Tropomyosin -- 1 unknown group
Troponin t -- 1 unknown group
WNT11 wingless-type MMTV integration site family, member 11 1 Extracellular Space other
YWHAZ tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide 1 Cytoplasm enzyme
AGTR1 angiotensin II receptor, type 1 2 Plasma Membrane G-protein coupled receptor
ATP5 -- 2 unknown group
ATP5A1 ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle 2 Cytoplasm transporter
ATP5E ATP synthase, H+ transporting, mitochondrial F1 complex, epsilon subunit 2 Cytoplasm transporter
ATP5O ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit 2 Cytoplasm transporter
Caspase -- 2 unknown group
CLIC4 chloride intracellular channel 4 2 Cytoplasm ion channel
DNAJC13 DnaJ (Hsp40) homolog, subfamily C, member 13 2 unknown other
FBXO45 F-box protein 45 2 unknown other
GPR37 G protein-coupled receptor 37 (endothelin receptor type B-like) 2 Plasma Membrane G-protein coupled receptor  
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Table 6.8 B continued. 
 
Symbol Entrez Gene Name Networks Location Type(s)
Hsp70 -- 2 unknown group
HSPA2 heat shock 70kDa protein 2 2 Cytoplasm other
Insulin -- 2 unknown group
IRS4 insulin receptor substrate 4 2 Cytoplasm other
MYOCD myocardin 2 Nucleus transcription regulator
PACRG PARK2 co-regulated 2 Cytoplasm other
PEG3 paternally expressed 3 2 Nucleus kinase
RICTOR RPTOR independent companion of MTOR, complex 2 2 Cytoplasm other
SDH -- 2 unknown group
SDHD succinate dehydrogenase complex, subunit D, integral membrane protein 2 Cytoplasm enzyme
SPAST spastin 2 Nucleus enzyme
SRPK2 SFRS protein kinase 2 2 Nucleus kinase
TBK1 TANK-binding kinase 1 2 Cytoplasm kinase
VEGFA vascular endothelial growth factor A 2 Extracellular Space growth factor
ACADM acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight chain 3 Cytoplasm enzyme
ACTG1 actin, gamma 1 3 Cytoplasm other
APOB apolipoprotein B (including Ag(x) antigen) 3 Extracellular Space transporter
CBL Cas-Br-M (murine) ecotropic retroviral transforming sequence 3 Nucleus transcription regulator
CFL1 cofilin 1 (non-muscle) 3 Nucleus other
CRYAB crystallin, alpha B 3 Nucleus other
D-glucose -- 3 unknown
chemical - 
endogenous 
mammalian
F Actin -- 3 Cytoplasm complex
fatty acid -- 3 unknown
chemical - 
endogenous 
mammalian  
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Table 6.8 B continued. 
Symbol Entrez Gene Name Networks Location Type(s)
FOXA2 forkhead box A2 3 Nucleus transcription regulator
HSPB1 heat shock 27kDa protein 1 3 Cytoplasm other
INSR insulin receptor 3 Plasma Membrane kinase
IRS1 insulin receptor substrate 1 3 Cytoplasm other
LDHA lactate dehydrogenase A 3 Cytoplasm enzyme
lipid -- 3 unknown
chemical - 
endogenous 
mammalian
MEF2 -- 3 unknown group
MEF2C myocyte enhancer factor 2C 3 Nucleus transcription regulator
melatonin -- 3 unknown
chemical - 
endogenous 
mammalian
norepinephrine -- 3 unknown
chemical - 
endogenous 
mammalian
PDPK1 3-phosphoinositide dependent protein kinase-1 3 Cytoplasm kinase
PPARG peroxisome proliferator-activated receptor gamma 3 Nucleus ligand-dependent nuclear receptor
PRKCA protein kinase C, alpha 3 Cytoplasm kinase
PRKCB protein kinase C, beta 3 Cytoplasm kinase
PRKCE protein kinase C, epsilon 3 Cytoplasm kinase
SKIV2L superkiller viralicidic activity 2-like (S. cerevisiae) 3 Cytoplasm translation regulator
SLC2A4 solute carrier family 2 (facilitated glucose transporter), member 4 3 Plasma Membrane transporter
TEAD4 TEA domain family member 4 3 Nucleus transcription regulator
THRA thyroid hormone receptor, alpha (erythroblastic leukemia viral (v-erb-a) oncogene homolog, avian) 3 Nucleus
ligand-dependent 
nuclear receptor  
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Table 6.8 B continued. 
Symbol Entrez Gene Name Networks Location Type(s)
TUBB3 tubulin, beta 3 3 Cytoplasm other
VAMP2 vesicle-associated membrane protein 2 (synaptobrevin 2) 3 Plasma Membrane other
VIM vimentin 3 Cytoplasm other
HNRNPK heterogeneous nuclear ribonucleoprotein K 2,3 Nucleus other  
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Figure 6.7 Three networks associated with the proteins altered in MI vs. 
BMMNC  A) Network 1. B) Network 2. C) Network 3. Proteins highlighted in 
red were found to be up-regulated, and those highlighted in green were down-
regulated in MI vs. BMMNC.  Full names of these proteins can be found in Table 
6.7. 
 
A 
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Figure 6.7 B 
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Figure 6.7 C 
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Network 3 contained only three proteins from our dataset and is linked to the 
functions of carbohydrate metabolism and molecular transport see Figure 6.7 C.   
There are several major hubs in this network, but the ones linked to the proteins 
from our dataset are solute carrier family 2 (facilitated glucose transporter) 
member 4 (Slc2a4) aka Glut-4, D-glucose and protein kinase C epsilon (Prkce).  
Glut-4 as a major hub and the interactions with many proteins from the MI vs. 
BMMNC dataset come from one study looking at insulin dependant interactions 
[140].  Glucose has a regulatory role in Wdr1 function, and an uncharacterised 
association with Des and Prkce is also highlighted. 
 
The top ten canonical pathways associated with the proteins altered in MI vs. 
BMMNC are shown in Table 6.9.  Oxidative phosphorylation and mitochondrial 
dysfunction are in the top as the expression changes in many of the proteins 
involved in these pathways were reversed in MI vs. BMMNC.  Again many  of 
the associated pathways relate to small molecule biochemistry. 
 
 
Table 6.9 Top 10 canonical pathways associated with the 27 proteins altered 
in MI vs. BMMNC 
 
 
 
 Page 219 
6.1.4 Summary  
 
 PANTHER analysis revealed muscle contraction, signal transduction and 
electron transport to be among the most highly represented processes in 
the down-regulated Sham vs. MI list, and in the up-regulated MI vs. 
BMMNC list. Individual pathways were poorly covered by our proteomics 
datasets .   
 
 DAVID highlighted that annotations relating to muscle structure and 
function were over-represented in the down-regulated Sham vs. MI list (in 
the up-regulated MI vs. BMMNC list).  Both apoptosis and functions 
related to oxidative stress were over-represented by proteins up-regulated 
in Sham vs. MI. 
 
 The networks created by IPA for the proteomics data are dominated by 
interactions identified in a limited number of studies looking at undefined 
protein-protein interactions [129, 140, 141].  NFkB and p38 MAPK were 
highlighted as potentially important interactors in Sham vs. MI altered 
proteins. Tgfβ1 and Slc4a2 were highlighted in the MI vs. BMMNC 
networks.  Beta-estradiol and Insulin were highlighted in both Sham vs. 
MI and MI vs. BMMNC networks.  
 
 The terms oxidative phosphorylation, oxidoreductase and mitochondrial 
dysfunction were highly associated with the proteomics dataset in all the 
bioinformatics analyses.  
 
 The proteomics dataset was relatively small (<100 different proteins) 
which resulted in several annotations being associated to only a small 
number of proteins from our dataset .. 
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6.2 Bioinformatic analysis of genes found to be differentially regulated in the 
Illumina RatRef12 analysis. 
 
6.2.1 Protein ANalysis THrough Evolutionary Relationships (PANTHER) 
 
Three different lists of genes were entered into PANTHER, the number of genes 
in each list is shown in Table 6.10.  The MI vs. BMMNC included 19 down-
regulated genes and the only up-regulated gene, cardiac calsequestrin (Casq2). 
 
Table 6.10 Three different lists of Refseq gene accession codes were entered 
into PANTHER 
 
PANTHER Dataset Number of Genes
Sham vs. MI - Up 860
Sham vs. MI - Down 677
MI vs. BMMNC 20  
 
 
6.2.1.1 Sham vs. MI  
The pathways represented by the 715/860 mapped up-regulated genes in Sham vs. 
MI are shown in Figure 6.8.  The pathways represented by the 544/677 genes 
down-regulated in Sham vs. MI are shown in Figure 6.9.   
 
Several pathways were represented in both lists including; inflammation mediated 
by chemokine and cytokine signalling pathway which was represented by 42 up-
regulated genes and five down-regulated genes,  integrin signalling was 
represented by 23 up-regulated genes and 2 down-regulated genes and 
angiogenesis was represented by 20 up-regulated and 2 down-regulated genes.   
Platelet derived growth factor (Pdgf) signalling was represented by 16 up-
regulated genes and 5 down-regulated genes and Wnt signalling was represented 
by 12 up-regulated and 6 down-regulated genes.    Oxidative stress response, 
TGF-β signalling and several growth factor signalling pathways were also 
common to both lists. 
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Pathways that were unique to the up-regulated gene list were apoptosis signalling, 
B-cell activation, Pi3k pathway and T-cell activation.  Pathways unique to the 
down-regulated list included glycolysis, ubiquitin proteasome pathway and heme 
biosynthesis. 
 
  
Figure 6.8 PANTHER Pathways represented by the genes up-regulated in Sham vs. MI Numbers in brackets indicate the number of 
proteins associated with the term. 
 
Inflammation mediated by chemokine and cytokine signaling pathway (42)
Apoptosis signaling pathway (23)
Integrin signalling pathway (23)
Huntington disease (21)
Angiogenesis (20)
PDGF signaling pathway (16)
Cytoskeletal regulation by Rho GTPase (15)
EGF receptor signaling pathway (14)
B cell activation (13)
Wnt signaling pathway (12)
PI3 kinase pathway (12)
T cell activation (11)
FGF signaling pathway (11)
VEGF signaling pathway (10)
Interleukin signaling pathway (10)
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha (10)
Blood coagulation (9)
p53 pathway (8)
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha (8)
Endothelin signaling pathway (8)
Axon guidance mediated by semaphorins (7)
Toll receptor signaling pathway (7)
TGF-beta signaling pathway (7)
Ras Pathway (7)
Axon guidance mediated by Slit/Robo (6)
Plasminogen activating cascade (6)
Parkinson disease (6)
Oxidative stress response (6)
Interferon-gamma signaling pathway (6)
p38 MAPK pathway (6)
Cadherin signaling pathway (5)
Other pathways (58 pathways, 123 genes)  
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Figure 6.9 PANTHER Pathways represented by the genes down-regulated in Sham vs. MI Numbers in brackets indicate the number of 
proteins associated with the term. 
 
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway (8)
Wnt signaling pathway (6)
PDGF signaling pathway (5)
Inflammation mediated by chemokine and cytokine signaling pathway (5)
Glycolysis (5)
Ubiquitin proteasome pathway (4)
Heme biosynthesis (4)
Muscarinic acetylcholine receptor 2 and 4 signaling pathway (4)
EGF receptor signaling pathway (4)
Alzheimer disease-amyloid secretase pathway (3)
p53 pathway (3)
Notch signaling pathway (3)
GABA-B_receptor_II_signaling (3)
Vitamin D metabolism and pathway (3)
Huntington disease (3)
Endothelin signaling pathway (3)
Angiogenesis (2)
Transcription regulation by bZIP transcription factor  (2)
TGF-beta signaling pathway  (2)
Oxidative stress response  (2)
Metabotropic glutamate receptor group I pathway  (2)
Metabotropic glutamate receptor group II pathway  (2)
Metabotropic glutamate receptor group III pathway  (2)
Androgen/estrogene/progesterone biosynthesis  (2)
Interleukin signaling pathway (2)
Integrin signalling pathway (2)
p53 pathway feedback loops 2  (2)
Heterotrimeric G-protein signaling pathway-rod outer segment phototransduction  (2)
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha (2)
Hedgehog signaling pathway  (2)
FGF signaling pathway (2)
Pyruvate metabolism (2)
Pyrimidine Metabolism (2)
Pentose phosphate pathway (2)
Other pathways (45 pathways, 45 genes)
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Biological processes represented by the up- and down-regulated lists are shown in 
Figure 6.10 and 6.11.  All of the processes were represented by members of both 
gene lists.  Top in both lists were signal transduction (216 up-regulated and 56 
down-regulated genes), protein metabolism and modification (132 up-regulated 
and 94 down-regulated genes), nucleic acid metabolism (121 up-regulated and 77 
down-regulated genes) and immunity and defence (128 up-regulated and 29 
down-regulated genes).  There were 111 unclassified up-regulated genes and 138 
unclassified down-regulated genes. 
 
Many of the genes had no molecular function classification.  The most highly 
represented molecular functions in both up- and down-regulated genes were 
nucleic acid binding, select regulatory molecules and transcription factors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 6.10 PANTHER Biological processes represented by the genes up-regulated in Sham vs. MI Numbers in brackets indicate the 
number of proteins associated with the term. 
 
Signal transduction (216)
Protein metabolism and modification (132)
Immunity and defense (128)
Nucleoside, nucleotide and nucleic acid metabolism (121)
Biological process unclassified (111)
Developmental processes (97)
Cell structure and motility (73)
Cell proliferation and differentiation (68)
Cell cycle (52)
Apoptosis (49)
Transport (42)
Intracellular protein traffic (38)
Oncogenesis (35)
Other metabolism (32)
Lipid, fatty acid and steroid metabolism (28)
Cell adhesion (23)
Neuronal activities (20)
Carbohydrate metabolism (18)
Homeostasis (16)
Amino acid metabolism (10)
Muscle contraction (8)
Blood circulation and gas exchange (7)
Electron transport (7)
Phosphate metabolism (6)
Protein targeting and localization (6)
Miscellaneous (6)
Coenzyme and prosthetic group metabolism (4)
Sulfur metabolism (3)
Sensory perception (3)
Nitrogen metabolism (2)  
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Figure 6.11 PANTHER Biological processes represented by the genes down-regulated in Sham vs. MI Numbers in brackets indicate the 
number of proteins associated with the term. 
 
Biological process unclassified (138)
Protein metabolism and modification (94)
Nucleoside, nucleotide and nucleic acid metabolism (77)
Signal transduction (56)
Intracellular protein traffic (44)
Transport (41)
Developmental processes (31)
Lipid, fatty acid and steroid metabolism (31)
Other metabolism (29)
Immunity and defense (29)
Electron transport (24)
Carbohydrate metabolism (21)
Coenzyme and prosthetic group metabolism (19)
Cell cycle (19)
Cell structure and motility (18)
Cell proliferation and differentiation (17)
Amino acid metabolism (12)
Apoptosis (11)
Neuronal activities (10)
Homeostasis (8)
Protein targeting and localization (B8)
Oncogenesis (6)
Cell adhesion (5)
Muscle contraction (4)
Sensory perception (4)
Miscellaneous (4)
Sulfur metabolism (3)
Phosphate metabolism (3)
Blood circulation and gas exchange (2)
Nitrogen metabolism (1)  
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6.2.1.2 MI vs. BMMNC 
Only a single pathway (angiogenesis) was associated with the 17 genes mapped 
by PANTHER, this was only linked to docking protein 3 (Dok3).   
 
Of the biological processes altered in MI vs. BMMNC, the most highly 
represented were ‘signal transduction’, associated with embigin (Emb), coronin 
actin binding protein 1A (Coro1a), sema domain immunoglobulin domain (Ig) 
transmembrane domain (TM) and short cytoplasmic domain (semaphorin) 4A 
(Sema4a), endothelial differentiation G-protein-coupled receptor 6 (Edg6), 
docking protein 3 (Dok3), antigen presenting cell lectin-like receptor A1 (Aplra1) 
and the up-regulated Casq2.   
 
‘Protein metabolism and modification’ was the next process represented by 4 
genes; serine/threonine kinase 17b (apoptosis-inducing) (Stk17b), ring finger 
protein 149 (Rnf149), stefin A2 (Stfa2) and similar to stefin A2 (RDG1560676). 
These were followed by ‘intracellular protein traffic’ (Coro1a, sortilin-related 
receptor, L(DLR class) A repeats-containing (Sorl1) and Alpra1) and ‘immunity 
and defence’ (2 ' -5 ' oligoadenylate synthetase 1K (Oas1k), Sema4a, Alpra1).   
 
Three other processes were represented by more than one member of the list 
‘transport’ (Sorl1 and Coro1a) ‘developmental processes’ (Emb and Sema4a) and 
‘cell structure and motility’ (Coro1a and Dok3).  All of the processes linked to 
this list are shown in Figure 6.12. 
 
There were several molecular functions associated with 13 of the 17 genes, the 
most common of these was ‘receptor’ associated with Sorl1, Edg6 and Alpra1.  
This was followed by ‘transferase’ associated with Oas1k and carbohydrate 
(keratan sulfate Gal-6) sulfotransferase 1 (Chst1) and ‘select regulatory molecule’ 
(Stfa2 and Stfa2).  The process ‘select calcium binding protein’ was associated 
with the only up-regulated gene Casq2. 
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Figure 6.12 PANTHER Biological processes represented by the genes 
differentially-regulated in MI vs. BMMNC Numbers in brackets indicate the 
number of proteins associated with the term. 
 
Signal transduction (7)
Biological process unclassified (4)
Protein metabolism and modification (4)
Intracellular protein traffic (4)
Immunity and defense (3)
Transport (2)
Developmental processes (2)
Cell structure and motility (2)
Nucleoside, nucleotide and nucleic acid metabolism (1)
Carbohydrate metabolism (1)
Other metabolism (1)
Lipid, fatty acid and steroid metabolism (1)
Cell cycle (1)
Cell adhesion (1)
Apoptosis (1)
Cell proliferation and differentiation (1)
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6.2.2 Database for Annotation, Visualization and Integrated Discovery 
(DAVID) 
 
The same three lists that were entered into PANTHER analysis were also entered 
into DAVID (see Table 6.10). 
 
6.2.2.1 Sham vs. MI  
Of the probes up-regulated in Sham vs. MI, 823 mapped to DAVID ID’s and 
when clustering analysis was performed on the biological process GO 
terminology, the terms grouped into 65 clusters.  Terms with significant 
Benjamini corrected p-values (<0.05) were found in clusters 1-25 and these are 
detailed in Table 6.11.  The general themes of the top 5 clusters were anatomical 
development, cell death, chemotaxis, vasculature development and immune 
system development.  Other clusters were related to NF-kappa-β regulation and 
mononuclear cell proliferation. 
 
665 probes down-regulated in Sham vs. MI mapped to DAVID ID’s and 
clustering analysis on biological process GO terms produced 11 clusters.  Only 
cluster 1 had significant Benjamini corrected p-values, (detailed in Table 6.12) 
contains terms relating to cellular metabolic processes and includes nearly 300 of 
the genes from our list.  Other clusters were related to protein transport, 
ubiquinone metabolic processing, glycolysis, and ATP metabolism.   
 
 
 
 
 
 
  
Table 6.11 1 -25 of 65 clusters of biological process GO terms associated with genes up-regulated in Sham vs. MI   The GO terms within 
each cluster, count (number of genes from list with this annotation), % (percentage of the input genes found with this annotation), p-value 
(modified Fisher’s exact test (EASE score) and fold enrichment (the fold enrichment of this annotation in the uploaded gene list versus the 
proportion of this annotation in the background dataset) and Benjamini adjusted p-values (corrected to control family-wide false discovery rate).     
 
Group GO Biological Process Term Count % PValue Fold Enrichment Benjamini
GO:0007275~multicellular organismal development 175 21.26% 0.00000 1.84 0.00000
GO:0048856~anatomical structure development 169 20.53% 0.00000 1.83 0.00000
GO:0048731~system development 152 18.47% 0.00000 1.92 0.00000
GO:0008219~cell death 82 9.96% 0.00000 2.43 0.00000
GO:0016265~death 82 9.96% 0.00000 2.43 0.00000
GO:0012501~programmed cell death 78 9.48% 0.00000 2.38 0.00000
GO:0006915~apoptosis 77 9.36% 0.00000 2.37 0.00000
GO:0006935~chemotaxis 25 3.04% 0.00000 5.11 0.00000
GO:0042330~taxis 25 3.04% 0.00000 5.11 0.00000
GO:0007626~locomotory behavior 29 3.52% 0.00000 3.65 0.00000
GO:0001944~vasculature development 34 4.13% 0.00000 3.87 0.00000
GO:0001568~blood vessel development 33 4.01% 0.00000 3.83 0.00000
GO:0048514~blood vessel morphogenesis 30 3.65% 0.00000 3.96 0.00000
GO:0001525~angiogenesis 27 3.28% 0.00000 4.35 0.00000
GO:0048646~anatomical structure formation 29 3.52% 0.00000 3.73 0.00000
GO:0002520~immune system development 33 4.01% 0.00000 3.37 0.00000
GO:0048534~hemopoietic or lymphoid organ development 32 3.89% 0.00000 3.40 0.00000
GO:0030097~hemopoiesis 30 3.65% 0.00000 3.42 0.00000
GO:0042035~regulation of cytokine biosynthetic process 14 1.70% 0.00000 5.55 0.00005
GO:0042089~cytokine biosynthetic process 15 1.82% 0.00000 5.00 0.00007
GO:0042107~cytokine metabolic process 15 1.82% 0.00000 4.92 0.00009
GO:0043066~negative regulation of apoptosis 29 3.52% 0.00000 2.68 0.00021
GO:0043069~negative regulation of programmed cell death 29 3.52% 0.00000 2.66 0.00023
GO:0006916~anti-apoptosis 23 2.79% 0.00001 3.04 0.00033
1
2
3
4
5
6
7
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Table 6.11 continued. 
Group GO Biological Process Term Count % PValue Fold Enrichment Benjamini
GO:0002460~adaptive immune response based on somatic 15 1.82% 0.00000 4.83 0.00010
GO:0002250~adaptive immune response 15 1.82% 0.00000 4.83 0.00010
GO:0002449~lymphocyte mediated immunity 14 1.70% 0.00000 4.84 0.00023
GO:0019724~B cell mediated immunity 12 1.46% 0.00002 4.96 0.00099
GO:0016064~immunoglobulin mediated immune response 11 1.34% 0.00009 4.65 0.00360
GO:0030036~actin cytoskeleton organization and biogenesis 27 3.28% 0.00000 3.21 0.00002
GO:0030029~actin filament-based process 27 3.28% 0.00000 3.02 0.00006
GO:0007010~cytoskeleton organization and biogenesis 36 4.37% 0.00235 1.70 0.05524
GO:0006417~regulation of translation 20 2.43% 0.00000 3.52 0.00019
GO:0031326~regulation of cellular biosynthetic process 20 2.43% 0.00003 3.04 0.00124
GO:0009889~regulation of biosynthetic process 22 2.67% 0.00003 2.83 0.00135
GO:0043549~regulation of kinase activity 26 3.16% 0.00003 2.56 0.00126
GO:0051338~regulation of transferase activity 26 3.16% 0.00004 2.48 0.00193
GO:0045859~regulation of protein kinase activity 25 3.04% 0.00005 2.53 0.00205
GO:0042108~positive regulation of cytokine biosynthetic 10 1.22% 0.00002 6.13 0.00105
GO:0045727~positive regulation of translation 11 1.34% 0.00002 5.36 0.00118
GO:0031328~positive regulation of cellular biosynthetic 11 1.34% 0.00007 4.75 0.00301
GO:0009891~positive regulation of biosynthetic process 12 1.46% 0.00021 3.87 0.00803
GO:0043122~regulation of I-kappaB kinase/NF-kappaB 16 1.94% 0.00001 3.95 0.00049
GO:0007249~I-kappaB kinase/NF-kappaB cascade 19 2.31% 0.00005 3.01 0.00218
GO:0043123~positive regulation of I-kappaB kinase/NF- 14 1.70% 0.00008 3.70 0.00335
GO:0009967~positive regulation of signal transduction 17 2.07% 0.00362 2.24 0.07849
GO:0032944~regulation of mononuclear cell proliferation 11 1.34% 0.00002 5.36 0.00118
GO:0050670~regulation of lymphocyte proliferation 11 1.34% 0.00002 5.36 0.00118
GO:0032943~mononuclear cell proliferation 13 1.58% 0.00003 4.41 0.00126
GO:0046651~lymphocyte proliferation 13 1.58% 0.00003 4.41 0.00126
GO:0042129~regulation of T cell proliferation 9 1.09% 0.00024 5.19 0.00876
8
9
10
14
11
12
13
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Table 6.11 continued. 
 
Group GO Biological Process Term Count % PValue Fold Enrichment Benjamini
GO:0051249~regulation of lymphocyte activation 12 1.46% 0.00029 3.74 0.01005
GO:0050865~regulation of cell activation 12 1.46% 0.00039 3.62 0.01209
GO:0050863~regulation of T cell activation 9 1.09% 0.00369 3.49 0.07921
GO:0043086~negative regulation of catalytic activity 14 1.70% 0.00017 3.46 0.00634
GO:0033673~negative regulation of kinase activity 11 1.34% 0.00037 3.95 0.01173
GO:0006469~negative regulation of protein kinase activity 11 1.34% 0.00037 3.95 0.01173
GO:0051348~negative regulation of transferase activity 11 1.34% 0.00051 3.80 0.01529
GO:0033674~positive regulation of kinase activity 18 2.19% 0.00023 2.78 0.00848
GO:0051347~positive regulation of transferase activity 18 2.19% 0.00034 2.69 0.01085
GO:0045860~positive regulation of protein kinase activity 17 2.07% 0.00047 2.72 0.01451
GO:0030030~cell projection organization and biogenesis 26 3.16% 0.00034 2.19 0.01106
GO:0048858~cell projection morphogenesis 26 3.16% 0.00034 2.19 0.01106
GO:0032990~cell part morphogenesis 26 3.16% 0.00034 2.19 0.01106
GO:0008361~regulation of cell size 20 2.43% 0.00014 2.70 0.00555
GO:0016049~cell growth 19 2.31% 0.00024 2.68 0.00873
GO:0001558~regulation of cell growth 15 1.82% 0.00114 2.72 0.02973
GO:0006796~phosphate metabolic process 65 7.90% 0.00029 1.57 0.01015
GO:0006793~phosphorus metabolic process 65 7.90% 0.00029 1.57 0.01015
GO:0006468~protein amino acid phosphorylation 49 5.95% 0.00080 1.63 0.02224
GO:0016310~phosphorylation 54 6.56% 0.00126 1.55 0.03249
GO:0030005~cellular di-, tri-valent inorganic cation 22 2.67% 0.00011 2.58 0.00451
GO:0055066~di-, tri-valent inorganic cation homeostasis 22 2.67% 0.00011 2.58 0.00451
GO:0030003~cellular cation homeostasis 23 2.79% 0.00032 2.34 0.01068
GO:0055080~cation homeostasis 23 2.79% 0.00032 2.34 0.01068
GO:0055082~cellular chemical homeostasis 25 3.04% 0.00054 2.16 0.01596
GO:0006873~cellular ion homeostasis 25 3.04% 0.00054 2.16 0.01596
GO:0019725~cellular homeostasis 29 3.52% 0.00099 1.94 0.02606
20
19
18
17
16
15
14 cont.
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Table 6.11 continued. 
 
Group GO Biological Process Term Count % PValue Fold Enrichment Benjamini
GO:0030182~neuron differentiation 28 3.40% 0.00083 1.99 0.02281
GO:0022008~neurogenesis 33 4.01% 0.00098 1.85 0.02612
GO:0048699~generation of neurons 30 3.65% 0.00150 1.86 0.03700
GO:0044238~primary metabolic process 330 40.10% 0.00029 1.14 0.01010
GO:0044237~cellular metabolic process 325 39.49% 0.00073 1.13 0.02069
GO:0051726~regulation of cell cycle 28 3.40% 0.00028 2.14 0.00988
GO:0000074~regulation of progression through cell cycle 27 3.28% 0.00053 2.09 0.01588
GO:0042533~tumor necrosis factor biosynthetic process 4 0.49% 0.00133 15.21 0.03347
GO:0032640~tumor necrosis factor production 4 0.49% 0.00133 15.21 0.03347
GO:0042534~regulation of tumor necrosis factor biosynthetic 4 0.49% 0.00133 15.21 0.03347
GO:0007599~hemostasis 12 1.46% 0.00156 3.08 0.0381625
24
23
22
21
 
 
Table 6.12  1 of 11 clusters of biological process GO terms associated with genes down-regulated in Sham vs. MI   The GO terms within 
each cluster, count (number of genes from list with this annotation), % (percentage of the input genes found with this annotation), p-value 
(modified Fisher’s exact test (EASE score), fold enrichment (the fold enrichment of this annotation in the uploaded gene list versus the 
proportion of this annotation in the background dataset), and Benjamini adjusted p-values (corrected to control family-wide false discovery rate).   
 
Group GO Biological Process Term Count % PValue Fold Enrichment Benjamini
GO:0008152~metabolic process 285 42.86% 0.00000 1.28 0.00000
GO:0044237~cellular metabolic process 259 38.95% 0.00000 1.31 0.00000
GO:0044238~primary metabolic process 243 36.54% 0.00001 1.22 0.00457
1
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Clustering of KEGG terms associated with the 823 mapped genes which were up-
regulated in Sham vs. MI produced three clusters but none contained significant 
corrected p-values.  The first cluster contains several pathways relating to 
signalling, including B-cell receptor signalling (significant), natural killer cell 
cytotoxicity and VEGF signalling. The second and third clusters consist of 
pathways relating to cancer. 
 
KEGG terms associated with the 665 genes down-regulated in Sham vs. MI also 
grouped into three clusters, although corrected p-values show only significance 
for the first pathway in the first cluster.   This first pathway is valine, leucine and 
isoleucine degredation and is shown with fatty acid metabolism and butanoate 
metabolism in the first cluster.  The second cluster is glycolysis related pathways 
and the third is phospholipid metabolism.  
 
6.2.2.2 MI vs. BMMNC 
All of the 20 genes altered in MI vs. BMMNC mapped to David IDs.  Only a 
single cluster of biological process GO terms was found and this contained no 
significant terms.  The three terms within the cluster were all relating to 
intracellular signalling.  The KEGG pathways associated with these genes did not 
cluster. 
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6.2.3 Ingenuity Pathway Analysis (IPA) 
 
Significant fold changes (not logged) and adjusted p-values were entered for all 
1538 probes for which a difference was found in either Sham vs. MI or MI vs. 
BMMNC. 
 
6.2.3.1 Sham vs. MI  
1248 genes were differentially expressed in Sham vs. MI that mapped in IPA.  
690 of these were associated within 25 networks (set as maximum number of 
networks to return) along with 177 other genes and endogenous chemicals.  
Details of the 25 networks are shown in Table 6.13.  All networks scored from 47 
to 21 and each contained between 35 and 23 genes from our dataset.   
 
Network 1 has Glut-4 as a major hub linking ~30 genes from our dataset (Figure 
6.13 A).  Approximately two thirds of these genes are down-regulated in our 
dataset.  All of the relationships are protein-protein associations that were found 
in the same study already mentioned [140].  Slc2a4 itself was found to be down-
regulated in Sham vs. MI.  Another hub gene in this network is ADP-ribosylation 
factor 6 (Arf6) which was up-regulated in our dataset and is linked to 5 other up-
regulated genes.   
 
 
 
 
 
 
 
 
 
  
Table 6.13  Top 25 networks associated with the genes altered in Sham vs. MI  Network ID (1-25) is shown on the left and all the genes in 
that network are listed with either red arrows (up-regulated) or green arrows (down-regulated), focus molecules (ones from our dataset) are in 
bold.  The network score is shown alongside the number of focus molecules in the network and the general functions represented by the network.  
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Table 6.13  continued. 
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Table 6.13  continued. 
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Network 2 has over 30 genes from our list associated with Myc, which was found 
to be up-regulated (Figure 6.13 B).  Many of the associations are known non-
specific protein-protein interactions.  Myc is thought to be involved in regulating 
the expression of several genes including Afr4 and 6, angiopoietin 2 (Angpt2), 
block of proliferation 1 (Bop1), Nop58 ribonucleoprotein homolog (Nop58) and 
fibrillarin (Fbl), which are all up-regulated in our dataset.  Myc is also supposed to 
increase expression of glucose phosphate isomerase (Gpi) which was down-
regulated in our dataset.  Myc is also known to down-regulate the expression of 
several other genes which are up-regulated in our analysis including LIM and 
senescent cell antigen-like domains 1 (Lims1), Casp8 and FADD-like apoptosis 
regulator (Cflar) and H3 histone family 3C (H3f3c).  Single stranded DNA 
binding protein 2 (Ssbp2) was down-regulated in our analysis and is known to 
inhibit expression of Myc. 
 
Network 3 has several interlinked small hubs; histone h3, eukaryotic translation 
elongation factor 1 alpha 1 (Eef1a1), serum/glucocorticoid regulated kinase 1 
(Sgk1) and neural precursor cell expressed developmentally down-regulated 4 
(Nedd4) (see Figure 6.13 C).  Nedd4 is down-regulated in our analysis and is 
associated with several up-regulated proteins including eNaC which it inhibits. 
SGK1 is up-regulated in our dataset and is linked in this network to 5 down-
regulated proteins, and also binds eNaC (and possibly increases phosphorylation 
of eNaC, reducing the inhibition by Nedd4). Sgk1 is also thought to inhibit 
NEDD4.    Eef1a1 is up-regulated in our analysis and is shown to be associated 
with several genes from our dataset which were down-regulated.  Histone H3 (up-
regulated) is associated with several up- and down-regulated genes in Network 3. 
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Figure 6.13 Networks associated with the genes altered in Sham vs. MI  A) 
Network 1. B) Network 2. C) Network 3. Genes highlighted in red were found to 
be up-regulated, and those highlighted in green were down-regulated in Sham vs. 
MI.   
 
A 
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Figure 6.13 B 
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Figure 6.13 C 
 
 
 
 
 
 
The main canonical pathways highlighted by the transcriptomic data are signalling 
pathways, some involved in inflammatory response (IL-10, IL-8, Fcγ-receptor, 
and acute phase response signalling) some involved in oxidative stress response 
(Nrf2).  The top 20 of these are detailed in Table 6.14.     
 
  
Table 6.14 Top 20 canonical pathways associated with the genes altered in Sham vs. MI   
Ingenuity Canonical Pathways -log(p-value) Ratio Molecules
Fc gamma Receptor-mediated Phagocytosis in 
Macrophages and Monocytes 8.27E+00 2.57E-01
RAC2,PTK2B,ARPC1B,ARPC5,FCGR1A,PTEN,HMOX1,ARF6,ACTR3,HCK,ARPC3, 
ACTC1,VASP,FGR,PRKCQ,FCGR2A,ACTB,RAC1,ACTG1,INPP5D,PLA2G6,WAS, 
SYK, RAB11A,VAV1,PRKCH
ILK Signaling 6.22E+00 1.82E-01
RAC2,FLNB,FN1,PPP2R5B,HIF1A,RHOH,ITGB7,PGF,PTEN,MYC,PARVB,RHOG, 
FLNA,PPAP2B,ATF4,ILKAP,NOS2,ACTC1,ACTN1,CFL1,TNFRSF1A,ACTB,SNAI1, 
RAC1,RHOJ,ACTG1,MYL7,PPP2CB,FOS,RHOQ,RND3,CFL2,PTGS2,MMP9
Integrin Signaling 4.94E+00 1.65E-01
RAC2,ARPC1B,ARPC5,ABL1,KRAS,LIMS1,RHOH,ITGB7,PTEN,TSPAN3,PARVB, 
ARF6,ACTR3,RHOG,ARF4,ARPC3,ILKAP,ACTC1,VASP,ACTN1,PAK2,NRAS,ACTB, 
RAC1,RHOJ,ARF2,ACTG1,MYL7,ITGAM,RHOQ,RND3,WAS,PLCG2
IL-10 Signaling 4.91E+00 2.29E-01 CCR1,SOCS3,CCR5,JAK1,IL10,FCGR2A,BLVRB,IKBKE,IL1R1,FCGR2B,IL1R2, HMOX1,FOS,IL1RN,IL1B,LBP
B Cell Receptor Signaling 4.81E+00 1.75E-01
RAC2,ABL1,KRAS,FCGR2B,PTEN,PTPRC,ATF4,ETS1,PTPN6,NRAS,CALM3, 
PRKCQ,MAP3K6,FCGR2A,EGR1,RAC1,IKBKE,MALT1,INPP5D,DAPP1,BCL10, 
SYK,PLCG2,MAP3K8,VAV1,PIK3AP1,BCL2A1
NRF2-mediated Oxidative Stress Response 4.50E+00 1.64E-01
FTL,GSTM5,DNAJB4,GCLC,KRAS,DNAJC15,DNAJA1,CLPP,HMOX1,GSTM2,ATF4,GS
TT2,DNAJB1,ACTC1,NFE2L2,GSTK1,PRKCQ,NRAS,ACTB,MAFK,MAFF,ACTG1,GST
O1,TXNRD1,FOS,STIP1,CAT,DNAJC18,DNAJC14,PRKCH
Leukocyte Extravasation Signaling 4.02E+00 1.55E-01
RAC2,MMP3,PTK2B,ABL1,RHOH,ROCK2,TIMP1,MMP8,ARHGAP12,RASSF5, 
ACTC1,ACTN1,VASP,ITK,PRKCQ,CXCR4,ACTB,RAC1,BMX,NCF4,ACTG1,GNAI3, 
ITGAM,ARHGAP9,WAS,PLCG2,CD44,VAV1,PRKCH,MMP9
TREM1 Signaling 3.94E+00 2.03E-01 RAC2,TREM1,IL10,TYROBP,RAC1,JAK2,FCGR2B,CCL3,TLR2,CCL7,PLCG2,TLR6, TLR13,IL1B
Colorectal Cancer Metastasis Signaling 3.93E+00 1.41E-01
RAC2,JAK1,MMP3,ADCY4,KRAS,JAK2,RHOH,PRKAG1,PGF,MYC,RHOG,MMP8, 
WNT4,NOS2,STAT1,NRAS,CASP3,TNFRSF1A,IL6R,RAC1,ADCY6,RHOJ,GNG10, 
TLR2,FOS,RHOQ,RND3,TLR6,PRKACA,TLR13,PTGER2,PTGS2,JAK3,MMP9, 
PRKAR1A
Acute Phase Response Signaling 3.88E+00 1.57E-01
SOCS3,RAC2,HAMP,FTL,FN1,KRAS,JAK2,HMOX1,LBP,SERPINE1,C3,NRAS, 
MYD88,TNFRSF1A,C1S,IL6R,RAC1,IKBKE,SOCS4,IL1R1,FOS,HP,RIPK1,TF,IL1RN, 
IL1B,A2M,SOCS5
NF-kappaB Signaling 3.83E+00 1.64E-01
RAC2,BMP4,BMP2,KRAS,NGF,IL1R2,PRKCQ,NRAS,TNFRSF1A,MYD88,RAC1, 
IL1R1,MALT1,TLR2,CSNK2A2,RIPK1,IL1RN,BCL10,PLCG2,TLR6,FCER1G,PRKACA, 
IL1B,BTRC,MAP3K8
Production of Nitric Oxide and Reactive Oxygen Species 
in Macrophages 3.79E+00 1.41E-01
RAC2,JAK1,PPP2R5B,JAK2,RHOH,RHOG,NOS2,STAT1,PTPN6,PRKCQ,MAP3K6, 
TNFRSF1A,RAC1,IKBKE,RHOJ,NCF4,TLR2,PPP2CB,FOS,RHOQ,RND3,PLCG2, 
CAT,PRKCH,MAP3K8,JAK3  
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Table 6.14 continued. 
Ingenuity Canonical Pathways -log(p-value) Ratio Molecules
Semaphorin Signaling in Neurons 3.79E+00 2.50E-01 PAK2,FES,CFL1,RAC1,RHOJ,RHOH,ROCK2,SEMA4D,RHOG,RHOQ,RND3,CFL2, PLXNB1
Oncostatin M Signaling 3.66E+00 2.86E-01 JAK1,NRAS,MMP3,OSM,OSMR,KRAS,PLAU,JAK2,STAT1,JAK3
IL-8 Signaling 3.59E+00 1.45E-01
RAC2,ANGPT2,PTK2B,KRAS,RHOH,PGF,ROCK2,HMOX1,RHOG,IL8RB,GNA13, 
PRKCQ,PAK2,NRAS,RAC1,HBEGF,IKBKE,RHOJ,GNG10,MYL7,GNAI3,ITGAM, 
RHOQ,RND3,PRKCH,PTGS2,MMP9
Endothelin-1 Signaling 3.59E+00 1.45E-01
ADCY4,KRAS,MYC,PLCD3,HMOX1,EDN1,GNAT2,PLA2G5,GNA13,NOS2,CASP8, 
NRAS,PRKCQ,CASP3,PLA2G12A,EDNRB,YWHAZ,ADCY6,GNAI3,PLA2G6,FOS, 
RNF111,PLCG2,PRKCH,SPR,PTGS2,PTGER2
Role of Macrophages, Fibroblasts and Endothelial Cells in 
Rheumatoid Arthritis 3.52E+00 1.26E-01
SOCS3,RAC2,FN1,MMP3,PDGFA,LTB,KRAS,JAK2,IL17RA,FCGR1A,CEBPG,PGF,MY
C,ROCK2,IL1R2,PLCD3,OSM,ATF4,WNT4,NOS2,ADAMTS4,MIF,CALM3, 
PRKCQ,NRAS,MYD88,IL10,TNFRSF1A,C1S,IL6R,RAC1,IKBKE,IL1R1,TLR2,FOS, 
HP,RIPK1,IL1RN,PLCG2,TLR6,TLR13,IL1B,PRKCH
Regulation of Actin-based Motility by Rho 3.48E+00 1.83E-01 RAC2,PAK2,CFL1,ARPC1B,ACTB,ARPC5,RAC1,RHOJ,RHOH,MYL7,RHOQ,ACTR3,RHOG,RND3,WAS,ARPC3,ACTC1
Sphingosine-1-phosphate Signaling 3.46E+00 1.70E-01 RAC2,PTK2B,CASP3,PDGFA,ADCY4,ADCY6,RAC1,RHOJ,RHOH,S1PR4,PLCD3, GNAI3,RHOG,RHOQ,RND3,PLCG2,SPHK1,GNA13,CASP8
Ephrin Receptor Signaling 3.42E+00 1.38E-01
RAC2,RGS3,ARPC1B,PDGFA,ARPC5,ABL1,KRAS,JAK2,PGF,ROCK2,ACTR3, 
GNAT2,ARPC3,ATF4,EFNB3,GNA13,PAK2,NRAS,CFL1,CXCR4,RAC1,GNG10, 
GNAI3,SDCBP,WAS,CFL2,EPHA2  
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6.2.3.2 MI vs. BMMNC 
15 genes were differentially expressed in MI vs. BMMNC that mapped in IPA 
(Table 6.15 A). These were associated with 63 other genes (other genes associated 
with network 1 shown in Table 6.15 B) within 10 different networks.  Network 1 
scored 11 and has 5 molecules from our dataset.  The other networks all contained 
only one gene from our dataset and all scored only 3 or 2.  Network 1 is illustrated 
in Figure 6.14. 
 
A major hub in network 1 was FBJ murine osteosarcoma viral oncogene homolog 
(Fos) a gene found to be significantly up-regulated in Sham vs. MI, it is also a 
central hub of network 8 in the Sham vs. MI IPA core analysis (Table 6.13).  Fos 
was not significantly differentially regulated in the MI vs. BMMNC dataset.   
Within this network Fos is known to decrease the expression of embigin (Emb) 
which is down-regulated in MI vs. BMMNC.  
 
Micro RNA 214 (Mir214) is known to target Sorl1 and Chst1 from our dataset as 
well as several other genes only found to differ in Sham vs. MI (Fos, Egr1 and 
Prkaca).  Signal transducer and activator of transcription 6, interleukin-4 induced 
(Stat6) also links Fos and several proteins not in this dataset with down-regulated 
resistin like alpha (Retnla).   
 
 
 
 
 
 
 
 
 
 
  
Table 6.15 Proteins and endogenous chemicals included in the IPA analysis of MI vs. BMMNC gene expression  data   A Gene expression 
results mapped into IPA for core analysis. B The associated genes and endogenous chemicals also included in the Sham vs. MI IPA core analysis 
which were found in network 1.  Protein symbol and Entrez gene names are shown alongside the network(s) the protein/chemical is found in, the 
sub-cellular localisation and molecule type. 
 
A 
Symbol Entrez Gene Name Networks Location Type(s)
CHST1 carbohydrate (keratan sulfate Gal-6) sulfotransferase 1 1 Cytoplasm enzyme
EMB embigin homolog (mouse) 1 Plasma Membrane other
F5 coagulation factor V (proaccelerin, labile factor) 1 Plasma Membrane other
RETNLA resistin like alpha 1 Extracellular Space other
SORL1
sortilin-related receptor, L(DLR class) A repeats-
containing 1 Plasma Membrane transporter
RNF149 ring finger protein 149 2 Unknown other
CASQ2 calsequestrin 2 (cardiac muscle) 3 Cytoplasm other
CLEC4C C-type lectin domain family 4, member C 4 Plasma Membrane other
S1PR4 sphingosine-1-phosphate receptor 4 5 Plasma Membrane
G-protein coupled 
receptor
DOK3 docking protein 3 6 Cytoplasm other
CORO1A coronin, actin binding protein, 1A 7 Cytoplasm other
GLIPR1 GLI pathogenesis-related 1 8 Extracellular Space other
SEMA4A
sema domain, immunoglobulin domain (Ig), 
transmembrane domain (TM) and short cytoplasmic 
domain, (semaphorin) 4A 9 Plasma Membrane other
STK17B serine/threonine kinase 17b 10 Nucleus kinase
1600029D21RIK RIKEN cDNA 1600029D21 gene Unknown other  
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Table 6.15 B 
Symbol Entrez Gene Name Networks Location Type(s)
A2M alpha-2-macroglobulin 1 Extracellular Space transporter
APP amyloid beta (A4) precursor protein 1 Plasma Membrane other
COL1A1 collagen, type I, alpha 1 1 Extracellular Space other
EGR1 early growth response 1 1 Nucleus transcription regulator
ELAVL1
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 
1 (Hu antigen R) 1 Cytoplasm other
ETS1
v-ets erythroblastosis virus E26 oncogene homolog 1 
(avian) 1 Nucleus transcription regulator
F3 coagulation factor III (thromboplastin, tissue factor) 1 Plasma Membrane
transmembrane 
receptor
FABP4 fatty acid binding protein 4, adipocyte 1 Cytoplasm transporter
FCER2 Fc fragment of IgE, low affinity II, receptor for (CD23) 1 Plasma Membrane other
FOS FBJ murine osteosarcoma viral oncogene homolog 1 Nucleus transcription regulator
FURIN furin (paired basic amino acid cleaving enzyme) 1 Cytoplasm peptidase
IFNG interferon, gamma 1 Extracellular Space cytokine
Ige -- 1 Extracellular Space complex
IGHE immunoglobulin heavy constant epsilon 1 Extracellular Space other
IL13 interleukin 13 1 Extracellular Space cytokine
LGALS3 lectin, galactoside-binding, soluble, 3 1 Extracellular Space other
MAF
v-maf musculoaponeurotic fibrosarcoma oncogene 
homolog (avian) 1 Nucleus transcription regulator
MIR125A (includes 
EG:406910) microRNA 125a 1 Unknown microRNA
MIR214 (includes 
EG:406996) microRNA 214 1 Unknown microRNA
NCOA3 nuclear receptor coactivator 3 1 Nucleus transcription regulator
NMI N-myc (and STAT) interactor 1 Cytoplasm transcription regulator
NPPA natriuretic peptide precursor A 1 Extracellular Space other
PACS1 phosphofurin acidic cluster sorting protein 1 1 Cytoplasm other  
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Table 6.15 B continued. 
Symbol Entrez Gene Name Networks Location Type(s)
PRKACA protein kinase, cAMP-dependent, catalytic, alpha 1 Cytoplasm kinase
PRKD1 protein kinase D1 1 Cytoplasm kinase
STAT -- 1 Unknown group
STAT5A signal transducer and activator of transcription 5A 1 Nucleus transcription regulator
STAT5B signal transducer and activator of transcription 5B 1 Nucleus transcription regulator
STAT6
signal transducer and activator of transcription 6, 
interleukin-4 induced 1 Nucleus transcription regulator  
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Figure 6.14 Top network associated with the 15 genes altered in MI vs. BMMNC  
Genes highlighted in green were found to be down-regulated in MI vs. BMMNC.  
Those in grey were found to be differentially expressed in Sham vs. MI, but not in MI 
vs. BMMNC. 
 
 
 
 
Six different canonical pathways were associated with the genes altered in MI vs. 
BMMNC (Table 6.16).  The coagulation system was highlighted by the presence of 
coagulation factor V (F5) which was down-regulated in MI vs. BMMNC.  The only 
up-regulated gene Casq2 highlighted the calcium signalling pathway.  Casq2 inhibits 
the ryanodine receptor calcium release channels and acts as a Ca2+ store [142].  
Sema4a highlighted the axonal guidance signalling pathway where it plays a role in 
binding to Plexin B which has many roles in regulating Rho and Rac pathways which 
lead to actin cytoskeletal reorganisation.   
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Table 6.16 Canonical Pathways associated with the genes altered in MI vs. 
BMMNC   
 
Ingenuity Canonical Pathways -log(p-value) Ratio Molecules
Coagulation System 1.45E+00 2.70E-02 F5
Ceramide Signaling 1.11E+00 1.15E-02 S1PR4
Sphingosine-1-phosphate Signaling 1.00E+00 8.93E-03 S1PR4
Human Embryonic Stem Cell Pluripotency 9.30E-01 6.76E-03 S1PR4
Calcium Signaling 7.87E-01 4.85E-03 CASQ2
Axonal Guidance Signaling 5.01E-01 2.48E-03 SEMA4A  
 
S1pr4 (a.k.a Egd6) is present in three different pathways.  Its role in those pathways 
is essentially the same and is best illustrated in ‘sphingosine-1-phosphate signalling’ 
which is illustrated in Figure 6.15.  S1pr4 (Edg6) S1pr5 (Edg8) are both known to 
activate Gαi complexes which are known to activate ERK1/2 and Pi3k activating cell 
survival pathways [143, 144]. 
 
Figure 6.15 Sphingosine-1-phosphate signalling  The gene highlighted in green 
was found to be down-regulated in MI vs. BMMNC.  Those in grey were found to be 
differentially expressed in Sham vs. MI, but not in MI vs. BMMNC. 
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6.2.4 Summary  
 
 PANTHER pathway analysis revealed apoptosis and inflammation 
(including b-cell and t-cell activation) to be over-represented by genes up-
regulated in Sham vs. MI. DAVID also highlighted apoptosis and immune 
system activation. General cellular metabolism were overrepresented in the 
down-regulated genes in Sham vs. MI.   
 
 A very large amount of information was provided by IPA network analysis 
for the Sham vs. MI gene list.  An interesting finding was that the transport 
protein Glut-4 and the transcription factor Myc were connected to many of 
the genes altered in Sham vs. MI.   
 
 Canonical pathway analysis on Sham vs. MI genes revealed inflammation 
(reflecting results from DAVID and PANTHER) and oxidative stress which 
was also highlighted in the proteomic dataset bioinformatics analyses. 
 
 The small number of genes differentially regulated in MI vs. BMMNC led 
to very little information from any of the bioinformatic analyses.  However 
one network highlighted two transcription factors as being interesting in 
relation to the MI vs. BMMNC affected genes (Fos and Stat6), however 
they were each only linked to a single gene from our dataset. 
 
 Sphingosine-1-phosphate receptor 4 (S1pr4) was highlighted in several 
pathways focusing on ceramide signalling and the activation of downstream 
survival kinases, including Akt/Pi3k which are known to be involved in 
cardioprotection signals initiated through IPC.   
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7. Studies of 14-3-3 epsilon and Bad proteins 
 
7.1 Validation experiments using samples 10-18  
 
Western blotting of 14-3-3ε, Sdha and Pebp1 were performed on samples 10-18 and 
results were compared to the Western blot analyses for samples 1-9.   The 
experimental conditions were as described in section 4.3.  Images of the Western 
blots for each protein are shown in Figure 7.1.  The Gapdh loading controls for the 
14-3-3ε and Pepb1 western blots did not show uniformity across samples, suggesting 
perhaps that protein loading was not uniform.  The calculations were however 
corrected to the Gapdh band intensities as before.  The average normalised band 
volumes for samples 10-18 are shown alongside samples 1-9 (Figure 7.2).   
 
Results for 14-3-3ε showed a significant difference between experimental groups for 
samples 10-18. The change in Sham vs. MI was non significant (3 fold significant 
decrease in samples 1-9) however there was a significant 14 fold increase in MI vs. 
BMMNC (3.2 fold in samples 1-9).  The MI associated decrease in 14-3-3 epsilon 
observed in samples 1-9 was not seen in samples 10-18, but there was a strong up-
regulation of 14-3-3ε in both sample sets.   
 
For Sdha significant differences between the experimental groups was observed. 
Although both sample sets did not have significant differences in Sham vs. MI, there 
was a significant 2 fold up-regulation in MI vs. BMMNC (1.75 fold in samples 1-9).  
The magnitude of the expression change is very similar. 
 
Pebp1 showed a similar pattern of regulation in samples 10-18 to that observed in 
samples 1-9.  None of the differences between the groups reached significance in 
either sample set. 
 
 Page 253 
The similarity of the differential regulation between experimental groups for these 
three proteins in separately prepared sets of myocardial samples suggested they were 
suitable to use for further studies of one of our proteins of interest (14-3-3ε). 
 
Figure 7.1 Western blots of 14-3-3 epsilon (14-3-3ε), succinate dehydrogenase 
(Shda), and phosphatidylethanolamine-binding protein 1 (Pebp1) in samples 10-
18 S = Sham operated group, M = MI group treated with PBS, B = MI group treated 
with bone marrow mononuclear cells.  Glyceraldehyde 3-phosphate dehydrogenase 
(Gapdh) was used for normalisation.  (See Figure 4.6 for western blots of these three 
proteins in samples 1-9) 
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Figure 7.2 The normalised band volumes from Western blot analysis of samples 
1-9 (left) and normalised band volumes from Western blot analysis of samples 
10-18 (right) for 14-3-3 epsilon (14-3-3ε), succinate dehydrogenase (Sdha), and 
phosphatidylethanolamine-binding protein 1 (Pebp1)  Sham = sham operated 
group, MI = MI group treated with PBS, BMMNC = MI group treated with bone 
marrow mononuclear cells.  Error bars indicate standard deviation. Significance in 
one way ANOVA indicated in top right hand corner of charts, significance in Sham 
vs. MI and MI vs. BMMNC comparisons indicated by the bars, * = post-hoc 
bonferroni p-value of 0.05-0.01, ** = post-hoc bonferroni p-value <0.01, ns = not 
significant. 
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7.2 Western blot analysis of Bad proteins 
 
Western blotting was also performed on samples 10-18 using antibodies for the pro-
apoptotic protein Bad which is known to interact with 14-3-3ε in its phosphorylated 
form.  We first measured non-phosphorylated Bad to ascertain whether it was present 
in our protein lysates, then we attempted to measure Bad phosphorylated at serine 
136, which is part of the phosphorylated binding motif for 14-3-3ε. 
 
7.2.1 Bad 
 
An assay using a rabbit monoclonal to Bad antibody was used to detect a band at 
approximately 20kDa using an antibody dilution of 1 in 2000 and 30ug total protein 
loading.  The bands from Bad and the Gapdh gel run simultaneously can be seen in 
Figure 7.3 A.  The average normalised band volumes and associated statistics are in 
Figure 7.3 B.  Bad protein was down-regulated 3 fold in Sham vs. MI and was up-
regulated 2.3 fold in MI vs. BMMNC, both differences were highly significant. 
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Figure 7.3 Western blots of Bad in samples 10-18 A) S = Sham operated group, M 
= MI group treated with PBS, B = MI group treated with bone marrow mononuclear 
cells.  Glyceraldehyde 3-phosphate dehydrogenase (Gapdh) was used for 
normalisation.  B) Normalised band volumes Sham = sham operated group, MI = MI 
group treated with PBS, BMMNC = MI group treated with bone marrow 
mononuclear cells.  Error bars indicate standard deviation. Significance in one way 
ANOVA indicated in top right hand corner of charts, significance in Sham vs. MI and 
MI vs. BMMNC comparisons indicated by the bars, ** = post-hoc bonferroni p-value 
<0.01, *** = post-hoc bonferroni p-value <0.001. 
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7.2.2 Bad (phospho s136) 
 
An assay using two different rabbit polyclonal to Bad (phospho s136) antibodies was 
not optimised after attempting several different variations in conditions including, 
primary antibody dilutions of 1 in 300, 1 in 1000 and 1 in 7000 (Abcam’s 
recommended dilution) for the Abcam antibody and 1 in 350, 1 in 500 and 1 in 1000 
for the New England Biolab supplied antibody.  Protein lysate concentrations utilised 
were from 10-40ug total loading.  Overnight primary antibody incubations were tried 
as well as 1.5 hour incubations.  BSA (fraction V) as a blocking agent as well as 5% 
non-fat milk, in concentrations of Tween-20 from 0.05% to 0.15% were also tested.  
Both antibodies produced multiple bands from 90-20kDa, but none of the tested 
conditions produced clear bands in the expected 22kDa range. 
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7.3 Preliminary pull-down assay of his-tagged 14-3-3 epsilon 
 
7.3.1 Pull-down assay and SDS-PAGE 
 
The pull-down methodology was tested using 60ug of his-tagged 14-3-3ε and the 
ProFoundTM Pull-Down PolyHis Protein:Protein Interaction Kit [Pierce, US].  The 
protein lysate was prepared from a mix of three tissue samples, one from each 
experimental group from samples 10-18.   
 
During the procedure, the no-bait control column collapsed before the prey could be 
added, however the procedure was continued and the bait flow-through, prey flow-
through and the eluate from the 60ug bait column were separated on an SDS-PAGE 
gel along with the bait-flow through for the no-bait control column (Figure 7.4 A).  
The no-bait control was repeated the next day using the same prey protein preparation 
which had been frozen overnight and the prey-flow through and eluate from this was 
run on a second SDS-PAGE gel (Figure 7.4 B). 
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Figure 7.4 SDS-PAGE of the preliminary 14-3-3 epsilon pull-down assay A) & B) 
Two SDS-PAGE gels were run with the products from the pull-down assay.  1,2 & 3 
are from the column loaded with 60µg his-tagged 14-3-3ε bait; 1 = Bait flow-through, 
2 = Prey flow-through, 3 = Eluate. 4, 5 & 6 are from the column loaded with buffer 
only (no-bait control); 4 = Bait flow-through, 5 = Prey flow-through, 6 = Eluate. X = 
Mw marker.  
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Several bands were visible that were in both the bait and no bait control eluate.  There 
were also differences in the patterns of the bands from the two eluates.  The bands 
from the bait flow through and from the eluates were given unique IDs as illustrated 
in Figure 7.5.    Bands were then excised and processed for protein identification 
using LC-MS/MS.    
 
7.3.2 Protein identification by LC-MS/MS 
 
Detailed results from the MASCOT searches are shown in Appendix 8.  A summary 
of the proteins identified are shown in Table 7.1.  Bovine milk proteins and the rat 
serum albumin were among the identified proteins but were excluded from the 
summarised results table (Table 7.1).  The only protein identified from the bait flow 
through was 14-3-3 epsilon. The fainter, higher mass bands did not yield an 
identification. 
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Figure 7.5 Band IDs from bait flow-through and eluate from the preliminary 14-
3-3 epsilon pull-down assay A) Bait flow through from the 60ug his-tagged 14-3-3ε 
column. B)  Bait flow through from the no-bait control column.  C) Eluate from the 
60ug his-tagged 14-3-3ε column. D) Eluate from the no-bait control column.   
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Several proteins were found in both the bait and no-bait control eluate suggesting 
their presence in the bait eluate was due to non-specific binding.  These were 
haemoglobin, cytochrome b-c1 complex subunit 6 and cytochrome c1, heme protein.   
Proteins identified only in the no-bait control were NADH ubiquinone 
oxidoreductase, elongation factor 1-alpha, succinyl-CoA ligase [GDP-forming] 
subunit alpha, NADH dehydrogenase [ubiquinone] flavoprotein 2, NADH 
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dehydrogenase [ubiquinone] iron-sulfur protein 6 and cytochrome c oxidase subunit 
6B1.  Proteins identified only in the bait eluate were oxoglutarate dehydrogenase E1 
component, ATP synthase subunit beta, trifunctional enzyme subunit beta, sarcomeric 
creatine kinase, up-regulated during skeletal muscle growth protein 5 (Usmg5) and 
ATP synthase subunit e.  Two of these six proteins, oxoglutarate dehydrogenase and 
creatine kinase, had peptide scores too low to be confident in the identification.   
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Table 7.1 Proteins identified by LC-MS/MS from the bands illustrated in Figure 
7.5 Estimated relative molecular mass (Mr) of the bands is shown on the left.  
Proteins identified from the bait flow through (BF) are shown in pink.  Proteins 
identified from the no-bait control eluate (BNB) and in orange and from the 60ug 14-
3-3ε bait eluate (BWB) are shown in green.   Protein names are shown alongside the 
band IDs shown in Figure 7.5.  Protein names highlighted in grey had scores below 
threshold. 
 
Band ID Protein Name Band ID Protein Name Band ID Protein Name
190kDa BWB3
oxoglutarate 
dehydrogenase E1 
component, mitochondrial 
120kDa BNB3
NADH-ubiquinone 
oxidoreductase 75 kDa 
subunit, mitochondrial 
62kDa BWB14 ATP synthase subunit beta, mitochondrial 
60kDa BNB7 Elongation factor 1-alpha BWB15 Trifunctional enzyme subunit beta, mitochondrial 
55kDa BWB17 Creatine kinase, sarcomeric mitochondrial (mouse) 
52kDa BNB8
Succinyl-CoA ligase [GDP-
forming] subunit alpha, 
mitochondrial
50 kDa BWB20 14-3-3 protein epsilon 
50 kDa BF4 14-3-3 epsilon BWB21 14-3-3 protein epsilon 
50 kDa BF5 14-3-3 epsilon BWB22 14-3-3 protein epsilon 
47kDa BWB24
Cytochrome c1, heme 
protein, mitochondrial 
(mouse)
45kDa BNB9
Cytochrome c1, heme 
protein, mitochondrial 
(Bovine)
40kDa BNB10
NADH dehydrogenase 
[ubiquinone] flavoprotein 2, 
mitochondrial 
35kDa BWB26 Hemoglobin subunit alpha-1/2 
31kDa BNB11 Hemoglobin subunit beta-2 
30kDa BWB27 Hemoglobin subunit alpha-1/2 
22kDa BNB12 Hemoglobin subunit beta-2 BWB28 Hemoglobin subunit alpha-1/2 
20kDa BNB13 Hemoglobin subunit alpha-1/2 
18kDa BNB14 Cytochrome b-c1 complex subunit 6, mitochondrial BWB29
Cytochrome b-c1 complex 
subunit 6, mitochondrial 
NADH dehydrogenase 
[ubiquinone] iron-sulfur 
protein 6, mitochondrial 
Up-regulated during 
skeletal muscle growth 
protein 5 
Cytochrome c oxidase 
subunit 6B1 (mouse)
ATP synthase subunit e, 
mitochondrial 
Hemoglobin subunit alpha-
1/2 
Bait Flow-through (BF) Bands No Bait (BNB) Bands With Bait (BWB)Estimated 
Mr  of Band
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8. Discussion and Future Work 
 
This thesis describes the results from protein and gene expression profiling studies in 
a rat model of I/R injury and BMMNC therapy. I found numerous alterations in 
mitochondrial, energy metabolism and stress related proteins, many of these changes 
are consistent with what has been reported in previous models of I/R injury.  
BMMNC treatment was shown to ‘correct’ many of the protein alterations induced by 
I/R injury, and increased expression of some proteins to above sham levels (heat 
shock proteins, myosin regulatory light chain 2, and some subunits of the 
mitochondrial oxidative phosphorylation chain). There are no prior reports in the 
literature comparing I/R induced changes in the proteome with those following 
treatment with BMMNCs.   
 
Validation was performed for a handful of differentially expressed proteins. Western 
blotting confirmed the changes in 14-3-3 epsilon (Ywhae/14-3-3ε) expression, this is 
a protein known to have pro-survival functions including an ability to bind and inhibit 
the Bcl-2 related protein Bad (phosphorylated form) [145].   Bad phosphorylation is 
thought to be one of the many downstream actions of the Pi3k/Akt pathway, a system 
activated in our model [146, 147].  Pilot experiments on 14-3-3ε did not provide data 
supporting an interaction with Bad, but a pull-down assay found an interaction with 
two subunits of ATP synthase, one of which has previously been shown to interact 
with 14-3-3ε.   
 
Gene expression was also found to be affected by I/R injury, with hundreds of genes 
showing increased or decreased expression.  Many of these genes are involved in 
inflammatory/immunological responses and apoptosis/cell death signalling, both are 
aspects of cellular behaviour recognised as being associated with I/R injury. A few 
BMMNC induced changes in gene expression were observed, however these could 
not be validated by QPCR.    
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8.1 Proteomic changes in I/R and after treatment with BMMNCs 
 
Numerous proteins were identified as being affected by I/R injury and BMMNC 
treatment in both the wide-range and narrow-range 2DE analyses.  Many of these 
protein changes are likely to be modifications to existing proteins rather than 
increases or decreases in actual expression. The timepoint at which samples were 
collected for proteomic analysis (namely 6hr post reperfusion and treatment) is 
possibly too soon to see results of changes in rates of protein expression. Many 
proteins were observed in decreased amounts in MI group compared to Sham and 
these changes are likely to be degradation of proteins by proteases during the 
processes of cellular damage and death.  Proteins which seem to increase in I/R are 
likely to be modified forms with the native version being undetected in our analysis, 
giving the appearance of a protein having much increased expression from near zero 
levels.  The proteins we identified as being affected mostly fall within the functional 
categories of mitochondrial/oxidative phosphorylaion, antioxidants, energy 
metabolism and heat shock/stress as well as cytoskeletal/sarcomeric proteins.  Protein 
changes in the first four categories will be discussed below. 
 
8.1.1 Mitochondrial/oxidative phosphorylation proteins 
 
Subunits of complex I, II, III and V of the oxidative phosphorylation chain were all 
found to be altered by I/R injury in our model, see Figure 8.1.  Many of these changes 
were seen to be ‘corrected’ in the treatment group however expression in some of the 
subunits increased after treatment compared to sham levels (Ndufa10).  I/R induced 
changes in some of these proteins have been observed before in 2DE studies, and the 
‘correction’ of these changes have been seen in both IPC and free radical scavenger 
treatment, both known to improve outcome after MI, in isolated perfused rabbit hearts 
[90, 91].  
 
Complex I (NADH dehydrogenase) is made of 45 different subunits, seven of which 
are encoded by the mitochondrial genome [148].  Two different subunits of complex 
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I, NADH-ubiquinone oxidoreductase 75kDa subunit (Ndufs1) and NADH 
dehydrogenase [ubiquinone] 1 alpha subcomplex 10 (Ndufa10) were identified in our 
study as being differentially expressed.  A fragment of the native Ndufs1 was found 
to be significantly down-regulated in Sham vs. MI, and up-regulated in MI vs. 
BMMNC but not significantly.  Ndufa10 was not significantly altered in Sham vs. MI 
but did show a significant up-regulation in MI vs. BMMNC.  Two different subunits 
of Complex 1 (Ndufa10, and Ndufv2) have been found to be up-regulated in I/R in an 
isolated perfused rabbit heart model, these were both subsequently found to be down-
regulated in IPC which is the opposite direction of regulation to what we observed 
[91].  Another study using a perfused rabbit heart model identified three further 
subunits of Complex I (Ndufs3, Ndufv1 and Ndufab1) from four spots of interest.  
One of the spots identified as Ndufs3 was up-regulated in I/R and subsequently 
down-regulated after treatment with oxygen free radical scavenger (MPG), the other, 
a slightly higher Mr variant, was down-regulated in I/R but unchanged by treatment.  
The Ndufv1 spot was up-regulated in  I/R and down-regulated in treatment, whereas 
the opposite was true of the Ndufab1 spot  [90].   
 
NADH dehydrogenase is a very large protein complex and the functions of all 45 
different subunits are still not fully understood.  It is clear from our results and others 
that I/R affects this complex but there may be a variation in the reaction of different 
subunits to I/R.  The difference between the changes we observed for Ndufa10 and 
those observed by Kim et al (2006) may be related to differences in the model or we 
may have measured different variants, there is no information on observed Mr and pI 
in their dataset to check this. 
  
The flavoprotein subunit of succinate dehydrogenase (Sdha) which is complex II of 
the oxidative phosphorylation chain was found to be down-regulated in Sham vs. MI 
and was subsequently up-regulated in MI vs. BMMNC in our study.  This complex 
has only four subunits and has not been identified in any of the proteomic analyses of 
I/R. 
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Complex III (ubiquinone-cytochrome b-c1 oxidoreductase) has 11 different subunits 
[149]. One of these were identified in our study as being differentially regulated; 
cytochrome b-c1 complex, subunit 6 (Uqcrh).  Uqcrh was found to be up-regulated in 
Sham vs. MI and down-regulated in MI vs. BMMNC .  Uqcrfs1 (rieske subunit of 
cytochrome b-c1 complex) was identified in an isolated rabbit heart model of I/R, in 
this study it was found to be down-regulated in I/R but unchanged in IPC [91].  
Cytochrome b-c1 complex, core protein 1 (Uqcrc1) has previously been shown to be 
up-regulated in I/R and down-regulated in after treatment with MPG [90].  Our data 
and that of others suggests the Complex III subunits may react to I/R in different 
ways, as was seen with Complex I subunits. 
 
ATP synthase is often referred to as complex V of the oxidative phosphorylation 
chain.  The β subunit (Atp5b) was identified in our study in 17 different spots, these 
showed Atp5b to be down-regulated in Sham vs. MI and up-regulated in MI vs. 
BMMNC.  The Atp5β Western blot shown in figure 4.10  suggests that fragments of 
Atp5β are present in all of the test groups.  The fainter bands in the MI may indicate 
that there is less Atp5β in the I/R injured tissue possibly due to further degradation.  
The higher mass band representing the full length protein (~56kDa) was too 
overexposed to see differences between the groups.  Atp5b was identified in a 
previous proteomic analysis of a hepatic I/R injury mouse model as being down-
regulated by I/R and subsequently up-regulated by IPC [150].   
 Page 267 
Figure 8.1 Mitochondrial oxidative phosphorylation chain  Proteins found to 
differ in our studies are indicated in blue, significant changes are indicated by salmon 
and teal arrows Sham vs. MI.  * indicated that the native protein was identified. 
NADH-ubiquinone oxidoreductase 75 kDa subunit (Ndufs1), NADH dehydrogenase 
[ubiquinone] 1 alpha subcomplex subunit 10 (Ndufa10), succinate dehydrogenase 
[ubiquinone] flavoprotein subunit (Sdha), cytochrome b-c1 complex subunit 6 
(Uqcrh), ATP synthase subunit  (Atp5b), thioredoxin-dependent peroxide reductase 
(Prdx3). 
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In general, there appears to be some overlap in the proteomic alterations that occur in 
I/R injury across species and across models whether it is in-vivo, ex-vivo or even in 
different organs (liver).  Alterations in the expression of these proteins,  especially the 
different regulation seen in different subunits of the larger complexes, suggest 
disarray of oxidative phosphorylation enzymes which would lead to mitochondrial 
dysfunction. Mitochondrial dysfunction is a well characterised aspect of I/R injury, 
the mitochondria are known to play an important role in the intrinsic mechanism of 
apoptosis.  Our data reveals a recovery or even an increase in expression levels of 
mitochondrial oxidative phosphorylation proteins after BMMNC treatment suggests 
the mitochondria have been protected from I/R damage and have been able to recover 
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function.  As mitochondrial damage is closely linked to apoptosis, there is evidence 
that protection of mitochondria inhibits the progression of apoptosis [151]. 
 
8.1.2 Antioxidant proteins 
 
The cytoplasmic antioxidant, peroxiredoxin-6 (Prdx6) was found to be down-
regulated in I/R and up-regulated in treatment in our model. A lower pI version of 
thioredoxin-dependant peroxide reductase (Prdx3), which is a mitochondrion specific 
antioxidant, was found to be up-regulated after I/R injury and remained unchanged 
from this in the treatment group.  Prdx3 is illustrated in Figure 8.1, these data may be 
further evidence that changes to proteins in the mitochondrial oxidative 
phosphorylation chain result in increased production of reactive oxygen species 
(ROS).  ROS would cause further damage to mitochondrial function by inactivating 
NADH dehydrogenase, NADH oxidase, succinate dehydrogenase and ATP synthase 
[152].   Nonn et al (2003) found that Prdx3-transfected cells showed resistance to 
hypoxia-induced ROS formation and resistance to apoptosis [153].  Prdx3 may be 
part of an innate cellular mechanism to protect mitochondria from ROS-induced 
damage during ischemia. 
 
Prdx3 and Prdx6 have both been identified in other 2DE studies looking at I/R injury. 
Prdx6 was found to be up-regulated after ischemia but down-regulated after I/R in an 
isolated rat heart model [93].  Prdx6 was up-regulated in both stunned and injured 
myocardium after reperfusion in an isolated rabbit heart model, but down-regulated 
after treatment with oxygen free radical scavenger MPG [89, 90].   In the same 
model, Prdx3 was observed to be down-regulated in both stunned and injured 
myocardium and up-regulated after treatment with MPG [89, 90].  These conflicting 
results may be explained by the presence of different pI variants of these proteins (i.e 
a shift from one pI to another) as observed by Cullingford et al (2006).  
Peroxiredoxins and heat shock proteins were found to be altered in response to 
oxidative stress in neonatal rat cardiomyocytes.  Both acidic and basic forms of Prdx3 
and Prdx6 were identified as well as several other forms.  The acidic forms of both of 
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these proteins were up-regulated by oxidative stress whereas the basic forms were 
down-regulated and this shift to a more acidic form is suggested to be super-oxidation 
of cysteine-residues [154].  The pI of Prdx6 identified in our proteomic analysis 
suggests this is a basic isoform and Prdx3 is more acidic than theoretical, which may 
explain why the two antioxidants are seen to be regulated differently.   
 
8.1.3 Energy metabolism proteins 
 
Various energy metabolism proteins were also affected by I/R in our model. Cellular 
energy metabolism is known to be seriously affected during ischemia and 
reperfusion. Cardiac substrate preference under normal conditions is a mixture of 
glycolysis, glucose oxidation and free fatty acids.  This is altered during ischemia, in 
part due to a reduction in phosphocreatine and ATP, which results in an increase in 
fatty acid metabolism and a reduction in glucose oxidation.  The outcome of this is an 
increase in lactic acid and faster consumption of oxygen, and eventually loss of 
cellular function [151].    
 
Energy substrate metabolism enzymes have been identified in several previous 2DE 
analyses of I/R injury.  Dihydrolipoyllysine-residue acetyltransferase component of 
pyruvate dehydrogenase complex (Dlat) was found to be up-regulated in Sham vs. 
MI, and down-regulated in MI vs. BMMNC in our study.  Pyruvate dehydrogenase 
was also found to be up-regulated after I/R in two different studies using isolated 
rabbit hearts [89, 91] this change was reversed in IPC [91].  However, other studies 
have seen changes in energy metabolism enzymes which differ from our results.  In 
our study lactate dehydrogenase was found to be down-regulated in two different 
spots in Sham vs. MI.  Lactate dehydrogenase was however up-regulated in I/R (1 
hour ischemia and 1 hour reperfusion) in isolated rabbit hearts, but was unchanged 
after 15 minutes ischemia and 1 hour reperfusion [89].   
 
In our study, Enoyl-CoA hydratase was up-regulated in Sham vs. MI and down-
regulated in MI vs. BMMNC.  This protein however has been found to be down-
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regulated after 30 minutes ischemia and 2h reperfusion in isolated rabbit hearts and 
the expression change was corrected after IPC [91].   
 
The differences in protein expression results between our study and others for these 
proteins may be due to the  differences in study designs.  For example, differences in 
the species used, differences in the type of model used (i.e. regional ischemia initiated 
by coronary artery ligation in our model vs. global ischemia simulated by anoxia, 
achieved by substitution of nitrogen for oxygen in the perfusate in Kim et al (2006) 
[91], and the timings used for ischemia and reperfusion (i.e. 25 minutes ischemia 
followed by 6 hours reperfusion in our model, whereas reperfusion was only 1-2 
hours in the other studies).  Cardiac substrate preference is quite dynamic over the 
course of ischemia and reperfusion so differences in the timings of the experiments 
would lead to different results in terms of the regulation of energy metabolism 
proteins that would be recorded.  There are also important differences between anoxia 
and ischemia models.  In ischemia (especially in-vivo) a lack of circulation would 
lead to poor supply and clearance of metabolites in the infarct, whereas isolated 
perfused hearts in which oxygen removal is the only variable, metabolites can still be 
cleared.  Perfusate is also different from blood in what it brings to the myocardium in 
terms of energy substrates.   
 
Metabolic pathways for different substrates overlap and are also further complicated 
by the alternative use of amino acids and ketone bodies as metabolites [155]. The few 
proteins we have observed as changing in our model do not give a definitive picture 
of what alterations are occurring in the system, only evidence that the systems are 
being perturbed.   
 
8.1.4 Heat shock proteins 
 
Various heat shock proteins (Hsp) were also found to be differentially expressed in 
our study.  Both Hspa9 and Hspb8 were down-regulated.   Previous studies have also 
identified various heat shock proteins to be differentially expressed.  White et al 
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(2005) found several spots containing Hsps in an isolated rabbit heart model of I/R. 
They had two different I/R timings, as described before (15 minutes ischemia / 60 
minutes reperfusion [stunned] and 60 minutes ischemia / 60 minutes reperfusion 
[infarct]), they also sub-fractionated the protein sample and ran separate 2DE 
analyses on whole tissue extracts, a myofilament enriched fraction and a cytosolic 
enriched fraction.   Hsp27kDa (Hspb1) was identified in one spot in both whole and 
cytosolic fractions and was up-regulated in both fractions in both models.  Hsp 70kDa 
(Hspa9) was identified in two spots in the whole tissue extract and although one 
Hspa9 spot was up-regulated in both models, the other was down-regulated in both 
models [89].  Although Hspa9 was found to be up-regulated back to sham levels in 
MI vs. BMMNC in our study, Hspb8 expression were unaffected, suggesting the 
mechanism of cardioprotection in BMMNC’s may not involve heat shock proteins.  
However, in light of the varying results seen in the paper by White and colleagues, 
there should be a more detailed study of the behaviour of these proteins before their 
actions could be ruled out.  
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8.2 Candidate proteins for involvement in BMMNC afforded cardioprotection 
 
One protein, 14-3-3 epsilon is a very good candidate for being directly involved in 
the cardioprotection afforded by treatment with BMMNCs. Expression changes in 
this protein were confirmed by Western blotting.  14-3-3 proteins are highly 
conserved molecular chaperones with more than 200 different client species [156].  
They bind to phosphorylated serine or threonine motifs and thereby mediate many 
different signal transduction pathways [156].   There are seven mammalian isoforms 
in the 14-3-3 protein family including β, γ, ε, η, σ, τ and ζ plus α and δ which are 
phosphorylated forms of β and ζ [157].  Much of the research to date in the literature 
on 14-3-3 proteins does not specify the isoform under investigation and although 14-
3-3 epsilon is suggested to have early evolutionary divergence from the other 
members of the family, an analysis of substrate specificities indicates a high level of 
overlap between the binding motifs recognised by the different isoforms [157, 158].  
This suggests that many functions will be common to several isoforms.  
 
One of the well documented functions of 14-3-3 proteins is the promotion of cell 
survival through the inhibition of several apoptotic pathways [145].  14-3-3 proteins 
are specifically known to be involved in cell survival signalling via their interaction 
with the B-cell lymphoma (BCL-2) protein Bad.  In fact all of the mammalian 
isoforms bind and inhibit Bad [159].   The BCL-2 family of proteins comprises a core 
of ~12 proteins split into three classes, namely class I, class II and BH3-only.  All are 
highly involved in the control of the mitochondrial apoptosis pathway, otherwise 
referred to as the intrinsic apoptotic pathway.   Class I includes Bcl-xL and Bcl-2 and 
these inhibit apoptosis.  Class II members promote apoptosis and include Bax and 
Bak among others.  The BH3-only group contain a BH3 domain and includes Bad. 
The BH3-only members can bind the anti-apoptotic Class I members thereby 
promoting apoptosis [160]. 
 
Phosphorylation of serine 136 and serine 112 in the Bad protein creates a binding 
motif for 14-3-3 and subsequent binding leads to improved accessibility of serine 155 
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(in the BH3 domain of Bad). Serine 155 is then phosphorylated by protein kinase A 
(PKA).   Phosphorylation of serine 155 by PKA disrupts the interaction of Bad and 
Bcl-xL causing Bcl-xL to be released to bind preferentially to the BH3 domain of 
Bax inhibiting the pro-apoptotic function of this member of the BCL-2 family [161-
163].  Therefore the phosphorylation state of Bad appears to be important in 
regulating mitochondrial apoptosis in conjunction with its interaction with 14-3-3.   
 
Akt is thought to be the agent responsible for phosphorylation of Bad at serine 136 
and therefore, the Pi3k/Akt pathway is thought to be involved in initiating the 
suppression of this otherwise pro-apoptotic pathway [146, 147].  The serine/threonine 
kinases Rsk-1 causes phosphorylation of Bad at serine 112 in response to protein 
kinase C activation [164].  Calcineurin has been shown to dephosphorylate Bad 
causing it to dissociate with 14-3-3 and thereby induce apoptosis [165].  Several 
studies have also shown that Jnk1/2 works in opposition to Akt in apoptosis signaling 
by interfering with Bad/14-3-3 binding.   Jnk1/2 phosphorylates serine 128 in Bad 
causing dissociation from 14-3-3, part of the pro-survival actions of Akt may be 
suppression of Jnk1/2 as well as its own direct actions on the phosphorylation state of 
Bad [166].  Interestingly Caspase-3, which is activated by the pro-apoptotic Class I 
BCL-2 proteins through cytochrome c release from leaking mitochondria, has been 
shown to cleave 14-3-3ε and prevent it’s interaction with Bad thereby further 
promoting apoptosis [167]. Many of these kinase pathways are known to be involved 
in cardioprotection.  
 
The candidacy of 14-3-3ε in cardioprotection is also supported by additional studies 
in the rat model developed as part of this programme of studies.  Western blot 
analysis of Akt (which is thought to be involved in IPC induced cardioprotection) 
showed that BMMNC treatment led to phosphorylation of serine 473 of Akt, and this 
activation was abolished by treatment with the Pi3k inhibitor LY294002 (see section 
1.4).  The anti-apoptotic effect of 14-3-3 would be dependant on Akt being activated 
and phosphorylating Bad.  Phosphorylated Bad would then be bound to 14-3-3 
leaving Bcl-xL to bind and sequester pro-apoptotic Bax (see Figure 8.2). 
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Further Western blotting showed inhibition of Gsk-3β was initiated through the 
phosphorlyation of serine 9 in the BMMNC group (also shown in Figure 8.2).  Gsk-
3β inhibition through phosphorylation of serine 9 is thought to be prosurvival and 
there are several kinases which may initiate this phosphorylation including Akt [168].   
 
Figure 8.2 Signalling pathway potentially triggered by BMMNC treatment: 
Evidence from our model   Stars indicate evidence from Western blotting and 
proteomics data produced in our programme of studies.  Akt has been shown to be 
phosphorlyated (activated) by BMMNC and appears to be Pi3k dependant (star 1 and 
2).  Gsk-3β has also been shown to be phosphorylated (inactivated) by treatment (star 
3).  14-3-3ε was shown to be one of the up-regulated proteins in the treatment group 
(star 4).  +P = activated through phosphorylation, -P = inactivated through 
phosphorylation.  
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Western blotting experiments to compare the two different batches of rat myocardial 
samples (samples 1-9 and 10-18) showed similar patterns of expression, however a 
striking difference was the 3-fold reduction in 14-3-3ε observed in Sham vs. MI in 
samples 1-9 that was not observed in samples 10-18.  However, up-regulation of 14-
3-3ε was observed in MI vs. BMMNC in both sample sets.   This may indicate a level 
of experimental variation between batches, which may be expected as they were 
produced at different time points.  However, there is certainly similarity in the 
expression patterns, especially in MI vs. BMMNC.  This comparison is where we 
might expect to find changes which may indicate mechanistic action of BMMNC 
treatment.    
 
In our preliminary investigations of 14-3-3ε and Bad we were able to show that 
overall protein expression of Bad was reduced in I/R injury and significantly 
increased ~ 3 fold after BMMNC treatment.  However, we were unable to measure 
phosphorylation of serine 136 in Bad which would have indicated whether it was in a 
configuration conducive to 14-3-3 binding.    
 
To look at which proteins were interacting with 14-3-3ε in our samples, a pull-down 
assay was performed using his-tagged 14-3-3ε as bait and protein lysate (treated with 
phosphatase inhibitors to preserve phosphorylated motifs) as prey.  A preliminary 
pull-down experiment revealed two different subunits of ATP synthase to bind.  ATP 
synthase subunit β (Atp5b) has a known 14-3-3 binding motif and has previously 
been shown to bind with 14-3-3 in an affinity chromatography assay using protein 
extracts from HeLa cells [169].  Several other studies also note an interaction of 14-3-
3 proteins and ATP synthase in plants [170, 171].  A phosphorylation dependant 
interaction between ATP synthase and 14-3-3 may also be anti-apoptotic [172].  
Atp5b was identified as a differentially regulated protein in our study, being 
significantly down-regulated in Sham vs. MI and significantly up-regulated in MI vs. 
BMMNC.  ATP synthase subunit e (Atp5i) is part of the membrane bound F0 
complex of ATP synthase.  Very little is known about the functional capacity of this 
subunit. It is known to be important for maintaining dimerisation and oligomerisation 
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of mitochondrial F1F0, which may be important in maintaining mitochondrial cristae 
structure [173].  Subunit e may have been pulled-down in a complex with the β 
subunit, rather than due to a direct interaction with 14-3-3ε.   
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8.3 Limitations of 2DE proteome analysis 
 
Due to variation in biological systems, a reasonable number of replicates are usually 
required to obtain statistically significant results; an ‘n’ of three is the absolute 
minimum from which any meaningful data can be obtained but larger ‘n’ is required 
as variation increases and the size of the difference you want to detect decreases.    
The pattern of expression change of four proteins (14-3-3ε, Sdha, Pepb1 and Atp5b) 
observed in the 2DE analysis was confirmed by Western blotting.  However, the 
exact fold change values observed by profiling were not always validated, illustrating 
that 2DE results must be confirmed before any firm conclusions can be made.  The 
low number of replicates in our study makes verification of results even more 
pressing.   
 
A common method for highlighting spots with a significant difference between 
groups is to use a simple statistical test.  We took a spot-by-spot approach, meaning 
we looked at data from each spot separately, not taking into account the entire dataset 
when considering whether a spot was significantly different between groups [174].   
This approach negated the need to perform correction for multiple testing, which aims 
to lower the false discovery rate which is increased in proportion to the number of 
tests performed.  Most methods of correction would lower the p-value threshold for 
significant data by a large margin, especially as many 2DE analyses include 1-2000 
spots.  This in all likelihood would result in very little significant data and 
overcorrection will increase the false negative rate.  There has been no consensus on 
the best way to analyse a 2DE datasets.  With so few samples, it is impossible to 
check for ‘normal’ distribution so the decision to use parametric or non-parametric 
test is not a simple one.  A t-test will compare the means of each of the two groups 
that are to be compared and will look for statistical differences based upon the ratio of 
the difference and the standard error of the difference [175].  As our comparisons 
were between two groups of independent samples the student’s t-test is an appropriate 
tool.   However, it could be argued that a non-parametric test such as the Mann 
Whitney U test which also compares two independent groups but which does not 
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assume the data is normally distributed should be used in this analysis.  The Mann 
Whitney test looks at the scale of the difference between groups and does not take 
standard error into account [175].  However with a low number of replicates, the 
power of the Mann Whitney U test may be reduced [174, 176]. Both Student’s t-test 
and Mann Whitney U tests were performed on the spot intensity data and the two 
tests were found to produce a very similar list of significantly altered spots. The 
Student’s t-test was chosen to present in this thesis and a p-value of <0.05 was taken 
as being significant.  We also used a fold-change cut-off as 1.5 as differences below 
this value are often thought of as being the limit of changes detectable by 2DE.  
However it must be noted that using a fold change cut-off will lead to some 
significant findings being overlooked.  In the case of the wide-range analysis, a large 
number of spots passed the criteria of having a p-value <0.05 and being >1.5 fold 
change difference between groups.  For this analysis we chose a cut-off value of 2.5 
fold change to highlight the most interesting spots to prioritise for protein 
identification.  Both of the narrow-range analyses produced much smaller numbers of 
spots with p-value <0.05 and >1.5 fold change difference, therefore all of these spots 
were taken forward for analysis.  There is as yet no gold-standard statistical analysis 
for 2DE data, which is another reason why it is important to validate findings with a 
different technique such as Western blotting.   
 
Comparative 2DE gels give a window onto the proteome but this window is limited 
to the range of proteins which are solubilised in the buffers used for protein sample 
preparation, and are sufficiently resolved within the 2DE gels (across the pH range of 
the IPG strip and across the length of the second dimension gel).  In this study we 
only had the potential to observe proteins in the range of pH4-7 and then only those 
which were solubilised and well focussed in the 2DE gels. This would have also 
excluded any proteins with very low abundance and particularly hydrophobic proteins 
which are also difficult to visualise using 2DE and would be under-represented.  
Another limitation to the amount of the proteome observed in 2DE experiments 
comes as a consequence of variability between gels.  For example, spots can be 
missing from one gel but well resolved in another for technical reasons rather than 
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biological ones, and regions of the gels may migrate differently (warping) which 
leads to difficulties in matching spots across the gels.  If there is any doubt as to the 
appropriate matching of spots, then these spots should be excluded from analysis.    
 
There are several ways to maximise the amount of proteome visualised using 2DE.  
These include sub-fractionating the protein sample, based on solubility or on 
subcellular compartmentalisation.  Running separate 2DE analyses on the different 
fractions will allow a larger portion of the proteome to be visualised.  The use of 
fractionation on the basis of subcellular compartmentalisation may also reveal 
translocation of various proteins in response to the experimental conditions.   
 
To increase the proportion of the proteome we could analyse in this study, two 
narrow-range analyses were performed.   These two pH ranges in the wide-range gels 
were dense with spots and in some cases spots were too dense to be matched and 
analysed with confidence.  High density of separated spots also causes many spots to 
yield more than one protein identification, in these cases, no conclusions can be 
drawn from the spot intensity data.   By stretching both of these pH ranges over a 
larger area it was hoped that better separation could be achieved and some new 
proteins would be identified that had not been identified in the wide-range analysis.   
 
Five proteins were identified in the narrow-range analyses that were already picked 
up by the wide-range analysis; these were ATP synthase subunit beta, stress 70 
protein, actin, myosin-6 and tropomyosin.   A further 14 different proteins were 
identified in the narrow-range analyses.  The effect of improved resolution in these 
pH ranges is illustrated in Figure 8.3, which shows examples of our 2DE gels from 
the wide-range analysis and both of the narrow-range analyses. 
 
Another 2DE method which addresses the issues of gel to gel variability, especially in 
regards to variations in the running pattern of spots, is difference gel electrophoresis 
(DIGE).  DIGE employs the use of fluorescent dyes to differentially label two 
samples which can then be separated on the same gel [177].  A sample from each 
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group is stained with a different fluorescent dye, pooled and then run together, 
proteins co-migrate enabling improved matching [178].  Additionally there is an 
option to use an internal control, which is made up from an equal portion of all 
samples stained with a third fluorescent dye and also run on the same gel.  The 
internal control should contain all of the protein species present in the different 
samples and further impove matching [179].  
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Figure 8.3 Example wide- and narrow-range gel images The top image is an 
example of a pH 4-7 gel image with the positions of identified proteins marked.  Pink 
circles indicate spots identified as ATP synthase beta, all other proteins labelled in 
yellow.  The two lower images show examples of the narrow-range gel images. A pH 
4.5-5.5 gel image is on the left and a pH 5.5-6.7 gel image is on the right.  Positions 
of identified proteins marked with circles.  The pH range is indicated on the top of the 
gel images and the Mr is labelled on the left in kDa. 
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8.4 Gene expression changes in I/R and after treatment with BMMNCs 
 
There were numerous genes altered in Sham vs. MI (>1500), 44% of which were 
down-regulated and 56% were up-regulated.  Very few genes were altered in MI vs. 
BMMNC (20).  Many of the genes which were observed to be altered in regulation in 
Sham vs. MI, have a function related to inflammatory response, integrin signalling 
and cytokine chemokine signalling.  Platelet derived growth factor (PDGF) signalling 
and transforming growth factor β (TGF-β) signalling were also strongly represented.  
As with the proteomic data, the 6 hour timescale must be considered as quite an early 
timepoint to observe changes in gene expression regulation within the existing cell 
population of the myocardial tissue.   
 
In the I/R damaged myocardial sample we expect the actual area of infarct to be made 
up of dead and dying cardiomyocytes and damaged extracellular matrix (ECM) as 
opposed to healthy myocardium made up of healthy cardiomyocytes and intact ECM.  
The dead and dying cardiomyocytes will trigger an inflammatory response.  There is 
also likely to be an activation of cardiac fibroblasts (which make up ~90% of the 
remaining myocardial cell population) which are responsible for regulation of the 
ECM [180]. Although many fibroblasts are likely to be damaged and subjected to I/R 
induced cell death along with the cardiomyocytes, they are probably a little more 
hardy to I/R induced damage as they have much lower energy requirements.  
Although, there was no histological evidence of tissue composition of the samples 
used for these proteomic and gene expression analysis.    
 
In the early stages of response to I/R injury activated cardiac fibroblasts induce the 
degradation of ECM through increased expression of matrix metalloproteinases 
(MMPs) [181].  The MMPs 8, 9 and 3 were found to be elevated in expression as 
well as tissue inhibitor of metalloproteinase (TIMP1) in Sham vs. MI.   Interleukin 1 
beta (IL-1β), IL-1 receptor type I and II and IL-1 receptor agonists as well as tumour 
necrosis factor (TNF) receptors were also found to be increased in expression in I/R 
injury.  IL-1β can stimulate increased expression of MMP9 and 3 and this is 
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augmented by TNFα  via  p38 MAPK signalling [182].  Induction of MMP9 
expression by IL-1β may also be through impaired iNOS function and via NF-κB 
activation [183].  These genes reflect the known initial stages of fibroblast response 
to injury.  
 
Of the genes found to be altered in Sham vs. MI, many were associated with 
inflammation and with apoptosis signalling, both cellular responses which make 
biological sense in relation to the phenotype, indicating that the analysis was 
reasonably successful at identifying genes changing in Sham vs. MI.   A large number 
of the genes and gene families we identified as differing in Sham vs. MI have also 
been found to differ in other gene expression analyses of I/R injured tissue.   
 
Gabrielson et al (2007) compared gene expression profiles after an acute ischemic 
episode in healthy myocardial biopsies and chronic ischemic biopsies taken from 
patients undergoing bypass surgery using Affymetrix HG_U133 A Genechip® arrays.   
They found several genes to be up-regulated by acute ischemia in the chronic 
ischemia samples compared to normal, many of these genes were also identified as 
being up-regulated in this analysis. These included; a disintegrin-like and 
metallopeptidse (reprolysin type) with thrombospondin type 1 motif 1 (Adamts1), 
activating transcription factor 3 (Atf3), chemokine (C-C motif) ligand 2 (Ccl2), Ccl3, 
dual specificity phosphatase 1 (Dusp1), Dusp5, early growth response 1 (Egr1), Egr2, 
FBJ murine osteosarcoma viral oncogene homolog (Fos), growth arrest and DNA-
damage-inducible 45 beta (Gadd45b), Gadd45g, matrix metallopeptidase 9 (Mmp9), 
myelocytomatosis viral oncogene homolog (Myc), nuclear receptor subfamily 4, 
group A, member 3 (Nr4a3), and  S100 calcium binding protein A8 (calgranulin A) 
(S100a8) [184].  Gabrielsen and colleagues also found various subunits of NADH 
dehydrogenase (ubiquinone) to be down-regulated in the acute ischemic episode in 
their study [184].  Several NADH dehydrogenase subunits were also identified as 
being down-regulated in our dataset.  Some of the cytokines, chemokines and 
adhesion molecules identified by Ip et al (2007) as being differentially regulated by 
ischemia in a mouse model were also identified in our analysis.  These included; 
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Adamts1, Ccl2, Ccl6, Ccl7, Ccr1, chemokine (C-X-C motif) ligand 2 (Cxcl2), 
interleukin 1 receptor type II (Il1r2), interleukin 1 receptor antagonist transcript 
variant 1 (Il1rn), Mmp8, plasminogen activator, tissue (Plat), plasminogen activator, 
urokinase (Plau), and tissue inhibitor of metallopeptidase 1 (Timp1) [103]. 
 
The 20 genes found to be altered in MI vs BMMNC were nearly all down regulated 
(with the exception of calsequestrin 2).  No particular pathway was highlighted by 
this list of genes as shown by the bioinformatic analyses, but there are several 
functionally interesting genes in the list.  Apoptosis inducing serine/threonine kinase 
17 beta (Stk17b) or DRAK2, was found to be down-regulated and is thought to be a 
positive regulator of apoptosis [185].  One candidate responsible for negative 
regulation of this gene may be Cyclooxygenase-2 (COX-2) [186].  Expression of 
COX-2 is known to be upregulated in the preconditioned heart and this may be 
initiated through Janus tyrosine kinease/signal transducers and activators of 
transcription (Jak/Stat) signalling, however the activity of COX-2 apears to be linked 
to inducible nitric oxide synthase (iNOS) production of NO [187, 188].  2’ 5’ 
oligoadenylate synthetases are a family of inteferon inducible enzymes which block 
protein synthesis (by causing mRNA degradation) as a response to infection. Oas1k is 
homologous to human OAS3 (100kDa) isoform which is known to form dimers of 2’-
5’ linked oligomers of adenosine and these are not thought to be capable of activating 
RNase L and therefore OAS3 is unlikely to have the same functionality as OAS1 and 
OAS2 [189].  Analogues of dimeric 2’-5’ adenosine however have been shown to 
regulate gene expression and DNA replication through inhibition of DNA 
topoisomerase I [190].  Rebouillat et al (2006) found expression of OAS3 caused 
human cells to be sensitive to apoptosis initiated by caspase-9 activation, and 
downstream cleavage of caspase-3 and Poly (ADP-ribose) polymerase (PARP) [191].  
Down-regulation of this gene could also give some resistance to apoptosis. 
 
Expression of Edg6, a sphingosine-1-phosphate receptor specifically expressed in 
lymphoid tissue and thought to be involved in lymphocyte trafficking, has been 
shown to be indirectly controlled by Pi3k through the transcription factor FOXO1 in 
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T-cells and hence the down-regulation of Edg6 in the treated group may be a 
consequence of parallel Pi3k signalling [192, 193].  Sema4a is a class 4 semaphorin 
and also appears to have a role in inflammatory responses.  It is expressed on both B-
cells and dendritic cells, and is involved in T-cell activation [194].  Sema4a has 
previously been shown to be involved in autoimmune myocarditis and autoimmune 
encephalomyelitis through regulation of T-cell differentiation [195, 196].   An anti-
angiogenic action of Sema4a in endothelial cells has been shown to be mediated 
through negative regulation of vascular endothelial growth factor (VEGF) signalling 
[197].  Down-regulation of Sema4a would therefore allow enhanced endothelial cell 
migration and vascular genesis. Dok-3 which is expressed on B-cells and 
macrophages is thought to be involved in negative regulation of B-cell activation 
[198, 199].   
 
These genes, although not apparently in the same signalling network as far as current 
evidence shows,  all appear to be expressed and involved in the regulation of 
lymocytes and may suggest a modulation of the adaptive immune response in treated 
myocardium which may be linked to apoptosis resistance.  These results provide 
many different interactions of interest to be explored in future work. 
 
Three genes were followed up for QPCR validation; sema domain immunoglobulin 
domain (Ig) transmembrane domain (TM) and short cytoplasmic domain 
(semaphorin) 4A (Sema4a), 2 ' -5 ' oligoadenylate synthetase 1K (Oas1k) and IQ 
motif containing GTPase activating protein 1 (Iqgap1).   Sema4a was found to be the 
most highly significantly altered gene in both the Sham vs. MI and the MI vs. 
BMMNC comparisons.  There was a 2.25 log fold-change in Sham vs. MI (adjusted 
p-value of 2.72e-9) and a -1.3 log fold change in MI vs. BMMNC (adjusted p-value 
of 0.007).   The QPCR results for this gene also showed up-regulation after I/R and a 
subsequent down-regulation in BMMNC, although these changes were not found to 
be statistically significant.  Oas1k was the second most highly significantly altered 
gene in both the Sham vs. MI and the MI vs. BMMNC comparisons.  There was a 
2.57 log fold-change in Sham vs. MI (adjusted p-value of 6.05e-9) and a -1.6 log fold 
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change in MI vs. BMMNC (adjusted p-value of 0.007).  The QPCR data for this gene 
showed an up-regulation in I/R, which did not reach statistical significance and no 
change was seen after BMMNC.  This gene was also measured by QPCR in samples 
10-18, these results showed an up-regulation in I/R, which reached statistical 
significance (p = 0.026) and a down-regulation in BMMNC, which did not reach 
significance.   Iqgap1 had a modest but statistically significant up-regulation in Sham 
vs. MI (log fold change of 0.41 and an adjusted p-value of 0.022) and was included in 
the QPCR analysis to see if we could validate less significant differences. The QPCR 
results for this gene showed a modest non-statistically significant up-regulation in I/R 
and no change in BMMNC.   
 
The QPCR results for all three genes, in general, reflected the results observed in the 
RatRef12 chip analysis.  Statistical significance however, was only reached in the 
Sham vs. MI comparison for Oas1k in tissue samples 10-18. There were 
amplification failures for some samples in these analyses and it is clear that RNA 
quality can be compromised during the process of finely grinding the sample to allow 
improved sampling.  Combined with low numbers of replicates, these factors are 
most likely to be responsible for the large error bars seen in the QPCR results which 
may account for the lack of statistically significant changes between groups.      
 
There was some overlap in the gene expression dataset and the proteomics data; 
subunits d and h of ATP synthase were found in the gene expression dataset (beta 
subunit in the proteomics dataset), Actin, Acads, Creatine kinase, Galectin 5, Pepb1 
and Cap1 as well as different subunits of succinate dehydrogenase and lactate 
dehydrogenase were all identified in both datasets.  In many instances, the same 
direction of change was seen in both datasets.  Cap1 was identified as being down 
regulated in the proteomics data (Sham vs. MI) but gene expression was up-regulated.  
The simplistic view of down-regulation in the proteomics dataset may be misleading 
as the Cap1 protein may have been modified rather than down-regulated in 
expression.  Due to such modifications and the dynamic relations between an mRNA 
being expressed, a protein being translated, processed and modified, as well as the 
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technical limitations inherent in comparative proteomics as mentioned previously,  
there will not always be a direct relationship between mRNA content and proteins 
observed in a 2DE analysis.    Different nomenclature can also make the task of 
comparing two datasets difficult.   
 
There were very few gene expression changes in MI vs. BMMNC, and both the p-
values and fold changes for these few results were more modest than those seen in the 
Sham vs. MI data.  The QPCR validation as mentioned above was also weak for the 
MI vs. BMMNC differences.  The lack of differentially expressed genes observed in 
the BMMNC group in our study indicates that myocardial restoration may be 
achieved through mechanisms not relying on gene expression, which would favours 
the theory of a paracrine mechanism being important or it may be a consequence of 
the 6 hour timepoint used in this study.   It would be preferable to confirm these 
findings using a larger number of experimental replicates also using a different 
platform for the gene expression chip analysis (for example Affymetrix, US).  
Measuring gene expression at a later timepoint or possibly a performing a time-series 
investigation would be of interest. 
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8.5 Bioinformatic analysis of proteomic and gene expression datasets 
 
Global proteomic and gene expression analyses similar to the ones presented here 
result in large lists of proteins and genes which are potentially involved in producing 
the phenotype under scrutiny.  To obtain biological meaning from these lists, a 
literature search on each protein could be performed to ascertain individual functions,  
this process however is very time consuming.  Most proteins or genes act in concert, 
and indeed can have different actions depending on cellular location and interactors.  
There are now several bioinformatic tools which will look for over-representation of 
functions, or pathways within a list of proteins.  The information gathered using these 
tools can be used to prioritise any further investigation.  In the case of our gene and 
protein datasets, some general functional groupings were revealed to be affected in 
our study, such as oxidative phosphorylation, apoptosis and inflammation.   
 
Overall, there was little in the way of key findings which implicated a mechanism for 
the actions of BMMNCs in our bioinformatic analyses.  This may be due to a 
relatively small size of the proteomic dataset (which is in part due to the restricted 
view of the proteome we are able to access using 2DE), and the even smaller list of 
genes affected in MI vs. BMMNC.  As the effects of BMMNCs appear to be 
mediated not through transcriptional activation, but through activation and 
mobilisation of the existing protein populations, bioinformatics results from the 
proteomic data may be more likely to contain clues to the mechanism.   
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8.6 Conclusions 
 
BMMNC therapy in our model was shown to considerably reduce infarct size 
(through reduced apoptosis and necrosis) to an extent comparable to that achieved 
through IPC and this correlated with improved cardiac function.  Survival kinase 
signalling pathways (Pi3k/Akt and Gsk-3β) known to be affected in IPC were also 
shown to be affected by BMMNC in our study.    The proteomic and gene expression 
data presented here have revealed many I/R induced changes which are in agreement 
with what is currently understood about I/R injury, and this indicates the validity of 
our data.  The proteomic data also shows that many I/R induced protein alterations 
are corrected by BMMNC therapy, this also reflects the results from other 2DE 
analysis looking at IPC and pharmacological preconditioning in rodent models.   
Myocardial restoration by BMMNC was not associated with many alterations in gene 
expression, which may be evidence of a mechanism which relies on modification and 
mobilisation of the existing protein population, possibly in response to a paracrine 
signal.  However, differential regulation in a few genes with potentially interesting 
functional parallels in B-cell and T-cell regulation as well as apoptosis resistance is 
worthy of further investigation.    
 
Knowledge of the signalling cascades which are activated by the paracrine signal may 
narrow down the possible identity of the signal itself.  However, when considering 
the possible source for this paracrine signal we must remember the nature of the bone 
marrow cell preparation used for treatment.  Mononuclear cells were enriched 
through percoll density gradient centrifugation but the cell preparation may be 
expected to include a mixture of several different cell types.  Several CD markers 
were measured in the BMMNC preparation used in this analysis but this only gives a 
limited picture of the range of cells in the preparation.   Evidence from studies 
conducted by Prokopi et al (2009) indicated that platelets, platelet derived 
microparticles and indeed megakaryocytes maybe contaminating the BMMNC prep 
and through mechanical perturbations inherent in the preparation procedures, the 
platelets within the preparation may be in an activated state [200].  Platelets are 
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anuclear cells originating from megakaryocytes and contain secretory granules which 
carry a wide variety of proteins with many different functions including contain 
growth factors such as VEGF and chemokines; they also carry membrane bound 
integrins and receptors on their surface [201].  This adds an extra dimesion to the 
interpretation of data as immune modulation and angiogenesis are among the many 
varied functions of plateles and platelet α-granules and must therefore be considered 
as potentially responsible for the cardioprotective effects of the BMMNC prepatation.    
 
In summary, there are now several pieces of evidence that suggest BMMNC cells 
work in a paracrine manner.  Data from our study indicates that whatever this 
paracrine signal is, it may invoke similar pathways to what has been observed in IPC, 
post-conditioning and pharmacological conditioning. There is a need to further 
characterise the signalling pathways initiated by BMMNC treatment, in the same way 
there has been lots of research characterising pathways involved in other 
cardioprotective mechanisms.  Improved definition of the mechanisms may uncover a 
downstream drug target for a drug which can be administered at the point of 
reperfusion.  No one has previously performed a proteomic and gene expression 
profile of myocardial tissue after treatment with BMMNCs, my experiments have 
revealed 14-3-3ε as one of the candidates to be considered for further study. 
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8.7 Future work 
 
There are many further experiments which can be done based on the findings from 
our global profiling studies. The investigation of proteins interacting with 14-3-3ε 
within our model remains incomplete and one of the first experiments that could be 
done is a more comprehensive pull-down assay.  Such an experiment would look at 
interactors within our samples and indeed differences in 14-3-3ε interactions between 
groups.  These results may indicate if 14-3-3ε interacts with Bad, or indeed it may 
show that other interactions form the basis for its functions within our model and 
several novel interactors may yet be forthcoming.  Identifying these interacting 
proteins would indicate if there is a role for 14-3-3ε in our model and help to 
elucidate whether it is involved directly in cardioprotection or not. Obtaining data on 
the phosphorylation state of Bad in our model would also be an important piece of 
evidence of the involvement of 14-3-3 and Bad and should be a priority.   If these 
experiments revealed evidence for the involvement of Bad and 14-3-3ε in BMMNC 
afforded cardioprotection, the dependence of this upon Pi3k/Akt activation could then 
be assessed using Pi3k inhibitors.  Measuring the presence of Bad in mitochondrial 
preparations and cytosolic fractions from our myocardial samples in Sham, I/R, 
BMMNC and BMMNC with a Pi3k inhibitor may also indicate whether Bad is 
translocating to the mitochondria in I/R, whether this is attenuated by BMMNC 
treatment and if this translocation is Pi3k dependant.    Bad is thought to interact with 
receptors on the mitochondrial membrane and initiate the opening of the permeability 
transition pore, therefore initiating apoptosis, there are currently several research 
groups trying to define the exact mechanisms involved [160].   In terms of BMMNC 
mechanism, the paracrine message is likely to be upstream of Pi3k/Akt signalling, 
therefore once the pathways that lead from Pi3k/Akt activation to apoptosis are 
confirmed, focus should be concentrated on what lies up-stream from Pi3k/Atk 
activation. 
 
As well as looking at known elements of apoptotic/protective signalling pathways to 
assess their regulation after BMMNC treatment and trying to assess the nature of the 
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paracrine trigger of this response; we must also consider the source of the trigger.  
Any of the components of the BMMNC preperation may be responsible for 
delivering the trigger and so a more detailed characterisation of the cell preparation 
should be a high priority.  Measuring CD markers is the most common way to get a 
‘phenotype’ of a mixture of cells, but this method lacks specificity and only gives an 
idea of composition.  One key aspect of the bone marrow cell preparation used in this 
study may be the presence of contaminating platelets or megakaryocytes and these 
should be quantified in any further work.  Further purifying the bone marrow cell 
preparation would allow a set of parallel experiments to look at the ability of different 
cell types (and supernatant from these isolated cell populations) to see if they can 
elicit any affect on cardiomyocytes post I/R.  Initially these could be performed on 
cell cultures (cultured adult rat cardiomyocytes (with the limitation that experiments 
would have to be completed within 48 hours), neonatal rat cardiomyocytes which can 
be cultured for 5-10 days or possibly stem cell-derived or induced pleuripotent 
cardiomyocyte-like cells which are being developed by Harding and colleagues at 
Imperial College London; with successful cell types being tested further in our I/R rat 
model.  The use of these novel in-vitro myocyte models would have to be validated 
against the conventional adult cells to assess response to I/R in relevant systems.  
 
We have shown 2DE methods yield some success in looking for mechanisms of 
BMMNC cardioprotection; to obtain further data more in-depth proteomic based 
methods could be employed.  A large amount of data was produced in these 2DE 
analyses, but only a fraction of the proteome was screened for alterations.  Further 
experiments could be performed to enhance our view of the proteome. For example, 
sub-fractionating myocardial samples according to subcellular location before 
performing 2DE analysis would enhance the number of proteins we can see, and will 
enrich our dataset with more insoluble proteins.  Phosphoprotein specific stains could 
also be used to look at phosphorylation modifications, as these have been shown to be 
common in the signalling pathways which we know about so far.  A shotgun 
approach, such as multidimensional protein identification technology (MudPIT), 
could also be used as this may cover areas of the proteome not seen using 2DE [202]. 
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As so many proteins were down-regulated in the I/R group and up-regulated with 
treatment, it would be of interest to perform a time-course experiment to ascertain 
how early after reperfusion protein expression is up-regulated in the treatment group, 
or to see if protein expression in this group remains at levels comparable to sham 
throughout reperfusion.  The expression of some of the proteins and genes identified 
in this work and the activation of some key signalling kinases could be measured in 
these time-course experiments.   
 
Aditionally, once more of the details of signalling pathways involved in BMMNC 
myocardial repair are understood, targeted experiments could be performed using 
cell-based models of hypoxia/ischemia (which have already shown value in the study 
of IPC) with and without BMMNC co-culture [203]. Targeting of the potentially 
involved signalling proteins with inhibitors in such a model may enable more details 
of signalling pathways to be elucidated.  Cell based models are often further from the 
human condition than are animal models, but are often cheaper and faster 
experiments to perform and findings from these models can then be taken on and 
used to perform more informed experiments in animal models and indeed humans.  
Another commonly used approach is the use of transgenic mice. Mice in which a 
certain gene of interest is under or over-expressed (in a cardiac specific manner) can 
be used to assess the physiological and molecular reactions to I/R injury (and 
BMMNC therapy) [204].  This can also enable the role of proteins of interest to be 
elucidated.  
 
For the time being there remain many basic questions about BMMNC therapy for I/R 
injury to be answered.  We have shown proteomics to be a helpful tool for answering 
these questions. Once some of the key cardioprotective pathways involved in 
BMMNC have been identified, the aspect of BMMNC treatment (whether paracrine 
signal or otherwise) which triggers these pathways may become clear.  Once the 
exact mechanism of BMMNC treatment is understood, this information may enable a 
pharmacological target to be identified which could be inhibited or activated in 
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conjunction with fast reperfusion to limit reperfusion injury and thereby rescue more 
of the myocardium.  These types of studies may translate into improvements in 
morbidity and mortality rates resulting from MI in the future. 
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APPENDIX 2: MASCOT search results from wide-range 2DE analysis   SSP are spot identification numbers assigned by 
PDQuest.  Next to the protein name are total scores assigned by mascot, the number of peptides matched in MASCOT, the species, 
the theoretical mass (Mr) and pI of the full length protein, the % coverage of the peptides matched.  Only peptides with ion scores 
over 35 are shown in the matched peptides column, and the corresponding ion score for these are also shown.  The shaded rows 
indicate the final MASCOT score, number of matched peptides and the coverage as calculated from the peptides with scores over 
35. 
 
Mr Pl
1206 MLRV_RAT Myosin regulatory light chain 2, ventricular/cardiac muscle isoform 142 8 Rat 18868 4.86 45% K.GADPEETILNAFK.V  57
1206 MLRV_RAT Myosin regulatory light chain 2 57 1 Rat 18868 4.86 8%
1207 NNTM_MOUSE NAD(P) transhydrogenase, mitochondrial precursor 58 1 Mouse 113780 8.4 2% R.SLGVGYAAVDNPIFYKPNTAMLLGDAK.K (M) 58
1207 NNTM_MOUSE NAD(P) transhydrogenase 58 1 Mouse 113780 8.4 2%
1213 MLRV_RAT Myosin regulatory light chain 2, ventricular/cardiac muscle isoform 211 7 Rat 18868 4.86 43% K.GADPEETILNAFK.V  70
K.NLVHIITHGEEKD.-  38
1213 MLRV_RAT Myosin regulatory light chain 2, 108 2 Rat 18868 4.86 16%
1223 Cationic trypsin precursor peptides only
1223 NO RESULT
1224 Cationic trypsin precursor peptides only
1224 NO RESULT
1225 ATPB_RAT ATP synthase subunit beta, mt precursor 203 6 Rat 56318 5.19 10% R.AIAELGIYPAVDPLDSTSR.I  87
R.IMDPNIVGSEHYDVAR.G (M) 108
1225 ATPB_RAT ATP synthase subunit beta 192 2 Rat 56318 5.19 7%
1226 ATPB_RAT ATP synthase subunit beta, mt precursor 50 1 Rat 56318 5.19 3% R.AIAELGIYPAVDPLDSTSR.I 50
CCS_RAT Copper chaperone for superoxide dismutase 33 1 Rat 28871 5.79 4% R.QAVLKGMGSSQLK.N (M) 33
1226 ATPB_RAT ATP synthase subunit beta, mt precursor 55 1 Rat 56318 5.19 3% R.IMDPNIVGSEHYDVAR.G  55
1226 ATPB_RAT ATP synthase subunit beta 105 2 Rat 56318 5.19 6%
1248 TNNT2_RAT Troponin T, cardiac muscle 64 2 Rat 35709 4.95 8% R.LFMPNLVPPK.I  (M) 59
1248 TNNT2_RAT Troponin T, cardiac muscle 59 1 Rat 35709 4.95 3%
1301 CASA1_BOVIN Alpha-S1-casein precursor 149 7 Bovine 24513 4.98 15% R.FFVAPFPEVFGK.E  38
R.YLGYLEQLLR.L  78
1301 CASA1_BOVIN Alpha-S1-casein 116 2 Bovine
1304 TPM1_RAT Tropomyosin alpha-1 chain 159 5 Rat 32661 4.69 13% K.ATDAEADVASLNR.R  74
K.HIAEDADR.K  44
TBB2C_RAT Tubulin beta-2C chain 110 3 Rat 49769 4.79 6% R.INVYYNEATGGK.Y  59
R.AVLVDLEPGTMDSVR.S (M) 51
1304 TPM1_RAT Tropomyosin alpha-1 chain 118 2 Rat 32661 4.69 7%
1304 TBB2C_RAT Tubulin beta-2C chain 110 2 Rat 49769 4.79 6%
1307 ATPB_RAT ATP synthase subunit beta, mt precursor 233 1 Rat 56318 5.19 5% R.VALTGLTVAEYFRDQEGQDVLLFIDNIFR.F 233
TNNT2_RAT  Troponin T, cardiac muscle 80 2 Rat 35709 4.95 8% R.DAEDGPVEDSKPKPSR.L 54
1307 ATPB_RAT ATP synthase subunit beta 233 1 Rat 56318 5.19 5%
1307 TNNT2_RAT  Troponin T, cardiac muscle 54 1 Rat 35709 4.95 5%
1320 TPM1_RAT Tropomyosin alpha-1 chain 58 1 Rat 32661 4.69 4% K.ATDAEADVASLNR.R  58
TPM2_RAT Tropomyosin beta chain 58 1 Rat 32817 4.66 4% K.ATDAEADVASLNR.R  58
TBB2C_RAT Tubulin beta-2C chain 33 1 Rat 49769 4.79 2% R.INVYYNEATGGK.Y 33
1320 Tropomyosin (general) 58 1 Rat 32661 4.69 4%
coverage Matched peptides MASCOT ion Score
MASCOT 
Score
Queries 
matched Species
TheoreticalSSP Protein Name
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1424 ATPB_RAT ATP synthase subunit beta, mitochondrial precursor 131 2 Rat 56318 5.19 8% R.AIAELGIYPAVDPLDSTSR.I  79
K.SLQDIIAILGMDELSEEDKLTVSR.A  (M) 52
1424 ATPB_RAT ATP synthase subunit beta 131 2 Rat 56318 5.19 8%
1429 Cationic trypsin precursor peptides only
1429 NO RESULT
1430 1433E_RAT 14-3-3 protein epsilon 75 2 Rat 29155 4.63 8% K.VAGMDVELTVEER.N  (M) 67
1430 1433E_RAT 14-3-3 protein epsilon 123 5 Rat 29155 4.63 22% R.QMVETELK.L  (M) 44
K.AAFDDAIAELDTLSEESYKDSTLIMQLLR.D  (M) 53
1430 1433E_RAT 14-3-3 protein epsilon 164 3 Rat 29155 4.63 20%
1705 Cationic trypsin precursor peptides only
1705 NO RESULT
2119 QCR6_RAT Cytochrome b-c1 complex subunit 6, mitochondrial precursor 146 3 Rat 10417 4.9 28% R.SQTEEDCTEELFDFLHAR.D  (C) 131
2119 QCR6_RAT Cytochrome b-c1 complex subunit 6 131 1 Rat 10417 4.9 20%
2226 1433T_RAT 14-3-3 protein theta 47 1 Rat 27761 4.69 9% R.SICTTVLELLDKYLIANATNPESK.V  (C) 47
HSP7C_RAT Heat shock cognate 71 kDa protein 60 2 Rat 70827 5.37 2% R.LSKEDIER.M  38
2226 1433T_RAT 14-3-3 protein theta 47 1 Rat 27761 4.69 9%
2226 HSP7C_RAT Heat shock cognate 71 kDa protein 60 1 Rat 70827 5.37 1%
2443 ATPB_RAT ATP synthase subunit beta, mitochondrial precursor 121 2 56318 5.19 6% R.AIAELGIYPAVDPLDSTSR.I  91
2443 ATPB_RAT ATP synthase subunit beta 91 1 Rat 56318 5.19 3%
2546 CAP1_RAT Adenylyl cyclase-associated protein 1 88 2 Rat 51556 7.16 8% K.LSDLLAPISEQIQEVITFR.E 55
2546 CAP1_RAT Adenylyl cyclase-associated protein 1 55 1 Rat 51556 7.16 4%
2607 Cationic trypsin precursor peptides only
2607 NO RESULT
2609 ATPB_RAT ATP synthase subunit beta, mitochondrial precursor 456 9 Rat 56318 5.19 12% R.TIAMDGTEGLVR.G  (M) 65
R.IMNVIGEPIDER.G  (M) 54
K.TVLIMELINNVAK.A  (M) 56
R.VALTGLTVAEYFR.D  60
R.VALTGLTVAEYFRDQEGQDVLLFIDNIFR.F  136
R.DQEGQDVLLFIDNIFR.F  86
2609 ATPB_RAT ATP synthase subunit beta 457 6 Rat 56318 5.19 12%
2616 RSSA_RAT 40S ribosomal protein SA 50 1 Rat 32803 4.8 4% K.FAAATGATPIAGR.F  50
2616 RSSA_RAT 40S ribosomal protein SA 50 1 Rat 32803 4.8 4%
2624 Cationic trypsin precursor peptides only
2624 NO RESULT
2626 ATPB_RAT ATP synthase subunit beta, mitochondrial precursor 197 4 Rat 56318 5.19 13% R.TIAMDGTEGLVR.G  (M) 45
R.IMNVIGEPIDER.G  (M) 50
R.AIAELGIYPAVDPLDSTSR.I 72
2626 ATPB_RAT ATP synthase subunit beta 167 3 Rat 56318 5.19 8%
2701 SPA3K_RAT Serine protease inhibitor A3K precursor 573 9 Rat 46532 5.31 25% K.IAELFSELDER.T  47
R.TSMVLVNYLLFK.G  (M) 60
K.FSISTDYNLEEVLPELGIR.K  135
R.KIFSQQADLSR.I  45
K.IFSQQADLSR.I  59
K.AVLDVDETGTEGAAATAVTAALK.S  168
SPA3L_RAT Serine protease inhibitor A3L precursor 134 4 Rat 46248 5.48 15% K.IAELFSDLEER.T  54
R.TSMVLVNYLLFK.G  (M) 60
FETUA_RAT Alpha-2-HS-glycoprotein precursor 54 1 Rat 37958 6.05 3% R.LGGEEVSVACK.L  (C) 54
2701 SPA3K_RAT Serine protease inhibitor A3K 514 6 Rat 46532 5.31 18%
2701 FETUA_RAT Alpha-2-HS-glycoprotein 54 1 Rat 37958 6.05 3%
Protein Name coverage Matched peptides MASCOT ion Score
MASCOT 
Score
Queries 
matched Species
TheoreticalSSP
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2712 ATPB_RAT ATP synthase subunit beta, mitochondrial precursor 733 14 Rat 56318 5.19 30% R.TIAMDGTEGLVR.G  (M) 55
R.IMNVIGEPIDER.G  (M) 59
K.TVLIMELINNVAK.A  (M) 68
R.VALTGLTVAEYFR.D  100
R.VALTGLTVAEYFRDQEGQDVLLFIDNIFR.F  158
R.DQEGQDVLLFIDNIFR.F  102
R.AIAELGIYPAVDPLDSTSR.I  75
K.SLQDIIAILGMDELSEEDKLTVSR.A  (M) 90
2712 ATPB_RAT ATP synthase subunit beta 707 8 Rat 56318 5.19 26%
2722 Cationic trypsin precursor peptides only
2722 NO RESULT
3208 ATPB_RAT ATP synthase subunit beta, mitochondrial precursor 55 2 Rat 56318 5.19 5% K.VLDSGAPIKIPVGPETLGR.I  51
3208 ATPB_RAT ATP synthase subunit beta 51 1 Rat 56318 5.19 4%
3209 ATPB_RAT ATP synthase subunit beta, mitochondrial precursor 176 5 Rat 56318 5.19 13% R.TIAMDGTEGLVR.G  (M) 77
R.IMNVIGEPIDER.G  (M) 67
3209 ATPB_RAT ATP synthase subunit beta 144 2 Rat 56318 5.19 5%
3228 MLRV_RAT Myosin regulatory light chain 2, ventricular/cardiac muscle isoform 163 4 Rat 18868 4.86 32% K.EAFTIMDQNR.D (M) 34
R.DGFIDKNDLR.D  65
R.VNVKNEEIDEMIK.E (M) 36
3228 MLRV_RAT Myosin regulatory light chain 2 135 3 Rat 18868 4.86 20%
3305 MYL3_RAT Myosin light chain 3 334 7 Rat 22142 5.03 33% R.ALGQNPTQAEVLR.V  88
K.MMDFETFLPMLQHISK.N  3 (M) 72
K.DTGTYEDFVEGLR.V  57
R.VFDKEGNGTVMGAELR.H  (M) 42
R.HVLATLGER.L  75
3305 MYL3_RAT Myosin light chain 3 334 5 Rat 22142 5.03 33%
3322 Cationic trypsin precursor peptides only
3322 NO RESULT
3433 ATPB_RAT ATP synthase subunit beta, mitochondrial precursor 478 9 Rat 56318 5.19 28% R.LVLEVAQHLGESTVR.T  72
R.TIAMDGTEGLVR.G  (M) 79
R.IMNVIGEPIDER.G  (M) 63
R.IMNVIGEPIDERGPIK.T  (M) 46
K.TVLIMELINNVAK.A  (M) 50
R.VALTGLTVAEYFRDQEGQDVLLFIDNIFR.F  126
3433 ATPB_RAT ATP synthase subunit beta 436 6 Rat 56318 5.19 18%
3441 ALBU_RAT Serum albumin precursor 46 1 Rat 68686 6.09 2% K.DVFLGTFLYEYSR.R  46
3441 ALBU_RAT Serum albumin 46 1 Rat 68686 6.09 2%
3518 GRP75_RAT Stress-70 protein, mitochondrial precursor 149 7 Rat 73812 5.97 8% R.QAASSLQQASLK.L  85
3518 GRP75_RAT Stress-70 protein 85 1 Rat 73812 5.97 2%
3523 ATPB_RAT ATP synthase subunit beta, mitochondrial precursor 281 4 Rat 56318 5.19 14% K.VALVYGQMNEPPGAR.A (M) 82
R.VALTGLTVAEYFRDQEGQDVLLFIDNIFR.F 36
R.AIAELGIYPAVDPLDSTSR.I 56
R.IMDPNIVGSEHYDVAR.G (M) 107
3523 ATPB_RAT ATP synthase subunit beta 280 4 Rat 56318 5.19 14%
SSP Protein Name MASCOT Score
Queries 
matched Species
Theoretical coverage Matched peptides MASCOT ion Score
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3526 K2C5_RAT Keratin, type II cytoskeletal 5 127 5 Rat 61788 7.6 5% R.SLDLDSIIAEVK.A  76
HSP7C_RAT Heat shock cognate 71 kDa protein 114 3 Rat 70827 5.37 5% R.TLSSSTQASIEIDSLYEGIDFYTSITR.A  85
H4_RAT Histone H4 [Contains: Osteogenic growth peptide 59 1 Rat 11360 11.36 9% R.ISGLIYEETR.G  59
3526 HSP7C_RAT Heat shock cognate 71 kDa protein 85 1 Rat 70827 5.37 2%
3526 K2C5_RAT Keratin, type II cytoskeletal 5 76 1 Rat 61788 7.6 4%
3526 H4_RAT Histone H4 [Contains: Osteogenic growth peptide 59 1 Rat 11360 11.36 9%
3622 ATPB_RAT ATP synthase subunit beta, mitochondrial precursor 824 16 Rat 56318 5.19 37% R.TIAMDGTEGLVR.G  (M) 57
R.IMNVIGEPIDER.G  (M) 67
K.QFAPIHAEAPEFIEMSVEQEILVTGIK.V  (M) 79
K.TVLIMELINNVAK.A  (M) 73
R.VALTGLTVAEYFR.D 115
R.VALTGLTVAEYFRDQEGQDVLLFIDNIFR.F  156
R.DQEGQDVLLFIDNIFR.F  101
R.FTQAGSEVSALLGR.I  87
R.AIAELGIYPAVDPLDSTSR.I  79
K.SLQDIIAILGMDELSEEDKLTVSR.A  (M) 122
R.FLSQPFQVAEVFTGHMGK.L 82
DESM_RAT Desmin 43 2 Rat 53424 5.21 4% R.TSGGAGGLGSLR.A  43
3622 ATPB_RAT ATP synthase subunit beta 1018 11 Rat 56318 5.19 35%
3622 DESM_RAT Desmin 43 1 Rat 53424 5.21 3%
3626 ATPB_RAT ATP synthase subunit beta, mitochondrial precursor 723 15 Rat 56318 5.19 30% R.TIAMDGTEGLVR.G  (M) 69
K.VLDSGAPIKIPVGPETLGR.I  97
R.IMNVIGEPIDER.G  (M) 70
K.TVLIMELINNVAK.A  (M) 73
R.VALTGLTVAEYFR.D  52
R.VALTGLTVAEYFRDQEGQDVLLFIDNIFR.F  97
R.FTQAGSEVSALLGR.I  84
R.AIAELGIYPAVDPLDSTSR.I  80
K.SLQDIIAILGMDELSEEDKLTVSR.A  (M) 89
3626 ATPB_RAT ATP synthase subunit beta 711 9 Rat 56318 5.19 29%
3627 DESM_RAT Desmin 486 10 Rat 53424 5.21 23% R.TSGGAGGLGSLR.A  63
R.APSYGAGELLDFSLADAVNQEFLATR.T  80
R.FLEQQNAALAAEVNR.L  118
R.VAELYEEEMR.E (M) 49
R.QVEVLTNQR.A  50
R.ADVDAATLAR.I  54
R.INLPIQTFSALNFR.E  49
3627 DESM_RAT Desmin 463 7 Rat 53424 5.21 20%
3629 ATPB_RAT ATP synthase subunit beta 193 7 Rat 56318 5.19 15% K.VALVYGQMNEPPGAR.A  62
R.IMDPNIVGSEHYDVAR.G  71
ACTA_RAT Actin, aortic smooth muscle 82 3 Rat 41982 5.23 10% K.AGFAGDDAPR.A  47
3629 ATPB_RAT ATP synthase subunit beta 125 4 Rat 56318 5.19 10% K.VVDLLAPYAK.G  44
R.AIAELGIYPAVDPLDSTSR.I 60
3629 ATPB_RAT ATP synthase subunit beta 237 4 Rat 56318 5.19 11%
3629 ACTA_RAT Actin, aortic smooth muscle 47 1 Rat 41982 5.23 3%
SSP Protein Name MASCOT Score
Queries 
matched Species
Theoretical coverage Matched peptides MASCOT ion Score
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3632 ATPB_RAT ATP synthase subunit beta, mitochondrial precursor 239 4 (4) Rat 56318 5.19 11% R.IMNVIGEPIDER.G  (M) 42
K.VALVYGQMNEPPGAR.A (M) 36
R.AIAELGIYPAVDPLDSTSR.I 60
R.IMDPNIVGSEHYDVAR.G (M) 101
ATPB_RAT ATP synthase subunit beta, mitochondrial precursor 114 4 (1) Rat 56318 5.19 13% K.SLQDIIAILGMDELSEEDKLTVSR.A (M) 75
3632 ATPB_RAT ATP synthase subunit beta 314 5 Rat 56318 5.19 16%
3636 ATPB_RAT ATP synthase subunit beta, mitochondrial precursor 202 11 Rat 56318 5.19 27% R.IMNVIGEPIDER.G  39
R.IMDPNIVGSEHYDVAR.G 56
R.FLSQPFQVAEVFTGHMGK.L  39
3636 ATPB_RAT ATP synthase subunit beta, mitochondrial precursor 196 8 Rat 56318 5.19 17% K.VLDSGAPIKIPVGPETLGR.I  37
R.FTQAGSEVSALLGR.I  55
3636 ATPB_RAT ATP synthase subunit beta 226 5 Rat 56318 5.19 15%
3638 Cationic trypsin precursor peptides only
3638 NO RESULT
3706 ATPB_RAT ATP synthase subunit beta, mitochondrial precursor 246 4 Rat 56318 5.19 10% R.TIAMDGTEGLVR.G (M) 71
K.VALVYGQMNEPPGAR.A (M) 76
R.AIAELGIYPAVDPLDSTSR.I  68
3706 ATPB_RAT ATP synthase subunit beta 215 3 Rat 56318 5.19 9%
4207 MYH6_RAT Myosin-6 278 9 Rat 223488 5.54 3% R.VVDSLQTSLDAETR.S  73
R.SRNEALR.V  35
R.NTLLQAELEELR.A  54
R.NTLLQAELEELRAVVEQTER.S  117
MYH3_RAT Myosin-3 35 2 Rat 223720 5.64 0% R.SRNEAIR.L  35
4207 MYH6_RAT Myosin-6 279 4 Rat 223370 5.59 3%
4217 ACTC_RAT Actin, alpha cardiac muscle 1 219 3 Rat 41992 5.23 10% K.SYELPDGQVITIGNER.F  114
K.EITALAPSTMK.I  (M) 36
K.QEYDEAGPSIVHR.K  68
Actin, alpha skeletal muscle 219 3 Rat 42024 5.23 10% K.SYELPDGQVITIGNER.F  114
K.EITALAPSTMK.I  (M) 36
K.QEYDEAGPSIVHR.K  68
Actin, aortic smooth muscle 217 3 Rat 41982 5.23 10% K.SYELPDGQVITIGNER.F  114
K.EITALAPSTMK.I  (M) 36
K.QEYDEAGPSIVHR.K  68
4217 ACTC_RAT Actin, alpha cardiac muscle 1 (or Actin, alpha skeletal muscle) 218 3 Rat ~42000 5.23 10%
4235 ATPB_RAT ATP synthase subunit beta, mitochondrial precursor 111 3 Rat 56318 5.19 4% R.TIAMDGTEGLVR.G  (M) 69
R.IMNVIGEPIDER.G  (M) 41
4235 ATPB_RAT ATP synthase subunit beta 110 2 Rat 56318 5.19 4%
4244 ATPB_RAT ATP synthase subunit beta, mitochondrial precursor 86 1 Rat 56318 5.19 3% R.AIAELGIYPAVDPLDSTSR.I  86
MYL3_RAT Myosin light chain 3 35 1 Rat 22142 5.03 6% R.ALGQNPTQAEVLR.V  35
4244 ATPB_RAT ATP synthase subunit beta 86 1 Rat 56318 5.19 3%
4244 MYL3_RAT Myosin light chain 3 35 1 Rat 22142 5.03 6%
4329 ATPB_RAT ATP synthase subunit beta, mitochondrial precursor 69 1 Rat 56318 5.19 2% R.TIAMDGTEGLVR.G (M) 69
4329 ATPB_RAT ATP synthase subunit beta 69 1 Rat 56318 5.19 2%
SSP Protein Name MASCOT Score
Queries 
matched Species
Theoretical coverage Matched peptides MASCOT ion Score
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4406 ATPB_RAT ATP synthase subunit beta, mitochondrial precursor 348 8 Rat 56318 5.19 16% R.VALTGLTVAEYFRDQEGQDVLLFIDNIFR.F  173
R.AIAELGIYPAVDPLDSTSR.I  69
K.SLQDIIAILGMDELSEEDKLTVSR.A  (M) 44
ACTC_RAT Actin, alpha cardiac muscle 1 120 1 Rat 41992 5.23 7% K.SYELPDGQVITIGNER.F  107
(or ACTA, ACTB, ACTG, ACTH and ACTS)
4406 ATP synthase subunit beta 286 3 Rat 56318 5.19 15%
4406 Actin, alpha cardiac muscle 1 107 1 Rat 41992 5.23 4%
4418 Cationic trypsin precursor peptides only
4418 NO RESULT
4511 Cationic trypsin precursor peptides only
4511 NO RESULT
4513 Cationic trypsin precursor peptides only
4513 NO RESULT
4521 LDHA_RAT L-lactate dehydrogenase A chain 72 1 Rat 36427 8.45 3% R.VIGSGCNLDSAR.F (C) 72
LDHB_RAT L-lactate dehydrogenase B chain 72 1 Rat 36589 5.7 3% R.VIGSGCNLDSAR.F (C) 72
4521 LDHA_RAT L-lactate dehydrogenase (or LDHB) 72 1 Rat 36427 8.45 3%
4522 Cationic trypsin precursor peptides only
4522 NO RESULT
4523 TBA4A_RAT Tubulin alpha-4A chain 225 4 Rat 49892 4.95 14% R.AVFVDLEPTVIDEIR.N  83
R.NLDIERPTYTNLNR.L  51
R.FDGALNVDLTEFQTNLVPYPR.I  57
4523 TBA4A_RAT Tubulin alpha-4A chain 191 3 Rat 49892 4.95 11%
4525 Cationic trypsin precursor peptides only
4525 NO RESULT
4702 GRP75_RAT Stress-70 protein, mitochondrial 440 23 Rat 73812 5.97 27% K.NAVITVPAYFNDSQR.Q  69
K.DAGQISGLNVLR.V  79
R.VINEPTAAALAYGLDK.S  78
K.SQVFSTAADGQTQVEIK.V  58
K.LLGQFTLIGIPPAPR.G  52
R.VEAVNMAEGIIHDTETK.M  110
4702 GRP75_RAT Stress-70 protein, mitochondrial 383 14 Rat 73812 5.97 19% R.AQFEGIVTDLIKR.T  77
K.SDIGEVILVGGMTR.M  73
K.VQQTVQDLFGR.A  60
R.QAASSLQQASLK.L  83
4702 GRP75_RAT Stress-70 protein 739 10 Rat 73812 5.97 21%
4703 Cationic trypsin precursor peptides only
4703 NO RESULT
4722 Cationic trypsin precursor peptides only
4722 NO RESULT
4734 Cationic trypsin precursor peptides only
4734 NO RESULT
4740 Cationic trypsin precursor peptides only
4740 NO RESULT
SSP Protein Name MASCOT Score
Queries 
matched Species
Theoretical coverage Matched peptides MASCOT ion Score
 
 
 
 
 
Page 318 
  
APPENDIX 2: continued 
 
Mr Pl
4741 DESM_RAT Desmin 252 8 Rat 53424 5.21 25% R.TSGGAGGLGSLR.A 54
R.QVEVLTNQR.A 50
ALBU_RAT Serum albumin precursor 205 4 Rat 68686 6.09 8% K.DVFLGTFLYEYSR.R  57
R.LPCVEDYLSAILNR.L (C) 102
4741 DESM_RAT Desmin 281 9 Rat 53424 5.21 24% R.APSYGAGELLDFSLADAVNQEFLATR.T  93
R.FLEQQNAALAAEVNR.L 107
R.DGEVVSEATQQQHEVL.- 35
4741 DESM_RAT Desmin 339 5 Rat 53424 5.21 17%
4741 ALBU_RAT Serum albumin 159 2 Rat 68686 6.09 4%
5311 PRDX3_RAT Thioredoxin-dependent peroxide reductase, mitochondrial precursor 89 2 Rat 28277 7.14 16% R.GLFIIDPNGVIK.H  37
K.AFQFVETHGEVCPANWTPESPTIKPSPTASK.E  
(C) 52
5311 PRDX3_RAT Thioredoxin-dependent peroxide reductase 89 2 Rat 28277 7.14 16%
5315 Cationic trypsin precursor peptides only
5315 NO RESULT
5408 PRDX6_RAT Peroxiredoxin-6 430 11 Rat 24803 5.64 51% M.PGGLLLGDEAPNFEANTTIGHIR.F  64
R.DFTPVCTTELGR.A  (C) 40
K.LIALSIDSVEDHFAWSK.D  73
R.VVFIFGPDK.K  36
K.LSILYPATTGR.N  52
R.VVDSLQLTASNPVATPVDWK.K  86
5408 PRDX6_RAT Peroxiredoxin-6 202 10 Rat 24803 5.64 34% R.NFDEILR.V  37
5408 PRDX6_RAT Peroxiredoxin-6 388 7 Rat 24803 5.64 44%
5422 Cationic trypsin precursor peptides only
5422 NO RESULT
5501 Cationic trypsin precursor peptides only
5501 NO RESULT
5601 Cationic trypsin precursor peptides only
5601 NO RESULT
5618 Cationic trypsin precursor peptides only
5618 NO RESULT
5715 ALBU_RAT Serum Albumin precursor 472 7 Rat 68648 5.75 14% K.GLVLIAFSQYLQK.C  76
K.LVQEVTDFAK.T  56
K.DVFLGTFLYEYSR.R  80
K.APQVSTPTLVEAAR.N  70
R.LPCVEDYLSAILNR.L  (C) 97
5715 ALBU_RAT Serum Albumin 379 5 Rat 68686 6.09 11%
5805 Cationic trypsin precursor peptides only
5805 NO RESULT
6123 UBE2N_RAT Ubiquitin-conjugating enzyme E2 N 216 6 (3) Rat 17113 6.13 19% R.LLAEPVPGIK.A  47
R.LLAEPVPGIKAEPDESNAR.Y  105
K.SNEAQAIETAR.A  64
KAP0_RAT cAMP-dependent protein kinase type I-alpha regulatory subunit 44 1 Rat 43068 5.27 4% R.LGPSDYFGEIALLMNRPR.A  (M) 44
6123 UBE2N_RAT Ubiquitin-conjugating enzyme E2 N 216 3 Rat 17113 6.13 19%
6123 KAP0_RAT cAMP-dependent protein kinase type I-alpha regulatory subunit 44 1 Rat 43068 5.27 4%
SSP Protein Name MASCOT Score
Queries 
matched Species
Theoretical coverage Matched peptides MASCOT ion Score
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6413 Cationic trypsin precursor peptides only
6413 NO RESULT
6424 LDHB_RAT L-lactate dehydrogenase B chain 127 4 Rat 36589 5.7 9% R.VIGSGCNLDSAR.F (C) 85
6424 LDHB_RAT L-lactate dehydrogenase B chain 85 1 Rat 36589 5.7 4%
6425 LDHB_RAT L-lactate dehydrogenase B chain 105 4 Rat 36589 5.7 10% R.VIGSGCNLDSAR.F (C ) 77
6425 LDHB_RAT L-lactate dehydrogenase B chain 77 1 Rat 36589 5.7 6%
6533 MYOZ2_MOUSE Myozenin-2 44 1 29743 8.53 4% R.FLAFANPLSGR.R  44
6533 NO RESULT
6538 Cationic trypsin precursor peptides only
6538 NO RESULT
6545 Cationic trypsin precursor peptides only
6545 NO RESULT
6603 ALBU_RAT Serum albumin precursor 134 3 Rat 68686 6.09 6% K.APQVSTPTLVEAAR.N  43
R.LPCVEDYLSAILNR.L (C) 61
HBB1_RAT Hemoglobin subunit beta-1 108 3 Rat 15969 7.88 15% K.VNPDDVGGEALGR.L  55
R.LLVVYPWTQR.Y  52
MYG_RAT Myoglobin 63 2 Rat 17146 7.83 9% K.HGCTVLTALGTILKK.K (C) 49
6603 ALBU_RAT Serum albumin 104 2 Rat 68686 6.09 5%
6603 HBB1_RAT Hemoglobin subunit beta-1 107 2 Rat 15969 7.88 15%
6603 MYG_RAT Myoglobin 49 1 Rat 17146 7.83 9%
6616 Cationic trypsin precursor peptides only
6616 NO RESULT
6636 HSP7C_RAT Heat shock cognate 71 kDa protein 46 1 Rat 70827 5.37 2% K.STAGDTHLGGEDFDNR.M  46
HSP72_RAT Heat shock-related 70 kDa protein 2 46 1 Rat 69599 5.51 2% K.STAGDTHLGGEDFDNR.M  46
6636 HSP7C_RAT Heat shock cognate 71Da OR HSP72 46 1 Rat 70827 5.37 2%
6732 Cationic trypsin precursor peptides only
6732 NO RESULT
6746 Cationic trypsin precursor peptides only
6746 NO RESULT
6813 EZRI_RAT Ezrin 152 8 Rat 69348 5.83 11% K.APDFVFYAPR.L  44
K.ALQLEEER.R  40
ENOA_RAT Alpha-enolase 35 1 Rat 47098 6.16 4% R.AAVPSGASTGIYEALELR.D  35
6813 EZRI_RAT Ezrin 84 2 Rat 69348 5.83 3%
6813 ENOA_RAT Alpha-enolase 35 1 Rat 47098 6.16 4%
7110 LEG5_RAT Galectin-5 158 6 Rat 16186 6.17 21% R.FDENAVVR.N  52
R.NTQINNSWGPEER.S  47
R.SLPGSMPFSR.G (M) 58
7110 LEG5_RAT Galectin-5 157 3 Rat 16186 6.17 21%
7111 Cationic trypsin precursor peptides only
7111 NO RESULT
7112 NDUS1_RAT NADH-ubiquinone oxidoreductase 75 kDa subunit, mt precursor 124 3 Rat 79362 5.65 3% K.VGMQIPR.F (M) 54
K.VVAACAMPVMK.G  (C); 2 (M) 48
7112 NDUS1_RAT NADH-ubiquinone oxidoreductase 75 kDa subunit 102 2 Rat 79362 5.65 2%
7228 CRYAB_RAT Alpha-crystallin B chain 129 7 Rat 20076 6.76 61% R.QDEHGFISR.E  43
7228 NO RESULT
SSP Protein Name MASCOT Score
Queries 
matched Species
Theoretical coverage Matched peptides MASCOT ion Score
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7306 ATPA_RAT ATP synthase subunit alpha, mitochondrial precursor 96 2 Rat 59717 9.22 6% K.QVAGTMKLELAQYR.E (M) 35
R.EVAAFAQFGSDLDAATQQLLSR.G 60
NSA2_RAT Ribosome biogenesis protein NSA2 homolog 36 1 Rat 30019 10.25 2% R.KPPKYEK.F  36
ATPA_RAT ATP synthase subunit alpha, mitochondrial precursor 116 3 Rat 59717 9.22 6% R.EVAAFAQFGSDLDAATQQLLSR.G 94
K.LKEIVTNFLAGFEP.- 72
K2C5_RAT Keratin, type II cytoskeletal  (varoius) 62 1 Rat 61788 7.6 2% R.SLDLDSIIAEVK.A  62
7306 ATPA_RAT ATP synthase subunit alpha 201 3 Rat 59717 9.22 9%
7306 K2C5_RAT Keratin, type II cytoskeletal  (varoius) 62 1 Rat 61788 7.6 2%
7306 NSA2_RAT Ribosome biogenesis protein NSA2 homolog 36 1 Rat 30019 10.25 2%
7323 ECHM_RAT Enoyl-CoA hydratase, mitochondrial precursor 71 1 Rat 31496 8.39 3% R.EGMSAFVEKR.K  (M) 73
7323 ECHM_RAT Enoyl-CoA hydratase 71 1 Rat 31496 8.39 3%
7327 Cationic trypsin precursor peptides only
7327 NO RESULT
7508 Cationic trypsin precursor peptides only
7508 NO RESULT
7515 Cationic trypsin precursor peptides only
7515 NO RESULT
7608 ALBU_RAT Serum albumin 256 8 Rat 68686 6.09 14% K.DVFLGTFLYEYSR.R 59
R.RHPDYSVSLLLR.L 45
K.TNCELYEK.L (C) 39
K.QTALAELVK.H 50
7608 ALBU_RAT Serum albumin 99 4 Rat 68686 6.09 8% K.APQVSTPTLVEAAR.N  60
7608 ALBU_RAT Serum albumin 349 5 Rat 68686 6.09 21%
7612 ALDH2_RAT Aldehyde dehydrogenase, mitochondrial precursor 96 6 Rat 56453 6.63 12% R.VVGNPFDSR.T  44
7612 NO RESULT
7702 HSDL2_RAT Hydroxysteroid dehydrogenase-like protein 2 73 2 Rat 58307 5.85 4% R.VDLMMSVNTR.G 2 (M) 40
R.IVKDSLSDEVVR.A  35
7702 HSDL2_RAT Hydroxysteroid dehydrogenase-like protein 2 75 2 Rat 58307 5.85 4%
7722 ODP2_RAT Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial precursor 239 7 Rat 67123 8.76 9% K.ILVPEGTR.D  41
K.AAPAAAAAAPPGPR.V 47
R.VAPTPAGVFIDIPISNIR.R 89
K.GLETIASDVVSLASK.A  51
7722 ODP2_RAT Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex 228 4 Rat 67123 8.76 9%
7723 DHSA_RAT Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial 73 1 Rat 71570 6.75 2% R.LGANSLLDLVVFGR.A  73
7723 DHSA_RAT Succinate dehydrogenase [ubiquinone] flavoprotein subunit 73 1 Rat 71570 6.75 2%
7730 Cationic trypsin precursor peptides only
7730 NO RESULT
7737 Cationic trypsin precursor peptides only
7737 NO RESULT
8128 Cationic trypsin precursor peptides only
8128 NO RESULT
8520 Cationic trypsin precursor peptides only
8520 NO RESULT
8525 Cationic trypsin precursor peptides only
8525 NO RESULT
SSP Protein Name Matched peptides MASCOT ion Score
MASCOT 
Score
Queries 
matched Species
Theoretical coverage
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8526 Cationic trypsin precursor peptides only
8526 NO RESULT
8710 WDR1_RAT WD repeat-containing protein 1 199 13 Rat 66140 6.15 24% R.NIDNPAVADIYTEHAHQVVVAK.Y  41
R.IAVVGEGR.E  36
R.LATGSDDNCAAFFEGPPFK.F  (C) 35
8710 WDR1_RAT WD repeat-containing protein 1 130 9 Rat 66140 6.15 19% K.YAPSGFYIASGDISGK.L  45
8710 WDR1_RAT WD repeat-containing protein 1 157 4 Rat 66140 6.15 11%
8853 MCCA_RAT Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial 215 6 Rat 79279 6.66 10% K.QEGIIFIGPPSTAIR.D  47
K.IPLSQEEIPLQGHAFEAR.I  81
R.TNVDFLLR.L  38
8853 MCCA_RAT Methylcrotonoyl-CoA carboxylase subunit alpha 166 3 Rat 79279 6.66 6%
SSP Protein Name coverage Matched peptides MASCOT ion Score
MASCOT 
Score
Queries 
matched Species
Theoretical
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APPENDIX 3: MASCOT search results from pH 4.5-5.5 2DE analysis  Spot numbers were assigned by Progenesis.  Next to the 
protein name are total scores assigned by mascot, the number of peptides matched in MASCOT, the species, the theoretical mass 
(Mr) and pI of the full length protein, the % coverage of the peptides matched.  Only peptides with ion scores over 35 are shown in 
the matched peptides column, and the corresponding ion score for these are also shown.  The shaded rows indicate the final 
MASCOT score, number of matched peptides and the coverage as calculated from the peptides with scores over 35. 
 
Mr Pl
Human keratin and porcine trypsin peptides only
NO RESULT
ATPB_RAT ATP synthase subunit beta, mitochondrial 197 10 Rat 56318 5.19 14% R.LVLEVAQHLGESTVR.T  71
R.IMNVIGEPIDER.G  52
K.VVDLLAPYAK.G  43
ATPB_RAT ATP synthase subunit beta 166 3 Rat 56318 5.19 7%
ATPB_RAT ATP synthase subunit beta, mitochondrial 422 9 Rat 56318 5.19 15% R.LVLEVAQHLGESTVR.T  87
R.TIAMDGTEGLVR.G  60
K.VLDSGAPIKIPVGPETLGR.I  78
R.IMNVIGEPIDER.G  65
R.IMNVIGEPIDER.G (M) 62
R.IMNVIGEPIDERGPIK.T  44
K.VVDLLAPYAK.G  46
DESM_RAT Desmin 199 3 Rat 53424 5.21 9% K.LQEEIQLREEAENNLAAFR.A  116
DESM_RAT Desmin 215 4 Rat 53424 5.21 10% R.FLEQQNAALAAEVNR.L  84
R.VDVERDNLIDDLQR.L  73
ATPB_RAT ATP synthase subunit beta, mitochondrial 187 9 Rat 56318 5.19 9% K.IPVGPETLGR.I  35
ATPB_RAT ATP synthase subunit beta 477 8 Rat 56318 5.19 14%
DESM_RAT Desmin 273 3 Rat 53424 5.21 10%
ACTC_RAT Actin, alpha cardiac muscle 1 402 21 Rat 41992 5.23 48% R.VAPEEHPTLLTEAPLNPK.A  69
K.SYELPDGQVITIGNER.F  100
K.QEYDEAGPSIVHR.K  60
ACTC_RAT Actin, alpha cardiac muscle 1 229 3 Rat 41992 5.23 13%
Human keratin and porcine trypsin peptides only
NO RESULT
PEBP1_RAT Phosphatidylethanolamine-binding protein 1 441 19 Rat 20788 5.48 57% R.VDYGGVTVDELGK.V  78
K.LYTLVLTDPDAPSR.K  66
K.GNDISSGTVLSEYVGSGPPK.D 115
K.YHLGAPVAGTCFQAEWDDSVPK.L (C) 77
K.LHDQLAGK.-  52
PEBP1_RAT Phosphatidylethanolamine-binding protein 1 388 5 Rat 20788 5.48 41%
Human keratin and porcine trypsin peptides only
NO RESULT
SpeciesProtein Name MASCOT Score
Queries 
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ACTC_RAT Actin, alpha cardiac muscle 1 978 44 Rat 41992 5.23 57% K.DSYVGDEAQSK.R  58
K.DSYVGDEAQSKR.G  61
K.IWHHTFYNELR.V  42
R.VAPEEHPTLLTEAPLNPK.A  102
R.TTGIVLDSGDGVTHNVPIYEGYALPHAIMR.L  53
R.TTGIVLDSGDGVTHNVPIYEGYALPHAIMR.L  94
R.DLTDYLMK.I  42
R.DLTDYLMK.I  (M) 40
R.GYSFVTTAER.E  49
K.LCYVALDFENEMATAASSSSLEK.S  (C) 57
K.SYELPDGQVITIGNER.F  94
R.KDLYANNVLSGGTTMYPGIADR.M  46
R.KDLYANNVLSGGTTMYPGIADR.M  (M) 40
K.DLYANNVLSGGTTMYPGIADR.M  103
K.DLYANNVLSGGTTMYPGIADR.M  (M) 115
K.EITALAPSTMK.I  52
K.EITALAPSTMK.I  (M) 52
K.IIAPPERK.Y  36
K.QEYDEAGPSIVHR.K  84
ACTC_RAT Actin, alpha cardiac muscle 1 1220 19 Rat 41992 5.23 48%
TPM1_RAT Tropomyosin alpha-1 chain 98 2 Rat 32661 4.69 9% R.IQLVEEELDRAQER.L  70
TPM2_RAT Tropomyosin beta chain 98 2 Rat 32817 4.66 9% R.IQLVEEELDRAQER.L  70
TPM3_RAT Tropomyosin alpha-3 chain 98 2 Rat 28989 4.75 10% R.IQLVEEELDRAQER.L  70
TPM4_RAT Tropomyosin alpha-4 chain 98 2 Rat 28492 4.66 10% R.IQLVEEELDRAQER.L  70
TPM1_RAT Tropomyosin alpha-1 chain (OR TPM2, 3 or 4) 70 1 Rat 32661 4.69 5%
DESM_RAT Desmin 828 22 Rat 53424 5.21 49% R.QVEVLTNQR.A  51
R.VDVERDNLIDDLQR.L  79
K.LQEEIQLREEAENNLAAFR.A  131
R.ADVDAATLAR.I  70
R.AQYETIAAK.N  39
R.FASEASGYQDNIARLEEEIR.H  45
K.LLEGEESR.I  56
R.DGEVVSEATQQQHEVL.-  57
ATPB_RAT ATP synthase subunit beta, mitochondrial 70 1 Rat 56318 5.19 3% R.AIAELGIYPAVDPLDSTSR.I  70
DESM_RAT Desmin 554 13 Rat 53424 5.21 31% R.APSYGAGELLDFSLADAVNQEFLATR.T 112
R.FLEQQNAALAAEVNR.L  104
R.INLPIQTFSALNFR.E  63
R.INLPIQTFSALNFRETSPEQR.G  35
DESM_RAT Desmin 842 12 Rat 53424 5.21 36%
ATPB_RAT ATP synthase subunit beta 70 1 Rat 56318 5.19 3%
Protein Name MASCOT Score
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HSPB8_RAT Heat shock protein beta-8 136 4 Rat 21579 4.92 19% R.LSSAWPGTLR.S  35
K.QQEGGIVSK.N  38
HSPB8_RAT Heat shock protein beta-8 73 2 Rat 21579 4.92 10%
CH60_RAT 60 kDa heat shock protein, mitochondrial 787 19 Rat 60917 5.91 34% K.APGFGDNR.K  49
K.VGEVIVTKDDAMLLK.G  105
K.VGEVIVTKDDAMLLK.G  (M) 80
R.IQEITEQLDITTSEYEKEK.L  113
R.VTDALNATR.A  61
R.CIPALDSLKPANEDQK.I  (C) 84
K.NAGVEGSLIVEK.I  81
CH60_RAT 60 kDa heat shock protein, mitochondrial 571 16 Rat 60917 5.91 24% K.VGLQVVAVK.A  64
K.NQLKDMAIATGGAVFGEEGLNLNLEDVQAHD
LGK.V  (M) 52
K.VGEVIVTK.D  47
K.LSDGVAVLK.V  65
R.AAVEEGIVLGGGCALLR.C  (C) 94
CH60_RAT 60 kDa heat shock protein 895 11 Rat 60917 5.91 26%
TPM1_RAT Tropomyosin alpha-1 chain 166 9 Rat 32661 4.69 12% K.QLEDELVSLQK.K  39
R.IQLVEEELDR.A  53
R.IQLVEEELDRAQER.L  40
TPM1_RAT Tropomyosin alpha-1 chain 132 3 Rat 32661 4.69 9%
ACTC_RAT Actin, alpha cardiac muscle 1 670 17 Rat 41992 5.23 45% R.TTGIVLDSGDGVTHNVPIYEGYALPHAIMR.L  125
R.TTGIVLDSGDGVTHNVPIYEGYALPHAIMR.L   149
R.GYSFVTTAER.E  41
K.SYELPDGQVITIGNER.F  87
R.KDLYANNVLSGGTTMYPGIADR.M  68
K.DLYANNVLSGGTTMYPGIADR.M  (M) 130
K.EITALAPSTMK.I 43
K.QEYDEAGPSIVHR.K  73
ACTA_RAT Actin, aortic smooth muscle 668 17 Rat 41982 5.23 45% R.TTGIVLDSGDGVTHNVPIYEGYALPHAIMR.L  125
R.TTGIVLDSGDGVTHNVPIYEGYALPHAIMR.L  149
R.GYSFVTTAER.E  41
K.SYELPDGQVITIGNER.F  87
R.KDLYANNVLSGGTTMYPGIADR.M  68
K.DLYANNVLSGGTTMYPGIADR.M  (M) 130
K.EITALAPSTMK.I  43
K.QEYDEAGPSIVHR.K  73
ACTC_RAT Actin, alpha cardiac muscle 1 510 19 Rat 41992 5.23 34% R.KDLYANNVLSGGTTMYPGIADR.M  (M) 70
K.DLYANNVLSGGTTMYPGIADR.M  123
ACTA_RAT Actin, aortic smooth muscle 510 19 Rat 41982 5.23 34% R.KDLYANNVLSGGTTMYPGIADR.M  (M) 70
K.DLYANNVLSGGTTMYPGIADR.M  123
ACTH_RAT Actin, gamma-enteric smooth muscle 510 19 Rat 41850 5.31 34% R.KDLYANNVLSGGTTMYPGIADR.M  (M) 70
K.DLYANNVLSGGTTMYPGIADR.M  123
ACTC_RAT Actin, alpha cardiac muscle 1 909 10 Rat 41992 5.23 27%
Protein Name MASCOT Score
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ATPB_RAT ATP synthase subunit beta, mitochondrial 209 5 Rat 56318 5.19 6% R.AIAELGIYPAVDPLDSTSR.I  96
R.IMDPNIVGSEHYDVAR.G  (M) 113
ATPB_RAT ATP synthase subunit beta 209 2 Rat 56318 5.19 6%
CH60_RAT 60 kDa heat shock protein, mitochondrial 324 9 Rat 60917 5.91 25% K.ISSVQSIVPALEIANAHR.K  127
K.VGEVIVTKDDAMLLK.G  41
R.VTDALNATR.A  37
R.AAVEEGIVLGGGCALLR.C  (C) 73
CH60_RAT 60 kDa heat shock protein, mitochondrial 180 10 Rat 60917 5.91 20% K.LSDGVAVLK.V  38
CH60_RAT 60 kDa heat shock protein 316 5 Rat 60917 5.91 12%
MYH6_RAT Myosin-6 153 7 Rat 223370 5.59 2% R.NTLLQAELEELRAVVEQTER.S  63
K.LAEQELIETSER.V  42
R.QAEEAEEQANTNLSK.F  50
MYH6_RAT Myosin-6 155 3 Rat 223370 5.59 2%
coverage Matched peptides MASCOT ion ScoreProtein Name
MASCOT 
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APPENDIX 4: MASCOT search results from pH 5.5-6.7 2DE analysis    Spot numbers were assigned by Progenesis.  Next to 
the protein name are total scores assigned by mascot, the number of peptides matched in MASCOT, the species, the theoretical 
mass (Mr) and pI of the full length protein, the % coverage of the peptides matched.  Only peptides with ion scores over 35 are 
shown in the matched peptides column, and the corresponding ion score for these are also shown.  The shaded rows indicate the 
final MASCOT score, number of matched peptides and the coverage as calculated from the peptides with scores over 35. 
 
Mr Pl
KCRS_MOUSE Creatine kinase, sarcomeric mitochondrial 189 6 Mouse 47443 8.64 17% R.EVENVAITALEGLK.G  56
K.LSEMTEQDQQR.L   (M) 63
KCRS_MOUSE Creatine kinase, sarcomeric mitochondrial 146 5 Mouse 47443 8.64 15% R.EVENVAITALEGLK.G  43
K.LSEMTEQDQQR.L  64
KCRS_MOUSE Creatine kinase, sarcomeric 183 3 Mouse 47443 8.64 6%
UCRI_RAT Cytochrome b-c1 complex subunit Rieske, mitochondrial 97 5 Rat 29427 9.04 13% R.AEVLDSTK.S  37NO RESULT
KCRM_RAT Creatine kinase M-type 120 6 Rat 43018 6.58 10% K.VLTPDLYNK.L  45
K.GGDDLDPNYVLSSR.V  37
KCRM_RAT Creatine kinase M-type 82 2 Rat 43018 6.58 4%
Human Keratin and Porcine Trypsin peptides only
NO RESULT
ACON_RAT Aconitate hydratase, mitochondrial 130 7 Rat 85380 7.87 11% R.VDVSPTSQR.L  41
NO RESULT
ENOB_RAT Beta-enolase 130 3 Rat 46984 7.08 12% R.AAVPSGASTGIYEALELR.D  119
ALBU_RAT Serum albumin 1 47 Rat 68686 6.09 1% R.FPNAEFAEITK.L  47
ENOB_RAT Beta-enolase 149 4 Rat 46984 7.08 14% K.TLGPALLEK.K  38
R.IEEALGDK.A  43
ENOB_RAT Beta-enolase 200 3 Rat 46984 7.08 8%
ALBU_RAT Serum Albumin 47 1 Rat 68686 6.09 1%
ETFA_RAT Electron transfer flavoprotein subunit alpha, mitochondrial 201 4 Rat 34929 8.62 18% R.LGGEVSCLVAGTK.C (C) 70
K.LNVAPVSDIIEIK.S  50
K.LLYDLADQLHAAVGASR.A  73
ETFA_RAT Electron transfer flavoprotein subunit alpha, mitochondrial 149 6 Rat 34929 8.62 22% R.AAVDAGFVPNDMQVGQTGK.I  39
ETFA_RAT Electron transfer flavoprotein subunit alpha 232 4 Rat 34929 8.62 18%
PGAM1_RAT Phosphoglycerate mutase 1 408 14 Rat 28814 6.67 43% R.DAGYEFDICFTSVQKR.A  (C) 72
R.YADLTEDQLPSCESLKDTIAR.A (C) 145
R.ALPFWNEEIVPQIK.E  73
K.AMEAVAAQGK.V  (M) 43
PGAM1_RAT Phosphoglycerate mutase 1 333 4 Rat 28814 6.67 24%
GRP75_RAT Stress-70 protein, mitochondrial 245 5 Rat 73812 5.97 9% K.VLENAEGAR.T  55
R.TTPSVVAFTPDGER.L  58
GRP75_RAT Stress-70 protein, mitochondrial 238 4 Rat 73812 5.97 7% K.NAVITVPAYFNDSQR.Q  51
K.DAGQISGLNVLR.V  77
GRP75_RAT Stress-70 protein 241 4 Rat 73812 5.97 7%
MASCOT 
ion Scorecoverage Matched peptidesSpecies
TheoreticalProtein Name MASCOT Score
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matched
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CH60_RAT 60 kDa heat shock protein, mitochondrial 1340 31 Rat 60917 5.91 48% R.TVIIEQSWGSPK.V  52
R.GVMLAVDAVIAELKK.Q (M) 57
K.DIGNIISDAMK.K  60
K.TLNDELEIIEGMK.F  72
R.GYISPYFINTSK.G  58
K.CEFQDAYVLLSEK.K [c] 83
K.ISSVQSIVPALEIANAHR.K  107
R.KPLVIIAEDVDGEALSTLVLNR.L  68
K.VGLQVVAVK.A  68
K.APGFGDNR.K  55
K.VGEVIVTK.D  44
K.VGEVIVTKDDAMLLK.G  102
K.VGEVIVTKDDAMLLK.G  (M) 72
R.IQEITEQLDITTSEYEKEK.L  101
K.LSDGVAVLK.V 63
K.VGGTSDVEVNEK.K  70
R.VTDALNATR.A  58
R.AAVEEGIVLGGGCALLR.C  © 90
CH60_RAT 60 kDa heat shock protein, mitochondrial 795 25 Rat 60917 5.91 30% K.LVQDVANNTNEEAGDGTTTATVLAR.S  99
K.TLNDELEIIEGMKFDR.G 39
K.CEFQDAYVLLSEKK.I  (C) 35
CH60_RAT 60 kDa heat shock protein 1453 21 Rat 60917 5.91 42%
NDUAA_RAT NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrial 726 19 Rat 40468 7.64 45% R.LLQYSDALEHLLSTGQGVVLER.S  147
R.SIYSDFVFLEAMYNQGFIR.K  (M) 36
K.VTSAYLQDIEDAYK.K  65
K.VTSAYLQDIEDAYKK.T  123
K.VVEDIEYLNYNK.G  72
R.EVLNYTTVPVYLPEITIGAHQGSR.I  77
NDUAA_RAT NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrial 348 10 Rat 40468 7.64 31% R.DIAEQLGMK.H  37
R.LQSWLYASR.L  58
R.LTLPEYLPPHAVIYIDVPVSEIQSR.I  64
NDUAA_RAT NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10 679 9 Rat 40468 7.64 38%
Protein Name MASCOT Score
Queries 
matched Species
Theoretical coverage Matched peptides MASCOT ion Score
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APPENDIX 4: continued  
 
Mr Pl
ODB2_MOUSE 
Lipoamide acyltransferase component of branched-
chain alpha-keto acid dehydrogenase complex, 
mitochondrial
468 12 Mouse 53127 8.88 20% R.YDGVIKR.L  39
R.LAMENNIK.L  46
R.LAMENNIK.L  (M) 46
K.LSEVVGSGK.D  55
K.QTGAILPPSPK.S  60
K.AQIMNVSWSADHR.V  82
R.VIDGATMSR.F  65
R.VIDGATMSR.F  (M) 51
K.SYLENPAFMLLDLK.-  79
ODB2_MOUSE 
Lipoamide acyltransferase component of branched-
chain alpha-keto acid dehydrogenase complex, 
mitochondrial
445 15 Mouse 53127 8.88 19% K.TLATPAVR.R  51
K.LSEVVGSGKDGR.I  64
K.LREELKPVALAR.G  41
K.SYLENPAFMLLDLK.- (M) 79
ODB2_MOUSE Lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex 758 13 Mouse 53127 8.88 19%
ACADS_RAT Short-chain specific acyl-CoA dehydrogenase, mitochondrial 260 9 Rat 44737 8.47 16% R.ASSTANLIFEDCR.I (C) 53
K.IAMQTLDMGR.I  54
K.LADMALALESAR.L  75
K.LADMALALESAR.L (M) 56
R.ITEIYEGTSEIQR.L  48
ACADS_RAT Short-chain specific acyl-CoA dehydrogenase 286 5 Rat 44737 8.47 12%
EFG1_RAT Elongation factor G 1, mitochondrial 130 5 Rat 83717 6.95 7% K.GIIDLIEER.A  45
R.AIYFDGDFGQIVR.Y  41
R.YDEIPADLR.A  34
EFG1_RAT Elongation factor G 1 120 3 Rat 83717 6.95 4%
Protein Name MASCOT Score
Queries 
matched Species
Theoretical coverage Matched peptides MASCOT ion Score
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APPENDIX 5: Abbreviations and identification codes for all proteins identified 
in the 2DE analyses  
 
Short-chain specific acyl-CoA dehydrogenase, 
mitochondrial Acads NP_071957.1 P15651 ACADS_RAT
Actin , alpha cardiac muscle 1 Actc1 NP_062056.1 P68035 ACTC_RAT 
Serum albumin precursor Alb NP_599153.2 P02770 ALBU_RAT
ATP synthase subunit beta, mitochondrial Atp5b NP_599191.1 P10719 ATPB_RAT 
Adenylyl cyclase-associated protein 1 C ap1 NP_071778.2 Q08163 CAP1_RAT
Creatine kinase M-type C km NP_036662.1 P00564 KCRM_RAT 
Creatine kinase, sarcomeric mitochondrial C kmt2 NP_940807.1 Q6P8J7 KCRS_MOUSE 
Lipoamide acyltransferase component of 
branched-chain alpha-keto acid dehydrogenase 
complex, mitochondrial 
Dbt NP_034152.1 P53395 ODB2_MOUSE 
Desmin Des NP_071976.1 P48675 DESM_RAT
Dihydrolipoyllysine-residue acetyltransferase 
component of pyruvate dehydrogenase complex Dlat NP_112287.1 P08461 ODP2_RAT
Enoyl-CoA hydratase E chs1 NP_511178.1 P14604 ECHM_RAT
Electron transfer flavoprotein subunit alpha, 
mitochondrial E tfa NP_001009668.1 P13803 ETFA_RAT 
Elongation factor G 1, mitochondrial G fm1 NP_446077.1 Q07803 EFG1_RAT 
Hydroxysteroid dehydrogenase-like protein 2 Hsdl2 NP_001020868.1 Q4V8F9 HSDL2_RAT
Heat shock cognate 71Da Hspa8 NP_077327.1 P63018 HSP7C_RAT
Stress-70 protein Hspa9 NP_001094128.1 P48721 GRP75_RAT 
Heat shock protein beta-8 Hspb8 NP_446064.1 Q9EPX0 HSPB8_RAT 
60 kDa heat shock protein, mitochondrial Hspd1 NP_071565.2 P63039 CH60_RAT 
L-lactate dehydrogenase B chain Ldhb NP_036727.1 P42123 LDHB_RAT
Galectin-5 Lgals5 NP_037108.1 P47967 LEG5_RAT
Methylcrotonoyl-CoA carboxylase subunit alpha, 
mitochondrial (mouse) Mccc1 NP_001009653.1 Q5I0C3 MCCA_RAT
Myosin-6 Myh6 NP_058935.1 P02563 MYH6_RAT
Myosin regularory light chain 2, 
ventricular/cardiac muscle isoform Myl2 NP_001030329.1 P08733 MLRV_RAT
Myosin light chain 3 Myl3 NP_036738.1 P16409 MYL3_RAT
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 10, mitochondrial Ndufa10 NP_872612.1 Q561S0 NDUAA_RAT 
NADH-ubiquinone oxidoreductase 75 kDa 
subunit Ndufs1 NP_001005550.1 Q66HF1 NDUS1_RAT
NAD(P) transhydrogenase, mitochondrial 
precursor Nnt NP_032736.2 Q61941 NNTM_MOUSE
Phosphatidylethanolamine-binding protein 1 Pebp1 NP_058932.1 P31044 PEBP1_RAT 
Phosphoglycerate mutase 1 Pgam1 NP_445742.1 P25113 PGAM1_RAT 
Thioredoxin-dependent peroxide reductase P rdx3 NP_071985.1 Q9Z0V6 PRDX3_RAT
Peroxiredoxin-6 P rdx6 NP_446028.1 O35244 PRDX6_RAT
40S ribosomal protein SA R psa NP_058834.1 P38983 RSSA_RAT
Succinate dehydrogenase [ubiquinone] 
flavoprotein subunit, mitochondrial S dha NP_569112.1 Q920L2 DHSA_RAT
Troponin T, cardiac muscle Tnnt2 NP_036808.1 P50753 TNNT2_RAT
Tropomyosin alpha-1 chain Tpm1 NP_001029241.1 P04692 TPM1_RAT 
Tubulin alpha-4A chain Tuba4a NP_001007005.1 Q5XIF6 TBA4A_RAT
Cytochrome b-c1 complex subunit 6 Uqcrh NP_001009480.1 Q5M9I5 QCR6_RAT
WD repeat-containing protein 1 Wdr1 NP_001014157.1 Q5RKI0 WDR1_RAT
14-3-3 protein epsilon Ywhae NP_113791.1 P62260 1433E_RAT
UniP rotK B / 
S wis s ‐P rot P rotein  Name 
RefSeq 
ACCESSION
UniProtKB/ 
Swiss-Prot 
Accession
Abbrev.
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APPENDIX 6: Additional information on protein identifications which were based on a single peptide hit. A) Table of proteins 
which were identified by a single peptide hit.  Spot numbers were assigned by PDQuest (Progenesis for 63).  Next to the protein name 
are the species, the theoretical mass (Mr) and pI of the full length protein, the % coverage of the peptides matched.  The peptide 
sequence, ion scores and Expect value are also shown.  Further detail of MASCOT fragment assignments for single ion scores below 
65 are in Appendix 6 B. B) Fragment assignments (MASCOT results) for 7 proteins with identificatons based on single peptides with 
ion scores below 65 (See table in Appendix 6 A. 
 
APPENDIX 6 A: 
 
Mr Pl
2119 QCR6_RAT Cytochrome b-c1 complex subunit 6 Rat 10417 4.9 20% R.SQTEEDCTEELFDFLHAR.D  (C) 131 8.30E-11
2443 ATPB_RAT ATP synthase subunit beta Rat 56318 5.19 3% R.AIAELGIYPAVDPLDSTSR.I  91 7.80E-07
3518 GRP75_RAT Stress-70 protein Rat 73812 5.97 2% R.QAASSLQQASLK.L  85 6.40E-06
6424 LDHB_RAT L-lactate dehydrogenase B chain Rat 36589 5.7 4% R.VIGSGCNLDSAR.F (C) 85 7.00E-06
6425 LDHB_RAT L-lactate dehydrogenase B chain Rat 36589 5.7 6% R.VIGSGCNLDSAR.F (C ) 77 4.60E-05
7723 DHSA_RAT Succinate dehydrogenase [ubiquinone] flavoprotein subunit Rat 71570 6.75 2% R.LGANSLLDLVVFGR.A  73 9.90E-05
4521 LDHA_RAT L-lactate dehydrogenase (or LDHB) Rat 36427 8.45 3% R.VIGSGCNLDSAR.F (C) 72 1.40E-04
7323 ECHM_RAT Enoyl-CoA hydratase Rat 31496 8.39 3% R.EGMSAFVEKR.K  (M) 73 1.10E-04
63 TPM1_RAT Tropomyosin alpha-1 chain (OR TPM2, 3 or 4) Rat 32661 4.69 5% R.IQLVEEELDRAQER.L  70 1.60E-04
4329 ATPB_RAT ATP synthase subunit beta Rat 56318 5.19 2% R.TIAMDGTEGLVR.G (M) 69 2.40E-04
1248 TNNT2_RAT Troponin T, cardiac muscle Rat 35709 4.95 3% R.LFMPNLVPPK.I  (M) 59 0.007
1207 NNTM_MOUSE NAD(P) transhydrogenase Rat 113780 8.4 2% R.SLGVGYAAVDNPIFYKPNTAMLL 58 0.002
1320 TPM1_RAT Tropomyosin alpha-1 chain (or Tropomyosin beta chain) Rat 32661 4.69 4% K.ATDAEADVASLNR.R 58 0.003
1206 MLRV_RAT Myosin regulatory light chain 2 Rat 18868 4.86 8% K.GADPEETILNAFK.V  57 0.005
2546 CAP1_RAT Adenylyl cyclase-associated protein 1 Rat 51556 7.16 4% K.LSDLLAPISEQIQEVITFR.E 55 0.003
3208 ATPB_RAT ATP synthase subunit beta Rat 56318 5.19 4% K.VLDSGAPIKIPVGPETLGR.I  51 0.006
2616 RSSA_RAT 40S ribosomal protein SA Rat 32803 4.8 4% K.FAAATGATPIAGR.F  50 0.024
3441 ALBU_RAT Serum albumin Rat 68686 6.09 2% K.DVFLGTFLYEYSR.R 46 0.037
6636 HSP7C_RAT Heat shock cognate 71Da OR HSP72 Rat 70827 5.37 2% K.STAGDTHLGGEDFDNR.M  46 0.043
ExpectProtein Name Theoretical coverage Matched peptides MASCOT ion ScoreSSP Species
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APPENDIX 6 B:  
 
1248_Troponin T, cardiac muscle 
 
K2C1_PANTR 
K22E_HUMAN
K1C10_HUMAN
TNNT2_RAT
Human keratin 
and TRY1_PIG
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APPENDIX 6 B: continued.  
 
1207_NAD(P) transhydrogenase 
 
TRY1_BOVINE
K2C1_HUMAN
K1C10_HUMAN
NNTM_MOUSE
K1C9_HUMAN
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APPENDIX 6 B: continued.  
 
1320_Tropomyosin alpha-1 chain (or Tropomyosin beta chain) 
 
TRY1_BOVINE
TPM1_RAT 
or TPM2_RAT
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APPENDIX 6 B: continued. 
  
1206_Myosin regulatory light chain 2 
 
K1C9_PANTR 
K1C9_HUMAN
K1C10_HUMAN
MLRV_RAT
Keratin and 
Mlrv of other 
species 
(peptides 
already 
matched), and 
TRY1_PIG
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APPENDIX 6 B: continued.  
 
2546_ Adenylyl cyclase-associated protein 1 
 
TRY1_BOVIN 
CAP1_RAT
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APPENDIX 6 B: continued.  
 
3208_ATP synthase subunit beta 
 
TRY1_BOVIN 
ALBU_BOVIN (contaminant 
- no hit for albu_rat)
ATPB_RATATPB_MOUSE
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APPENDIX 6 B: continued.  
 
2616_40S ribosomal protein SA 
 
TRY1_BOVIN 
RSSA_RAT
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APPENDIX 6 B: continued.  
 
3441_Serum albumin 
 
TRY1_BOVINALBU_RAT
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APPENDIX 6 B: continued.  
 
6636_Heat shock cognate 71Da OR HSP72 
 
TRY1_BOVIN 
HSP7C_RAT
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APPENDIX 7: LIMMA differential gene expression results for the top 433 
probes. Including all probes with significant difference in MI vs. BMMNC (p<0.05) 
and all probes with significant alteration in Sham vs. MI (p<0.01).  Illumina probe 
IDs and gene symbols are shown alongside the log fold change (log FC), FDR 
adjusted p-value and B statistic for the Sham vs. MI, MI vs. BMMNC and Sham vs. 
BMMNC comparisons. 
 
ID SYMBOL logFC adj.P.Val B logFC adj.P.Val B logFC adj.P.Val B
ILMN_1376428 Sema4a 2.252 0.00003 11.029 -1.319 0.00667 5.530 0.933 0.03663 2.992
ILMN_1358567 Oas1k 2.567 0.00003 10.480 -1.585 0.00667 5.316
ILMN_1352951 Stfa2_predicted 4.630 0.00003 10.298 -2.477 0.01200 4.250 2.153 0.03663 2.980
ILMN_1364315 RGD1560676_predicted 4.700 0.00003 10.146 -2.559 0.01200 4.214 2.141 0.03795 2.720
ILMN_1376740 Glipr1 2.341 0.00026 8.189 -1.619 0.01369 3.970
ILMN_1651187 LOC497712 1.715 0.00033 7.778 1.068 0.03795 2.609
ILMN_1362269 Actg_predicted 1.769 0.00033 7.710 1.089 0.03952 2.491
ILMN_1349760 Pygl 2.342 0.00039 7.438
ILMN_1650752 Aplra1 1.819 0.00042 7.273 -1.627 0.00861 4.846
ILMN_1350326 LOC308990 1.509 0.00042 7.151 -1.041 0.02831 3.052
ILMN_1376765 Lcp1 1.913 0.00042 7.079
ILMN_1361302 Klf5 1.314 0.00050 6.790 1.660 0.00220 5.620
ILMN_1369190 Pdlim7 1.460 0.00050 6.715
ILMN_1371753 F5_mapped 1.749 0.00050 6.731 -1.118 0.04691 2.173
ILMN_1351274 RGD1565374_predicted 3.232 0.00057 6.525
ILMN_1371493 Edg6_predicted 1.630 0.00067 6.318 -1.224 0.03012 2.912
ILMN_1364468 Coro1a 1.890 0.00070 6.218 -1.274 0.04691 2.097
ILMN_1349113 Sell 3.062 0.00071 6.162
ILMN_1376772 Stom 1.446 0.00075 5.969
ILMN_1374896 Napsa 2.981 0.00075 5.955
ILMN_1371081 Mmp8 3.197 0.00075 5.994
ILMN_1359464 Emb 1.079 0.00077 5.818 -0.747 0.04691 1.933
ILMN_1350897 Pfc_mapped 1.366 0.00077 5.715
ILMN_1370817 Stk17b 1.477 0.00077 5.798 -1.024 0.04691 1.932
ILMN_1362534 Retnla 1.535 0.00077 5.681 -1.115 0.04691 2.150
ILMN_1376557 Nfe2 2.065 0.00077 5.668
ILMN_1374845 MGC105649 2.161 0.00077 5.821
ILMN_1349895 RGD1565140_predicted 2.490 0.00077 5.714
ILMN_1366212 Errfi1 2.443 0.00082 5.571
ILMN_1368490 LOC24906 1.528 0.00084 5.512
ILMN_1376621 Adck4 1.446 0.00089 5.431
ILMN_1357059 Alox5ap 2.163 0.00092 5.365
ILMN_1370198 LOC363060 1.153 0.00092 5.335 -0.873 0.04691 2.139
ILMN_1368846 Pacsin2 -1.159 0.00097 5.110
ILMN_1364945 LOC315883 1.008 0.00097 5.244 0.996 0.03663 3.447
ILMN_1350738 Gpr109a 1.181 0.00097 5.165
ILMN_1353693 Cd53 1.495 0.00097 5.229
ILMN_1373383 Tiparp_predicted 1.516 0.00097 5.145
ILMN_1368402 Uap1_predicted 2.082 0.00097 5.104
ILMN_1350798 Slc16a3 3.702 0.00097 5.109
ILMN_1372724 RGD1562136_predicted 1.132 0.00098 5.028
ILMN_1362834 Dusp6 1.623 0.00098 5.024
ILMN_1370981 Akap12 2.237 0.00098 5.005
ILMN_1375048 LOC684525 3.839 0.00098 5.052
ILMN_1361277 Il1rn 1.802 0.00100 4.931
ILMN_1367672 RGD1564330_predicted 1.830 0.00100 4.948
ILMN_1354586 Ptafr 1.973 0.00100 4.913
ILMN_1357030 Laptm5 0.939 0.00101 4.753
ILMN_1355211 Pim1 0.964 0.00101 4.782
ILMN_1355039 Actb 1.228 0.00101 4.847
ILMN_2040884 RGD1309802_predicted 1.233 0.00101 4.840
ILMN_1354445 Rassf1 1.442 0.00101 4.753
ILMN_1358241 Adamts9_predicted 1.615 0.00101 4.777
ILMN_1362702 Gmfg 2.158 0.00101 4.761
ILMN_1356721 Ccr1 2.271 0.00101 4.863
ILMN_1369063 LOC497722 1.146 0.00103 4.714
ILMN_1376726 Dgat2 2.026 0.00108 4.655
ILMN_1348962 Lrrc10_predicted -1.596 0.00113 4.580
ILMN_1366128 RGD1562311_predicted 1.027 0.00113 4.565 -0.835 0.04691 1.979
ILMN_1360909 Ednrb 1.204 0.00113 4.595
ILMN_1349030 Il1r2 4.183 0.00113 4.546
ILMN_1351430 Serpinb10 2.044 0.00114 4.508
ILMN_1351830 Retnlg 3.781 0.00114 4.523
Sham vs. MI MI vs. BMMNC Sham vs. BMMNC
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APPENDIX 7: continued 
 
ID SYMBOL logFC adj.P.Val B logFC adj.P.Val B logFC adj.P.Val B
ILMN_1356202 Tlr6 1.107 0.00116 4.471
ILMN_1372185 RGD1566118_predicted 0.949 0.00119 4.406
ILMN_1362741 Ccr5 1.091 0.00119 4.406
ILMN_1376363 Cnksr3 1.665 0.00119 4.431
ILMN_1376301 Enpp3 1.783 0.00121 4.370
ILMN_1370914 Dok3_predicted 1.179 0.00130 4.286 -1.065 0.04206 2.472
ILMN_1348979 MGC93707 -1.083 0.00140 4.175
ILMN_1376851 Rnd3 1.392 0.00140 4.199
ILMN_1357799 LOC497748 2.069 0.00140 4.174
ILMN_1376661 Lbp 1.194 0.00140 4.152
ILMN_1360947 Tgm1 1.407 0.00140 4.130
ILMN_1351237 Txnrd1 1.749 0.00140 4.138
ILMN_1353208 G7c -0.949 0.00143 4.040
ILMN_1359365 Mtmr7_predicted 0.873 0.00143 4.048
ILMN_1376641 Chst1 1.015 0.00143 4.053 -1.095 0.01897 3.479
ILMN_1364252 Btg3_predicted 1.101 0.00143 4.035
ILMN_1357312 Mcl1 1.445 0.00143 4.041
ILMN_1376579 Bst1 1.505 0.00143 4.026
ILMN_1351679 LOC500040 1.829 0.00143 4.042
ILMN_1357171 Adfp 1.649 0.00145 3.994
ILMN_1353817 Prok2 3.131 0.00148 3.968
ILMN_1375025 Fgr 1.189 0.00150 3.943
ILMN_1358168 LOC363897 0.865 0.00151 3.916
ILMN_1356655 Il17r_predicted 1.583 0.00151 3.909
ILMN_1351690 LOC500687 1.075 0.00159 3.847
ILMN_1375922 Nr4a3 2.273 0.00163 3.814
ILMN_2038944 RGD1309802_predicted 1.041 0.00165 3.780
ILMN_1651184 Hp 3.531 0.00165 3.790
ILMN_1374611 RGD1306595 -0.956 0.00168 3.745
ILMN_1363228 Ell2 1.240 0.00168 3.726
ILMN_1358531 Tubb6 1.967 0.00168 3.732
ILMN_1373523 Igfbp3 1.114 0.00170 3.707
ILMN_1370551 RGD1563888_predicted 1.230 0.00173 3.681
ILMN_1350690 S100a8 3.645 0.00175 3.654
ILMN_1359028 RGD1559988_predicted 0.735 0.00176 3.640
ILMN_1370088 LOC311984 1.250 0.00177 3.627
ILMN_1367232 RGD1307396_predicted 1.115 0.00180 3.599
ILMN_1373122 Arpc5 0.801 0.00184 3.564
ILMN_1354808 LOC500904 1.219 0.00185 3.552
ILMN_1353924 Anxa1 1.612 0.00187 3.529
ILMN_1376249 Tf 1.814 0.00187 3.524
ILMN_1650006 Angpt2 1.155 0.00187 3.513
ILMN_1354357 Jmjd1c 0.996 0.00187 3.492
ILMN_1352340 Il8rb 2.213 0.00187 3.501
ILMN_2040847 Adrb2 0.752 0.00188 3.477
ILMN_1363594 Zfp655 0.872 0.00192 3.450
ILMN_1369168 Ccl6 2.130 0.00197 3.413
ILMN_1357948 Trem1_predicted 2.881 0.00199 3.395
ILMN_1374520 RGD1563073_predicted 1.138 0.00201 3.377
ILMN_1362898 Clecsf9 2.174 0.00204 3.354
ILMN_1363939 Ccnl1 1.521 0.00204 3.337
ILMN_1367877 Fcgr3 1.716 0.00204 3.332
ILMN_1366054 Abcc8 -0.887 0.00207 3.229
ILMN_1367596 Mocs2 -0.803 0.00207 3.232
ILMN_1364579 Gnai3 0.750 0.00207 3.236
ILMN_1364576 Verge 0.880 0.00207 3.255
ILMN_1366777 Slc2a6_predicted 0.955 0.00207 3.235
ILMN_1650307 Galnt3 0.979 0.00207 3.311
ILMN_1353336 Rbm3 1.158 0.00207 3.292
ILMN_1364910 RGD1561967_predicted 1.835 0.00207 3.289
ILMN_1368419 Sat 1.874 0.00207 3.239
ILMN_1359143 Samsn1 2.019 0.00207 3.272
ILMN_2040190 Ifit1_predicted 3.072 0.00207 3.238
ILMN_1363716 Sorl1_predicted 1.051 0.00209 3.206 -1.017 0.04691 2.025
ILMN_1649963 Tpm3 1.356 0.00209 3.205
ILMN_1650056 RGD1306658 1.145 0.00214 3.170
ILMN_1370898 RGD1308872_predicted 0.893 0.00216 3.156
ILMN_1370369 Egr2 1.539 0.00220 3.128
ILMN_1376442 Nedd9 0.933 0.00222 3.110
ILMN_1359590 Fgl2 1.979 0.00224 3.096
ILMN_1355177 Dusp5 1.223 0.00225 3.077
ILMN_1359732 Tfpi2 2.580 0.00225 3.080
Sham vs. MI MI vs. BMMNC Sham vs. BMMNC
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APPENDIX 7: continued 
 
ID SYMBOL logFC adj.P.Val B logFC adj.P.Val B logFC adj.P.Val B
ILMN_1363727 Thbd 1.540 0.00227 3.058
ILMN_1354499 Ltb 2.069 0.00234 3.022
ILMN_1374656 RGD1565451_predicted 0.678 0.00238 2.998
ILMN_1366607 Trh 0.987 0.00243 2.969 1.211 0.03663 3.082
ILMN_1373357 Sphk1 2.672 0.00243 2.963
ILMN_1359089 Coq3 -0.813 0.00250 2.925
ILMN_1369798 Hnrpf 0.704 0.00252 2.907
ILMN_1351496 Pglyrp1 3.535 0.00252 2.905
ILMN_1375583 Crem 1.966 0.00255 2.884
ILMN_1357658 Wsb1 1.349 0.00260 2.860
ILMN_1372404 Tyrobp 1.357 0.00261 2.848
ILMN_1359659 Mrpl50_predicted -0.754 0.00262 2.838
ILMN_1359578 RGD1305574_predicted -0.640 0.00275 2.778
ILMN_1372165 Nckap1l_predicted 0.733 0.00275 2.761
ILMN_1356132 RGD1561016_predicted 0.929 0.00275 2.760
ILMN_1365682 Pdk3_mapped 0.988 0.00275 2.771
ILMN_1351139 LOC498279 1.382 0.00275 2.757
ILMN_1650285 Hmox1 1.200 0.00276 2.739
ILMN_1365751 Kpnb3_predicted 1.314 0.00276 2.738
ILMN_1354240 Ripk3 0.882 0.00277 2.721
ILMN_1358144 Hspca 1.928 0.00277 2.724
ILMN_1356369 Glrx1 1.930 0.00277 2.708
ILMN_1363160 Plac8_predicted 2.169 0.00277 2.708
ILMN_1358127 Plat 1.319 0.00278 2.697
ILMN_1354457 LOC316207 1.187 0.00285 2.669
ILMN_1358847 Fcar 1.177 0.00285 2.660
ILMN_1651181 Cap1 0.874 0.00285 2.637
ILMN_1369735 Odc1 0.931 0.00285 2.635
ILMN_1374672 Nol5 1.298 0.00285 2.642
ILMN_1368002 Snag1_predicted 1.534 0.00285 2.640
ILMN_1370665 Zfand2a 2.502 0.00301 2.576
ILMN_1349466 Plp2 0.692 0.00303 2.546
ILMN_1358946 Cotl1_predicted 0.959 0.00303 2.542
ILMN_1376877 Arhgap9 1.337 0.00303 2.558
ILMN_1368364 Pstpip1_predicted 1.366 0.00303 2.548
ILMN_1355213 Ppp1r3b 1.412 0.00303 2.538
ILMN_1360286 Slpi 3.302 0.00304 2.530
ILMN_1364243 MGC94207 -0.717 0.00308 2.510
ILMN_1372349 Arhgdib 0.864 0.00313 2.487
ILMN_1372294 LOC499078 1.077 0.00315 2.458
ILMN_1366909 LOC683463 1.509 0.00315 2.462
ILMN_1371053 RGD1562655_predicted 1.687 0.00315 2.466
ILMN_1352135 Ceacam10 3.236 0.00315 2.464
ILMN_1361027 Mafb 0.829 0.00329 2.410
ILMN_1373913 Ywhaz 0.985 0.00329 2.402
ILMN_1362451 Rgs2 1.951 0.00330 2.395
ILMN_1359219 Aif1 0.688 0.00341 2.350
ILMN_1373687 RGD1307618_predicted 0.796 0.00341 2.349
ILMN_1349555 RGD1359509 1.428 0.00344 2.337
ILMN_1357127 Nalp12_predicted 0.710 0.00346 2.319
ILMN_1368423 Fbxl5_predicted 1.074 0.00346 2.320
ILMN_1352911 Plek 2.248 0.00353 2.294
ILMN_1359982 Ccdc51 -1.003 0.00365 2.255
ILMN_1356828 Arg1 1.045 0.00372 2.228
ILMN_1366543 RGD1560119_predicted 1.305 0.00372 2.224
ILMN_1355936 Adss_predicted 0.929 0.00374 2.214
ILMN_1374695 Oldlr1 1.266 0.00384 2.182
ILMN_1650241 Tmem60_predicted -0.727 0.00386 2.154
ILMN_1353169 Sema4d_predicted 0.604 0.00386 2.156
ILMN_1356425 Ptbp1 0.857 0.00386 2.163
ILMN_2038799 Actb 0.951 0.00386 2.164
ILMN_1367061 RGD1561141_predicted -0.865 0.00391 2.112
ILMN_1349844 Maea -0.719 0.00391 2.116
ILMN_1368068 RGD1562105_predicted 0.709 0.00391 2.114
ILMN_1353551 Itgb7 0.955 0.00391 2.130
ILMN_1370840 Lgals3 0.963 0.00391 2.107
ILMN_1356957 LOC687856 1.104 0.00391 2.105
ILMN_1362050 RGD1563994_predicted 1.333 0.00391 2.108
ILMN_1365809 Ptprc 1.147 0.00391 2.100
ILMN_1373013 Hck 1.160 0.00392 2.094
Sham vs. MI MI vs. BMMNC Sham vs. BMMNC
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ID SYMBOL logFC adj.P.Val B logFC adj.P.Val B logFC adj.P.Val B
ILMN_1371475 Gmpr -0.774 0.00393 2.077
ILMN_1357924 Gnl3 1.026 0.00393 2.081
ILMN_1371943 Runx1 1.135 0.00393 2.084
ILMN_1364500 Hspcal3_predicted 1.905 0.00399 2.057
ILMN_1371205 Map4k1_predicted 1.258 0.00399 2.051
ILMN_1363936 Fem1a -0.861 0.00407 2.014
ILMN_1350981 Ripk1_predicted 0.897 0.00407 2.013
ILMN_1355065 Ptpn1 0.975 0.00407 2.021
ILMN_1365729 Slc7a5 1.349 0.00407 2.014
ILMN_1349008 H3f3b 0.948 0.00407 2.008
ILMN_1352529 Ier2 1.202 0.00413 1.988
ILMN_1352096 Cspg4 -1.059 0.00414 1.962
ILMN_1361386 Abhd14a -0.623 0.00414 1.959
ILMN_1350279 Syk 0.670 0.00414 1.962
ILMN_1350976 Arpc3_predicted 0.730 0.00414 1.957
ILMN_1359095 Mat2a 0.969 0.00414 1.976
ILMN_1369914 Rasd1 1.064 0.00414 1.964
ILMN_1361387 Trim45_predicted -0.868 0.00422 1.915
ILMN_1350620 Gp1bb 0.988 0.00422 1.919
ILMN_1361672 Tm4sf1_predicted 1.143 0.00422 1.933
ILMN_1349889 Cyp4f5 1.154 0.00422 1.928
ILMN_1368412 Jmjd3_predicted 1.473 0.00422 1.920
ILMN_1353022 Jph2 -0.751 0.00425 1.899
ILMN_1359516 Gclc 1.118 0.00425 1.902
ILMN_1363777 Scap2 1.056 0.00429 1.886
ILMN_2040557 Serpine1 2.271 0.00431 1.876
ILMN_1362293 RGD1562305_predicted -0.885 0.00435 1.860
ILMN_1364569 Cd24 0.752 0.00435 1.853
ILMN_2039240 Mmp9 1.775 0.00435 1.855
ILMN_1353276 RGD1559981_predicted -0.706 0.00440 1.833
ILMN_1353943 Lrg1 0.983 0.00440 1.832
ILMN_1352095 Myl7_predicted -1.108 0.00441 1.827
ILMN_1348782 Etfdh -0.584 0.00443 1.818
ILMN_1367516 LOC363331 -1.092 0.00450 1.798
ILMN_1360607 Numbl_predicted 0.797 0.00450 1.793
ILMN_1376913 Zc3h8 -0.698 0.00459 1.769
ILMN_1359661 Nasp 0.783 0.00460 1.754
ILMN_1368793 Cdr2 1.102 0.00460 1.758
ILMN_1353896 Tlr2 2.223 0.00460 1.762
ILMN_1366783 Vps13d_predicted -0.737 0.00461 1.732
ILMN_1365622 Pcyt2 -0.664 0.00461 1.730
ILMN_1364613 Rhoj 0.764 0.00461 1.718
ILMN_1356330 Lst1 0.998 0.00461 1.718
ILMN_2038798 Actb 1.123 0.00461 1.741
ILMN_1357368 LOC497841 1.702 0.00461 1.738
ILMN_1370638 LOC498277 2.038 0.00461 1.725
ILMN_1352285 Serpinb1a 3.028 0.00461 1.746
ILMN_1364192 RGD1560523_predicted 1.012 0.00487 1.659
ILMN_1365557 Cyb5r3 -0.698 0.00487 1.655
ILMN_1359146 Zswim6 0.664 0.00488 1.638
ILMN_1370131 RGD1564130_predicted 1.042 0.00488 1.644
ILMN_1351826 Ippk 1.073 0.00488 1.647
ILMN_1353078 Pde4b 1.877 0.00488 1.636
ILMN_1361128 Acat2 0.687 0.00491 1.626
ILMN_1364095 LOC362703 1.095 0.00495 1.613
ILMN_2040035 Trem1_predicted 1.783 0.00496 1.608
ILMN_1358347 Pls3 1.088 0.00498 1.599
ILMN_1349016 Rabgef1_predicted 0.767 0.00505 1.583
ILMN_1363372 Ets2_mapped 0.773 0.00505 1.578
ILMN_1362278 Slc5a3 2.139 0.00505 1.573
ILMN_1349287 Hiat1_predicted 0.794 0.00512 1.556
ILMN_1363628 Nt5m_predicted -0.868 0.00516 1.541
ILMN_1361561 Pten 0.654 0.00516 1.532
ILMN_1356110 Klf4 1.136 0.00516 1.536
ILMN_1360736 Ugdh 1.887 0.00516 1.537
ILMN_1353729 Pgd 0.771 0.00523 1.505
ILMN_1353820 Actr3 0.816 0.00523 1.504
ILMN_1359024 Myd88 1.247 0.00523 1.511
ILMN_1357730 Npy 3.309 0.00523 1.509
ILMN_1364203 Pcna 0.713 0.00535 1.478
Sham vs. MI MI vs. BMMNC Sham vs. BMMNC
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ILMN_1368356 Fos 3.750 0.00542 1.461
ILMN_1360418 RGD1302996 -0.819 0.00545 1.448
ILMN_1359200 Timp1 2.038 0.00545 1.449
ILMN_1349137 Ptpro 0.964 0.00551 1.433
ILMN_1367417 Polrmt_predicted -0.669 0.00552 1.416
ILMN_1358564 Pabpc1 0.736 0.00552 1.426
ILMN_1367519 Idi1 0.821 0.00552 1.417
ILMN_1360373 Ptpn6 0.998 0.00552 1.417
ILMN_1530409 Ier5 1.038 0.00552 1.413
ILMN_1374891 Cyp11a1 -0.651 0.00555 1.395
ILMN_1351646 Gpr4 0.930 0.00555 1.402
ILMN_2039673 Arc 1.405 0.00555 1.398
ILMN_1365610 RGD1565319_predicted 2.368 0.00555 1.393
ILMN_1650001 Ociad1 -0.560 0.00560 1.377
ILMN_1350180 Emp1 1.938 0.00560 1.376
ILMN_1376722 MGC94736 -0.599 0.00562 1.364
ILMN_1359287 LOC310086 0.568 0.00562 1.363
ILMN_1374870 Pafah1b1 1.103 0.00562 1.364
ILMN_1359784 LOC362115 0.929 0.00564 1.356
ILMN_1350250 Soat1 0.577 0.00576 1.330
ILMN_1376946 Clec4d 1.113 0.00584 1.313
ILMN_1375131 MGC125015 0.953 0.00584 1.309
ILMN_1373952 Cspg2 1.714 0.00586 1.302
ILMN_1370049 Zfp180 -0.622 0.00605 1.263
ILMN_1351911 RGD1310168_predicted 0.743 0.00605 1.264
ILMN_1373876 Pmp22 0.728 0.00607 1.257
ILMN_1359759 Scnn1a 0.885 0.00609 1.243
ILMN_1362786 Cias1_predicted 1.156 0.00609 1.242
ILMN_1376417 Serpine1 2.025 0.00609 1.247
ILMN_1650650 Gypc -0.618 0.00629 1.206
ILMN_1371223 Fbl 0.756 0.00636 1.192
ILMN_1374737 Ifitm6_predicted 3.015 0.00639 1.183
ILMN_1370087 LOC498062 -0.597 0.00648 1.164
ILMN_1366126 RGD1564040_predicted 0.709 0.00648 1.159
ILMN_1375100 Atf4 1.266 0.00648 1.159
ILMN_1375084 RGD1559897_predicted 0.678 0.00651 1.151
ILMN_1371126 Procr 2.277 0.00659 1.135
ILMN_1362330 Slc25a29 -0.733 0.00665 1.123
ILMN_1355677 RGD1305246 0.952 0.00669 1.110
ILMN_1367946 Baz1a_predicted 0.967 0.00669 1.108
ILMN_1369706 Dnajb1_predicted 2.419 0.00669 1.108
ILMN_1357240 RGD1564549_predicted -0.600 0.00671 1.101
ILMN_1364370 Klrb1b 0.838 0.00671 1.097
ILMN_1365821 RGD1566093_predicted 0.539 0.00683 1.076
ILMN_1361776 MGC72584 -0.754 0.00687 1.064
ILMN_1375833 Crem 2.041 0.00687 1.065
ILMN_1373900 MGC72974 -1.236 0.00696 1.039
ILMN_1363911 MGC94339 -0.698 0.00696 1.045
ILMN_1350548 Neurl2_predicted -0.598 0.00696 1.032
ILMN_1373883 S100a11 0.848 0.00696 1.041
ILMN_1360748 Pgsg 0.887 0.00696 1.034
ILMN_1365695 Dnaja1 1.471 0.00696 1.032
ILMN_1357140 Irx4_predicted -0.782 0.00698 1.012
ILMN_1358668 Ddt -0.768 0.00698 1.009
ILMN_1362991 Vps45 -0.580 0.00698 1.006
ILMN_1364441 Gja3 -0.553 0.00698 0.999
ILMN_1650489 Isoc2b -0.550 0.00698 1.020
ILMN_1375233 Vps24 -0.517 0.00698 1.009
ILMN_1373962 Gp9 0.712 0.00698 0.995
ILMN_1372586 Ell_predicted 0.715 0.00698 1.012
ILMN_1374460 Yars 0.969 0.00698 1.018
ILMN_1365800 Rac2 1.031 0.00698 0.995
ILMN_1362080 Klf6 1.121 0.00698 0.996
ILMN_1373510 Pskh1_predicted -0.554 0.00705 0.982
ILMN_1350364 RGD1563798_predicted -0.762 0.00705 0.979
ILMN_1371051 Hk3 0.924 0.00705 0.975
ILMN_1367615 Spsb1_predicted 0.845 0.00708 0.965
ILMN_1349218 Casp3 1.023 0.00708 0.968
ILMN_1365196 Sertad1 1.147 0.00711 0.958
ILMN_1376319 Fus 0.585 0.00711 0.955
Sham vs. MI MI vs. BMMNC Sham vs. BMMNC
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ID SYMBOL logFC adj.P.Val B logFC adj.P.Val B logFC adj.P.Val B
ILMN_1360968 Arl5a 0.676 0.00721 0.937
ILMN_1357555 LOC307907 -0.811 0.00727 0.926
ILMN_1373668 RGD1310553 -0.728 0.00727 0.917
ILMN_1356615 Gpr65_predicted 0.537 0.00727 0.921
ILMN_1360656 Gfpt2 2.044 0.00727 0.918
ILMN_1366301 RGD1561143_predicted 0.648 0.00729 0.911
ILMN_1370116 LOC501594 0.591 0.00731 0.903
ILMN_1367573 Slc25a25 1.071 0.00731 0.902
ILMN_1366898 Irf2bp1_predicted -0.701 0.00735 0.894
ILMN_1348939 C1qr1 1.014 0.00740 0.884
ILMN_1362859 Mrpl22_predicted -0.527 0.00741 0.881
ILMN_1371034 Acsl4 0.642 0.00748 0.867
ILMN_1376914 Akap2 1.526 0.00748 0.864
ILMN_1372499 Lad1_predicted -0.746 0.00750 0.857
ILMN_1376380 P2ry13 0.766 0.00750 0.859
ILMN_1366394 Timm13 -0.570 0.00756 0.842
ILMN_1367954 Ddx39 0.687 0.00756 0.842
ILMN_1355362 Mca32 0.744 0.00758 0.837
ILMN_1357130 Cflar 0.897 0.00759 0.833
ILMN_1357039 RGD1310357_predicted 0.815 0.00762 0.826
ILMN_1363774 Tpm3 0.713 0.00773 0.807
ILMN_1360221 Tacstd1 1.765 0.00773 0.806
ILMN_1369005 Egr1 2.664 0.00776 0.799
ILMN_1367927 Ly49i8 0.695 0.00783 0.785
ILMN_1349873 Cd302 0.881 0.00783 0.784
ILMN_1363263 Lrrc8c 0.743 0.00797 0.763
ILMN_1372107 Nos2 1.905 0.00800 0.756
ILMN_1353390 Mxd1 1.368 0.00802 0.751
ILMN_1352342 Eif5 0.823 0.00802 0.745
ILMN_1376646 Bag3 0.859 0.00802 0.741
ILMN_1349269 Sgk 1.012 0.00802 0.743
ILMN_1362622 Rhoh 1.293 0.00802 0.740
ILMN_1376312 Mar-07 0.960 0.00814 0.722
ILMN_1357241 Pmm1 -0.618 0.00816 0.717
ILMN_1351668 Pcf11_predicted 0.676 0.00818 0.712
ILMN_1371731 LOC501284 -0.750 0.00822 0.705
ILMN_1357763 Rhoq 0.781 0.00832 0.689
ILMN_1350091 G0s2 1.818 0.00838 0.679
ILMN_1356563 Ptges2_predicted -0.584 0.00853 0.658
ILMN_1369599 Cxcl4 2.063 0.00853 0.655
ILMN_1366226 RGD1359713 0.672 0.00860 0.644
ILMN_1349422 Ptgs2 2.647 0.00865 0.636
ILMN_1368524 Glg1 -0.762 0.00865 0.633
ILMN_1357506 Gpsm1 -0.657 0.00867 0.624
ILMN_1357886 Mrpl16 -0.582 0.00867 0.627
ILMN_1650950 Josd3 0.825 0.00867 0.623
ILMN_1367384 Mox2r 0.949 0.00871 0.616
ILMN_1367435 Pdzd7_predicted -0.581 0.00871 0.612
ILMN_1355544 LOC498276 1.684 0.00871 0.610
ILMN_1364338 Zcchc12 0.783 0.00873 0.606
ILMN_1351557 Tmem9_predicted -0.548 0.00885 0.589
ILMN_1357664 Sema6a_predicted 0.557 0.00898 0.571
ILMN_1361429 Arih1 1.117 0.00905 0.561
ILMN_1359238 Rock2 0.563 0.00907 0.555
ILMN_1363954 Nip7 0.863 0.00914 0.545
ILMN_1372842 Cars_predicted 0.845 0.00928 0.524
ILMN_1369410 Sec23b_predicted 0.882 0.00928 0.524
ILMN_1354751 Leng4_predicted 0.632 0.00933 0.517
ILMN_1352021 Tmx2 -0.652 0.00933 0.511
ILMN_1351674 Gdf15 1.061 0.00933 0.511
ILMN_1349147 Mar-03 1.448 0.00933 0.508
ILMN_1370633 Itpkc 1.651 0.00937 0.502
ILMN_1376777 Mpst -0.663 0.00937 0.496
ILMN_1376818 Tubb3 0.626 0.00937 0.495
ILMN_1371385 Gpsm3 0.770 0.00937 0.494
ILMN_1367486 Dusp1 1.266 0.00940 0.489
ILMN_1373864 RGD1308113 -0.535 0.00949 0.474
ILMN_1352642 Spp1 1.816 0.00949 0.475
ILMN_1362482 Nkx2-5 -0.749 0.00950 0.470
ILMN_1349318 Tmem49 0.651 0.00950 0.468
Sham vs. MI MI vs. BMMNC Sham vs. BMMNC
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ILMN_1361287 Surb7_predicted 0.595 0.00951 0.464
ILMN_1364113 Ctgf 1.265 0.00956 0.456
ILMN_1363587 Slc25a19 -0.549 0.00959 0.446
ILMN_1369550 RGD1305622 -0.501 0.00959 0.451
ILMN_1349697 Midn_predicted 0.704 0.00959 0.446 1.115 0.03795 2.678
ILMN_1351900 Fcnb 1.580 0.00959 0.444
ILMN_1353563 Aacs 0.572 0.00962 0.438
ILMN_1352848 Cdc42ep3_predicted 0.584 0.00962 0.435
ILMN_1354419 Bcl2a1 1.952 0.00967 0.428
ILMN_1349102 RGD1562922_predicted -1.096 0.00968 0.422
ILMN_1363106 Ndel1 0.538 0.00968 0.422
ILMN_1366871 Bmyc -0.652 0.00969 0.416
ILMN_1356848 Btg1 1.075 0.00969 0.416
ILMN_1366459 LOC499612 -0.519 0.00971 0.411
ILMN_1367494 Vdac3 -0.611 0.00996 0.382
ILMN_1365578 RGD1561055_predicted 0.747 0.00996 0.380
ILMN_1357616 Casq2 -0.690 0.01157 0.061 1.253 0.01897 3.553
ILMN_1372230 Rnf149 -1.778 0.03978 2.595
Sham vs. MI MI vs. BMMNC Sham vs. BMMNC
 
 
 
 
  
APPENDIX 8:  Probe level data for the top 433 probes found to be altered in the LIMMA analysis  Including all probes with 
significant difference in MI vs. BMMNC (p<0.05) and all probes with significant alteration in Sham vs. MI (p<0.01).  Illumina probe 
ID, gene symbol, gene accession code and gene definition are shown alongside the average signal and standard deviation for each 
experimental group for every probe found to be significantly altered in the LIMMA analysis.   
 
ID SYMBOL ACCESSION DEFINITION Ave Sham StDev Sham Ave    MI
StDev 
MI Ave MNC
StDev 
MNC
ILMN_1349147 Mar-03 NM_001007759.1 membrane-associated ring finger (C3HC4) 3 (March3), mRNA. 310.27 127.65 805.87 96.58 656.82 146.01
ILMN_1376312 Mar-07 NM_001012087.1 membrane-associated ring finger (C3HC4) 7 (March7), mRNA. 65.03 3.23 128.15 26.46 84.69 19.24
ILMN_1353563 Aacs NM_023104.1 acetoacetyl-CoA synthetase (Aacs), mRNA. 69.56 4.28 103.34 4.51 73.87 8.34
ILMN_1366054 Abcc8 NM_013039.1
ATP-binding cassette, sub-family C (CFTR/MRP), member 8 (Abcc8), 
mRNA. 349.47 25.65 188.78 7.87 279.42 41.74
ILMN_1361386 Abhd14a NM_001009670.1 abhydrolase domain containing 14A (Abhd14a), mRNA. 122.07 5.55 79.26 2.79 96.01 5.11
ILMN_1361128 Acat2 NM_001006995.1 acetyl-Coenzyme A acetyltransferase 2 (Acat2), mRNA. 142.35 16.10 228.24 8.25 185.16 3.38
ILMN_1371034 Acsl4 NM_053623.1 acyl-CoA synthetase long-chain family member 4 (Acsl4), mRNA. 57.67 3.59 90.15 8.78 63.07 4.85
ILMN_1355039 Actb NM_031144.2 actin, beta (Actb), mRNA. 2171.06 190.60 5099.52 661.78 3093.01 347.33
ILMN_2038799 Actb NM_031144.2 actin, beta (Actb), mRNA. 6518.84 445.31 12717.95 2202.32 9038.88 622.88
ILMN_2038798 Actb NM_031144.2 actin, beta (Actb), mRNA. 1824.31 95.97 4011.43 688.48 2575.02 701.59
ILMN_1362269 Actg_predicted XM_213540.3  actin, gamma, cytoplasmic (predicted) (Actg_predicted), mRNA. 2320.65 284.09 7905.07 912.57 4916.95 306.69
ILMN_1353820 Actr3 NM_031068.1 ARP3 actin-related protein 3 homolog (yeast) (Actr3), mRNA. 877.15 61.60 1554.57 239.11 1223.41 27.10
ILMN_1358241 Adamts9_predicted XM_232202.3
  a disintegrin-like and metalloprotease (reprolysin type) with 
thrombospondin type 1 motif, 9 (predicted) (Adamts9_predicted), mRNA.
224.34 47.34 682.70 106.97 486.05 54.44
ILMN_1376621 Adck4 XM_001077748.1  aarF domain containing kinase 4 (Adck4), mRNA. 105.76 10.89 289.94 47.95 183.14 5.75
ILMN_1357171 Adfp NM_001007144.1 adipose differentiation related protein (Adfp), mRNA. 998.42 277.46 3057.84 314.88 1799.12 132.96
ILMN_2040847 Adrb2 NM_012492.2 adrenergic receptor, beta 2 (Adrb2), mRNA. 135.12 2.97 227.67 10.20 166.96 11.30
ILMN_1355936 Adss_predicted XM_001059694.1
 adenylosuccinate synthetase, non muscle (predicted) (Adss_predicted), 
mRNA. 335.87 53.56 634.73 27.10 470.35 64.74
ILMN_1359219 Aif1 NM_017196.2 allograft inflammatory factor 1 (Aif1), mRNA. 445.08 22.78 717.68 50.58 485.35 1.68
ILMN_1370981 Akap12 NM_001033653.1
A kinase (PRKA) anchor protein (gravin) 12 (Akap12), transcript variant 2, 
mRNA. 92.18 24.28 430.43 93.11 248.46 37.10
ILMN_1376914 Akap2 NM_001011974.1 A kinase (PRKA) anchor protein 2 (Akap2), mRNA. 217.57 94.66 596.60 104.70 515.17 34.89
ILMN_1357059 Alox5ap NM_017260.2 arachidonate 5-lipoxygenase activating protein (Alox5ap), mRNA. 124.13 15.81 572.79 190.00 204.58 5.30
ILMN_1650006 Angpt2 XM_001065522.1  angiopoietin 2 (Angpt2), mRNA. 80.77 6.57 180.85 27.02 134.11 20.16
ILMN_1353924 Anxa1 NM_012904.1 annexin A1 (Anxa1), mRNA. 776.54 203.90 2337.85 367.13 1199.98 183.60
ILMN_1650752 Aplra1 NM_001005896.1 antigen presenting cell lectin-like receptor A1 (Aplra1), mRNA. 31.56 1.61 112.74 23.00 36.05 1.03
ILMN_2039673 Arc NM_019361.1 activity regulated cytoskeletal-associated protein (Arc), mRNA. 55.01 2.68 149.95 45.66 123.59 39.37
ILMN_1356828 Arg1 NM_017134.1 arginase 1 (Arg1), mRNA. 67.68 11.87 139.29 21.43 93.98 0.91
ILMN_1376877 Arhgap9 XM_001056068.1  Rho GTPase activating protein 9 (Arhgap9), mRNA. 122.64 7.06 318.54 94.72 154.14 0.17
ILMN_1372349 Arhgdib NM_001009600.1 Rho, GDP dissociation inhibitor (GDI) beta (Arhgdib), mRNA. 704.63 90.43 1278.90 113.09 755.44 10.56
ILMN_1361429 Arih1 NM_001013108.1
ariadne ubiquitin-conjugating enzyme E2 binding protein homolog 1 
(Drosophila) (Arih1), mRNA. 240.10 27.32 524.82 97.23 351.20 116.69
ILMN_1360968 Arl5a NM_053979.1 ADP-ribosylation factor-like 5A (Arl5a), mRNA. 159.18 16.90 253.42 1.82 220.25 29.14
ILMN_1350976 Arpc3_predicted XM_213782.4
 actin related protein 2/3 complex, subunit 3 (predicted) 
(Arpc3_predicted), mRNA. 521.98 8.95 869.53 96.85 593.22 45.73  
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ILMN_1373122 Arpc5 NM_001025717.1 actin related protein 2/3 complex, subunit 5 (Arpc5), mRNA. 1395.58 64.48 2433.05 147.58 1672.33 108.13
ILMN_1375100 Atf4 NM_024403.1 activating transcription factor 4 (Atf4), mRNA. 715.20 225.85 1680.93 276.36 1048.78 78.58
ILMN_1376646 Bag3 NM_001011936.1 Bcl2-associated athanogene 3 (Bag3), mRNA. 5864.32 561.22 10637.38 1066.30 10072.59 2513.78
ILMN_1367946 Baz1a_predicted XM_001079067.1
 bromodomain adjacent to zinc finger domain, 1A (predicted) 
(Baz1a_predicted), mRNA. 106.82 8.80 211.15 40.89 141.76 24.05
ILMN_1354419 Bcl2a1 NM_133416.1 B-cell leukemia/lymphoma 2 related protein A1 (Bcl2a1), mRNA. 218.10 62.25 884.98 404.62 435.03 183.89
ILMN_1366871 Bmyc NM_001013163.2 brain expressed myelocytomatosis oncogene (Bmyc), mRNA. 106.32 2.40 68.13 10.07 78.78 4.95
ILMN_1376579 Bst1 NM_030848.1  bone marrow stromal cell antigen 1 (Bst1), mRNA. 82.83 9.12 237.59 47.59 122.61 22.63
ILMN_1356848 Btg1 NM_017258.1 B-cell translocation gene 1, anti-proliferative (Btg1), mRNA. 2563.41 778.38 5278.74 660.71 4233.48 381.62
ILMN_1364252 Btg3_predicted XM_346415.2  B-cell translocation gene 3 (predicted) (Btg3_predicted), mRNA. 154.27 21.63 329.58 29.31 251.54 11.98
ILMN_1348939 C1qr1 NM_053383.1  complement component 1, q subcomponent, receptor 1 (C1qr1), mRNA. 715.02 144.89 1433.00 179.24 1044.88 212.32
ILMN_1651181 Cap1 NM_022383.2 CAP, adenylate cyclase-associated protein 1 (yeast) (Cap1), mRNA. 331.75 17.46 609.94 68.15 390.66 51.21
ILMN_1372842 Cars_predicted XM_001065753.1  cysteinyl-tRNA synthetase (predicted) (Cars_predicted), mRNA. 86.23 4.67 156.43 28.47 128.03 23.55
ILMN_1349218 Casp3 NM_012922.2 caspase 3, apoptosis related cysteine protease (Casp3), mRNA. 100.94 18.45 205.83 42.52 154.22 9.37
ILMN_1357616 Casq2 NM_017131.1 calsequestrin 2 (Casq2), mRNA. 373.51 51.14 231.13 27.15 548.56 14.68
ILMN_1359982 Ccdc51 NM_001014098.1 coiled-coil domain containing 51 (Ccdc51), mRNA. 275.64 52.15 135.85 4.39 180.62 13.43
ILMN_1369168 Ccl6 NM_001004202.1 chemokine (C-C motif) ligand 6 (Ccl6), mRNA. 79.52 23.23 354.56 136.29 139.11 4.22
ILMN_1363939 Ccnl1 NM_053662.3 cyclin L1 (Ccnl1), mRNA. 545.56 54.46 1601.94 420.60 1145.80 58.62
ILMN_1356721 Ccr1 NM_020542.2 chemokine (C-C motif) receptor 1 (Ccr1), mRNA. 157.20 9.02 800.35 339.03 337.93 11.42
ILMN_1362741 Ccr5 NM_053960.3 chemokine (C-C motif) receptor 5 (Ccr5), mRNA. 149.85 20.62 317.37 14.72 189.77 9.37
ILMN_1364569 Cd24 NM_012752.2 CD24 antigen (Cd24), mRNA. 72.41 7.90 121.66 9.31 75.91 2.40
ILMN_1349873 Cd302 NM_001013916.1 CD302 antigen (Cd302), mRNA. 404.90 72.67 743.44 108.43 532.18 15.96
ILMN_1353693 Cd53 NM_012523.1 CD53 antigen (Cd53), mRNA. 49.61 4.63 141.19 27.52 69.84 2.47
ILMN_1352848 Cdc42ep3_predicted XM_233815.3
 CDC42 effector protein (Rho GTPase binding) 3 (predicted) 
(Cdc42ep3_predicted), mRNA. 86.19 1.60 129.28 4.26 113.97 17.67
ILMN_1368793 Cdr2 NM_001025682.1 cerebellar degeneration-related 2 (Cdr2), mRNA. 77.06 16.02 163.32 7.68 127.90 29.74
ILMN_1352135 Ceacam10 NM_173339.1 CEA-related cell adhesion molecule 10 (Ceacam10), mRNA. 106.51 88.67 825.24 188.88 323.97 37.71
ILMN_1357130 Cflar NM_057138.2
CASP8 and FADD-like apoptosis regulator (Cflar), transcript variant 2, 
mRNA. 163.20 23.45 303.36 36.92 298.58 60.51
ILMN_1376641 Chst1 NM_001011955.1  carbohydrate (keratan sulfate Gal-6) sulfotransferase 1 (Chst1), mRNA. 125.50 10.53 254.17 30.19 118.42 3.41
ILMN_1362786 Cias1_predicted XM_220513.4
 cold autoinflammatory syndrome 1 homolog (human) (predicted) 
(Cias1_predicted), mRNA. 42.57 3.09 95.89 18.11 59.38 18.58
ILMN_1376946 Clec4d NM_001003707.1 C-type lectin domain family 4, member d (Clec4d), mRNA. 43.52 3.97 95.59 23.01 46.77 9.49
ILMN_1362898 Clecsf9 NM_001005897.1  macrophage-inducible C-type lectin (Clecsf9), mRNA. 61.15 17.33 278.70 89.36 133.05 36.45
ILMN_1376363 Cnksr3 NM_001012061.1 Cnksr family member 3 (Cnksr3), mRNA. 226.39 30.31 715.76 65.37 605.90 205.24
ILMN_1359089 Coq3 NM_019187.1 coenzyme Q3 homolog, methyltransferase (yeast) (Coq3), mRNA. 1902.05 142.71 1083.30 90.34 1600.73 75.83
ILMN_1364468 Coro1a NM_130411.2 coronin, actin binding protein 1A (Coro1a), mRNA. 266.39 63.32 974.45 115.04 401.07 14.26
ILMN_1358946 Cotl1_predicted XM_341700.3   coactosin-like 1 (Dictyostelium) (predicted) (Cotl1_predicted), mRNA. 136.57 3.01 268.14 45.36 191.22 15.73
ILMN_1375583 Crem NM_013086.1 cAMP responsive element modulator (Crem), transcript variant 1, mRNA. 240.86 102.82 891.12 50.86 518.30 141.69
ILMN_1375833 Crem NM_017334.1 cAMP responsive element modulator (Crem), transcript variant 2, mRNA. 120.33 66.63 454.24 57.72 249.39 98.22
ILMN_1373952 Cspg2 XM_215451.4  chondroitin sulfate proteoglycan 2 (Cspg2), mRNA. 220.02 84.84 685.31 94.23 467.99 92.62  
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ILMN_1352096 Cspg4 NM_031022.1 chondroitin sulfate proteoglycan 4 (Cspg4), mRNA. 383.02 71.90 181.61 9.62 284.08 49.70
ILMN_1364113 Ctgf NM_022266.2 connective tissue growth factor (Ctgf), mRNA. 2627.23 292.69 6377.17 1333.44 4432.42 1881.46
ILMN_1369599 Cxcl4 NM_001007729.1 chemokine (C-X-C motif) ligand 4 (Cxcl4), mRNA. 401.42 125.03 1812.68 1028.71 747.93 63.31
ILMN_1365557 Cyb5r3 NM_138877.1 cytochrome b5 reductase 3 (Cyb5r3), mRNA. 172.20 15.31 105.96 5.84 134.74 12.27
ILMN_1374891 Cyp11a1 NM_017286.1
cytochrome P450, family 11, subfamily a, polypeptide 1 (Cyp11a1), 
mRNA. 928.96 92.56 589.78 8.86 775.62 54.54
ILMN_1349889 Cyp4f5 NM_173124.1 cytochrome P450 4F5 (Cyp4f5), mRNA. 112.13 28.52 245.60 27.47 231.84 20.71
ILMN_1358668 Ddt NM_024131.1 D-dopachrome tautomerase (Ddt), mRNA. 794.24 58.87 469.30 73.96 736.45 57.57
ILMN_1367954 Ddx39 NM_053563.2 DEAD (Asp-Glu-Ala-Asp) box polypeptide 39 (Ddx39), mRNA. 367.17 52.35 587.75 31.95 421.64 7.41
ILMN_1376726 Dgat2 NM_001012345.1 diacylglycerol O-acyltransferase homolog 2 (mouse) (Dgat2), mRNA. 324.31 45.07 1353.14 424.38 693.82 150.36
ILMN_1365695 Dnaja1 NM_022934.1 DnaJ (Hsp40) homolog, subfamily A, member 1 (Dnaja1), mRNA. 3209.10 518.65 9060.12 2422.20 7138.14 2588.04
ILMN_1369706 Dnajb1_predicted XM_001069407.1
 DnaJ (Hsp40) homolog, subfamily B, member 1 (predicted) 
(Dnajb1_predicted), mRNA. 1344.65 300.56 7498.73 2955.22 5987.70 4038.05
ILMN_1370914 Dok3_predicted XM_001069255.1  docking protein 3 (predicted) (Dok3_predicted), mRNA. 45.54 2.57 103.67 14.44 49.42 6.51
ILMN_1367486 Dusp1 NM_053769.2 dual specificity phosphatase 1 (Dusp1), mRNA. 2072.98 249.79 5006.80 805.89 2747.02 1212.61
ILMN_1355177 Dusp5 NM_133578.1 dual specificity phosphatase 5 (Dusp5), mRNA. 59.71 2.10 140.01 17.29 111.27 31.88
ILMN_1362834 Dusp6 NM_053883.2 dual specificity phosphatase 6 (Dusp6), mRNA. 357.57 24.08 1103.01 107.52 560.51 178.21
ILMN_1371493 Edg6_predicted XM_234930.2
 endothelial differentiation, G-protein-coupled receptor 6 (predicted) 
(Edg6_predicted), mRNA. 56.54 6.17 176.20 31.04 74.68 1.26
ILMN_1360909 Ednrb NM_017333.1 endothelin receptor type B (Ednrb), mRNA. 368.70 23.34 854.64 126.16 561.09 47.29
ILMN_1369005 Egr1 NM_012551.1 early growth response 1 (Egr1), mRNA. 827.65 642.83 4409.36 983.34 3400.53 1181.62
ILMN_1370369 Egr2 NM_053633.1 early growth response 2 (Egr2), mRNA. 309.83 21.28 909.30 165.34 731.31 258.58
ILMN_1352342 Eif5 NM_020075.1 eukaryotic translation initiation factor 5 (Eif5), mRNA. 241.20 39.49 425.35 56.25 310.67 4.11
ILMN_1372586 Ell_predicted XM_001070626.1   elongation factor RNA polymerase II (predicted) (Ell_predicted), mRNA. 160.00 21.30 261.41 14.73 235.28 20.98
ILMN_1363228 Ell2 XM_001054852.1  elongation factor RNA polymerase II 2 (Ell2), mRNA. 230.65 31.36 545.77 81.39 324.11 36.40
ILMN_1359464 Emb NM_053719.1 embigin (Emb), mRNA. 59.57 1.27 126.22 11.37 75.02 1.62
ILMN_1350180 Emp1 NM_012843.2 epithelial membrane protein 1 (Emp1), mRNA. 649.71 180.90 2475.14 562.87 1242.37 682.92
ILMN_1376301 Enpp3 NM_019370.1 ectonucleotide pyrophosphatase/phosphodiesterase 3 (Enpp3), mRNA. 205.62 33.34 710.41 133.16 356.94 94.76
ILMN_1366212 Errfi1 NM_001014071.1 ERBB receptor feedback inhibitor 1 (Errfi1), mRNA. 315.12 36.61 1742.82 423.28 845.72 316.24
ILMN_1348782 Etfdh NM_198742.2 electron-transferring-flavoprotein dehydrogenase (Etfdh), mRNA. 2596.67 61.04 1733.27 71.60 1881.43 1.67
ILMN_1363372 Ets2_mapped XM_239510.4
 v-ets erythroblastosis virus E26 oncogene homolog 2 (avian) (mapped) 
(Ets2_mapped), mRNA. 99.53 7.54 169.83 7.87 138.36 25.16
ILMN_1371753 F5_mapped XM_222831.4  coagulation factor 5 (mapped) (F5_mapped), mRNA. 43.26 4.42 146.05 21.85 67.12 9.81
ILMN_1371223 Fbl NM_001025643.1 fibrillarin (Fbl), mRNA. 907.53 134.23 1522.98 73.94 1264.83 89.42
ILMN_1368423 Fbxl5_predicted XM_001060082.1
 F-box and leucine-rich repeat protein 5 (predicted) (Fbxl5_predicted), 
mRNA. 1162.82 157.99 2456.44 416.12 1545.52 90.81
ILMN_1358847 Fcar NM_201992.1 IgA Fc receptor (Fcar), mRNA. 41.23 4.12 94.55 22.02 49.32 0.98
ILMN_1367877 Fcgr3 XM_001077008.1  Fc receptor, IgG, low affinity III (Fcgr3), mRNA. 90.73 16.12 302.49 85.59 151.52 34.22
ILMN_1351900 Fcnb NM_053634.1 ficolin B (Fcnb), mRNA. 84.93 29.52 253.33 85.20 108.97 29.92
ILMN_1363936 Fem1a NM_001025706.1 feminization 1 homolog a (C. elegans) (Fem1a), mRNA. 1909.15 239.71 1048.28 96.73 1588.27 149.15
ILMN_1359590 Fgl2 NM_053455.1 fibrinogen-like 2 (Fgl2), mRNA. 139.23 15.32 555.69 126.98 312.10 153.32  
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ILMN_1375025 Fgr NM_024145.2
Gardner-Rasheed feline sarcoma viral (Fgr) oncogene homolog (Fgr), 
mRNA. 61.50 2.31 141.81 27.51 80.08 6.47
ILMN_1368356 Fos NM_022197.1 FBJ murine osteosarcoma viral oncogene homolog (Fos), mRNA. 320.70 294.32 3277.88 574.70 2391.67 1583.58
ILMN_1376319 Fus NM_001012137.1
fusion, derived from t(12;16) malignant liposarcoma (human) (Fus), 
mRNA. 654.15 14.52 982.40 62.21 762.66 71.98
ILMN_1350091 G0s2 NM_001009632.1 G0/G1 switch gene 2 (G0s2), mRNA. 615.29 151.77 2275.52 1077.79 712.73 187.97
ILMN_1353208 G7c NM_212499.1 G7c protein (G7c), mRNA. 686.94 30.26 356.72 35.45 532.58 49.06
ILMN_1650307 Galnt3 NM_001015032.2
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 3 (Galnt3), mRNA. 40.45 4.04 79.83 9.22 45.20 3.61
ILMN_1359516 Gclc NM_012815.2 glutamate-cysteine ligase, catalytic subunit (Gclc), mRNA. 341.60 41.42 747.93 150.56 456.10 72.12
ILMN_1351674 Gdf15 NM_019216.1 growth differentiation factor 15 (Gdf15), mRNA. 47.89 3.97 102.32 26.84 71.54 8.05
ILMN_1360656 Gfpt2 NM_001002819.2 glutamine-fructose-6-phosphate transaminase 2 (Gfpt2), mRNA. 187.72 81.63 744.63 184.08 550.46 290.15
ILMN_1364441 Gja3 NM_024376.1 gap junction membrane channel protein alpha 3 (Gja3), mRNA. 93.91 5.36 63.98 2.62 84.87 0.75
ILMN_1368524 Glg1 NM_017211.1 golgi apparatus protein 1 (Glg1), mRNA. 634.21 68.54 373.10 23.29 595.10 118.57
ILMN_1376740 Glipr1 NM_001011987.1 GLI pathogenesis-related 1 (glioma) (Glipr1), mRNA. 101.54 8.77 520.91 105.49 167.67 19.60
ILMN_1356369 Glrx1 NM_022278.1 glutaredoxin 1 (thioltransferase) (Glrx1), mRNA. 212.56 91.60 771.83 132.65 326.59 10.13
ILMN_1362702 Gmfg NM_181091.2 glia maturation factor, gamma (Gmfg), mRNA. 292.50 58.00 1339.99 472.57 519.47 16.75
ILMN_1371475 Gmpr NM_057188.1 guanosine monophosphate reductase (Gmpr), mRNA. 1417.92 143.76 828.62 73.13 1089.18 50.54
ILMN_1364579 Gnai3 NM_013106.1 guanine nucleotide binding protein, alpha inhibiting 3 (Gnai3), mRNA. 1289.60 56.72 2167.86 29.73 1769.68 163.11
ILMN_1357924 Gnl3 NM_175580.2 guanine nucleotide binding protein-like 3 (nucleolar) (Gnl3), mRNA. 106.09 18.75 215.48 31.63 132.62 3.69
ILMN_1350620 Gp1bb NM_053930.3 glycoprotein Ib, beta polypeptide (Gp1bb), mRNA. 207.90 33.79 411.73 58.17 325.76 26.56
ILMN_1373962 Gp9 NM_001031825.1 glycoprotein 9 (Gp9), mRNA. 36.27 1.93 59.63 7.32 44.67 4.94
ILMN_1350738 Gpr109a NM_181476.1 G protein-coupled receptor 109A (Gpr109a), mRNA. 33.34 1.43 75.95 9.76 43.16 3.47
ILMN_1351646 Gpr4 NM_001025680.1 G protein-coupled receptor 4 (Gpr4), mRNA. 172.94 14.90 333.22 67.27 241.20 5.88
ILMN_1356615 Gpr65_predicted XM_234367.3  G-protein coupled receptor 65 (predicted) (Gpr65_predicted), mRNA. 40.67 1.70 59.00 2.74 41.74 0.31
ILMN_1357506 Gpsm1 NM_144745.1
G-protein signalling modulator 1 (AGS3-like, C. elegans) (Gpsm1), 
mRNA. 178.72 14.61 113.27 8.22 162.19 21.73
ILMN_1371385 Gpsm3 NM_001003974.2
G-protein signalling modulator 3 (AGS3-like, C. elegans) (Gpsm3), 
mRNA. 59.73 6.51 102.39 17.64 61.55 2.81
ILMN_1650650 Gypc NM_001013233.1 glycophorin C (Gerbich blood group) (Gypc), mRNA. 503.54 34.24 328.19 23.58 418.98 15.72
ILMN_1349008 H3f3b NM_053985.2 H3 histone, family 3B (H3f3b), mRNA. 1318.13 211.92 2530.97 262.41 2047.19 217.86
ILMN_1373013 Hck NM_013185.2 hemopoietic cell kinase (Hck), mRNA. 70.02 13.10 156.37 28.86 113.44 12.67
ILMN_1349287 Hiat1_predicted XM_001067587.1
 hippocampus abundant gene transcript 1 (predicted) (Hiat1_predicted), 
mRNA. 202.69 15.08 353.18 49.25 258.83 9.68
ILMN_1371051 Hk3 NM_022179.2 hexokinase 3 (Hk3), mRNA. 56.24 12.12 105.58 11.47 75.29 5.17
ILMN_1650285 Hmox1 NM_012580.2 heme oxygenase (decycling) 1 (Hmox1), mRNA. 1619.45 246.27 3735.65 709.27 2799.72 320.78
ILMN_1369798 Hnrpf NM_001037285.1
heterogeneous nuclear ribonucleoprotein F (Hnrpf), transcript variant 2, 
mRNA. 1471.44 38.38 2399.29 144.07 1831.40 72.42
ILMN_1651184 Hp NM_012582.2 haptoglobin (Hp), mRNA. 157.98 123.35 1526.51 227.31 585.06 53.07
ILMN_1358144 Hspca NM_175761.2 heat shock protein 1, alpha (Hspca), mRNA. 381.31 44.09 1451.86 180.53 920.48 506.44
ILMN_1364500 Hspcal3_predicted XM_216334.3
 heat shock 90kDa protein 1, alpha-like 3 (predicted) (Hspcal3_predicted), 
mRNA. 356.34 61.51 1334.04 224.31 966.14 548.05  
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ILMN_1367519 Idi1 NM_053539.1 isopentenyl-diphosphate delta isomerase (Idi1), mRNA. 89.76 2.64 159.31 19.31 111.20 21.14
ILMN_1352529 Ier2 NM_001009541.1 immediate early response 2 (Ier2), mRNA. 459.09 99.66 1050.29 178.42 752.11 113.85
ILMN_1530409 Ier5 NM_001025137.1 immediate early response 5 (Ier5), mRNA. 43.33 8.34 88.17 8.45 66.44 14.37
ILMN_2040190 Ifit1_predicted XM_220058.2
 interferon-induced protein with tetratricopeptide repeats 1 (predicted) 
(Ifit1_predicted), mRNA. 92.50 49.38 760.25 310.13 275.58 70.23
ILMN_1374737 Ifitm6_predicted XM_219476.3
 interferon induced transmembrane protein 6 (predicted) 
(Ifitm6_predicted), mRNA. 117.43 86.70 889.26 510.79 405.87 103.70
ILMN_1373523 Igfbp3 NM_012588.1 insulin-like growth factor binding protein 3 (Igfbp3), mRNA. 289.42 20.22 631.42 107.59 422.74 26.05
ILMN_1356655 Il17r_predicted XM_232247.4  interleukin 17 receptor (predicted) (Il17r_predicted), mRNA. 77.23 17.75 228.73 34.40 133.41 19.36
ILMN_1349030 Il1r2 NM_053953.1 interleukin 1 receptor, type II (Il1r2), mRNA. 222.44 133.60 3658.11 1179.89 1091.62 555.73
ILMN_1361277 Il1rn XM_001071294.1  interleukin 1 receptor antagonist, transcript variant 1 (Il1rn), mRNA. 61.63 13.44 213.78 35.47 115.86 20.60
ILMN_1352340 Il8rb NM_017183.1 interleukin 8 receptor, beta (Il8rb), mRNA. 38.09 4.42 188.36 89.92 84.66 10.98
ILMN_1351826 Ippk NM_001008556.1 inositol 1,3,4,5,6-pentakisphosphate 2-kinase (Ippk), mRNA. 63.32 4.44 133.19 9.04 109.85 36.63
ILMN_1366898 Irf2bp1_predicted XM_001075292.1
 interferon regulatory factor 2 binding protein 1 (predicted) 
(Irf2bp1_predicted), mRNA. 278.63 18.30 172.27 24.85 207.48 2.58
ILMN_1357140 Irx4_predicted XM_001057125.1
 Iroquois related homeobox 4 (Drosophila) (predicted), transcript variant 1 
(Irx4_predicted), mRNA. 204.69 24.63 119.21 16.01 148.31 6.68
ILMN_1650489 Isoc2b NM_001008367.1 isochorismatase domain containing 2b (Isoc2b), mRNA. 241.92 8.59 165.34 9.50 232.00 4.31
ILMN_1353551 Itgb7 XM_001067562.1  integrin, beta 7 (Itgb7), mRNA. 54.54 4.35 106.68 20.27 73.18 2.10
ILMN_1370633 Itpkc NM_178094.2 inositol 1,4,5-trisphosphate 3-kinase C (Itpkc), mRNA. 107.58 37.68 341.10 121.61 238.06 27.95
ILMN_1354357 Jmjd1c XM_001080424.1  jumonji domain containing 1C (Jmjd1c), mRNA. 234.74 13.50 470.55 65.14 401.53 36.70
ILMN_1368412 Jmjd3_predicted XM_001079385.1  jumonji domain containing 3 (predicted) (Jmjd3_predicted), mRNA. 139.10 19.69 397.01 118.94 348.85 22.84
ILMN_1650950 Josd3 NM_001014207.1 Josephin domain containing 3 (Josd3), mRNA. 114.46 17.62 201.56 16.67 123.67 20.58
ILMN_1353022 Jph2 NM_001037974.1 junctophilin 2 (Jph2), mRNA. 106.87 11.58 63.38 4.26 99.68 6.71
ILMN_1356110 Klf4 NM_053713.1 Kruppel-like factor 4 (gut) (Klf4), mRNA. 369.84 73.72 807.42 105.04 475.08 110.07
ILMN_1361302 Klf5 NM_053394.2 Kruppel-like factor 5 (Klf5), mRNA. 146.91 9.81 365.79 36.37 463.67 16.35
ILMN_1362080 Klf6 NM_031642.2 Kruppel-like factor 6 (Klf6), mRNA. 1029.62 275.41 2208.02 339.40 2168.59 191.84
ILMN_1364370 Klrb1b NM_173292.1  killer cell lectin-like receptor subfamily B member 1B (Klrb1b), mRNA. 36.66 2.71 66.04 11.11 40.80 4.53
ILMN_1365751 Kpnb3_predicted XM_224534.3  karyopherin (importin) beta 3 (predicted) (Kpnb3_predicted), mRNA. 428.79 45.77 1079.59 239.95 644.26 133.79
ILMN_1372499 Lad1_predicted XM_001063663.1  ladinin (predicted) (Lad1_predicted), mRNA. 208.54 29.72 124.00 13.30 151.84 4.05
ILMN_1357030 Laptm5 NM_053538.2 lysosomal-associated protein transmembrane 5 (Laptm5), mRNA. 162.16 9.08 310.66 12.64 201.94 17.84
ILMN_1376661 Lbp NM_017208.1 lipopolysaccharide binding protein (Lbp), mRNA. 90.41 14.35 206.15 23.06 113.00 1.09
ILMN_1376765 Lcp1 NM_001012044.1 lymphocyte cytosolic protein 1 (Lcp1), mRNA. 804.18 138.86 3023.13 478.44 1662.49 40.19
ILMN_1354751 Leng4_predicted XM_001056203.1
 leukocyte receptor cluster (LRC) member 4 (predicted) 
(Leng4_predicted), mRNA. 55.30 4.72 85.78 8.62 64.38 3.53
ILMN_1370840 Lgals3 NM_031832.1 lectin, galactose binding, soluble 3 (Lgals3), mRNA. 1292.35 150.44 2525.01 354.08 1305.17 142.72
ILMN_1368490 LOC24906 NM_031537.1 RoBo-1 (LOC24906), mRNA. 55.55 7.67 160.68 27.00 78.63 3.54
ILMN_1357555 LOC307907 XM_226529.3   similar to RIKEN cDNA 6430548M08 (predicted) (LOC307907), mRNA. 908.46 126.97 514.58 7.67 768.92 151.18
ILMN_1350326 LOC308990 NM_001025001.1 hypothetical protein LOC308990 (LOC308990), mRNA. 43.14 1.71 123.58 17.81 59.66 1.42
ILMN_1359287 LOC310086 XM_226757.3   similar to RIKEN cDNA D130064H19 (predicted) (LOC310086), mRNA. 125.07 4.38 185.50 8.42 139.24 5.21
ILMN_1370088 LOC311984 XM_001062783.1  similar to RIKEN cDNA A530088I07 gene (LOC311984), mRNA. 166.78 35.97 390.94 24.39 301.87 2.46
ILMN_1364945 LOC315883 NM_001014094.1 similar to phospholipid scramblase 2 (LOC315883), mRNA. 140.49 8.27 282.82 21.15 279.95 5.36  
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ILMN_1354457 LOC316207 XM_236901.3
 similar to RIKEN cDNA B430306N03 gene (predicted) (LOC316207), 
mRNA. 34.11 2.66 78.93 18.95 41.92 3.44
ILMN_1359784 LOC362115 XM_342417.2  similar to RIKEN cDNA 9130404D14 (predicted) (LOC362115), mRNA. 174.18 8.06 336.60 69.53 205.17 3.12
ILMN_1364095 LOC362703 XM_001061088.1  similar to WD-repeat protein 43 (LOC362703), mRNA. 221.29 52.64 464.93 43.40 340.27 29.15
ILMN_1370198 LOC363060 NM_001014209.1 similar to RIKEN cDNA 1600029D21 (LOC363060), mRNA. 57.54 1.92 128.17 10.41 70.23 10.31
ILMN_1367516 LOC363331 XM_343669.2  similar to S3-12 (LOC363331), mRNA. 250.70 41.26 117.72 21.33 184.88 16.46
ILMN_1358168 LOC363897 XR_009066.1
 similar to Ras-related protein Rap-1b precursor (GTP-binding protein 
smg p21B) (LOC363897), mRNA. 1701.37 53.12 3101.58 166.30 2162.57 241.79
ILMN_1651187 LOC497712 XM_579055.1  hypothetical gene supported by NM_001001511 (LOC497712), mRNA. 187.46 11.55 619.18 92.86 392.81 25.09
ILMN_1369063 LOC497722 XM_579583.1  hypothetical gene supported by NM_053905 (LOC497722), mRNA. 75.17 6.32 167.01 23.11 93.33 0.80
ILMN_1357799 LOC497748 XM_579551.1  hypothetical gene supported by NM_053313 (LOC497748), mRNA. 47.19 12.72 198.74 57.90 73.63 7.37
ILMN_1357368 LOC497841 XM_579384.1  hypothetical gene supported by NM_016994 (LOC497841), mRNA. 85.45 27.92 269.65 47.92 151.28 43.21
ILMN_1370087 LOC498062 XM_573260.1  similar to RIKEN cDNA 1190017O12 (LOC498062), mRNA. 598.42 33.23 395.75 27.77 522.03 17.68
ILMN_1355544 LOC498276 XM_573502.1
 similar to Fc gamma (IgG) receptor II (low affinity) alpha precursor - rat 
(LOC498276), mRNA. 1119.06 412.70 3610.21 1428.77 2359.73 170.17
ILMN_1370638 LOC498277 XR_007542.1
 similar to Low affinity immunoglobulin gamma Fc region receptor III 
precursor (IgG Fc receptor III) (Fc-gamma RIII) (FcRIII) (LOC498277), 
mRNA.
265.68 118.18 1068.85 389.98 537.18 56.89
ILMN_1351139 LOC498279 XM_001053627.1
 similar to High affinity immunoglobulin epsilon receptor gamma-subunit 
precursor (FceRI gamma) (IgE Fc receptor gamma-subunit) (Fc-epsilon RI-
gamma) (LOC498279), mRNA.
997.36 200.37 2604.83 574.13 1355.74 165.69
ILMN_1372294 LOC499078 XM_001070660.1  similar to glycoprotein 49b (LOC499078), mRNA. 40.48 1.65 86.72 18.92 48.42 2.63
ILMN_1366459 LOC499612 XM_574939.1
 similar to NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 1 
(LOC499612), mRNA. 88.77 2.72 62.00 3.66 73.56 3.91
ILMN_1351679 LOC500040 XM_575396.1  similar to Testis derived transcript (LOC500040), mRNA. 275.12 57.81 985.04 245.20 449.82 60.33
ILMN_1351690 LOC500687 XM_580105.1  LOC500687 (LOC500687), mRNA. 68.81 4.84 145.61 19.37 96.26 9.54
ILMN_1354808 LOC500904 XM_576306.2  similar to neutrophil cytosolic factor 4 (LOC500904), mRNA. 66.19 10.79 153.63 21.98 83.60 0.10
ILMN_1371731 LOC501284 XM_576699.1  similar to mKIAA1881 protein (LOC501284), mRNA. 233.07 11.76 139.83 23.93 191.24 11.06
ILMN_1370116 LOC501594 XM_580217.1  LOC501594 (LOC501594), mRNA. 720.42 34.82 1087.15 88.71 891.42 32.15
ILMN_1366909 LOC683463 XM_001066042.1  similar to paired-Ig-like receptor B (LOC683463), mRNA. 51.20 9.74 148.41 45.35 59.52 2.71
ILMN_1375048 LOC684525 XM_001070830.1  similar to stefin A2 like 1 (LOC684525), mRNA. 72.22 20.06 1106.89 547.23 261.25 110.29
ILMN_1356957 LOC687856 XM_001080365.1
 similar to Myeloid cell surface antigen CD33 precursor (Siglec-3) 
(LOC687856), mRNA. 45.80 4.06 99.22 18.08 67.93 14.67
ILMN_1353943 Lrg1 NM_001009717.1 leucine-rich alpha-2-glycoprotein 1 (Lrg1), mRNA. 78.21 9.45 155.08 24.90 98.68 14.15
ILMN_1348962 Lrrc10_predicted XM_001080952.1   leucine-rich repeat-containing 10 (predicted) (Lrrc10_predicted), mRNA. 927.68 171.55 305.51 46.52 483.32 65.76
ILMN_1363263 Lrrc8c NM_001037179.1 leucine rich repeat containing 8 family, member C (Lrrc8c), mRNA. 187.50 21.26 312.84 21.04 241.51 38.96
ILMN_1356330 Lst1 NM_022634.1 leucocyte specific transcript 1 (Lst1), mRNA. 54.58 9.92 108.43 12.98 67.80 8.23
ILMN_1354499 Ltb NM_212507.2 lymphotoxin B (Ltb), mRNA. 64.67 13.30 280.95 107.97 136.67 33.79
ILMN_1367927 Ly49i8 NM_001009486.1 Ly49 inhibitory receptor 8 (Ly49i8), mRNA. 46.13 6.42 74.34 5.32 51.68 2.37
ILMN_1349844 Maea NM_001008319.1 macrophage erythroblast attacher (Maea), mRNA. 1042.82 108.39 631.44 19.11 816.16 43.48
ILMN_1361027 Mafb NM_019316.1
v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B 
(avian) (Mafb), mRNA. 94.92 12.87 167.59 4.40 122.56 3.74  
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ILMN_1371205 Map4k1_predicted XM_001074916.1
 mitogen activated protein kinase kinase kinase kinase 1 (predicted) 
(Map4k1_predicted), mRNA. 77.68 14.51 187.05 41.10 119.02 3.76
ILMN_1359095 Mat2a NM_134351.1 methionine adenosyltransferase II, alpha (Mat2a), mRNA. 124.22 2.21 245.77 46.07 159.38 24.68
ILMN_1355362 Mca32 NM_021585.1 mast cell antigen 32 (Mca32), mRNA. 43.37 3.61 72.91 9.92 46.93 3.95
ILMN_1357312 Mcl1 NM_021846.2 myeloid cell leukemia sequence 1 (Mcl1), mRNA. 775.05 80.62 2102.88 38.08 1250.33 412.47
ILMN_1374845 MGC105649 NM_001008518.1 hypothetical LOC302884 (MGC105649), mRNA. 60.83 15.83 269.28 50.66 128.55 20.01
ILMN_1375131 MGC125015 NM_001037356.1 similar to PAK/PLC-interacting protein 1 (MGC125015), mRNA. 123.09 20.62 237.93 36.86 201.99 10.61
ILMN_1361776 MGC72584 NM_001009535.1 similar to postmeiotic segregation increased 1 (MGC72584), mRNA. 283.51 34.42 167.92 17.53 201.73 9.64
ILMN_1373900 MGC72974 NM_198772.1 hypothetical LOC316976 (MGC72974), mRNA. 572.32 148.92 239.71 44.21 330.37 18.56
ILMN_1348979 MGC93707 NM_001005556.1 similar to RIKEN cDNA D430028G21 (MGC93707), mRNA. 757.48 33.82 357.45 11.87 532.07 112.63
ILMN_1364243 MGC94207 NM_001007751.1 similar to RIKEN cDNA C030006K11 (MGC94207), mRNA. 277.60 17.90 168.89 11.81 230.81 3.08
ILMN_1363911 MGC94339 NM_001007703.1 similar to BC002216 protein (MGC94339), mRNA. 157.69 19.78 96.80 6.46 129.80 0.55
ILMN_1376722 MGC94736 NM_001007685.1 similar to hypothetical protein MGC35097 (MGC94736), mRNA. 239.50 13.32 158.09 8.49 235.24 9.80
ILMN_1349697 Midn_predicted XM_001076784.1  midnolin (predicted) (Midn_predicted), mRNA. 61.48 3.61 100.93 17.15 132.99 0.75
ILMN_1371081 Mmp8 NM_022221.1 matrix metallopeptidase 8 (Mmp8), mRNA. 68.25 16.86 634.17 210.11 192.97 79.93
ILMN_2039240 Mmp9 NM_031055.1 matrix metallopeptidase 9 (Mmp9), mRNA. 68.78 14.46 239.77 77.34 127.06 48.33
ILMN_1367596 Mocs2 XM_001067999.1   molybdenum cofactor synthesis 2, transcript variant 1 (Mocs2), mRNA. 2299.10 37.03 1319.29 71.40 1878.18 228.46
ILMN_1367384 Mox2r NM_023953.1
antigen identified by monoclonal antibody MRC OX-2 receptor (Mox2r), 
mRNA. 55.50 6.31 108.67 25.79 72.75 6.18
ILMN_1376777 Mpst NM_138843.1 mercaptopyruvate sulfurtransferase (Mpst), mRNA. 860.99 114.67 540.78 24.65 742.18 46.13
ILMN_1357886 Mrpl16 NM_001009647.1 mitochondrial ribosomal protein L16 (Mrpl16), mRNA. 409.72 36.47 273.26 16.68 396.72 2.15
ILMN_1362859 Mrpl22_predicted XM_213307.4
 mitochondrial ribosomal protein L22 (predicted) (Mrpl22_predicted), 
mRNA. 1180.24 23.60 819.95 43.23 971.27 15.75
ILMN_1359659 Mrpl50_predicted XM_342835.2
 mitochondrial ribosomal protein L50 (predicted) (Mrpl50_predicted), 
mRNA. 601.49 38.59 356.60 22.66 499.33 26.93
ILMN_1359365 Mtmr7_predicted XM_240417.4  myotubularin related protein 7 (predicted) (Mtmr7_predicted), mRNA. 38.96 0.59 71.49 5.49 46.61 3.89
ILMN_1353390 Mxd1 XM_001074696.1  max dimerization protein 1 (Mxd1), mRNA. 57.54 13.70 148.83 38.83 94.83 27.91
ILMN_1359024 Myd88 NM_198130.1 myeloid differentiation primary response gene 88 (Myd88), mRNA. 210.97 63.76 489.85 67.26 381.41 34.71
ILMN_1352095 Myl7_predicted XM_214074.4 mRNA. 156.75 28.88 72.73 13.88 91.28 1.94
ILMN_1357127 Nalp12_predicted XM_001066862.1
 NACHT, leucine rich repeat and PYD containing 12 (predicted) 
(Nalp12_predicted), mRNA. 43.95 1.34 72.00 5.20 45.06 3.97
ILMN_1374896 Napsa NM_031670.1 napsin A aspartic peptidase (Napsa), mRNA. 135.04 49.64 1045.92 279.59 437.30 109.46
ILMN_1359661 Nasp NM_001005543.1 nuclear autoantigenic sperm protein (histone-binding) (Nasp), mRNA. 191.73 19.78 330.21 36.88 252.29 1.95
ILMN_1372165 Nckap1l_predicted XM_001070373.1 NCK associated protein 1 like (predicted) (Nckap1l_predicted), mRNA. 87.78 4.54 146.05 10.96 102.93 0.60
ILMN_1363106 Ndel1 NM_133320.1
nudE nuclear distribution gene E homolog like 1 (A. nidulans) (Ndel1), 
mRNA. 1367.59 55.34 1985.93 80.85 1630.05 159.65
ILMN_1376442 Nedd9 NM_001011922.1
neural precursor cell expressed, developmentally down-regulated gene 9 
(Nedd9), mRNA. 363.14 15.30 695.11 68.06 501.56 81.14
ILMN_1350548 Neurl2_predicted XM_230848.4 neuralized-like 2 (Drosophila) (predicted) (Neurl2_predicted), mRNA. 492.37 32.52 325.37 23.82 464.72 6.51
ILMN_1376557 Nfe2 NM_001012224.1 nuclear factor, erythroid derived 2 (Nfe2), mRNA. 46.31 12.39 191.83 38.04 76.78 0.09
ILMN_1363954 Nip7 NM_138847.1 nuclear import 7 homolog (S. cerevisiae) (Nip7), mRNA. 214.10 49.21 382.77 11.36 258.86 19.92  
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ILMN_1362482 Nkx2-5 NM_053651.1 NK2 transcription factor related, locus 5 (Drosophila) (Nkx2-5), mRNA. 236.89 26.98 140.87 15.21 180.21 26.75
ILMN_1374672 Nol5 NM_021754.1 nucleolar protein 5 (Nol5), mRNA. 705.98 160.46 1721.32 287.68 1177.47 66.15
ILMN_1372107 Nos2 NM_012611.2 nitric oxide synthase 2, inducible (Nos2), mRNA. 44.56 16.40 167.91 61.36 104.26 33.95
ILMN_1357730 Npy NM_012614.1 neuropeptide Y (Npy), mRNA. 155.37 125.07 1334.89 620.78 404.56 141.81
ILMN_1375922 Nr4a3 NM_031628.1
nuclear receptor subfamily 4, group A, member 3 (Nr4a3), transcript 
variant 1, mRNA. 82.53 28.13 395.77 112.96 298.34 65.78
ILMN_1363628 Nt5m_predicted XM_213318.4  5',3'-nucleotidase, mitochondrial (predicted) (Nt5m_predicted), mRNA. 140.50 20.78 76.85 9.49 109.20 1.90
ILMN_1360607 Numbl_predicted XM_218360.3  numb-like (predicted) (Numbl_predicted), mRNA. 84.64 10.52 146.72 13.29 102.42 6.78
ILMN_1358567 Oas1k NM_001009489.1 2 ' -5 ' oligoadenylate synthetase 1K (Oas1k), mRNA. 76.05 6.23 452.29 58.14 150.21 13.88
ILMN_1650001 Ociad1 NM_001013874.1 OCIA domain containing 1 (Ociad1), mRNA. 4272.09 187.72 2896.93 82.75 3988.63 101.31
ILMN_1369735 Odc1 NM_012615.1 ornithine decarboxylase 1 (Odc1), mRNA. 226.70 15.92 433.98 59.05 310.55 37.38
ILMN_1374695 Oldlr1 NM_133306.1  oxidized low density lipoprotein (lectin-like) receptor 1 (Oldlr1), mRNA. 48.48 7.96 116.15 14.02 84.84 25.55
ILMN_1376380 P2ry13 NM_001002853.1 purinergic receptor P2Y, G-protein coupled, 13 (P2ry13), mRNA. 54.55 4.92 93.24 14.57 64.82 3.61
ILMN_1358564 Pabpc1 NM_134353.2 poly(A) binding protein, cytoplasmic 1 (Pabpc1), mRNA. 1173.91 109.23 1950.43 101.30 1483.39 207.30
ILMN_1368846 Pacsin2 NM_130740.2
protein kinase C and casein kinase substrate in neurons 2 (Pacsin2), 
mRNA. 279.08 26.19 125.08 13.38 223.29 0.70
ILMN_1374870 Pafah1b1 NM_031763.3
platelet-activating factor acetylhydrolase, isoform Ib, alpha subunit 45kDa 
(Pafah1b1), mRNA. 65.57 17.87 137.79 10.68 109.03 9.92
ILMN_1351668 Pcf11_predicted XM_001062815.1
 cleavage and polyadenylation factor subunit homolog (S. cerevisiae) 
(predicted) (Pcf11_predicted), mRNA. 304.06 23.75 485.90 39.64 318.60 43.67
ILMN_1364203 Pcna NM_022381.2 proliferating cell nuclear antigen (Pcna), mRNA. 978.97 106.37 1600.08 75.53 1061.50 104.31
ILMN_1365622 Pcyt2 NM_053568.1 phosphate cytidylyltransferase 2, ethanolamine (Pcyt2), mRNA. 489.48 17.65 309.62 28.75 455.53 9.47
ILMN_1353078 Pde4b NM_017031.2 phosphodiesterase 4B, cAMP specific (Pde4b), mRNA. 127.64 65.36 435.45 66.14 324.68 6.86
ILMN_1365682 Pdk3_mapped XM_001056460.1
 pyruvate dehydrogenase kinase, isoenzyme 3 (mapped) 
(Pdk3_mapped), mRNA. 52.51 3.91 104.79 16.33 62.44 7.11
ILMN_1369190 Pdlim7 NM_173125.1 PDZ and LIM domain 7 (Pdlim7), mRNA. 257.62 25.10 709.05 74.89 397.81 27.06
ILMN_1367435 Pdzd7_predicted XM_001057829.1  PDZ domain containing 7 (predicted) (Pdzd7_predicted), mRNA. 171.34 9.97 114.68 9.88 123.73 3.48
ILMN_1350897 Pfc_mapped XM_001056015.1  properdin factor, complement (mapped) (Pfc_mapped), mRNA. 106.40 6.17 276.18 42.57 145.29 11.63
ILMN_1353729 Pgd XM_342979.2  phosphogluconate dehydrogenase (Pgd), mRNA. 482.53 65.54 820.60 72.28 566.39 7.06
ILMN_1351496 Pglyrp1 NM_053373.1 peptidoglycan recognition protein 1 (Pglyrp1), mRNA. 104.08 78.40 1064.75 445.19 326.43 53.91
ILMN_1360748 Pgsg NM_020074.2 proteoglycan peptide core protein (Pgsg), mRNA. 81.93 2.93 153.37 30.95 90.72 13.28
ILMN_1355211 Pim1 NM_017034.1 proviral integration site 1 (Pim1), mRNA. 68.04 2.52 132.99 12.22 102.12 1.99
ILMN_1363160 Plac8_predicted XM_001067597.1  placenta-specific 8 (predicted) (Plac8_predicted), mRNA. 332.93 171.50 1375.66 94.19 746.39 15.21
ILMN_1358127 Plat NM_013151.2 plasminogen activator, tissue (Plat), mRNA. 545.29 60.06 1357.55 105.18 820.87 285.04
ILMN_1352911 Plek NM_001025750.1 pleckstrin (Plek), mRNA. 314.79 132.73 1467.68 485.05 805.87 268.58
ILMN_1349466 Plp2 NM_207601.1 proteolipid protein 2 (Plp2), mRNA. 686.52 22.31 1108.94 40.08 874.21 80.64
ILMN_1358347 Pls3 XM_001057425.1  plastin 3 (T-isoform) (Pls3), mRNA. 164.24 6.51 353.26 65.61 205.21 51.73
ILMN_1357241 Pmm1 NM_001008323.1 phosphomannomutase 1 (Pmm1), mRNA. 502.91 40.26 327.77 26.88 414.60 26.64
ILMN_1373876 Pmp22 NM_017037.1 peripheral myelin protein 22 (Pmp22), mRNA. 553.39 50.47 918.55 113.50 608.41 9.99
ILMN_1367417 Polrmt_predicted XM_001074109.1
 polymerase (RNA) mitochondrial (DNA directed) (predicted) 
(Polrmt_predicted), mRNA. 213.57 13.80 134.29 7.69 162.87 18.33
ILMN_1355213 Ppp1r3b NM_138912.2 protein phosphatase 1, regulatory (inhibitor) subunit 3B (Ppp1r3b), 133.96 15.60 365.25 108.45 259.00 22.72  
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ILMN_1371126 Procr NM_001025733.2 protein C receptor, endothelial (Procr), mRNA. 243.22 40.05 1212.86 379.12 802.35 561.64
ILMN_1353817 Prok2 NM_138852.1 prokineticin 2 (Prok2), transcript variant 2, mRNA. 56.56 25.76 497.54 203.18 138.22 19.10
ILMN_1373510 Pskh1_predicted XM_344760.2  protein serine kinase H1 (predicted) (Pskh1_predicted), mRNA. 153.84 7.36 104.75 4.06 144.94 8.00
ILMN_1368364 Pstpip1_predicted XM_217152.3
 proline-serine-threonine phosphatase-interacting protein 1 (predicted) 
(Pstpip1_predicted), mRNA. 76.13 10.25 199.72 54.58 98.43 9.00
ILMN_1354586 Ptafr NM_053321.2 platelet-activating factor receptor (Ptafr), mRNA. 107.31 17.37 424.03 90.33 182.54 47.91
ILMN_1356425 Ptbp1 NM_022516.4  polypyrimidine tract binding protein 1 (Ptbp1), transcript variant 2, mRNA. 293.32 27.71 531.93 58.42 398.81 43.25
ILMN_1361561 Pten NM_031606.1 phosphatase and tensin homolog (Pten), mRNA. 130.21 7.82 204.85 12.82 151.60 13.17
ILMN_1356563 Ptges2_predicted XM_231144.4  prostaglandin E synthase 2 (predicted) (Ptges2_predicted), mRNA. 340.60 13.80 227.18 8.21 344.92 44.58
ILMN_1349422 Ptgs2 NM_017232.2 prostaglandin-endoperoxide synthase 2 (Ptgs2), mRNA. 224.50 156.54 1202.39 224.74 626.41 315.74
ILMN_1355065 Ptpn1 NM_012637.1 protein tyrosine phosphatase, non-receptor type 1 (Ptpn1), mRNA. 199.35 40.74 386.19 7.61 331.03 5.03
ILMN_1360373 Ptpn6 NM_053908.1 protein tyrosine phosphatase, non-receptor type 6 (Ptpn6), mRNA. 183.89 19.78 371.32 78.38 233.35 21.16
ILMN_1365809 Ptprc XM_001063971.1  protein tyrosine phosphatase, receptor type, C (Ptprc), mRNA. 57.39 8.62 127.89 27.54 67.15 3.77
ILMN_1349137 Ptpro NM_017336.1 protein tyrosine phosphatase, receptor type, O (Ptpro), mRNA. 99.28 19.03 192.56 26.05 107.90 5.40
ILMN_1349760 Pygl NM_022268.1 liver glycogen phosphorylase (Pygl), mRNA. 79.13 16.61 399.31 65.97 170.98 25.87
ILMN_1349016 Rabgef1_predicted XM_001072217.1
 RAB guanine nucleotide exchange factor (GEF) 1 (predicted) 
(Rabgef1_predicted), mRNA. 123.75 8.42 211.55 27.85 167.00 8.06
ILMN_1365800 Rac2 NM_001008384.1 RAS-related C3 botulinum substrate 2 (Rac2), mRNA. 549.40 132.23 1107.26 144.55 770.88 0.74
ILMN_1369914 Rasd1 XM_340809.3  RAS, dexamethasone-induced 1 (Rasd1), mRNA. 145.41 15.69 307.52 62.98 254.11 10.42
ILMN_1354445 Rassf1 NM_001007754.1
Ras association (RalGDS/AF-6) domain family 1 (Rassf1), transcript 
variant 2, mRNA. 267.11 43.39 721.87 66.95 456.31 85.23
ILMN_1353336 Rbm3 XM_001063211.1  RNA binding motif protein 3 (Rbm3), mRNA. 115.28 17.05 256.52 28.62 177.26 29.26
ILMN_1362534 Retnla NM_053333.1 resistin like alpha (Retnla), mRNA. 54.61 1.29 160.33 31.13 73.17 6.18
ILMN_1351830 Retnlg NM_181625.1 resistin-like gamma (Retnlg), mRNA. 139.04 99.32 1683.53 474.49 423.33 48.37
ILMN_1360418 RGD1302996 NM_213610.1 hypothetical protein MGC:15854 (RGD1302996), mRNA. 1116.47 65.83 635.16 74.67 915.61 157.12
ILMN_1355677 RGD1305246 NM_001014028.1 similar to Cgi67 serine protease precursor (RGD1305246), mRNA. 236.23 12.61 464.14 107.32 374.05 46.03
ILMN_1359578 RGD1305574_predicteXM_341388.2
 similar to polymerase (RNA) III (DNA directed) (155kD) (predicted) 
(RGD1305574_predicted), mRNA. 167.35 0.92 107.40 1.74 116.00 3.83
ILMN_1369550 RGD1305622 NM_001013854.1 hypothetical LOC287173 (RGD1305622), mRNA. 470.85 26.94 332.45 3.98 426.20 4.70
ILMN_1374611 RGD1306595 NM_001025626.1 similar to hypothetical protein (RGD1306595), mRNA. 390.42 30.05 201.57 20.12 299.96 22.61
ILMN_1650056 RGD1306658 NM_001014216.1 similar to 5830411E10Rik protein (RGD1306658), mRNA. 328.28 51.00 725.00 100.22 535.91 22.80
ILMN_1367232 RGD1307396_predicteXM_341029.3
 similar to RIKEN cDNA 6330406I15 (predicted) 
(RGD1307396_predicted), mRNA. 168.75 28.59 362.29 24.39 278.81 0.76
ILMN_1373687 RGD1307618_predicteXM_001070654.1
 similar to chondroitin beta1,4 N-acetylgalactosaminyltransferase 
(predicted), transcript variant 3 (RGD1307618_predicted), mRNA. 77.38 6.43 134.55 13.39 112.13 5.24
ILMN_1373864 RGD1308113 NM_001008296.1 similar to CGI-112 protein (RGD1308113), mRNA. 474.44 14.46 327.77 20.57 419.55 28.19
ILMN_1370898 RGD1308872_predicteXM_214620.4
 similar to Retinoblastoma-binding protein 8 (RBBP-8) (CtBP interacting 
protein) (CtIP) (Retinoblastoma-interacting protein and myosin-like) (RIM) 
(predicted) (RGD1308872_predicted), mRNA.
105.91 5.60 197.17 19.92 148.90 17.19
ILMN_2040884 RGD1309802_predicteXM_233480.3
 similar to RIKEN cDNA 3110037I16 (predicted) 
(RGD1309802_predicted), mRNA. 89.29 6.70 210.77 29.56 113.78 12.13  
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ILMN_2038944 RGD1309802_predicteXM_233480.3
 similar to RIKEN cDNA 3110037I16 (predicted) 
(RGD1309802_predicted), mRNA. 91.43 5.37 189.39 29.86 107.77 1.45
ILMN_1351911 RGD1310168_predicteXM_219540.4
 similar to cDNA sequence BC032204 (predicted) 
(RGD1310168_predicted), mRNA. 68.49 5.59 115.07 15.56 78.81 3.51
ILMN_1357039 RGD1310357_predicteXM_001065047.1
 similar to RIKEN cDNA 2810457I06 (predicted) 
(RGD1310357_predicted), mRNA. 82.31 6.11 145.83 23.56 131.92 16.42
ILMN_1373668 RGD1310553 NM_001008517.1 similar to expressed sequence AI597479 (RGD1310553), mRNA. 274.91 18.44 166.63 22.34 208.90 21.29
ILMN_1349555 RGD1359509 NM_001009671.1 similar to hypothetical protein FLJ13448 (RGD1359509), mRNA. 898.78 210.14 2405.41 476.33 1697.21 179.72
ILMN_1366226 RGD1359713 NM_001005882.1 hypothetical RNA binding protein RGD1359713 (RGD1359713), mRNA. 49.47 4.64 78.94 9.29 63.54 0.77
ILMN_1375084 RGD1559897_predicteXM_001066538.1
 similar to osteoclast-associated receptor mOSCAR-M1 (predicted) 
(RGD1559897_predicted), mRNA. 39.50 1.08 63.54 8.57 36.86 0.18
ILMN_1353276 RGD1559981_predicteXM_001056018.1
 similar to leucine rich repeat containing 27 (predicted), transcript variant 1 
(RGD1559981_predicted), mRNA. 1099.02 47.57 674.26 47.79 987.32 115.99
ILMN_1359028 RGD1559988_predicteXM_222107.4
 similar to RIKEN cDNA 2410018M08 (predicted) 
(RGD1559988_predicted), mRNA. 49.87 1.75 82.99 2.54 69.51 1.50
ILMN_1366543 RGD1560119_predicteXR_008328.1
 similar to actin alpha 1 skeletal muscle protein (predicted) 
(RGD1560119_predicted), mRNA. 73.72 14.73 183.26 45.11 125.64 0.15
ILMN_1364192 RGD1560523_predicteXM_573428.2
  similar to S-adenosylmethionine synthetase gamma form (Methionine 
adenosyltransferase) (predicted) (RGD1560523_predicted), mRNA. 346.17 57.33 695.54 94.40 565.18 66.52
ILMN_1364315 RGD1560676_predicteXM_573293.1  similar to stefin A2 (predicted) (RGD1560676_predicted), mRNA. 124.35 41.77 3162.73 733.71 527.78 27.13
ILMN_1356132 RGD1561016_predicteXM_575925.2  similar to BC013712 protein (predicted) (RGD1561016_predicted), 49.49 8.47 93.39 2.56 68.46 1.49
ILMN_1365578 RGD1561055_predicteXM_577041.2
 similar to Ferritin light chain 2 (Ferritin L subunit 2) (Ferritin subunit LG) 
(predicted) (RGD1561055_predicted), mRNA. 1790.45 312.18 2983.14 265.73 2081.58 111.28
ILMN_1367061 RGD1561141_predicteXR_007837.1
 similar to solute carrier family 25 (mitochondrial carrier, Aralar), member 
12 (predicted) (RGD1561141_predicted), mRNA. 1690.24 215.21 926.47 98.85 1443.93 1.53
ILMN_1366301 RGD1561143_predicteXM_222031.4
 similar to cell surface receptor FDFACT (predicted) 
(RGD1561143_predicted), mRNA. 49.71 4.49 77.81 5.99 50.48 3.70
ILMN_1364910 RGD1561967_predicteXM_573497.2
 similar to UDP-N-acteylglucosamine pyrophosphorylase 1 homolog 
(predicted) (RGD1561967_predicted), mRNA. 1161.06 247.13 4166.40 1038.30 2879.18 674.82
ILMN_1368068 RGD1562105_predicteXM_001070699.1
 similar to Rho-GTPase-activating protein 25 (predicted) 
(RGD1562105_predicted), mRNA. 42.02 0.94 68.75 4.24 44.19 5.40
ILMN_1372724 RGD1562136_predicteXM_001070947.1  similar to D1Ertd622e protein (predicted) (RGD1562136_predicted), 139.30 17.80 304.06 19.33 176.43 6.88
ILMN_1362293 RGD1562305_predicteXM_214902.4
 similar to suprabasal-specific protein suprabasin (predicted) 
(RGD1562305_predicted), mRNA. 154.52 10.66 83.69 6.14 119.67 26.55
ILMN_1366128 RGD1562311_predicteXR_008266.1  similar to PIRA5 (predicted) (RGD1562311_predicted), mRNA. 43.86 4.51 89.26 7.07 49.94 0.30
ILMN_1371053 RGD1562655_predicteXR_007646.1  similar to toll-like receptor 13 (predicted) (RGD1562655_predicted), 98.54 18.28 325.91 111.82 151.88 5.58
ILMN_1349102 RGD1562922_predicteXM_001057256.1
 similar to ankyrin repeat-containing SOCS box protein 10 (predicted) 
(RGD1562922_predicted), mRNA. 159.99 35.80 74.98 17.72 89.10 13.25
ILMN_1374520 RGD1563073_predicteXR_009371.1   similar to SIGLEC-like 1 (predicted) (RGD1563073_predicted), mRNA. 38.55 2.04 85.64 14.68 42.02 5.47
ILMN_1350364 RGD1563798_predicteXR_007778.1  similar to BC040823 protein (predicted) (RGD1563798_predicted), 193.88 27.13 114.09 12.60 193.44 5.81
ILMN_1370551 RGD1563888_predicteXM_001068357.1
 similar to DNA segment, Chr 16, ERATO Doi 472, expressed (predicted) 
(RGD1563888_predicted), mRNA. 75.61 10.16 177.46 24.27 125.57 18.62  
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ILMN_1362050 RGD1563994_predicteXM_001064713.1
 similar to hypothetical protein A330042H22 (predicted) 
(RGD1563994_predicted), mRNA. 37.64 4.37 96.88 28.14 49.41 7.50
ILMN_1366126 RGD1564040_predicteXM_001062502.1
 similar to methylenetetrahydrofolate dehydrogenase (NAD) (EC 
1.5.1.15)/methenyltetrahydrofolate cyclohydrolase (EC 3.5.4.9) precursor 
(predicted) (RGD1564040_predicted), mRNA.
102.13 12.56 166.40 11.69 129.87 1.44
ILMN_1370131 RGD1564130_predicteXM_347206.3
 similar to TBP-associated factor 172 (TAF-172) (TAF(II)170) (predicted) 
(RGD1564130_predicted), mRNA. 148.49 16.52 308.98 64.66 203.66 18.10
ILMN_1367672 RGD1564330_predicteXM_343179.3
 similar to PML-RAR alpha-regulated adaptor molecule-1 (predicted) 
(RGD1564330_predicted), mRNA. 44.31 6.40 160.20 39.97 67.57 1.50
ILMN_1357240 RGD1564549_predicteXM_214831.4
 similar to hypothetical protein FLJ20512 (predicted) 
(RGD1564549_predicted), mRNA. 944.73 76.18 622.44 33.09 888.45 7.81
ILMN_1349895 RGD1565140_predicteXM_001067977.1   similar to Clecsf12 protein (predicted) (RGD1565140_predicted), mRNA. 55.13 3.25 321.56 110.97 116.31 31.47
ILMN_1365610 RGD1565319_predicteXM_001070153.1
 similar to Delta-interacting protein A (Hepatitis delta antigen interacting 
protein A) (predicted) (RGD1565319_predicted), mRNA. 109.44 47.94 564.76 231.02 257.77 102.31
ILMN_1351274 RGD1565374_predicteXM_573339.2
 similar to hypothetical protein LOC199675 (predicted) 
(RGD1565374_predicted), mRNA. 62.83 21.05 579.22 132.62 149.33 54.37
ILMN_1374656 RGD1565451_predicteXR_007981.1
 similar to ring finger protein 127 (predicted) (RGD1565451_predicted), 
mRNA. 39.39 1.76 62.98 0.99 50.14 0.60
ILMN_1365821 RGD1566093_predicteXM_001060226.1
 similar to Fusion (involved in t(12;16) in malignant liposarcoma) 
(predicted) (predicted) (RGD1566093_predicted), mRNA. 1538.69 45.20 2236.50 97.12 1844.17 46.52
ILMN_1372185 RGD1566118_predicteXM_001076548.1  RGD1566118 (predicted) (RGD1566118_predicted), mRNA. 323.39 28.20 623.03 31.58 464.06 26.69
ILMN_1362451 Rgs2 NM_053453.1 regulator of G-protein signaling 2 (Rgs2), mRNA. 583.76 173.37 2257.89 721.32 1280.72 341.84
ILMN_1362622 Rhoh NM_001013430.1 ras homolog gene family, member H (Rhoh), mRNA. 103.19 22.28 257.22 74.85 126.16 4.28
ILMN_1364613 Rhoj NM_001008320.1 ras homolog gene family, member J (Rhoj), mRNA. 364.52 23.96 619.29 47.19 631.05 95.00
ILMN_1357763 Rhoq NM_053522.1 ras homolog gene family, member Q (Rhoq), mRNA. 811.99 98.33 1391.56 116.30 1086.59 196.17
ILMN_1350981 Ripk1_predicted XM_225262.4
 receptor (TNFRSF)-interacting serine-threonine kinase 1 (predicted) 
(Ripk1_predicted), mRNA. 74.12 7.75 138.32 18.19 134.05 16.08
ILMN_1354240 Ripk3 NM_139342.1 receptor-interacting serine-threonine kinase 3 (Ripk3), mRNA. 51.51 6.71 94.64 8.00 62.26 1.95
ILMN_1376851 Rnd3 NM_001007641.1 Rho family GTPase 3 (Rnd3), mRNA. 128.58 12.42 336.72 16.40 277.47 82.71
ILMN_1372230 Rnf149 XM_343561.3  ring finger protein 149 (Rnf149), mRNA. 247.84 57.38 324.53 95.53 92.18 5.85
ILMN_1359238 Rock2 NM_013022.1 Rho-associated coiled-coil forming kinase 2 (Rock2), mRNA. 182.54 4.36 270.48 25.41 229.64 9.04
ILMN_1371943 Runx1 NM_017325.1 runt related transcription factor 1 (Runx1), mRNA. 135.27 34.31 291.56 19.63 231.01 23.68
ILMN_1373883 S100a11 NM_001004095.1 S100 calcium binding protein A11 (calizzarin) (S100a11), mRNA. 2054.54 371.03 3675.86 401.00 2787.39 9.15
ILMN_1350690 S100a8 NM_053822.1 S100 calcium binding protein A8 (calgranulin A) (S100a8), mRNA. 718.96 527.49 7860.78 2652.69 3148.98 532.70
ILMN_1359143 Samsn1 NM_130821.1
SAM domain, SH3 domain and nuclear localization signals, 1 (Samsn1), 
mRNA. 65.72 16.51 268.31 79.28 151.82 50.14
ILMN_1368419 Sat NM_001007667.1 spermidine/spermine N1-acetyl transferase (Sat), mRNA. 678.58 182.52 2504.56 720.99 1506.77 79.16
ILMN_1363777 Scap2 NM_130413.1 src family associated phosphoprotein 2 (Scap2), mRNA. 151.43 26.88 314.80 55.32 216.52 7.89
ILMN_1359759 Scnn1a NM_031548.2 sodium channel, nonvoltage-gated 1 alpha (Scnn1a), mRNA. 43.71 7.29 80.30 9.35 59.86 3.99
ILMN_1369410 Sec23b_predicted XM_001054580.1  SEC23B (S. cerevisiae) (predicted) (Sec23b_predicted), mRNA. 170.46 2.18 319.06 68.35 252.47 39.02
ILMN_1349113 Sell NM_019177.1 selectin, lymphocyte (Sell), mRNA. 69.50 28.71 557.81 104.89 151.57 39.20  
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ILMN_1376428 Sema4a NM_001012078.1
 sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) 
and short cytoplasmic domain, (semaphorin) 4A (Sema4a), mRNA. 138.78 2.66 662.06 47.25 265.59 26.33
ILMN_1353169 Sema4d_predicted XM_001053912.1
 sema domain, immunoglobulin domain (Ig), transmembrane domain 
(TM) and short cytoplasmic domain, (semaphorin) 4D (predicted) 
(Sema4d_predicted), mRNA.
44.75 1.66 67.97 0.26 50.54 1.44
ILMN_1357664 Sema6a_predicted XM_341612.3
 sema domain, transmembrane domain (TM), and cytoplasmic domain, 
(semaphorin) 6A (predicted) (Sema6a_predicted), mRNA. 93.46 4.16 137.76 11.47 106.47 1.55
ILMN_1351430 Serpinb10 NM_153733.2
serine (or cysteine) peptidase inhibitor, clade B (ovalbumin), member 10 
(Serpinb10), mRNA. 36.48 4.15 155.97 56.66 53.00 7.85
ILMN_1352285 Serpinb1a NM_001031642.1
serine (or cysteine) proteinase inhibitor, clade B, member 1a (Serpinb1a), 
mRNA. 226.46 187.90 1543.90 475.42 948.79 65.11
ILMN_2040557 Serpine1 NM_012620.1 serine (or cysteine) peptidase inhibitor, clade E, member 1 (Serpine1), 374.87 134.64 1808.98 685.09 942.06 388.97
ILMN_1376417 Serpine1 NM_012620.1 mRNA. 401.65 119.17 1639.90 500.09 1222.81 584.15
ILMN_1365196 Sertad1 NM_001007735.1 SERTA domain containing 1 (Sertad1), mRNA. 154.62 45.51 333.88 22.09 268.26 51.74
ILMN_1349269 Sgk NM_019232.1 serum/glucocorticoid regulated kinase (Sgk), mRNA. 1246.45 152.58 2506.70 224.04 1908.03 619.89
ILMN_1350798 Slc16a3 NM_030834.1
solute carrier family 16 (monocarboxylic acid transporters), member 3 
(Slc16a3), mRNA. 163.41 95.65 2006.89 779.92 540.08 79.08
ILMN_1363587 Slc25a19 NM_001007674.1
solute carrier family 25 (mitochondrial thiamine pyrophosphate carrier), 
member 19 (Slc25a19), mRNA. 361.32 16.07 247.33 20.69 312.83 8.88
ILMN_1367573 Slc25a25 NM_145677.1
solute carrier family 25 (mitochondrial carrier, phosphate carrier), member 
25 (Slc25a25), mRNA. 231.67 10.76 493.30 99.54 414.07 116.11
ILMN_1362330 Slc25a29 NM_001010958.1
solute carrier family 25 (mitochondrial carrier, palmitoylcarnitine 
transporter), member 29 (Slc25a29), mRNA. 261.58 9.33 157.78 14.69 189.38 32.22
ILMN_1366777 Slc2a6_predicted XM_238321.4
 solute carrier family 2 (facilitated glucose transporter), member 6 
(predicted) (Slc2a6_predicted), mRNA. 47.24 3.90 91.92 12.23 62.09 0.22
ILMN_1362278 Slc5a3 NM_053715.2 solute carrier family 5 (inositol transporters), member 3 (Slc5a3), mRNA. 148.78 21.03 697.49 282.97 462.26 194.77
ILMN_1365729 Slc7a5 NM_017353.1
solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 5 (Slc7a5), mRNA. 115.18 27.55 290.88 56.60 215.60 21.06
ILMN_1360286 Slpi NM_053372.1 secretory leukocyte peptidase inhibitor (Slpi), mRNA. 814.07 610.81 6911.15 2215.57 2699.06 60.41
ILMN_1368002 Snag1_predicted XM_226769.4
 sorting nexin associated golgi protein 1 (predicted) (Snag1_predicted), 
mRNA. 103.52 9.72 300.16 34.40 183.10 79.09
ILMN_1350250 Soat1 NM_031118.1 sterol O-acyltransferase 1 (Soat1), mRNA. 36.72 2.13 54.72 1.05 44.00 2.21
ILMN_1363716 Sorl1_predicted XM_001065506.1
 sortilin-related receptor, L(DLR class) A repeats-containing (predicted) 
(Sorl1_predicted), mRNA. 117.63 4.67 246.28 45.18 120.59 8.87
ILMN_1373357 Sphk1 NM_133386.2 sphingosine kinase 1 (Sphk1), mRNA. 174.40 97.11 1017.34 222.37 744.30 114.44
ILMN_1352642 Spp1 NM_012881.1 secreted phosphoprotein 1 (Spp1), mRNA. 69.25 14.16 261.23 113.96 98.64 2.57
ILMN_1367615 Spsb1_predicted XM_001075317.1
 splA/ryanodine receptor domain and SOCS box containing 1 (predicted) 
(Spsb1_predicted), mRNA. 274.79 45.21 489.31 18.68 431.18 71.66
ILMN_1352951 Stfa2_predicted XM_001070786.1  stefin A2 (predicted) (Stfa2_predicted), mRNA. 126.73 43.19 3042.27 493.95 545.40 88.64
ILMN_1370817 Stk17b NM_133392.1 serine/threonine kinase 17b (apoptosis-inducing) (Stk17b), mRNA. 107.00 5.26 300.92 55.99 146.57 12.05
ILMN_1376772 Stom NM_001011965.1 stomatin (Stom), mRNA. 104.52 9.08 284.28 14.35 193.70 41.15  
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ILMN_1361287 Surb7_predicted XM_001074060.1
 SRB7 (suppressor of RNA polymerase B) homolog (S. cerevisiae) 
(predicted) (Surb7_predicted), mRNA. 310.59 28.26 468.28 26.11 371.14 29.01
ILMN_1350279 Syk NM_012758.1 spleen tyrosine kinase (Syk), mRNA. 52.06 0.71 83.00 6.96 51.10 3.23
ILMN_1360221 Tacstd1 NM_138541.1 tumor-associated calcium signal transducer 1 (Tacstd1), mRNA. 36.87 3.67 133.22 59.79 87.62 34.94
ILMN_1376249 Tf NM_001013110.1 transferrin (Tf), mRNA. 1058.85 21.41 3870.74 1343.10 1975.94 431.07
ILMN_1359732 Tfpi2 NM_173141.1 tissue factor pathway inhibitor 2 (Tfpi2), mRNA. 150.35 61.07 860.96 129.71 454.37 250.93
ILMN_1360947 Tgm1 NM_031659.1 transglutaminase 1 (Tgm1), mRNA. 70.92 8.64 189.66 36.52 139.59 14.78
ILMN_1363727 Thbd NM_031771.2 thrombomodulin (Thbd), mRNA. 261.50 68.98 743.89 57.04 385.82 92.83
ILMN_1366394 Timm13 NM_145781.1
translocase of inner mitochondrial membrane 13 homolog (yeast) 
(Timm13), mRNA. 175.81 9.77 118.51 7.99 156.13 5.86
ILMN_1359200 Timp1 NM_053819.1 tissue inhibitor of metallopeptidase 1 (Timp1), mRNA. 1987.37 1022.76 7652.86 1713.85 5378.48 1201.80
ILMN_1373383 Tiparp_predicted XM_001060648.1
 TCDD-inducible poly(ADP-ribose) polymerase (predicted) 
(Tiparp_predicted), mRNA. 321.23 29.93 927.12 170.06 680.68 79.09
ILMN_1353896 Tlr2 NM_198769.2 toll-like receptor 2 (Tlr2), mRNA. 225.41 123.74 987.04 297.04 431.23 60.43
ILMN_1356202 Tlr6 NM_207604.1 toll-like receptor 6 (Tlr6), mRNA. 131.21 17.10 281.48 20.57 157.43 9.98
ILMN_1361672 Tm4sf1_predicted XM_001060042.1
 transmembrane 4 superfamily member 1 (predicted) (Tm4sf1_predicted), 
mRNA. 883.72 172.10 1930.61 116.98 1381.63 346.34
ILMN_1349318 Tmem49 NM_138839.2 transmembrane protein 49 (Tmem49), mRNA. 730.41 46.35 1148.61 111.71 799.03 106.46
ILMN_1650241 Tmem60_predicted XM_001063081.1  transmembrane protein 60 (predicted) (Tmem60_predicted), mRNA. 441.07 33.77 266.57 22.68 341.11 4.47
ILMN_1351557 Tmem9_predicted XM_001063617.1  transmembrane protein 9 (predicted) (Tmem9_predicted), mRNA. 123.42 5.72 84.44 4.75 105.98 7.19
ILMN_1352021 Tmx2 NM_001007643.1 thioredoxin-related transmembrane protein 2 (Tmx2), mRNA. 454.56 13.32 289.75 23.26 388.13 65.57
ILMN_1649963 Tpm3 NM_173111.1 tropomyosin 3, gamma (Tpm3), transcript variant 2, mRNA. 290.51 75.31 731.52 86.76 426.76 20.77
ILMN_1363774 Tpm3 NM_057208.2 tropomyosin 3, gamma (Tpm3), transcript variant 1, mRNA. 46.04 4.40 75.38 4.98 51.43 8.34
ILMN_1357948 Trem1_predicted XM_217336.4
 triggering receptor expressed on myeloid cells 1 (predicted) 
(Trem1_predicted), mRNA. 73.74 29.13 563.45 296.86 180.36 15.81
ILMN_2040035 Trem1_predicted XM_217336.4
 triggering receptor expressed on myeloid cells 1 (predicted) 
(Trem1_predicted), mRNA. 58.11 13.68 209.13 95.15 90.69 5.17
ILMN_1366607 Trh NM_013046.2 thyrotropin releasing hormone (Trh), mRNA. 133.94 20.47 263.55 11.61 308.35 29.69
ILMN_1361387 Trim45_predicted XM_215666.4  tripartite motif protein 45 (predicted) (Trim45_predicted), mRNA. 319.90 52.11 174.12 13.12 300.45 5.12
ILMN_1376818 Tubb3 NM_139254.1 tubulin, beta 3 (Tubb3), mRNA. 46.55 2.91 71.93 5.87 66.72 8.18
ILMN_1358531 Tubb6 NM_001025675.1 tubulin, beta 6 (Tubb6), mRNA. 323.13 128.48 1200.03 54.74 870.44 14.77
ILMN_1351237 Txnrd1 NM_031614.1 thioredoxin reductase 1 (Txnrd1), mRNA. 187.87 60.30 611.44 40.72 363.16 13.89
ILMN_1372404 Tyrobp NM_212525.1 Tyro protein tyrosine kinase binding protein (Tyrobp), mRNA. 92.37 22.05 234.61 39.68 120.07 10.15
ILMN_1368402 Uap1_predicted XM_222863.4
 UDP-N-acetylglucosamine pyrophosphorylase 1 (predicted) 
(Uap1_predicted), mRNA. 179.04 17.63 768.40 167.01 475.60 158.24
ILMN_1360736 Ugdh NM_031325.1 UDP-glucose dehydrogenase (Ugdh), mRNA. 651.00 314.27 2271.01 406.04 1445.61 356.63
ILMN_1367494 Vdac3 NM_031355.1 voltage-dependent anion channel 3 (Vdac3), mRNA. 6275.70 772.14 4092.54 197.67 5355.04 226.18
ILMN_1364576 Verge NM_001003403.1 vascular early response gene protein (Verge), mRNA. 115.96 8.67 213.56 17.96 170.45 16.94
ILMN_1366783 Vps13d_predicted XM_001073610.1
 vacuolar protein sorting 13D (yeast) (predicted) (Vps13d_predicted), 
mRNA. 581.05 75.28 346.87 9.12 522.07 21.93
ILMN_1375233 Vps24 NM_172331.1 vacuolar protein sorting 24 (yeast) (Vps24), mRNA. 1015.45 6.69 709.81 24.66 895.42 16.15
ILMN_1362991 Vps45 NM_172072.2 vacuolar protein sorting 45 (yeast) (Vps45), mRNA. 135.69 5.96 90.88 7.12 131.71 0.04  
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ILMN_1357658 Wsb1 NM_001025664.1 WD repeat and SOCS box-containing 1 (Wsb1), transcript variant 2, 281.42 20.58 732.82 186.89 475.90 34.11
ILMN_1374460 Yars NM_001025696.1 tyrosyl-tRNA synthetase (Yars), mRNA. 294.88 49.12 576.29 85.34 495.76 72.70
ILMN_1373913 Ywhaz NM_013011.2
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, zeta polypeptide (Ywhaz), mRNA. 1647.25 172.62 3276.01 542.88 2166.15 156.36
ILMN_1376913 Zc3h8 NM_001012090.1 zinc finger CCCH type containing 8 (Zc3h8), mRNA. 228.20 12.20 141.00 13.36 164.61 9.93
ILMN_1364338 Zcchc12 NM_001014065.1 zinc finger, CCHC domain containing 12 (Zcchc12), mRNA. 51.28 1.44 89.35 16.70 71.38 0.22
ILMN_1370665 Zfand2a NM_001008363.1 zinc finger, AN1-type domain 2A (Zfand2a), mRNA. 263.29 40.16 1554.32 551.71 960.21 552.65
ILMN_1370049 Zfp180 NM_144757.1 zinc finger protein 180 (Zfp180), mRNA. 261.91 0.72 170.61 14.08 261.85 22.32
ILMN_1363594 Zfp655 NM_001008362.1 zinc finger protein 655 (Zfp655), mRNA. 338.78 24.44 620.30 47.24 484.53 40.74
ILMN_1359146 Zswim6 XM_226779.4 zinc finger, SWIM domain containing 6 (Zswim6), mRNA. 60.34 2.22 95.84 9.06 80.02 3.59  
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Mr Pl
BF1
BF1 NO RESULT
BF2
BF2 NO RESULT
BF3
BF3 NO RESULT
BF4 1433E_RAT 14-3-3 protein epsilon 1549 106 Rattus 29155 4.63 72% K.LAEQAER.Y  53
K.LAEQAERYDEMVESMK.K  97
K.VAGMDVELTVEER.N  103
K.VAGMDVELTVEER.N  (M) 93
R.NLLSVAYK.N  46
R.IISSIEQK.E  49
K.LICCDILDVLDK.H  2 (C) 94
K.HLIPAANTGESK.V  75
R.YLAEFATGNDR.K  89
R.YLAEFATGNDRK.E  59
R.KEAAENSLVAYK.A  90
K.EAAENSLVAYK.A  79
K.AASDIAMTELPPTHPIR.L  109
K.AASDIAMTELPPTHPIR.L  (M) 157
K.AAFDDAIAELDTLSEESYK.D  87
K.AAFDDAIAELDTLSEESYKDSTLIMQLLR.D  199
K.AAFDDAIAELDTLSEESYKDSTLIMQLLR.D (M) 180
K.DSTLIMQLLR.D  60
K.DSTLIMQLLR.D  (M) 60
BF4 1433E_RAT 14-3-3 protein epsilon 1779 19 Rattus 29155 4.63 54%
BF5 1433E_RAT 14-3-3 protein epsilon 337 31 Rattus 29155 4.63 49% K.VAGMDVELTVEER.N  91
K.VAGMDVELTVEER.N  (M) 102
R.NLLSVAYK.N  43
K.LICCDILDVLDKHLIPAANTGESK.V  2 (C) 46
BF5 1433E_RAT 14-3-3 protein epsilon 282 4 Rattus 29155 4.63 18%
BF07
NBF07 NO RESULT
BF08 74 6 Bovine 24513 4.98 17% R.FFVAPFPEVFGK.E  41
NBF08 NO RESULT 41 1
BWB01
BWB01 NO RESULT
Band Protein Name MASCOT Score
Queries 
matched Species
Theoretical coverage Matched peptides MASCOT ion Score
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Mr Pl
BWB02 156 5 Rattus 68686 6.09 7% R.FPNAEFAEITK.L  65
BWB02 NO RESULT 111 2 Rattus 68686 6.09 4%
BWB03 ODO1_RAT oxoglutarate dehydrogenase E1 component, mt 89 10 Rattus 116221 6.3 8%
BWB03 NO RESULT
BWB04
BWB04 NO RESULT
BWB05
BWB05 NO RESULT
BWB06
BWB06 NO RESULT
BWB07
BWB07 NO RESULT
BWB08
BWB08 NO RESULT
BWB09
BWB09 NO RESULT
BWB10
BWB10 NO RESULT
BWB11
BWB11 NO RESULT
BWB12
BWB12 NO RESULT
BWB13
BWB13 NO RESULT
BWB14 ATPB_RAT    ATP synthase subunit beta, mitochondrial 419 18 Rattus 56318 5.19 36% R.LVLEVAQHLGESTVR.T  56
K.VVDLLAPYAK.G  43
R.VALTGLTVAEYFR.D  72
R.FTQAGSEVSALLGR.I  49
R.AIAELGIYPAVDPLDSTSR.I  42
BWB14 ATPB_RAT    ATP synthase subunit beta, mt 262 5 Rattus 56318 5.19 14%
BWB15 ECHB_RAT Trifunctional enzyme subunit beta, mitochondrial 68 4 Rattus 51382 9.5 8% K.VGAPPLEK.F  36
BWB15 ECHB_RAT Trifunctional enzyme subunit beta, mt 36 1 Rattus 51382 9.5 2%
BWB16
BWB16 NO RESULT
BWB17 KCRS_MOUSE Creatine kinase, sarcomeric mitochondrial 105 8 Mouse 47443 8.64 18%
BWB17 NO RESULT
BWB18 55 2 Bovine 19870 4.93 15% R.VYVEELKPTPEGDLEILLQK.W  51
BWB18 NO RESULT 51 1 Bovine 19870 4.93 11%
BWB19 64 2 Bovine 19870 4.93 15% R.VYVEELKPTPEGDLEILLQK.W  46
BWB19 NO RESULT 46 1 Bovine 19870 4.93 11%
BWB20 1433E_RAT 14-3-3 protein epsilon 70 3 Rattus 29155 4.63 10% R.YLAEFATGNDR.K  36
BWB20 1433E_RAT 14-3-3 protein epsilon 36 1 Rattus 29155 4.63 4%
Band Protein Name MASCOT Score
Queries 
matched Species
Theoretical coverage Matched peptides MASCOT ion Score
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Mr Pl
BWB21 1433E_RAT 14-3-3 protein epsilon 103 8 Rattus 29155 4.63 29% K.LAEQAER.Y  35
BWB21 1433E_RAT 14-3-3 protein epsilon 35 1 Rattus 29155 4.63 3%
BWB22 1433E_RAT 14-3-3 protein epsilon 1090 61 Rattus 29155 4.63 55% K.LAEQAER.Y  49
K.VAGMDVELTVEER.N  83
K.VAGMDVELTVEER.N  (M) 95
R.NLLSVAYK.N  48
R.IISSIEQK.E  50
R.IISSIEQKEENK.G  78
R.QMVETELK.L  (M) 45
K.LICCDILDVLDK.H  2 (C) 94
K.HLIPAANTGESK.V  72
R.YLAEFATGNDR.K  85
K.EAAENSLVAYK.A  73
K.AASDIAMTELPPTHPIR.L  103
K.AASDIAMTELPPTHPIR.L (M) 89
K.AAFDDAIAELDTLSEESYK.D  71
K.AAFDDAIAELDTLSEESYKDSTLIMQLLR.D  133
K.DSTLIMQLLR.D  51
K.DSTLIMQLLR.D  (M) 44
BWB22 1433E_RAT 14-3-3 protein epsilon 1263 17 Rattus 29155 4.63 55%
BWB23
BWB23 NO RESULT
BWB24 CY1_MOUSE Cytochrome c1, heme protein, mitochondrial 98 8 Mouse 35305 9.24 17% R.AANNGALPPDLSYIVR.A  58
BWB24 CY1_MOUSE Cytochrome c1, heme protein, mt 58 1 Mouse 35305 9.24 5%
BWB25 HBB1_RAT Hemoglobin subunit beta-1 70 6 Rattus 15969 7.88 25%
BWB25 NO RESULT
BWB26 HBB1_RAT Hemoglobin subunit beta-1  (or HBB2_RAT) 78 4 Rattus 15969 7.88 19%
HBA_RAT Hemoglobin subunit alpha-1/2 55 3 Rattus 15319 7.82 25% R.MFAAFPTTK.T  36
BWB26 HBA_RAT Hemoglobin subunit alpha-1/2 36 1 Rattus 15319 7.82 6%
BWB27 HBA_RAT Hemoglobin subunit alpha-1/2 210 12 Rattus 15319 7.82 57% R.MFAAFPTTK.T  37
R.MFAAFPTTK.T  (M) 46
K.TYFSHIDVSPGSAQVK.A  63
HBB1_RAT Hemoglobin subunit beta-1 128 8 Rattus 15969 7.88 25% M.VHLTDAEK.A  39
R.LLVVYPWTQR.Y  52
BWB27 HBA_RAT Hemoglobin subunit alpha-1/2 146 3 Rattus 15319 7.82 18%
BWB27 HBB1_RAT Hemoglobin subunit beta-1 91 2 Rattus 15969 7.88 12%
BWB28 HBA_RAT Hemoglobin subunit alpha-1/2 289 13 Rattus 15319 7.82 57% R.MFAAFPTTK.T  38
R.MFAAFPTTK.T (M) 42
K.TYFSHIDVSPGSAQVK.A  93
K.KVADALAK.A  38
K.AADHVEDLPGALSTLSDLHAHK.L  74
HBB1_RAT Hemoglobin subunit beta-1 159 10 Rattus 15969 7.88 38% M.VHLTDAEK.A  46
R.LLVVYPWTQR.Y  48
BWB28 HBA_RAT Hemoglobin subunit alpha-1/2 285 5 Rattus 15319 7.82 39%
BWB28 HBB1_RAT Hemoglobin subunit beta-1 94 2 Rattus 15969 7.88 12%
Matched peptides MASCOT ion Score
Queries 
matched Species
Theoretical coverageBand Protein Name MASCOT Score
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Mr Pl
BWB29 QCR6_RAT Cytochrome b-c1 complex subunit 6, mitochondrial 147 6 Rattus 10417 4.9 29% R.SQTEEDCTEELFDFLHAR.D (C) 114
USMG5_RAT Up-regulated during skeletal muscle growth protein 5 92 3 Rattus 6403 9.84 43% M.AGPESDGQFQFTGIK.K  72
ATP5I_RAT ATP synthase subunit e, mitochondrial 92 2 Rattus 8249 9.34 32% M.VPPVQVSPLIK.F  62
BWB29 QCR6_RAT Cytochrome b-c1 complex subunit 6, mt 114 1 Rattus 10417 4.9 20%
BWB29 USMG5_RAT
Up-regulated during skeletal muscle growth 
protein 5 72 1 Rattus 6403 9.84 26%
BWB29 ATP5I_RAT ATP synthase subunit e, mt 62 1 Rattus 8249 9.34 15%
BNB01
BNB01 NO RESULT
BNB02 54 3 Bovine 19870 4.93 23%
BNB02 NO RESULT
BNB03 NDUS1_RAT
NADH-ubiquinone oxidoreductase 75 kDa subunit, 
mitochondrial 78 5 Rattus 79362 5.65 7%
K1C15_RAT Keratin, type I cytoskeletal 15 70 3 Rattus 48840 4.8 5%
BNB03 NO RESULT
BNB04
BNB04 NO RESULT
BNB05
BNB05 NO RESULT
BNB06
BNB06 NO RESULT
BNB07 EF1A2_RAT Elongation factor 1-alpha 259 10 Rattus 50422 9.11 12% K.YYITIIDAPGHR.D  38
R.EHALLAYTLGVK.Q  56
R.LPLQDVYK.I 51
K.IGGIGTVPVGR.V  65
BNB07 EF1A2_RAT Elongation factor 1-alpha 210 4 Rattus 50422 9.11 9%
BNB08 SUCA_RAT 
Succinyl-CoA ligase [GDP-forming] subunit alpha, 
mitochondrial 704 27 Rattus 36125 9.54 35% R.KNIYIDK.N  50
K.VICQGFTGK.Q  (C) 48
K.QGTFHSQQALEYGTK.L  95
K.LVGGTTPGK.G  65
K.HLGLPVFNTVK.E  73
R.LIGPNCPGIINPGECK.I  2 (C) 107
K.DPATEGIVLIGEIGGHAEENAAEFLK.E  123
K.AKPVVSFIAGITAPPGR.R  44
R.MGHAGAIIAGGK.G  (M) 84
BNB08 SUCA_RAT 
Succinyl-CoA ligase [GDP-forming] subunit alpha, 
mt 689 9 Rattus 36125 9.54 35%
BNB09 CY1_BOVIN Cytochrome c1, heme protein, mitochondrial 91 5 Bovine 35274 9.14 16%
BNB09 NO RESULT
BNB10 HBB2_RAT Hemoglobin subunit beta-2 105 7 Rattus 15972 8.91 25%
NDUV2_RAT 
NADH dehydrogenase [ubiquinone] flavoprotein 2, 
mitochondrial 89 3 Rattus 27361 6.23 12% R.DSDSILETLQR.K  40
BNB10 NDUV2_RAT 
NADH dehydrogenase [ubiquinone] flavoprotein 2, 
mt 40 1 Rattus 27361 6.23 4%
Band Protein Name MASCOT Score
Queries 
matched Species
Theoretical coverage Matched peptides MASCOT ion Score
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Mr Pl
BNB11 HBB2_RAT Hemoglobin subunit beta-2 141 5 Rattus 15972 8.91 25% R.LLVVYPWTQR.Y  40
K2C4_RAT Keratin, type II cytoskeletal 4 53 1 Rattus 57631 7.52 1% K.NEISELNR.M  54
BNB11 HBB2_RAT Hemoglobin subunit beta-2 141 5 Rattus 15972 8.91 7%
BNB11 K2C4_RAT Keratin, type II cytoskeletal 4 53 1 Rattus 57631 7.52 1%
BNB12 HBB2_RAT Hemoglobin subunit beta-2 289 11 Rattus 15972 8.91 53% M.VHLTDAEK.A  49
K.ATVSGLWGK.V  38
R.LLVVYPWTQR.Y  52
K.FGDLSSASAIMGNPQVK.A  (M) 35
K.VINAFNDGLK.H  46
K.VVAGVASALAHK.Y 69
HBA_RAT Hemoglobin subunit alpha-1/2 52 5 Rattus 15319 7.82 33%
BNB12 HBB2_RAT Hemoglobin subunit beta-2 289 6 Rattus 15319 7.82 53%
BNB13 HBA_RAT Hemoglobin subunit alpha-1/2 680 21 Rattus 15319 7.82 71% M.VLSADDKTNIK.N  52
K.IGGHGGEYGEEALQR.M  125
R.MFAAFPTTK.T  38
R.MFAAFPTTK.T  (M) 70
K.TYFSHIDVSPGSAQVK.A  119
K.KVADALAK.A  55
K.AADHVEDLPGALSTLSDLHAHK.L  127
K.LRVDPVNFK.F  47
K.FLASVSTVLTSK.Y  91
HBB1_RAT Hemoglobin subunit beta-1 545 21 Rattus 15969 7.88 78% M.VHLTDAEK.A  51
K.VNPDDVGGEALGR.L  90
R.LLVVYPWTQR.Y  52
R.YFDSFGDLSSASAIMGNPK.V (M) 40
K.VINAFNDGLK.H  55
K.GTFAHLSELHCDK.L  (C) 53
K.LHVDPENFR.L  46
K.EFTPCAQAAFQK.V  (C) 61
K.VVAGVASALAHK.Y  86
HBB2_RAT Hemoglobin subunit beta-2 441 19 Rattus 15972 8.91 56% M.VHLTDAEK.A  51
K.ATVSGLWGK.V  37
R.LLVVYPWTQR.Y  52
K.VINAFNDGLK.H  55
K.GTFAHLSELHCDK.L  (C) 53
K.LHVDPENFR.L  46
K.EFTPCAQAAFQK.V  (C) 61
K.VVAGVASALAHK.Y  86
BNB13 HBA_RAT Hemoglobin subunit alpha-1/2 724 9 Rattus 15319 7.82 71%
BNB13 HBB1_RAT Hemoglobin subunit beta-1 534 9 Rattus 15969 7.88 78%
BNB13 HBB2_RAT Hemoglobin subunit beta-2 441 8 Rattus 15972 8.91 56%
Matched peptides MASCOT ion ScoreBand Protein Name
MASCOT 
Score
Queries 
matched Species
Theoretical coverage
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Mr Pl
BNB14 QCR6_RAT Cytochrome b-c1 complex subunit 6, mitochondrial 168 5 Rattus 10417 4.9 38% R.SQTEEDCTEELFDFLHAR.D  (C) 112
HBA_RAT Hemoglobin subunit alpha-1/2 85 3 Rattus 15319 7.82 35% K.FLASVSTVLTSK.Y  58
CX6B1_MOUSECytochrome c oxidase subunit 6B1 60 3 Rattus 10065 8.96 34% K.GGDVSVCEWYR.R (C) 44
NDUS6_RAT
NADH dehydrogenase [ubiquinone] iron-sulfur protein 
6, mitochondrial 57 1 Rattus 12775 9.37 12% R.IIACDGGGGALGHPK.V  (C) 57
BNB14 QCR6_RAT Cytochrome b-c1 complex subunit 6, mt 112 1 Rattus 10417 4.9 20%
BNB14 HBA_RAT Hemoglobin subunit alpha-1/2 58 1 Rattus 15319 7.82 3%
BNB14 CX6B1_MOUSECytochrome c oxidase subunit 6B1 44 1 Rattus 10065 8.96 13%
BNB14 NDUS6_RAT
NADH dehydrogenase [ubiquinone] iron-sulfur 
protein 6, mt 57 1 Rattus 12775 9.37 12%
Matched peptides MASCOT ion ScoreBand Protein Name
MASCOT 
Score
Queries 
matched Species
Theoretical coverage
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Abstract  
Objective - Adult bone marrow mononuclear cells (BMMNCs) can restore cardiac 
function following myocardial necrosis. Protocols used to date have administered 
cells relatively late after ischemia/reperfusion injury, but there is the opportunity with 
elective procedures to infuse cells shortly after restoration of blood flow, for example 
after angioplasty. Our aim was therefore to try and quantify protection from 
myocardial injury by early infusion of BMMNCs in a rat ischaemia reperfusion (I/R) 
model. 
 
Methods and Results - Male Wistar rats underwent 25 minutes of ischaemia followed 
by 2 hours reperfusion of the left anterior descending coronary artery. Ten million 
BMMNCs were injected i.v. at reperfusion. We found BMMNCs caused a significant 
reduction in infarct size at two hours when assessed by staining the area at risk with 
p-nitro blue tetrazolium (42% reduction, P<0.01). Apoptosis and necrosis of isolated 
cardiomyocytes was significantly reduced in the area at risk. Functional assessment at 
7 days using echocardiography and left ventricular catheterisation showed improved 
systolic and diastolic function in the BMMNC treatment group (LVEF: BMMNC 
71±3% vs PBS 48±4%, P<0.0001). In functional studies BMMNC injected animals 
showed increased activation of Akt, inhibition of GSK-3β, amelioration of p38 MAP 
kinase phosphorylation and NF-κB activity compared to control myocardium. 
Inhibition of PI3K with LY294002 abolished all beneficial effects of BMMNC 
treatment. Proteomic analysis also demonstrated that BMMNC treatment induced 
alterations in proteins within known cardioprotective pathways, e.g., heat shock 
proteins, stress-70 protein as well as the chaperone protein 14-3-3epsilon. 
 
Conclusions - Early BMMNC injection during reperfusion preserves the 
myocardium, with evidence of reduced apoptosis, necrosis, and activation of survival 
pathways. 
 
Introduction 
Bone marrow mononuclear cells (BMMNCs) are emerging as a therapeutic modality 
for the treatment of ischaemic heart disease and its sequelae. The majority of animal 
experiments, forming the foundation for clinical translation of cell therapy, have been 
conducted after myocardial infarction has been established, i.e., cells were injected 
more than one hour after reperfusion or whilst the coronary artery remained  
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occluded[1]. The possibility that cell therapy may have a beneficial outcome if 
administered near the time of reperfusion, in a model many ways analogous to 
patients undergoing primary angioplasty (i.e. ischaemia-reperfusion injury - IRI) for 
acute myocardial infarction, has not been investigated. 
 
BMMNCs have been demonstrated to improve cardiac function and a variety of 
explanations have been promoted as the cause of induced benefit. A key suggested 
mechanism of action is transdifferentiation or plasticity, these terms describe the 
observation that BMMNCs can engraft within ischaemic and non-ischaemic 
myocardium and modify their cell phenotype to that of cardiac muscle or vascular 
cells thus improving cardiac function by direct contribution to contractile function 
and increasing perfusion of cardiac tissue[2]. 
 
Others have failed to observe transdifferentiation[3] and subsequent investigators 
have suggested local release of paracrine factors as the key mechanism of action of 
transplanted cells. BMMNCS are capable of secreting a wide range of cytokines[4]. 
The paracrine factors themselves have been shown to induce a number of beneficial 
effects including induction of angiogenesis in host tissues[1], reducing apoptosis[4], 
immunomodulation of injury, e.g., benefits of transplantation following myocardial 
ischaemia have been shown to be dependent on cytokines such as IL-10[5], a further 
documented paracrine benefit is the stimulation of, the recently described, resident 
cardiac stem cells[6]. 
 
The optimum timing of BMMNC cell injection in acute myocardial infarction has 
been identified as an unanswered question[7], and currently there is little published 
data to answer this question. 
 
We speculated that an early time point of injection could optimise benefits: the earlier 
the offending coronary artery is treated during myocardial infarction the more cardiac 
tissue is preserved, and the better the outcome[8]. If the stem cells evoke their 
beneficial effect through paracrine actions, rather than ‘de-novo’ myogenesis, in 
acute myocardial infarction, then the biggest opportunity to save muscle would be 
before completion of infarction. Thus we suggest that the stem cell delivery would 
ideally be in less than three hours after ischaemia onset, an important threshold 
observed in thrombolysis trials[8]. This viewpoint is underlined by observations in a 
rat stroke model that earlier intervention led to greater brain tissue survival and 
improved functional outcome[9]. Early intervention, ideally in minutes, is also 
needed to ameliorate ischaemia-reperfusion injury, an important modifiable 
determinant of infarct size, and an obvious potential target for paracrine factors 
released by BMMNCs[10]. 
 
Our hypothesis was that early injection of BMMNCs would induce a significant 
benefit after ischaemia-reperfusion injury and that this benefit would be induced by 
paracrine factors affecting the ischaemia-reperfusion injury pathway. Thus, we  
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designed a series of experiments to test whether there is an early window of 
opportunity during which injection of bone marrow derived cells leads to a significant 
decrease in infarct size, in an animal model of IRI. 
 
Materials and methods 
All experiments were performed in accordance with the Guide for the Care and Use 
of Laboratory Animals published by the US National Institutes of Health (NIH 
Publication No. 85-23, revised 1996). All studies were performed using male Wistar 
rats (Charles River, UK) weighing 250-350 g receiving a standard diet and water ad 
libitum. 
 
1 Experiment Outline 
We performed five experimental protocols in parallel, due to the mutually exclusive 
nature of the outcome measures used in our study (See supplementary Figure 1). The 
aim of each study was to assess the effect of intravenous delivery of 107 BMMNCs 
in a rat IRI model. The first two studies were designed to assess changes in infarct 
size, and effects on apoptosis and necrosis. The third study evaluated cardiac function 
and myocardial fibrosis after seven days reperfusion. The fourth study evaluated 
activation of the PI3K/Akt survival pathway including downstream mediators, finally 
we attempted to quantify proteomic changes (See online supplementary Figure 1 for 
the experimental designs). We chose 107 BMMNCs as our therapeutic dose since 
several studies have shown functional benefit at this dose[11,12], in addition a dose 
response effect has been documented so we tried to take advantage of this[13]. 
 
2 Donor bone marrow mononuclear cell preparation 
Whole bone marrow was harvested from femurs and tibias of male Wistar rats, 
BMMNCs were isolated by Percoll (Amersham Biosciences, UK) density gradient 
centrifugation, as previously described[14]. BMMNCs were characterised by flow 
cytometry using monoclonal antibodies for c-kit (Santa Cruz, sc-5535, USA), CD34 
(Santa Cruz, sc-9095, USA), CD45 (BD, 554875, USA) and CD133 (Santa Cruz, sc- 
30219, USA). BMMNCs were c-Kit+ (7 ± 1%, n = 10), CD34+ (7 ± 1%, n = 10), 
CD45+ (54 ± 6 %, n = 10), and CD133+ (15 ± 1%, n = 10). 
 
3 Measurement of infarct size 
Rats were anesthetised with thiopentone, tracheotomised and ventilated with air 
oxygen mix (30 %), and subjected to LAD occlusion (25 minutes)[15] and 
reperfusion (for 30 min, 2 hours or 7 days). Area at risk (AAR) of the left ventricle 
was demarcated by perfusion with Evans Blue and infarct size was measured by 
staining the AAR with nitro blue tetrazolium, as previously described[16]. 
 
4 Detection of apoptosis and necrosis in cardiac myocytes 
Cardiomyocytes (CMCs) from the AAR of the previously ischaemic and reperfused 
(2 hours) myocardium were isolated and analysed for CMC apoptosis and necrosis by 
flow cytometry as previously described[17]. Gating of the CMC population was  
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determined by the degree of binding of troponin-T monoclonal antibody (SC-20025, 
Santa Cruz, USA). Troponin-T binding in the gated population was 70 ± 6% (n = 5). 
Annexin 5-FITC/propodium iodide apoptosis detection kit (BD Biosciences 
Pharmingen, UK) was used to dual stain live AAR CMC isolates. All stained AAR 
CMC isolate samples were analysed within 1 hour using a flow cytometer (FACScan, 
Becton Dickinson, UK) with Cell-Quest software (BD, UK). Cardiomyocyte 
apoptosis was also confirmed using a caspase-9 FLICA assay kit (Sigma-Aldrich, 
UK). 
 
5 Determination of cardiac function after 7 days reperfusion  
Cardiac function was analysed using echocardiography (Vevo-770 imaging system 
and 23.5MHz probe, Visual Sonics, USA) under anesthetic (1.5% isoflurane) on the 
day before and 7 days post I/R injury. The percentage fractional area of contraction 
(%FAC) was assessed with 2-D images at the papillary muscle level. Left ventricle 
ejection fraction (LVEF) was measured by M-mode. Haemodynamic catheter 
analysis of LV function was performed (on the same days as above) by inserting a 2 
Fr micro tipped pressure transducer (Millar Instruments; SPR-320) through the right 
carotid artery and advanced into the LV for measurement of ventricular pressure. Left 
ventricular peak systolic pressure (LVPSP), end diastolic pressure (LVEDP), 
maximal slope of systolic pressure increment (+dP/dt), diastolic decrement (−dP/dt), 
the relaxation time constant (tau), and heart rate were all analysed using ChartPro 
software. 
 
6 Determination of LV fibrosis after 7 days reperfusion 
Excised hearts were immediately fixed by perfusion (via aortic cannulation) with 4% 
paraformaldehyde, followed by immersion in 4% paraformaldehyde, on ice for 30 
minutes. The hearts were then washed with PBS and incubated in PBS containing 
30% sucrose (w/v) at 4°C overnight. The fixed hearts were then cut transversely into 
three pieces, each of which was embedded in OCT compound (BDH, UK), frozen in 
liquid nitrogen-cooled isopentane and stored at -80°C. Subsequently, cryosections 
were stained with 0.1% picrosirius red F3B (BDH, UK) for 10 minutes at room 
temperature. The sections were rinsed 5 times in deionised water and then rinsed for 1 
minute in picric alcohol (20 ml absolute alcohol; 70 ml H2O; 10 ml saturated aqueous 
picric acid). The sections were then dehydrated through a methanol series and 
mounted in DPX (VWR, UK). The degree of picrosirius red staining was visualized 
by an all-in-one microscope (Keyence BZ8000, UK). 
 
7 Determination of activation of the PI3K/Akt-signaling pathways by Western blot 
analysis 
Animals were subjected to 25 minutes ischaemia followed by 30 minutes reperfusion 
and ex vivo hearts were frozen in liquid nitrogen. Cytosolic and nuclear protein 
homogenates were prepared from the frozen myocardium (AAR only) as 
described[18]. Protein extracts from the cytosol were analysed for phosphorylation of 
Akt, GSK-3β, and p38 MAPK by western blots as previously described[19]. Protein  
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extracts from both the cytosol and nucleus were analysed for nuclear translocation of 
p65 NF-κB, as described[19]. Immunodetection was performed using primary 
antibodies against mouse anti-phosphorylated AktSer473 mouse, antiphosphorylated 
p38 MAPK (both from Cell Signaling Biotechnology), rabbit antitotal Akt, rabbit 
anti-total GSK-3β, goat anti-phosphorylated GSK-3βSer9, and mouse anti-NF-κB 
p65 (all from Santa Cruz). Blots were then incubated with specific secondary 
antibodies conjugated with horseradish peroxidase and developed with an ECL 
detection system (Amersham). Immunoreactive bands were visualised by 
autoradiography and band density was evaluated using the Gel Pro®Analyzer 4.5, 
2000 software (Media Cybernetics). The proportion of phosphorylated to total protein 
was normalised to the vehicle treated group. Membranes were then stripped and 
incubated with β-actin monoclonal antibody and subsequently with anti-mouse 
antibody to assess gel-loading homogeneity. 
 
8 Analysis of the cardiac proteome after LAD-occlusion and reperfusion (6 hours) 
We assessed changes in the cardiac proteome by two-dimensional gel electrophoresis 
(2-DE) coupled with electro-spray ionization (ESI) mass spectrometry (MS) to 
identify differentially expressed protein spots in myocardial samples from sham 
operated animals plus PBS, ischaemia/reperfusion (25min/6h) plus PBS, and from 
ischaemia/reperfusion (25min/6h) plus BMMNC (n=3, for all groups). Protein 
homogenates were individually prepared for each rat from 80–140 mg of ground 
frozen myocardium (AAR only) using 1 ml lysis buffer per 100 ug tissue (9.5M Urea, 
4% CHAPS, 1% DTT, complete protease inhibitor [Roche, UK], Phosphatase 
inhibitor cocktail [Sigma]). Protein concentration of homogenates was quantified by 
Bio-Rad protein assay (Bio-Rad). Duplicate 2D gels were produced for each sample 
using 200 ug total protein separated on 18 cm non-linear (NL) pH4-7 immobilised pH 
gradient (IPG) strips (GE-Healthcare Lifesciences, UK). Large format, homogenous, 
12% SDS PAGE gels were used for second dimension separation and then stained 
using the plus one silver staining kit (GE-Healthcare Lifesciences, UK). Images were 
scanned and analyzed using PDQuest software (BioRad, UK). Spot intensity values 
were ‘normalised’ using ‘total density in gel’ method. Fold changes and unpaired 
Mann-Whitney p-values were calculated for ‘SHAM vs. PBS’ and ‘PBS vs. 
BMMNC’ comparisons. Over a hundred spots had significant > 2.5 fold differences 
(p≤0.05) in either or both of the comparisons, and were selected for trypsin digestion, 
peptide extraction, and protein identification using LC-MS/MS, Q-Tof Micro 
(Micromass, UK). The resultant peak list data (PKL file) was then used to search the 
SwissProt database using the MASCOT (Matrix Science) online server for a match. 
Only peptides with scores over 45 were considered to be significant, the MASCOT 
scores were calculated from these. 
 
9 Validation of proteomic data 
Twenty ug of protein homogenate was electrophoresed in duplicate on 10% Bis-tris 
gels (Invitrogen, UK) and transferred to PVDF membranes (GE Healthcare 
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 Lifesciences, UK), and subsequently blocked in Tris buffered saline containing 
0.05% Tween-20 (TBS-Tween) with 3% non-fat dry milk at 4oC overnight. Blots 
were probed with either anti-14-3-3ε or anti-SDHA antibodies (Abcam, UK). 
Loading was verified by probing the duplicate gel with anti-GAPDH antibodies 
(Abcam, UK) for each experiment. Blots were incubated with the appropriate 
secondary antibody (Santa Cruz Biotechnology, USA). Chemiluminescence was 
detected using ECL reagents (GE Healthcare, UK). Bands were detected and 
quantified using TotalLab v1.1 (Phoretix, UK), and volumes were normalised to the 
GAPDH volumes for the duplicate gels. 
 
10 Statistical Analyses 
GraphPad Prism 5 statistics package was used to analyse the results. Data for 
physiological variables are expressed as means ± standard error, and analysed by one 
way ANOVA followed by Dunnet’s post hoc test for multiple comparisons. For 
western blots, a one-way ANOVA followed by Bonferroni’s post hoc test for 
multiple comparisons was used. For 2-DE data a two-tailed unpaired Mann-Whitney 
P-value <0.05 was considered to be statistically significant. 
 
 
Results 
1 Intravenous administration of BMMNCs upon reperfusion reduces infarct size 
Intravenous jugular administration of 10 million BMMNCs, in 0.5 ml PBS, 
immediately upon reperfusion to animals subjected to ischaemia then reperfusion for 
2 hours resulted in a 42% reduction in infarct size (Figure 1). There was no 
significant difference in the percentage of left ventricle at risk for the BMMNC group 
compared to the PBS control group (50.85 vs 49.65% respectively, P=0.68). From 
experiments not shown here, we quantified donor cells within the rat hearts using a 
cell tracker dye, CDFA SE, we estimate that <1% of the injected cells remained in the 
heart two hours following injection. We next demonstrated that administration of 
BMMNCs, at the beginning of a 7 days reperfusion period, reduced IRI-induced 
infarct size and fibrosis, i.e., cardiac scar formation. These findings were associated 
with prevention of impairment in systolic and diastolic LV function measured by 
echocardiography and haemodynamic catheterization. Improvements in systolic 
function by BMMNC therapy were demonstrated by significantly higher values for 
LVEF (BMMNC 71 ± 3% vs. PBS 48 ± 4%, n=11, P < 0.0001); FAC (BMMNC 47 ± 
2% vs. PBS 36 ± 3%, n=11, P < 0.01); dP/dtmax (BMMNC 10 x 103 mmHgs-1 ± 
0.4% vs. PBS 8 x 103 mmHgs-1 ± 1% n=7, P < 0.05); and Contractility Index 
(BMMNC 162 ± 10 vs. PBS 113 ± 3, n=7, P < 0.001). Similarly, improvements in 
diastolic function by BMMNC-therapy were demonstrated by lower values for 
LVEDP (BMMNC 4 ± 1 mmHg vs. PBS 16 ± 3 mmHg, n=7, P < 0.01); dP/dtmin 
(BMMNC -9 x 103 ± 0.5 mmHgs-1 vs. PBS -7 x 103 ± 1 mmHgs-1, n=7, P < 0.01); 
and Tau (BMMNC 12 x 10-3 ± 0.5 vs. PBS 10 x 10-3 ± 1, n=7, P = 0.075)(Figures 
1b-i). 
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2 Apoptosis and Necrosis 
A significant decrease in the number of necrotic myocytes was seen when BMMNCs 
were injected immediately upon reperfusion (n=5 all groups, 6.1 ± 1.1% in shams vs 
16.3 ± 1.3% myocyte necrosis in control vs 4.9 ± 1% myocyte necrosis in BMMNC 
treated animals, P<0.01). Similarly, injection of BMMNCs immediately after 
ischaemia significantly reduced the proportion of cells undergoing apoptosis (n=5 all 
groups, 7.8 ± 0.5% in shams, 27.7 ± 3.2% in vehicle controls, and 13.9 ± 3.4% in 
BMMNC group, P<0.05, Figure 2). This observation was confirmed by measurement 
of caspase 9 expression, the percentage of cells isolated from the area at risk 
expressing caspase 9 was measured and found to be significantly reduced in cell 
treated compared to vehicle treated animals (BMMNCs 12.7±2.6% vs PBS 
30.6±4.2%, n=5, P<0.01). 
3 The reduction in infarct size caused by BMMNC is associated with activation of 
PI3K/Akt survival pathway 
The cardioprotective effect of BMMNCs was associated with the increased 
expression of the pro-survival PI3K/Akt signalling pathway. BMMNCs resulted in a 
significant increase, in phosphorylation of serine-473Akt and serine-9GSK-3β 
(Figure 3) which was abolished by the pre-treatment of animals with the PI3-K 
inhibitor LY294002 (0.3mg/ kg i.v.), indicating that the activation of Akt (and the 
subsequent inhibition of GSK-3β) were secondary to the activation of PI3K. 
Furthermore, BMMNCs resulted in a significant reduction in the phosphorylation of 
p38-MAPK and nuclear translocation of NF-κB, and both effects were attenuated by 
the PI3K inhibitor (0.3mg/kg i.v.). 
 
4 The cardioprotection afforded by BMMNCs is associated with a reversal in 
metabolism and mitochondrial protein disturbances 
We next investigated changes in the cardiac proteome of hearts that had been 
subjected to IRI by comparing the Sham operated group to PBS, and then we 
investigated the proteomic alterations attributable to BMMNC application by 
comparing the PBS group to the BMMNC group in the hope this would elucidate pro 
survival mechanisms afforded by the treatment. The proteins identified from spots 
found to be significantly altered are detailed in Table 1. Fold changes and p-values of 
these proteins are shown in Table 2 along with the observed and theoretical Mr and 
pI.  The proteins identified as being altered by IRI were involved in mitochondrial 
respiration, stress, cellular energy metabolism, and sarcomeric/cytoskeletal structure 
and function. Disturbances in mitochondrial oxidative phosphorylation components 
(complex I and complex III and ATP synthase) were observed in IRI suggesting 
mitochondrial dysfunction. Several stress responsive proteins were also altered in 
IRI: stress-70 protein (Hspa9), and the cytoplasmic antioxidant Peroxiredoxin-6 were 
both affected by IRI. The expression levels of several energy metabolism enzymes 
were also disturbed, possibly reflecting a switch in substrate preference[20]. Galectin-
5, a beta-galactoside-binding lectin, was up-regulated from undetectable levels in the 
PBS myocardial samples compared to Sham. Many of these alterations were largely 
reversed when the BMMNC group was compared to PBS, such that levels were  
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similar to that seen in the Sham group. For example, the spots identified as NADH-
ubiquinone oxidoreductase 75kDa subunit, and cytochrome b-c1 subunit 6 which had 
-10 and 6 fold changes respectively in the Sham vs. PBS comparison were seen to 
have 7 and -10 fold changes respectively in PBS vs. BMMNC. Fragments of ATP 
synthase subunit beta, identified in 16 different spots, all showed down-regulation in 
Sham vs. PBS, possibly reflecting enhanced protein degradation in IRI, and up-
regulation in PBS vs. BMMNC, four of these had significant alteration in both 
comparisons showing similar degree of expression change (-13, -6, -3 and -2 fold 
decrease in Sham vs. PBS; 13, 9, 3 and 3 fold increase in PBS vs. BMMNC). IRI 
related expression changes were also ‘corrected’ for Enoyl CoA hydratase and lactate 
dehydrogenase, hinting at a reversal of the IRI related substrate switch. We also 
observed a 12-fold up-regulation in the chaperone protein 14-3-3epsilon in the 
BMMNC group compared to PBS. The expression of two proteins (Shda and 14-3-3 
epsilon) were validated by Western blot (see Figure 4). 
Discussion 
We have discovered that the intravenous systemic administration of BMMNCs (10 
million: c-Kit+, CD34+, CD45+, CD133+) at the beginning of reperfusion, in a 
myocardial ischaemia-reperfusion injury model (25 minutes ischaemia, 2 hours 
reperfusion), results in a significant reduction in myocardial infarct size, and reduces 
the number of cardiomyocytes undergoing apoptosis within the area subjected to IRI. 
The cardioprotection induced by BMMNCs was not transient, but remained evident 
when hearts were subjected to regional myocardial ischaemia and treated with 
BMMNCs upon reperfusion, followed by 7 days of reperfusion. Under these 
experimental conditions, BMMNCs reduced the development of a scar tissue 
(reduction of necrosis and intra-mural fibrosis assessed by histology) and prevented 
the development of a significant systolic and diastolic cardiac dysfunction, which was 
seen in control animals. Notably, the cardioprotection afforded by BMMNCs was 
similar to that afforded by ischaemic preconditioning, a known gold standard for the 
experimental reduction of myocardial infarct size[21]. The cardioprotective effect of 
preconditioning is induced by pro-survival kinases such as PI3K-Akt and 
MEK1/Erk1/2, these protective kinases are collectively termed the reperfusion injury 
salvage kinase pathway (RISK). 
 
Activation of the RISK pathway at the time of myocardial reperfusion can confer 
powerful infarct size reduction. A diverse range of activating mechanisms have been 
demonstrated, these include growth factors[22], many of which have been shown to 
be released by stem cells, for example VEGF and FGF[23]. The cardioprotective 
actions of RISK pathway activation remain to be completely resolved, but leading 
suggestions with experimental evidence include inhibition of the mitochondrial 
permeability transition pore (mPTP), activation of anti-apoptotic mechanisms 
including inhibition of pro-apoptotic factors, e.g., BAD and BAX, and facilitation of 
calcium uptake into the sarcoplasmic reticulum ameliorating calcium triggered mPTP 
opening[24].  
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We next investigated possible mechanisms for our observations. The small quantity 
of cell engraftment two hours after injection, <1%, (measured in experiments not 
shown here), combined with the speed of the cardioprotective effect of BMMNC 
administration, coupled to the finding that BMMNCs can secrete mediators of the 
RISK pathway suggested to us that the observed cardioprotective effects could be due 
to activation of the RISK pathway. Various mediators of reperfusion injury — 
oxidative stress, changes in pH, inflammation, intracellular calcium levels,` and the 
mitochondrial permeability transition pore are all possible targets for interaction with 
BMMNCs injected at the time of reperfusion. As BMMNCs have already been shown 
to exhibit release of paracrine factors and expression of cardioprotective genes that 
may act beneficially on the RISK pathway we chose to investigate this possibility 
preferentially over other hypotheses[4]. Specific growth factors released by 
BMMNCs that have been shown to be cardioprotective include vascular endothelial 
growth factor (VEGF), hepatocyte growth factor (HGF), fibroblast growth factor 
(FGF), insulin-like growth factor 1 (IGF-1), and transforming growth factor (TGF) 
[23]. 
 
A number of our observations support the hypothesis that paracrine growth factors 
secreted by BMMNCs contribute to the cardioprotective effects of BMMNCs 
observed here. This hypothesis is supported by the following findings, administration 
of BMMNCs upon reperfusion was associated with activation of the PI3K/Akt 
phosphorylation survival kinase pathway, and when PI3K activity was inhibited, with 
LY294002, the cardioprotective effect seen with injection of BMMNCs was negated, 
highlighting the key importance of the activation of the PI3K/ Akt pro-survival 
pathway in the observed beneficial effects. The increase in Ser-473Akt 
phosphorylation also resulted in the inhibition of GSK3β, suppression of which has 
been documented to reduce infarct size and to cause pronounced anti inflammatory 
effects[25], which are, at least in part, due to prevention of the activation of NF-
κB24. The findings that the inhibition of activation of PI3K withLY294002 abolished  
all of the above effects of BMMNCs on cell signaling as well as their 
cardioprotective effects supports the view that the cardioprotective effects of 
BMMNC may be secondary to activation of the PI3K/Akt survival pathway. In order 
to further investigate the down stream molecular mechanisms associated with 
PI3K/Akt signaling we analysed changes in the global proteome of hearts subjected 
to IRI and treated upon reperfusion with BMMNCs. Within the proteomic dataset, 
many of the protein alterations measured in the BMMNC group compared to PBS 
control seem likely to be secondary to the reduced cell death associated with 
treatment, however, several proteins with a possible mechanistic role in 
cardioprotection were identified in the BMMNC treated group. Two significant 
proteins were the heat shock protein stress-70 protein (aka HSPA9 or HSP70), which 
has also been shown to be up-regulated in cardioprotection as afforded by hydrogen 
sulphide[26], and the chaperone protein 14-3-3epsilon which is known to have pro-
survival functions including its ability to bind and inhibit the Bcl-2 related protein  
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Bad in it’s phosphorylated conformation[27]. Bad phosphorylation is thought to be 
one of the many downstream actions of the PI3K/Akt pathway [28]. 
 
In conclusion, a single dose of systemic intravenous BMMNCs upon reperfusion 
reduces infarct size and cardiac dysfunction caused by regional myocardial ischaemia 
and reperfusion. This reduction in infarct size was associated with activation of the 
PI3K/Akt survival pathway. Furthermore, BMMNC treatment induced alterations in 
protein expression consistent with known cardioprotective pathways. Results from 
clinical BMMNC trials suggest positive effects on cardiac function when cells are 
administered 5 days after successful reperfusion of myocardial infarction[29]. 
However, in another study when cells were injected at a time closer to the point of 
successful reperfusion (24 hours) no beneficial effect was seen[30]. The data 
presented in this paper suggests that there may be a very early window of opportunity 
(i.e., less than 24 hours following reperfusion) that exists for bone marrow derived 
cell therapy to prevent myocardial necrosis, and that this time point should be 
considered when designing future clinical trials. In addition, it appears that the 
cardioprotective benefit shown here is too rapid to be related to stem cell plasticity 
and may be attributable to activation of the RISK pathway. This raises the possibility 
of unearthing one or more molecules that could be administered ‘in lieu’ of 
BMMNCs to achieve similar protection, thus avoiding the need for cell collection and 
any potential harmful effects that may manifest as a consequence of cell injection. 
 
Figure Legends 
Figure 1: (A) Infarct size was measured in animals subjected to 25 minutes regional 
myocardial ischaemia followed by 2 hours reperfusion (I/R2h) treated with phosphate 
buffered saline (PBS), bone marrow mononuclear cells (BMMNCs) or ischaemic 
preconditioning (IPC), sham animals received a thoracotomy only and were not 
rendered ischaemic. The area at risk (AAR) was expressed as a % of the left ventricle 
(LV) and the infarct size was expressed as a % of the AAR. (B-H) Cardiac function 
was analysed by echocardiography and LV hemodynamic catheterisation in animals 
subjected to 25 minutes LAD occlusion followed by 7 days reperfusion (I/R7D). 
When compared to vehicle, administration of BMMNCs upon reperfusion prevented 
systolic and diastolic dysfunction. (I) Myocardial fibrosis in hearts subjected to 
(I/R7D) was assessed by picrosirius red staining of myocardial cryosections. When 
compared with PBS, administration of BMMNC dramatically attenuated the degree 
of post I/R fibrosis. Statistical significance was determined by ANOVA followed by 
Dunnett’s post hoc test * P < 0.05, ** P < 0.01. 
 
Figure 2: BMMNC treatment significantly reduced apoptosis, necrosis and caspase 9 
activation compared to controls. The area at risk (AAR) of rat myocardium, following 
LAD ischaemia for 25 minutes then reperfusion for 2 hours, was isolated from 
animals in sham, vehicle, and BMMNC treated groups. The cardiomyocyte (CMC) 
fraction, for all groups, was then assessed for: (A) Necrosis (B) Apoptosis (C)  
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Caspase 9 activation. Statistical significance was determined by ANOVA followed 
by Dunnett’s post hoc test * P < 0.05, ** P < 0.01. 
 
Figure 3: (A) Infarct size was measured in animals subjected to 25 minutes regional 
myocardial ischemia followed by 2 hours reperfusion (I/R2h) or sham animals. The 
area at risk (AAR) was expressed as a % of the left ventricle (LV) and the infarct size 
was expressed as a % of the AAR. When compared with PBS, pre-treatment with the 
LY294002 (0.3mg/kg IV) abolished the attenuation of infarct size caused by the 
systemic intravenous injection of 10 million BMMNC upon reperfusion in I/R2h (B-
E). Western blots demonstrating that systemic intravenous injection of 10 million 
BMMNC upon reperfusion significantly augmented the phosphorylation of 
Aktserine-473 and GSK-3βserine-9, reduced the phosphorylation of p38-mitogen 
activated protein kinase (MAPK) and the nuclear translocation of NF-κB. The PI3-K 
inhibitor LY294002 abolished all of these effects of BMMNCs. Statistical 
significance was determined by ANOVA followed by Dunnett’s post hoc test * P < 
0.05, ** P < 0.01. 
 
Figure 4: A Western blot of expression levels of 14-3-3 epsilon with the normalized 
volumes shown in panel B. C shows western blot of expression levels of succinate 
dehydrogenase with the normalised volumes shown in D. Figure B and D show 
average normalised volumes and standard deviations, lines with stars indicate 
significance as calculated by one-way ANOVA followed by Bonferroni’s post hoc 
test for multiple comparisons. 
 
Table Legends 
Table 1: Spots with significant fold changes for which a single protein ID was found. 
SSP are spot identification numbers assigned by PDQuest software. Mascot details 
are as follows; mascot score (the sum of the peptide scores), the number of peptides 
found and the sequence coverage of these peptides (only including peptides with 
individual scores over 35). Theoretical Mr and PI values for the protein identified are 
shown as well as the observed Mr and PI of the spot as estimated from it’s position in 
the gel. 
 
Table 2: Proteins identified from spots that had significant fold changes in either the 
Sham vs. PBS or the PBS vs. BMMNC comparisons. Average spot volumes and 
standard deviations for each group are shown alongside fold changes and p-values 
(unpaired, 2 tailed, Mann-Whitney). ‘On’ and ‘Off’ in the FC column indicate 
changes to presence or absence in spots, e.g, in spot 1206 ‘On’ indicates the spot was 
absent in Sham but present in PBS. 
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Figure 4 
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Table 1 
 
Mr Pl Mr Pl Score pep's % sc
1430 34500 4.40 29155 4.63 14-3-3 protein epsilon P62260 164 3 20
2616 47500 4.80 32803 4.80 40S ribosomal protein SA P38983 50 1 4
2546 45000 4.80 51556 7.16 Adenylyl cyclase-associated protein 1 Q08163 55 1 4
3209 20000 5.00 56318 5.19 ATP synthase subunit beta P10719 144 2 5
1225 21000 4.50 56318 5.19 ATP synthase subunit beta P10719 192 2 7
3208 22000 5.00 56318 5.19 ATP synthase subunit beta P10719 51 1 4
4235 24000 5.40 56318 5.19 ATP synthase subunit beta P10719 110 2 4
4329 29000 5.40 56318 5.19 ATP synthase subunit beta P10719 69 1 2
1424 34000 4.60 56318 5.19 ATP synthase subunit beta P10719 131 2 8
3433 34000 5.00 56318 5.19 ATP synthase subunit beta P10719 436 6 18
2443 35000 4.80 56318 3.00 ATP synthase subunit beta P10719 91 1 3
3523 40000 5.20 56318 5.19 ATP synthase subunit beta P10719 280 4 14
3632 47000 5.20 56318 5.19 ATP synthase subunit beta P10719 314 5 16
2609 47500 4.80 56318 5.19 ATP synthase subunit beta P10719 457 6 12
2626 52500 4.90 56318 5.19 ATP synthase subunit beta P10719 167 3 8
3626 54500 5.20 56318 5.19 ATP synthase subunit beta P10719 711 9 29
3636 57000 5.10 56318 5.19 ATP synthase subunit beta P10719 226 5 15
3706 57000 5.10 56318 5.19 ATP synthase subunit beta P10719 215 3 9
2712 57500 4.90 56318 5.19 ATP synthase subunit beta P10719 707 8 26
2119 14500 4.80 10417 4.90 Cytochrome b-c1 complex subunit 6 Q5M9I5 131 1 20
3627 57000 5.20 53424 5.21 Desmin P48675 463 7 20
7722 62000 6.60 67123 8.76 Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex P08461 228 4 9
7323 31500 6.60 31496 8.39 Enoyl-CoA hydratase P14604 71 1 3
7110 16000 6.30 16186 6.17 Galectin-5 P47967 157 3 21
7702 70000 6.40 58307 5.85 Hydroxysteroid dehydrogenase-like protein 2 Q4V8F9 75 2 4
6425 37000 6.20 36589 5.70 L-lactate dehydrogenase B chain P42123 77 1 6
4521 37000 5.40 36589 5.70 L-lactate dehydrogenase B chain (or LDHA) P42123 72 1 3
8853 67500 6.70 79293 7.70 Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial (mouse) Q5I0C3 166 3 6
3305 25000 5.00 22142 5.03 Myosin light chain 3 P16409 334 5 33
1206 17500 4.40 18868 4.86 Myosin regulatory light chain 2 P08733 57 1 8
1213 17500 4.40 18868 4.86 Myosin regulatory light chain 2 P08733 108 2 16
3228 15000 5.20 18868 4.86 Myosin regulatory light chain 2 P08733 135 3 20
4207 19000 5.40 223370 5.59 Myosin-6 P02563 279 4 3
1207 19000 4.40 113780 8.4 NAD(P) transhydrogenase Q61941 58 1 2
7112 17000 6.50 79362 5.65 NADH-ubiquinone oxidoreductase 75 kDa Q66HF1 102 2 2
5408 32000 5.80 24803 5.64 Peroxiredoxin-6 O35244 388 7 44
3518 42500 5.10 73812 5.97 Stress-70 protein (aka HSPA9) P48721 85 1 2
4702 60000 5.20 73812 5.97 Stress-70 protein (aka HSPA9) P48721 739 10 21
7723 67500 6.60 71570 6.75 Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial Q920L2 73 1 2
1320 29000 4.50 32661 4.69 Tropomyosin alpha-1 chain  (or Tropomyosin beta chain) P04692 58 1 4
1248 25000 4.50 35709 4.95 Troponin T, cardiac muscle P50753 59 1 3
4523 43000 5.60 49892 4.95 Tubulin alpha-4A chain Q5XIF6 191 3 11
8710 67000 6.60 66140 6.15 WD repeat-containing protein 1 Q5RKI0 157 4 11
SSP
Observed Theoretical
Protein name
UniProtKB/
Swiss-Prot 
Accession
Mascot
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Table 2 
 
SSP Protein name Average StDEv Average StDEv Average StDEv FC p-value FC p-value 
4329 ATP synthase subunit beta 110.16 35.61 19.83 23.57 106.70 92.44 -5.6 0.0095 5.4 ns
1225 ATP synthase subunit beta 291.53 151.54 22.25 23.86 283.33 231.65 -13.10 0.0238 12.7 0.0476
3636 ATP synthase subunit beta 271.00 120.04 47.25 52.81 411.01 114.47 -5.7 0.0190 8.7 0.0095
3433 ATP synthase subunit beta 924.75 333.91 357.85 251.86 1052.96 350.05 -2.6 0.0022 2.9 0.0087
2609 ATP synthase subunit beta 621.15 297.10 311.42 168.21 781.41 136.07 -2.0 ns 2.5 0.0022
3523 ATP synthase subunit beta 468.32 318.28 244.35 136.88 670.89 119.11 -1.9 ns 2.7 0.0022
1424 ATP synthase subunit beta 394.95 298.27 272.46 165.49 776.50 227.39 -1.5 ns 2.8 0.0022
3632 ATP synthase subunit beta 130.97 81.35 76.08 59.83 218.44 101.06 -1.7 ns 2.9 0.0152
3626 ATP synthase subunit beta 846.73 155.91 386.66 214.61 1178.68 396.37 -2.2 0.0043 3.0 0.0022
2712 ATP synthase subunit beta 708.74 441.93 292.35 251.10 955.57 597.67 -2.4 ns 3.3 0.0260
2443 ATP synthase subunit beta 652.00 498.23 177.28 268.43 639.85 170.64 -3.7 ns 3.6 0.0152
2626 ATP synthase subunit beta 91.75 60.28 90.81 52.64 334.31 223.37 -1.0 ns 3.7 0.0303
3208 ATP synthase subunit beta 248.58 168.64 133.85 129.33 511.89 119.33 -1.9 ns 3.8 0.0043
3706 ATP synthase subunit beta 368.77 159.79 172.42 95.57 776.99 334.44 -2.1 ns 4.5 0.0095
3209 ATP synthase subunit beta 261.67 224.65 101.93 124.18 470.32 252.87 -2.6 ns 4.6 0.0260
4235 ATP synthase subunit beta 70.55 65.79 21.61 12.18 176.25 102.63 -3.3 ns 8.2 0.0238
2119 Cytochrome b-c1 complex subunit 6 330.30 406.92 1901.07 1217.20 185.77 128.67 5.8 0.0303 -10.2 0.0087
7112 NADH-ubiquinone oxidoreductase 75 kDa subunit 156.83 102.34 16.00 10.00 113.15 111.86 -9.8 0.0022 7.1 0.0260
1207 NAD(P) transhydrogenase 384.6 636.9 1474.3 808.7 1325.4 851.1 3.83 0.026 -1.1 ns
7723 Succinate dehydrogenase [ubiquinone] flavoprotein subunit 314.78 202.61 115.62 63.81 282.54 143.14 -2.7 ns 2.4 0.0260
7722
Dihydrolipoyllysine-residue acetyltransferase 
component of pyruvate dehydrogenase 
complex
39.01 24.22 225.82 164.74 45.42 22.77 5.8 0.0411 -5.0 ns
7323 Enoyl-CoA hydratase 696.98 400.62 1634.53 371.06 639.89 608.94 2.4 0.0022 -2.6 0.0152
6425 L-lactate dehydrogenase B chain 426.25 148.40 69.00 82.66 385.72 480.03 -6.2 0.0087 5.6 0.0303
4521 L-lactate dehydrogenase B chain (or LDHA) 700.40 749.67 252.34 315.77 676.73 160.45 -2.8 ns 2.7 0.0317
8853 Methylcrotonoyl-CoA carboxylase subunit alpha (mouse) 320.41 221.74 120.29 80.60 403.40 239.65 -2.7 ns 3.4 0.0173
Sham PBS BMMNC SHAM vs. PBS PBS vs. BMMNC
Mitochondrial/Oxidative Phosphorylation
Energy Metabolism
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Table 2 continued. 
 
5408 Peroxiredoxin-6 410.63 200.37 162.61 156.60 393.45 123.55 -2.5 ns 2.4 0.0260
3518 Stress-70 protein (aka HSPA9) 369.67 142.60 112.02 144.99 323.75 223.68 -3.3 0.0260 2.9 0.0411
4702 Stress-70 protein (aka HSPA9) 508.89 402.11 1035.09 584.46 360.54 271.60 -1.9 ns 2.7 0.0152
3627 Desmin 491.87 264.82 206.72 46.34 545.80 182.40 -2.4 0.0159 2.6 0.0043
3305 Myosin light chain 3 1691.27 957.03 545.68 498.17 1472.06 904.54 -3.1 0.0411 2.7 ns
1206 Myosin regulatory light chain 2 490.18 236.51 305.05 331.21 On -1.6 ns
1213 Myosin regulatory light chain 2 147.58 126.06 1049.19 385.02 626.65 440.62 7.1 0.0095 -1.7 ns
3228 Myosin regulatory light chain 2 204.57 219.47 1850.40 1241.85 1218.78 1357.75 9.1 0.0022 -1.5 ns
4207 Myosin-6 508.89 402.11 1035.09 584.46 360.54 271.60 2.0 ns -2.9 0.0152
1320 Tropomyosin alpha-1 chain  (or Tropomyosin beta chain) 172.31 68.46 17.32 9.72 195.82 115.85 -9.95 0.0238 11.30 0.0238
1248 Troponin T, cardiac muscle 133.87 228.64 173.79 243.95 Off On
4523 Tubulin alpha-4A chain 705.21 218.21 157.23 193.67 404.76 319.42 -4.5 0.0087 2.6 ns
1430 14-3-3 protein epsilon 225.70 167.56 24.77 15.25 309.80 180.01 -9.1 ns 12.5 0.0043
2616 40S ribosomal protein SA 98.56 104.48 83.32 54.58 278.01 167.07 -1.2 ns 3.3 0.0173
2546 Adenylyl cyclase-associated protein 1 89.10 44.41 21.66 13.56 134.59 57.71 -4.1 0.0303 6.2 0.0043
7110 Galectin-5 654.97 1246.68 66.30 101.51 On -9.9 ns
7702 Hydroxysteroid dehydrogenase-like protein 2 150.13 98.79 54.77 48.38 200.66 103.56 -2.7 ns 3.7 0.0087
8710 WD repeat-containing protein 1 358.36 214.12 169.16 88.09 454.56 216.81 -2.1 ns 2.7 0.0043
Cytoskeletal/Sarcomeric
Others
Antioxidants
Heat Shock Proteins
 
 
 
 
 
 
 
 
